<SEC-DOCUMENT>0001144204-12-029578.txt : 20120515
<SEC-HEADER>0001144204-12-029578.hdr.sgml : 20120515
<ACCEPTANCE-DATETIME>20120515162153
ACCESSION NUMBER:		0001144204-12-029578
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20120131
FILED AS OF DATE:		20120515
DATE AS OF CHANGE:		20120515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				87042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-25809
		FILM NUMBER:		12845061

	BUSINESS ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-507-4617

	MAIL ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v312954_10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND
EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C.
20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><I>(Mark One)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXCHANGE ACT OF
1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the fiscal
period ended January 31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Wingdings"><B>o
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXCHANGE ACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition
period from <B>___________</B> to <B>____________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File
No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>000-25809</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Apollo Medical
Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%; font-weight: bold; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 20%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 38%; font-weight: bold; text-align: center"><B>20-8046599</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">State of Incorporation</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">IRS Employer Identification No.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>700 North Brand
Blvd., Suite 450</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Glendale, California
91203</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(818) 396-8050</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Issuer&rsquo;s telephone
number)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">Securities Registered Pursuant to Section 12(b) of the Act:&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">Title of each Class</TD>
    <TD STYLE="width: 4%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 46%; text-align: center">Name of each Exchange on which Registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">None</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">Securities Registered Pursuant to Section 12(g) of the Act:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">Common Stock, $.001 Par Value</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;No
</FONT><FONT STYLE="font-family: Wingdings; color: black">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is not required to
file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;No
</FONT><FONT STYLE="font-family: Wingdings; color: black">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check whether the issuer (1) filed all reports required to
be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes
</FONT><FONT STYLE="font-family: Wingdings; color: black">&thorn;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
&nbsp;&nbsp;No</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate website, if any, every interactive data file required to be submitted and posted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that registrant was required to submit
and post such files).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes
</FONT><FONT STYLE="font-family: Wingdings; color: black">&thorn;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
&nbsp;&nbsp;No </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (229.405 of this chapter) is not contained
herein and, will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated
filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act. (Check
one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 28%; padding-right: 0.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Large
    accelerated filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD NOWRAP STYLE="width: 22%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accelerated
    filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD NOWRAP STYLE="width: 22%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-accelerated
    filer </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD NOWRAP STYLE="width: 22%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller
    reporting company </FONT><FONT STYLE="font-family: Wingdings; color: black">&thorn;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule&nbsp;12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Yes
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;No
</FONT><FONT STYLE="font-family: Wingdings; color: black">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate market value of the shares of voting common stock
held by non-affiliates of the Registrant computed by reference to the price at which the common stock was last sold on OTCQB on
July 31, 2011, the last business day of the Registrant&rsquo;s most recently completed second fiscal quarter, was $988,413. Solely
for purposes of the foregoing calculation, all of the registrant&rsquo;s directors and officers as of July 31, 2011 are deemed
to be affiliates. This determination of affiliate status for this purpose does not reflect a determination that any persons are
affiliates for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of April 30, 2012, there were 30,635,774 shares of common
stock, $.001 par value per share, issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APOLLO MEDICAL
HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>FOR
THE TWELVE MONTHS ENDED JANUARY 31, 2012</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="width: 10%; vertical-align: top; padding-right: 0.8pt; font-weight: bold"><B>PART I</B></TD>
    <TD STYLE="width: 82%; vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 2%; vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 1</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Description of Business</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">4</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 1A</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Risk Factors</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">11</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 1B</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Unresolved Staff Comments</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">18</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 2</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Description of Properties</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 3</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Legal Proceedings</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">18</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 4</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Mine Safety Disclosure</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">18</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font-weight: bold"><B>PART II</B></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 5</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters
    and Issuer Purchase of Equity Securities</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">19</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 6</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Selected Financial Data</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">20</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 7</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Management&rsquo;s Discussion and Analysis of Financial Condition and
    Results of Operations</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">20</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 7A</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Quantitative and Qualitative Disclosures about Market Risk</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">24</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 8</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Financial Statements and Supplementary Data</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">24</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 9</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Changes in and Disagreements with Accountants and Financial Disclosures</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">24</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 9A&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Controls and Procedures</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">24</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 9B</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Other Information</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font-weight: bold"><B>PART III</B></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 10</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Directors, Executive Officers and Corporate Governance</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">25</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 11</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Executive Compensation</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">27</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 12</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Security Ownership of Certain Beneficial Owners and Management and related
    Stockholder Matters</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">30</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 13</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Certain Relationships and Related Transactions, and Director Independence</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">31</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 14</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Principal Accounting Fees and Services</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">32</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; font-weight: bold"><B>PART IV</B></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Item 15</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Exhibits, Financial Statement Schedules</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">33</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Signatures</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0.8pt; text-align: right">34</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Introductory Comment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless context dictates otherwise, references in this
Annual Report on Form 10-K (the &ldquo;Report&rdquo;) to the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our&rdquo;, (&ldquo;Apollo&rdquo;) and similar words are to Apollo Medical Holdings, Inc., and its wholly owned
subsidiaries and affiliated medical groups:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following discussion and analysis provides information
that management believes is relevant to an assessment and understanding of our results of operations and financial operations.
This discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere
herein, and with our prior filings with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Disclosure Regarding Forward-Looking Statements - Cautionary
Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We caution readers that this Report contains &ldquo;forward-looking
statements&rdquo;. Forward-looking statements, written, oral or otherwise, are based on the Company&rsquo;s current expectations
or beliefs rather than historical facts concerning future events, and they are indicated by words or phrases such as, "but
not limited to", &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;should,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;believe,&rdquo;
&ldquo;think,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;envision,&rdquo; &ldquo;continue,&rdquo; &ldquo;intend,&rdquo;
&ldquo;target,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;budgeted,&rdquo; or &ldquo;will&rdquo; and similar words or phrases or
comparable terminology. Forward-looking statements involve risks and uncertainties. The Company cautions that these statements
are further qualified by important economic, competitive, governmental and technological factors that could cause the Company&rsquo;s
business, strategy, or actual results or events to differ materially, or otherwise, from those in the forward-looking statements.
We have based such forward-looking statements on our current expectations, assumptions, estimates and projections, and therefore
there can be no assurance that any forward-looking statement contained herein, or otherwise made by the Company, will prove to
be accurate. The Company assumes no obligation to update the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has a relatively limited operating history compared
to others in the same business and is operating in a rapidly changing industry environment; as a result its ability to predict
results or the actual effect of future plans or strategies, based on historical results or trends or otherwise, is inherently
uncertain. While we believe that these forward-looking statements are reasonable, they are merely predictions or illustrations
of potential outcomes, and they involve known and unknown risks and uncertainties, many beyond our control, that are likely to
cause actual results, performance, or achievements to be materially different from those expressed or implied by such forward-looking
statements. Factors that could have a material adverse affect on the operations and future prospects of the Company on a condensed
basis include those factors discussed under Item 1A &ldquo;Risk Factors&rdquo; and Item 7, &ldquo;Management&rsquo;s Discussion
and Analysis or Plan of Operation&rdquo; in this Report, and include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
                                                                                                               ability to attract
                                                                                                               and retain management,
                                                                                                               and to integrate
                                                                                                               and maintain technical
                                                                                                               information and
                                                                                                               management information
                                                                                                               systems;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.05pt; text-indent: -0.4in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
                                                                                                               ability to raise
                                                                                                               capital when needed
                                                                                                               and on acceptable
                                                                                                               terms and conditions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.05pt; text-indent: -0.4in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                                                                                               intensity of competition;
                                                                                                               and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.05pt; text-indent: -0.4in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">General
                                                                                                               economic conditions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All written and oral forward-looking statements made in connection
with this Report that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these
cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on
such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 1. DESCRIPTION OF BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc. was originally
incorporated in Delaware on November 1, 1985 as McKinnely Investments, Inc. The Company changed its name (i) to Accoline
Industries, Inc. on November 5, 1986, and (ii) to Siclone Industries, Inc. on May 24, 1988. Until June 2008, the Company had
no active business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc. and its subsidiaries are a leading
provider of hospitalist and hospital based physician services, such as ICU management in Los Angeles and the Central Valley of
California. Hospitalist medicine is organized around the admission and care of patients in inpatient facilities such as hospitals
and Long Term Acute Care (LTAC) facilities and is focused on providing, managing and coordinating the care of hospitalized patients.
As of January 31, 2012, the Company provides hospitalist services to a range of medical groups, health plans, community physicians
and hospital clients at&nbsp;23 hospitals. The Company is currently headquartered in Glendale, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company operates as a medical management holding company
that focuses on managing the provision of hospital-based medicine through a wholly owned subsidiary-management company, Apollo
Medical Management, Inc. (&ldquo;AMM&rdquo;). Through AMM, the Company manages affiliated medical groups under long-term Management
Service Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Organizational History </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 13, 2008, Siclone Industries, Inc. (&ldquo;Siclone&rdquo;),
Apollo Acquisition Co., Inc., a wholly owned subsidiary of Siclone (&ldquo;Acquisition&rdquo;), Apollo Medical Management, Inc.
(&ldquo;Apollo Medical&rdquo;) and the shareholders of Apollo Medical entered into an Agreement and Plan of Merger (the &ldquo;Merger
Agreement&rdquo;). Pursuant to the terms of the Merger Agreement, Apollo Medical merged with and into Acquisition, becoming a
wholly owned subsidiary of Siclone. The former shareholders of Apollo Medical received 20,933,490 shares of Siclone&rsquo;s common
stock in the acquisition.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 1, 2008, the surviving entity (i.e., the combined entity
of Acquisition and Apollo Medical) changed its name to Apollo Medical Management, Inc. ("AMM"). On July 3, 2008, Siclone
changed its name to Apollo Medical Holdings, Inc. Following the merger, the Company is headquartered in Glendale, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 1, 2008, AMM completed negotiations and executed
a formal Management Services Agreement with ApolloMed Hospitalists (&ldquo;AMH&rdquo;), under which AMM will provide management
services to AMH. The Agreement was effective as of August 1, 2008, and allows AMM, which operates as a Physician Practice Management
Company, to consolidate AMH, which operates as a Physician Practice, in accordance with ASC 810-10 &ldquo;Consolidation of Entities
Controlled By Contract&rdquo; subsections. The Management Services Agreement was amended on March 20, 2009 to allow for the calculation
of the fee on a monthly basis with payment of the calculated fee each month. AMH is controlled by Dr. Hosseinion and Dr. Vazquez.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 15, 2011, the Company completed  an
acquisition, whereby&nbsp;Aligned Healthcare Group, Inc. became a wholly-owned subsidiary of Apollo Medical Holdings, Inc.
Pursuant to a Stock Purchase Agreement, dated February 15, 2011, by and among Aligned Healthcare Group &ndash; California,
Inc., Raouf Khalil, Jamie McReynolds, M.D. BJ Reese and BJ Reese &amp; Associates, LLC and the Company, under which the
Company acquired all of the issued and outstanding shares of capital stock of Aligned
Healthcare, Inc., a California corporation (&ldquo;AHI&rdquo;), from AHI&rsquo;s shareholders.&nbsp;&nbsp;AHI is engaged in
the business of operating 24-hour physician call centers and provides specialized care management services (See Note 17).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 2, 2011, Apollo Medical Holdings, Inc. entered into
a stock purchase agreement (the &ldquo;PCCM Purchase Agreement&rdquo;) with the sole shareholder of Pulmonary Critical Care Management,
Inc. ("PCCM"), a provider of management services to the Los Angeles Lung Center (&ldquo;LALC&rdquo;), under which the
Company acquired all of the issued and outstanding shares of capital stock of PCCM (the &ldquo;PCCM Acquisition&rdquo;) and the
associated intangible asset in the management services agreement that PCCM has with LALC (the &ldquo;PCCM Services Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hospitalist Industry Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hospitalists are physicians who spend their professional
time serving as the physicians-of-record for inpatients. Today, many primary care physicians (&ldquo;PCPs&rdquo;) use
hospitalists to care for their patients when they visit emergency rooms or are admitted to the hospital. A hospitalist
handles the patient&rsquo;s care during the time spent in the hospital, and communicates often with the patient&rsquo;s
PCP about the patient&rsquo;s progress. At the time of discharge from the hospital, the hospitalists
return the patient back to the care of their PCPs. According to the Society of Hospital Medicine, the
number of hospitalists in the U.S. has grown from a few hundred in 1996 to over 20,000 today in response to a need for more
efficient delivery of inpatient care. It is anticipated that as many as 33,000 hospitalists may be currently needed for full
coverage of inpatients in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rising healthcare expenditures is a key motivating factor behind
the utilization of hospitalists. An aging population, advancements in medical technology, and the rising cost of pharmaceuticals
are just some of the forces driving up healthcare costs. Hospital medicine has developed as a specialty with unique characteristics
and expertise. Hospitalists have specialized skills, knowledge, and relationships that contribute value to hospitals, physicians,
patients, and health plans. These skills go beyond the delivery of quality patient care to hospital inpatients and include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Providing
                                                                                                               measurable quality
                                                                                                               improvement through
                                                                                                               setting standards
                                                                                                               and compliance;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Saving
                                                                                                               money and resources
                                                                                                               by reducing the
                                                                                                               patient&rsquo;s
                                                                                                               length of stay
                                                                                                               and achieving better
                                                                                                               utilization;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Improving
                                                                                                               the efficiency
                                                                                                               of the hospital
                                                                                                               by early patient
                                                                                                               discharge, better
                                                                                                               throughput in the
                                                                                                               emergency department
                                                                                                               (ED), and reducing utilization of ICU beds;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Creating
                                                                                                               a seamless continuity
                                                                                                               from inpatient
                                                                                                               to outpatient care,
                                                                                                               from the ED to
                                                                                                               the hospital floor,
                                                                                                               and from the ICU
                                                                                                               to the hospital
                                                                                                               floor;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Creating
                                                                                                               teams of healthcare
                                                                                                               professionals that
                                                                                                               make better use
                                                                                                               of the resources
                                                                                                               at the hospital
                                                                                                               and create a better
                                                                                                               working environment
                                                                                                               for nurses and
                                                                                                               others;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Creating
                                                                                                               synergies between
                                                                                                               emergency and inpatient
                                                                                                               hospital services
                                                                                                               by the management
                                                                                                               of both areas through
                                                                                                               the Company&rsquo;s
                                                                                                               strategy of acquisitions
                                                                                                               of both ER and
                                                                                                               hospitalist groups;
                                                                                                               and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Managing
                                                                                                               acutely ill, complex
                                                                                                               hospitalized patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In today&rsquo;s healthcare environment, patients are generally
admitted to hospitals and cared for by PCPs. The demands of modern medical practice, however,
require that PCPs spend most of their time in outpatient practices, limiting their availability to care for hospitalized patients.
These requirements and demands have led to ever-diminishing quality of inpatient care, longer hospital stays, and higher costs
to the insurance companies. Over the past few years, hospital-based physicians, or hospitalists (i.e. those physicians that do
not have a separate outpatient practice), are becoming a regular part of the healthcare landscape allowing PCPs to focus on outpatient
office visits. Generally hospital-based physicians:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">are
                                                                                                               medical doctors
                                                                                                               that spend their
                                                                                                               time in the inpatient
                                                                                                               environment, making
                                                                                                               them familiar with
                                                                                                               hospital systems,
                                                                                                               policies, services,
                                                                                                               departments, and
                                                                                                               staff;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">are
                                                                                                               in-patient experts
                                                                                                               who possess clinical
                                                                                                               credibility when
                                                                                                               addressing key
                                                                                                               issues regarding
                                                                                                               the inpatient environment;
                                                                                                               and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">understand
                                                                                                               the tradeoffs involved
                                                                                                               in balancing the
                                                                                                               needs of the hospital
                                                                                                               with those of the
                                                                                                               medical staff;
                                                                                                               they tend to have
                                                                                                               an intimate knowledge
                                                                                                               of the issues that
                                                                                                               the hospital is
                                                                                                               facing and are
                                                                                                               invested in finding
                                                                                                               solutions to these
                                                                                                               problems.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Principal Services and Markets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company provides a comprehensive set of integrated medical
services to hospitals, health carriers and medical groups as well as individual physicians, through our affiliated medical groups,
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Services for Hospitals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Providing
                                                                                                               care from the emergency
                                                                                                               room through hospital
                                                                                                               discharge;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Admission
                                                                                                               and care of unassigned
                                                                                                               and/or uninsured
                                                                                                               patients;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Inpatient
                                                                                                               internal medicine
                                                                                                               consultation services;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Emergency
                                                                                                               room Clinical Decision
                                                                                                               Unit services to
                                                                                                               improve throughput
                                                                                                               and ease overcrowding;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Development
                                                                                                               of hospital-based
                                                                                                               physicians programs,
                                                                                                               including pulmonary,
                                                                                                               critical care,
                                                                                                               cardiology and
                                                                                                               nephrology;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">24/7
                                                                                                               in-hospital inpatient
                                                                                                               coverage services;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Development
                                                                                                               of evidence-based
                                                                                                               medicine protocols
                                                                                                               for common diagnoses;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Implementation
                                                                                                               of patient safety
                                                                                                               guidelines;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Education
                                                                                                               of nurses and hospital
                                                                                                               staff;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Analysis
                                                                                                               of statistics via
                                                                                                               the ApolloWeb database,
                                                                                                               including length
                                                                                                               of stay, bed days/1000
                                                                                                               admissions, and
                                                                                                               readmission rates;
                                                                                                               and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Care
                                                                                                               of patients at
                                                                                                               academic medical
                                                                                                               centers, including
                                                                                                               the education of
                                                                                                               medical students,
                                                                                                               interns and residents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Services for Health Carriers and Medical
Groups</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Admission
                                                                                                               and care of assigned
                                                                                                               patients;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consistent
                                                                                                               communication with
                                                                                                               primary care physicians
                                                                                                               upon admission,
                                                                                                               during the patient&rsquo;s
                                                                                                               hospital stay,
                                                                                                               and upon discharge;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Rapid
                                                                                                               transfer of out-of-network
                                                                                                               patients back to
                                                                                                               designated hospitals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">24/7
                                                                                                               in-hospital inpatient
                                                                                                               coverage services;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consistent
                                                                                                               communication with
                                                                                                               case managers,
                                                                                                               social workers,
                                                                                                               and medical group
                                                                                                               personnel;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Hospital-based
                                                                                                               physician consulting
                                                                                                               services; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Analysis
                                                                                                               of statistics via
                                                                                                               the ApolloWeb database
                                                                                                               technology.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Services for Individual Physicians</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hospital-based services for physicians on weekends, holidays,
or for those who do not wish to come to the hospital; PCPs can benefit from this arrangement because they have
more time to focus on outpatient care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The healthcare industry is highly competitive, and the market
for hospitalists within this industry is highly fragmented. The Company faces competition from numerous small hospitalist practices
as well as large physician groups. Some of these competitors operate on a national level, such as Emcare, Team Health and IPC
and may have greater financial and other resources available to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, because the market for hospitalist services is
highly fragmented and the ability of individual physicians to provide services in any hospital where they have certain credentials
and privileges, competition for growth in existing and expanding markets is not limited to our largest competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We anticipate that we will grow our business by two primary
methods, organic growth and acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Organic Growth</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company continues to market its services to medical groups,
hospitals, health plans and individual physicians in Los Angeles and the Central Valley of California. Our physician recruitment
campaign is aimed at attracting high quality physicians to meet the expected increase in demand for our services. This campaign
will be driven by utilizing direct contacts with internal medicine residency programs, advertising in professional journals, and
on-line advertising programs. We believe we have a competitive advantage in attracting highly qualified physicians by offering
recruits, through our affiliated medical groups, competitive salary and benefits including, if appropriate, incentive-based stock
options as part of the compensation package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Acquisitions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company's management team continues to identify and evaluate
hospitalist groups, other hospital-based specialty physicians and care and utilization management groups as potential acquisition.
We believe we have a competitive advantage in closing potential mergers/acquisitions due to our presence, our scope of contracts
and the benefit of being a publicly-traded company, which provides us with access to additional capital and the ability to utilize
our stock as part of the compensation package offered to the stockholders of target companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has developed, a proprietary web-based, practice
management software program for hospital-based physicians. The system, known as ApolloWeb allows a physician to enter patient
information in real-time at a patient&rsquo;s bedside via a 3G broadband-enabled PDA or a desktop computer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">ApolloWeb is capable of generating:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">real-time,
                                                                                                               comprehensive statistical
                                                                                                               data</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">complete
                                                                                                               HCFA(Health Care
                                                                                                               Financing Administration)
                                                                                                               billing forms</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">patient
                                                                                                               admissions and
                                                                                                               discharge summaries,
                                                                                                               including major
                                                                                                               test results and
                                                                                                               necessary follow-ups;
                                                                                                               and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">faxes
                                                                                                               or emails to primary
                                                                                                               care physicians
                                                                                                               with the aforementioned
                                                                                                               information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Geographic Coverage</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of January 31, 2012, we provide hospitalist services at
23 acute-care hospitals and LTAC facilities in Los Angeles and the Central Valley of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Professional Liability and Other Insurance Coverage</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business has an inherent risk of claims of medical
malpractice against our affiliated physicians and us. We or our independent physician contractors pay premiums for
third-party professional liability insurance that indemnifies us and our affiliated hospitalists on a claims-made basis for
losses incurred related to medical malpractice litigation. Professional liability coverage is required in order for our
affiliated hospitalists to maintain hospital privileges. All of our physicians carry first dollar coverage with limits of
coverage with limits of liability equal to $1,000,000 for all claims based on occurrence up to an aggregate of $3,000,000 per
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that our insurance coverage is appropriate based
upon our claims experience and the nature and risks of our business. In addition to the known incidents that have resulted in
the assertion of claims, we cannot be certain that our insurance coverage will be adequate to cover liabilities arising out of
claims asserted against us, our affiliated professional organizations or our affiliated hospitalists in the future where the outcomes
of such claims are unfavorable. We believe that the ultimate resolution of all pending claims, including liabilities in excess
of our insurance coverage, will not have a material adverse effect on our financial position, results of operations or cash flows;
however, there can be no assurance that future claims will not have such a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also maintain worker&rsquo;s compensation, director and
officer, and other third-party insurance coverage subject to deductibles and other restrictions in accordance with industry standards.
We believe that our insurance coverage is appropriate based upon our claims experience and the nature and risks of our business.
However, we cannot assure that any pending or future claim will not be successful or if successful will not exceed the limits
of available insurance coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulatory Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Significant Federal and State Healthcare Laws Governing
Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a healthcare company, our operations and relationships with
healthcare providers such as hospitals, other healthcare facilities, and healthcare professionals are subject to extensive and
increasing regulation by numerous federal, state, and local government entities. These laws and regulations often are interpreted
broadly and enforced aggressively by multiple government agencies, including the U.S. Department of Health and Human Services
Office of the Inspector General, or the ("OIG"), the U.S. Department of Justice, and various state authorities. We have
included brief descriptions of some, but not all, of the laws and regulations that affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Imposition of sanctions associated with a violation of any
of these healthcare laws and regulations could have a material adverse effect on our business, financial condition and results
of operations. The Company cannot guarantee that its arrangements or business practices will not be subject to government scrutiny
or be found to violate certain healthcare laws. Government investigations and prosecutions, even if we are ultimately found to
be without fault, can be costly and disruptive to our business. Moreover, changes in healthcare legislation or government regulation
may restrict our existing operations, limit the expansion of our business or impose additional compliance requirements and costs,
any of which could have a material adverse affect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>False Claims Acts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The federal False Claims Act imposes civil liability on individuals
or entities that submit false or fraudulent claims for payment to the federal government. The False Claims Act provides, in part,
that the federal government may bring a lawsuit against any person whom it believes has knowingly or recklessly presented, or
caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement
or used a false record to get a claim for payment approved. Private parties may initiate <I>qui tam</I> whistleblower lawsuits
against any person or entity under the False Claims Act in the name of the government and may share in the proceeds of a successful
suit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The federal government has used the False Claims Act to prosecute
a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs. By way
of illustration, these prosecutions may be based upon alleged coding errors, billing for services not rendered, billing services
at a higher payment rate than appropriate, and billing for care that is not considered medically necessary. The government and
a number of courts also have taken the position that claims presented in violation of certain other statutes, including the federal
Anti-Kickback Statute or the Stark Law, can be considered a violation of the False Claims Act based on the theory that a provider
impliedly certifies compliance with all applicable laws, regulations, and other rules when submitting claims for reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Penalties for False Claims Act violations include fines ranging
from $5,500 to $11,000 for each false claim, plus up to three times the amount of damages sustained by the government. A False
Claims Act violation may provide the basis for the imposition of administrative penalties as well as exclusion from participation
in governmental healthcare programs, including Medicare and Medicaid. In addition to the provisions of the False Claims Act, which
provide for civil enforcement, the federal government also can use several criminal statutes to prosecute persons who are alleged
to have submitted false or fraudulent claims for payment to the federal government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A number of states have enacted false claims acts that are
similar to the federal False Claims Act. Even more states are expected to do so in the future because Section&nbsp;6031 of the
Deficit Reduction Act of 2005 ("DRA"), amended the federal law to encourage these types of changes, along with
a corresponding increase in state initiated false claims enforcement efforts. Under the DRA, if a state enacts a false claims
act that is at least as stringent as the federal statute and that also meets certain other requirements, the state will be eligible
to receive a greater share of any monetary recovery obtained pursuant to certain actions brought under the state&rsquo;s false
claims act. The OIG, in consultation with the Attorney General of the United States, is responsible for determining if a state&rsquo;s
false claims act complies with the statutory requirements. Currently, 19 states, including California have some form of state false claims act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Kickback Statutes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The federal Anti-Kickback Statute is a provision of the
Social Security Act that prohibits as a felony offense the knowing and willful offer, payment, solicitation or receipt of any
form of remuneration in return for, or to induce, (1)&nbsp;the referral of a patient for items or services for which payment
may be made in whole or part under Medicare, Medicaid or other federal healthcare programs, (2)&nbsp;the furnishing or
arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other federal healthcare programs
or (3)&nbsp;the purchase, lease, or order or arranging or recommending the purchasing, leasing or ordering of any item or
service reimbursable under Medicare, Medicaid or other federal healthcare programs. Patient Protection and Affordable Care
Act (&ldquo;PPACA&rdquo;) amended section 1128B of the Social Security Act to make it clear that a person need not have actual knowledge
of the statute, or specific intent to violate the statute, as a predicate for a violation. The OIG, which has the
authority to impose administrative sanctions for violation of the statute, has adopted as its standard for review a judicial
interpretation which concludes that the statute prohibits any arrangement where even one purpose of the remuneration is to
induce or reward referrals. A violation of the Anti-Kickback Statute is a felony punishable by imprisonment, criminal fines
of up to $25,000, civil fines of up to $50,000 per violation and three times the amount of the unlawful remuneration. A
violation also can result in exclusion from Medicare, Medicaid or other federal healthcare programs. In addition, pursuant to
the changes of PPACA, a claim that includes items or services resulting from a violation of the Anti-Kickback Statute is a
false claim for purposes of the False Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to the breadth of the Anti-Kickback Statute&rsquo;s broad
prohibitions, statutory exceptions exist that protect certain arrangements from prosecution. In addition, the OIG has published
safe harbor regulations that specify arrangements that also are deemed protected from prosecution under the Anti-Kickback Statute,
provided all applicable criteria are met. The failure of an activity to meet all of the applicable safe harbor criteria does not
necessarily mean that the particular arrangement violates the Anti-Kickback Statute, but these arrangements may be subject to
scrutiny and prosecution by enforcement agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some states have enacted statutes and regulations similar to
the Anti-Kickback Statute, but which may be applicable regardless of the payer source for the patient. These state laws may contain
exceptions and safe harbors that are different from and/or more limited than those of the federal law and that may vary from state
to state.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Federal Stark Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The federal Stark Law, also known as the physician self-referral
law, generally prohibits a physician from referring Medicare and Medicaid patients to an entity (including hospitals) providing
&lsquo;&lsquo;designated health services,&rsquo;&rsquo; if the physician or a member of the physician&rsquo;s immediate family
has a &lsquo;&lsquo;financial relationship&rsquo;&rsquo; with the entity, unless a specific exception applies. Designated health
services include, among other services, inpatient and outpatient hospital services, clinical laboratory services, certain imaging
services, and other items or services that our affiliated physicians may order. The prohibition applies regardless of the reasons
for the financial relationship and the referral; and therefore, unlike the federal Anti-Kickback Statute, intent to violate the
law is not required. Like the Anti-Kickback Statute, the Stark Law contains a number of statutory and regulatory exceptions intended
to protect certain types of transactions and business arrangements from penalty. Compliance with all elements of the applicable
Stark Law exception is mandatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The penalties for violating the Stark Law can include the denial
of payment for services ordered in violation of the statute, mandatory refunds of any sums paid for such services and civil penalties
of up to $15,000 for each violation, double damages, and possible exclusion from future participation in the governmental healthcare
programs. A person who engages in a scheme to circumvent the Stark Law&rsquo;s prohibitions may be fined up to $100,000 for each
applicable arrangement or scheme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some states have enacted statutes and regulations similar to
the Stark Law, but which may be applicable to the referral of patients regardless of their payer source and which may apply to
different types of services. These state laws may contain statutory and regulatory exceptions that are different from those of
the federal law and that may vary from state to state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Health Information Privacy and Security Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Among other directives, the Administrative Simplification Provisions
of the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), required the Department of Health
and Human Services, or the HHS, to adopt standards to protect the privacy and security of certain health-related information.
The HIPAA privacy regulations contain detailed requirements concerning the use and disclosure of individually identifiable health
information by &ldquo;HIPAA covered entities,&rdquo; which include entities like the Company, our affiliated hospitalists, and
practice groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the privacy requirements, HIPAA covered entities
must implement certain administrative, physical, and technical security standards to protect the integrity, confidentiality and
availability of certain electronic health information received, maintained, or transmitted. HIPAA also implemented the use of
standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic
healthcare transactions, including activities associated with the billing and collection of healthcare claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The American Recovery and Reinvestment Act enacted on February&nbsp;18,
2009, included the Health Information Technology for Economic and Clinical Health Act (HITECH) which modified the HIPAA legislation
significantly. Pursuant to HITECH, certain provisions of the HIPAA privacy and security regulations become directly applicable
to &ldquo;HIPAA business associates&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Violations of the HIPAA privacy and security standards may
result in civil and criminal penalties. Historically, these included: (1)&nbsp;civil money penalties of $100 per incident, to
a maximum of $25,000, per person, per year, per standard violated and (2)&nbsp;depending upon the nature of the violation, fines
of up to $250,000 and imprisonment for up to ten years. The passage of HITECH significantly modified the enforcement structure,
creating a tiered system of civil money penalties that range from $100 to $50,000 per violation, with a cap of $1.5 million per
year for identical violations. We must also comply with the &ldquo;breach notification&rdquo; regulations,
which implement certain provisions of HITECH. Under these regulations, in addition to reasonable remediation, covered entities
must promptly notify affected individuals in the case of a breach of &ldquo;unsecured PHI,&rdquo; which is defined by HHS guidance,
as well as the HHS Secretary and the media in cases where a breach affects more than 500 individuals. Breaches affecting fewer
than 500 individuals must be reported to the HHS Secretary on an annual basis. The regulations also require business associates
of covered entities to notify the covered entity of breaches at or by the business associate. Formal enforcement of the new breach
notification regulations began on February&nbsp;22, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect increased federal and state
HIPAA privacy and security enforcement efforts. Under HITECH, State Attorney Generals now have the right to prosecute HIPAA violations
committed against residents of their states. In addition, HITECH mandates that the Secretary of HHS conduct periodic compliance
audits of HIPAA covered entities and business associates. It also tasks HHS with establishing a methodology whereby harmed individuals
who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine or monetary settlement
paid by the violator. This methodology for compensation to harmed individuals is required to be in place by February&nbsp;17,
2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Many states also have laws that protect the privacy and security
of confidential, personal information. These laws may be similar to or even more stringent than the federal provisions. Not only
may some of these state laws impose fines and penalties upon violators, but some may afford private rights of action to individuals
who believe their personal information has been misused.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Information and Privacy Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to privacy and security laws focused on health
care data, multiple other federal and state laws regulate the use and disclosure of consumer&rsquo;s financial information ("Personal
Information"). Many of these laws also require administrative, technical, and physical safeguards to prevent unauthorized
use or disclosure of Personal Information, including mandated processes and timeframes for notification of possible or actual
breaches of Personal Information to the affected individual. The Federal Trade Commission primarily oversees compliance with the
federal laws relevant to us, while state laws are addressed by the state attorney general or other respective state agencies.
As with HIPAA, enforcement of laws protecting financial information is increasing. Examples of relevant federal laws include the
Fair Credit Reporting Act, the Electronic Communications Privacy Act, and the Computer Fraud and Abuse Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fee-Splitting and Corporate Practice of Medicine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some states have laws that prohibit business entities, such
as us, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians,
also known collectively as the corporate practice of medicine, or engaging in certain arrangements, such as fee-splitting, with
physicians. In some states these prohibitions are expressly stated in a statute or regulation, while in other states the prohibition
is a matter of judicial or regulatory interpretation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company operates by maintaining long-term management contracts
with affiliated professional organizations, which are each owned and operated by physicians and which employ or contract with
additional physicians to provide hospitalist services. Under these arrangements, we perform only non-medical administrative services,
do not represent that we offer medical services, and do not exercise influence or control over the practice of medicine by the
physicians or the affiliated professional organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For financial reporting purposes, however, we consolidate the
revenues and expenses of all our practice groups that we own or manage because we have a controlling financial interest in these
practices based on applicable accounting rules and as described in our accompanying consolidated financial statements. In states
where fee-splitting is prohibited between physicians and non-physicians, the fees that we receive through our management contracts
have been established on a basis that we believe complies with the applicable state laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some of the relevant laws, regulations, and agency interpretations
in the State of California have been subject to limited judicial and regulatory interpretation. Moreover, state laws are subject
to change and regulatory authorities and other parties, including our affiliated physicians, may assert that, despite these arrangements,
we are engaged in the prohibited corporate practice of medicine or that our arrangements constitute unlawful fee-splitting. If
this occurred, we could be subject to civil or criminal penalties, our contracts could be found legally invalid and unenforceable
(in whole or in part), or we could be required to restructure our contractual arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Deficit Reduction Act of 2005</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Among other mandates, the Deficit Reduction Act of 2005, or
the DRA, created a new Medicaid Integrity Program designed to enhance federal and state efforts to detect Medicaid fraud, waste
and abuse. Additionally, section 6032 of the DRA requires entities that make or receive annual Medicaid payments of $5.0 million
or more from any one state to provide their employees, contractors and agents with written policies and employee handbook materials
on federal and state False Claims Acts and related statues. At this time, we are not required to comply with section 6032 because
we receive less than $5.0 million in Medicaid payments annually from any one state. However, we may likely be required to comply
in the future as our Medicaid billings increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Federal Healthcare Compliance Laws </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also subject to other federal healthcare laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 1995, Congress amended the federal criminal statutes set
forth in Title 18 of the United States Code by defining additional federal crimes that could have an impact on our business, including
&ldquo;Health Care Fraud&rdquo; and &ldquo;False Statements Relating to Health Care Matters.&rdquo; The Health Care Fraud provision
prohibits any person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit
program. As defined in this provision of Title 18, a &ldquo;healthcare benefit program&rdquo; can be either a government or private
payer plan. A violation of this statute may be charged as a felony offense and may result in fines, imprisonment or both. PPACA
amended section 1347 of Title 18 to provide that a person may be convicted under the Health Care Fraud provision even in the absence
of proof that the person had actual knowledge of, or specific intent to violate, the statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The False Statements Relating to Health Care Matters provision
prohibits, in any matter involving a federal health care program, anyone from knowingly and willfully falsifying, concealing or
covering up, by any trick, scheme or device, a material fact, or making any materially false, fictitious or fraudulent statement
or representation, or making or using any materially false writing or document knowing that it contains a materially false or
fraudulent statement. A violation of this statute may be charged as a felony offense and may result in fines, imprisonment or
both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Civil Monetary Penalties law of the Social Security
Act, a person, including any individual or organization, may be subject to civil monetary penalties, treble damages and exclusion
from participation in federal health care programs for certain specified conduct. One provision of the Civil Monetary Penalties
law precludes any person (including an organization) from knowingly presenting or causing to be presented to any United States
officer, employee, agent, or department, or any state agency, a claim for payment for medical or other items or services that
the person knows or should know (a)&nbsp;were not provided as described in the coding of the claim, (b)&nbsp;is a false or fraudulent
claim, (c)&nbsp;is for a service furnished by an unlicensed physician, (d)&nbsp;is for medical or other items or service furnished
by a person or an entity that is in a period of exclusion from the program or (e)&nbsp;are medically unnecessary items or services.
Violations of the law may result in penalties of up to $10,000 per claim, treble damages, and exclusion from federal healthcare
programs. In addition, the OIG may impose civil monetary penalties against any physician who knowingly accepts payment from a
hospital (as well as against the hospital making the payment) as an inducement to reduce or limit services provided to Medicare
or Medicaid program beneficiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other State Healthcare Compliance Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the state laws previously described, we also
are subject to other state fraud and abuse statutes and regulations. Many of the states in which we operate have adopted a form
of anti-kickback law, self-referral prohibition, and false claims and insurance fraud prohibition. The scope of these laws and
the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad
discretion. Generally, state laws reach to all healthcare services and not just those covered under a governmental healthcare
program. A determination of liability under any of these laws could result in fines and penalties and restrictions on our ability
to operate in these states. We cannot assure that our arrangements or business practices will not be subject to government scrutiny
or be found to violate applicable fraud and abuse laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fair Debt Collection Practices Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some of our operations may be subject to compliance with certain
provisions of the Fair Debt Collection Practices Act and comparable state statutes. Under the Fair Debt Collection Practices Act,
a third-party collection company is restricted in the methods it uses to contact consumer debtors and elicit payments with respect
to placed accounts. Requirements under state collection agency statutes vary, with most requiring compliance similar to that required
under the Fair Debt Collection Practices Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. Sentencing Guidelines</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The U.S. Sentencing Guidelines are used by federal judges in
determining sentences in federal criminal cases. The guidelines are advisory, not mandatory. With respect to corporations, the
guidelines state that having an effective ethics and compliance program may be a relevant mitigating factor in determining sentencing.
To comply with the guidelines, the compliance program must be reasonably designed, implemented, and enforced such that it is generally
effective in preventing and detecting criminal conduct. The guidelines also state that a corporation should take certain steps
such as periodic monitoring and appropriately responding to detected criminal conduct. We have yet to develop a formal ethics
and compliance program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Licensing, Certification, Accreditation and Related Laws
and Guidelines</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our clinical personnel are subject to numerous federal, state
and local licensing laws and regulations, relating to, among other things, professional credentialing and professional ethics.
Since the Company performs services at hospitals and other types of healthcare facilities, it may indirectly be subject to laws
applicable to those entities as well as ethical guidelines and operating standards of professional trade associations and private
accreditation commissions, such as the American Medical Association and the Joint Commission on Accreditation of Health Care Organizations.
There are penalties for non-compliance with these laws and standards, including loss of professional license, civil or criminal
fines and penalties, loss of hospital admitting privileges, and exclusion from participation in various governmental and other
third-party healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Professional Licensing Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s affiliated hospitalists must satisfy and
maintain their professional licensing in the states where they practice medicine. Activities that qualify as professional misconduct
under state law may subject them to sanctions, or to even lose their license and could, possibly, subject us to sanctions as well.
Some state boards of medicine impose reciprocal discipline, that is, if a physician is disciplined for having committed professional
misconduct in one state where he or she is licensed, another state where he or she is also licensed may impose the same discipline
even though the conduct occurred in another state. Professional licensing sanctions may also result in exclusion from participation
in governmental healthcare programs, such as Medicare and Medicaid, as well as other third-party programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of January 31, 2012, we had 5 full-time employees. None
of our full-time employees is a member of a labor union, and we have never experienced a work stoppage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 1A. RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the following risks occur, our business,
financial condition or results of operations could be materially harmed. The risks and uncertainties described below are not
the only ones facing the Company. Additional risks and uncertainties may also impair its business operations or
financial condition. You should consider carefully the following factors, in addition to the other information concerning the
Company and its business, before you decide to buy or hold shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Risk Relating to Our Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The Company has a limited operating history that makes
it difficult to reliably predict future growth and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical, the predecessor to our operating subsidiary,
was incorporated on October 18, 2006, and served initially as the management company for our affiliated medical group, AMH. Accordingly,
we have a limited operating history upon which you can evaluate our business prospects, which makes it difficult to forecast Apollo&rsquo;s
future operating results. The evolving nature of the current medical services industry increases these uncertainties. You must
consider the Company&rsquo;s business prospects in light of the risks, uncertainties and problems frequently encountered by companies
with limited operating histories. Our ability to predict growth at any time in the future may be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The Company has an unproven business model with no assurance
of significant revenues or operating profit.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The current business model is unproven and the profit potential,
if any, is unknown at this time. The Company is subject to all of the risks inherent in the creation of a relatively new business.
Our ability to achieve profitability is dependent, among other things, on our marketing to generate sufficient operating cash
flow to fund future expansion. There can be no assurance that our results of operations or business strategy will achieve significant
revenue or profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The growth strategy of the Company may not prove viable
and expected growth and value may not be realized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business strategy is to rapidly grow by managing a network
of medical groups providing certain hospital-based services. Where permitted by local law, we may also acquire such medical groups.
Identifying quality acquisition candidates is a time-consuming and costly process. There can be no assurance that we will be successful
in identifying and establishing relationships with these and other candidates. If the Company is successful in identifying and
acquiring other businesses, there is no assurance that it will be able to manage the growth of such businesses effectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The success of the Company&rsquo;s growth strategy depends
on the successful identification, completion and integration of acquisitions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s future success will depend on the ability
to identify, complete, and integrate the acquired businesses with its existing operations. The growth strategy will result in
additional demands on our infrastructure, and will place further strain on limited management, administrative, operational, financial
and technical resources. Acquisitions involve numerous risks, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>the possibility that we will not able to identify suitable
                                                                      acquisition candidates or consummate acquisitions on acceptable
                                                                      terms, if at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>possible decreases in capital resources or dilution
                                                                      to existing stockholders;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>difficulties and expenses incurred in connection with
                                                                      an acquisition;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>the diversion of management&rsquo;s attention from other
                                                                      business concerns;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>the difficulties of managing an acquired business;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>the potential loss of key employees and customers of
                                                                      an acquired business; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>in the event that the operations of an acquired business
                                                                      do not meet expectations, we may be required to restructure
                                                                      the acquired entity or write-off the value of some or all
                                                                      of the assets of the acquisition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our future growth could be harmed if we lose the services
of certain key personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our success depends to a significant extent on the continued
contributions of our key management personnel, including our Chief Executive Officer, Warren Hosseinion, M.D., for the management
of our business and implementation of our business strategy. We have entered into employment agreements with Dr. Hosseinion as
well as our other named executive officers. The loss of Dr. Hosseinion or other key management personnel could have a material
adverse effect on our business, financial condition and results of operations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The healthcare industry is complex and intensely regulated
at the federal, state, and local levels and government authorities may determine that we have failed to comply with applicable
laws or regulations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a company involved in the provision of healthcare services,
we are subject to a myriad of federal, state, and local laws and regulations. There are significant costs involved in complying
with these laws and regulations. Moreover, if we are found to have violated any applicable laws or regulations, we could be subject
to civil and/or criminal damages, fines, sanctions, or penalties, including exclusion from participation in governmental healthcare
programs, such as Medicare and Medicaid. We may also be required to change our method of operations. These consequences could
be the result of current conduct or even conduct that occurred a number of years ago. We also could incur significant costs merely
if we become the subject of an additional investigation or legal proceeding alleging a violation of these laws and regulations.
We cannot predict whether a federal, state, or local government will determine that we are not operating in accordance with law,
or whether the laws will change in the future and impact our business. Any of these actions could have a material adverse effect
on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a non-exhaustive list
of some of the more significant healthcare laws and regulations that affect us:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">federal
                                                                                                            laws, including the
                                                                                                            federal False Claims
                                                                                                            Act, that provide
                                                                                                            for penalties against
                                                                                                            entities and individuals
                                                                                                            which knowingly or
                                                                                                            recklessly make claims
                                                                                                            to Medicare, Medicaid,
                                                                                                            and other governmental
                                                                                                            healthcare programs,
                                                                                                            as well as third-party
                                                                                                            payors, that contain
                                                                                                            or are based upon
                                                                                                            false or fraudulent
                                                                                                            information;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
                                                                                                            provision of the federal
                                                                                                            Social Security Act,
                                                                                                            commonly referred
                                                                                                            to as the &ldquo;anti-kickback&rdquo;
                                                                                                            statute, that prohibits
                                                                                                            the knowing and willful
                                                                                                            offering, payment,
                                                                                                            solicitation or receipt
                                                                                                            of any bribe, kickback,
                                                                                                            rebate or other remuneration,
                                                                                                            in cash or in kind,
                                                                                                            in return for the
                                                                                                            referral or recommendation
                                                                                                            of patients for items
                                                                                                            and services covered,
                                                                                                            in or in part, by
                                                                                                            federal healthcare
                                                                                                            programs such as Medicare
                                                                                                            and Medicaid;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
                                                                                                            provision of the Social
                                                                                                            Security Act, commonly
                                                                                                            referred to as the
                                                                                                            Stark Law or physician
                                                                                                            self-referral law,
                                                                                                            that (subject to limited
                                                                                                            exceptions) prohibits
                                                                                                            physicians from referring
                                                                                                            Medicare patients
                                                                                                            to an entity for the
                                                                                                            provision of certain
                                                                                                            &ldquo;designated
                                                                                                            health services&rdquo;
                                                                                                            if the physician or
                                                                                                            a member of such physician&rsquo;s
                                                                                                            immediate family has
                                                                                                            a direct or indirect
                                                                                                            financial relationship
                                                                                                            with the entity, and
                                                                                                            prohibits the entity
                                                                                                            from billing for services
                                                                                                            arising out of such
                                                                                                            prohibited referrals;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
                                                                                                            provision of the Social
                                                                                                            Security Act that
                                                                                                            provides for criminal
                                                                                                            penalties for healthcare
                                                                                                            providers who fail
                                                                                                            to disclose known
                                                                                                            overpayments;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
                                                                                                            provision of the Social
                                                                                                            Security Act that
                                                                                                            provides for civil
                                                                                                            monetary penalties
                                                                                                            for healthcare providers
                                                                                                            who fail to repay
                                                                                                            known overpayments
                                                                                                            within 60 days of
                                                                                                            discovery, and also
                                                                                                            allows improper retention
                                                                                                            of known overpayments
                                                                                                            to serve as a basis
                                                                                                            for false claims act
                                                                                                            violations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">state
                                                                                                            law provisions pertaining
                                                                                                            to anti-kickback,
                                                                                                            self-referral and
                                                                                                            false claims issues,
                                                                                                            which typically are
                                                                                                            not limited to relationships
                                                                                                            involving governmental
                                                                                                            payors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">provisions
                                                                                                            of, and regulations
                                                                                                            relating to, HIPAA
                                                                                                            that provide penalties
                                                                                                            for knowingly and
                                                                                                            willfully executing
                                                                                                            a scheme or artifice
                                                                                                            to defraud a healthcare
                                                                                                            benefit program or
                                                                                                            falsifying, concealing
                                                                                                            or covering up a material
                                                                                                            fact or making any
                                                                                                            material false, fictitious
                                                                                                            or fraudulent statement
                                                                                                            in connection with
                                                                                                            the delivery of or
                                                                                                            payment for healthcare
                                                                                                            benefits, items or
                                                                                                            services;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">provisions
                                                                                                            of HIPAA and HITECH
                                                                                                            limiting how covered
                                                                                                            entities and business
                                                                                                            associates may use
                                                                                                            and disclose PHI and
                                                                                                            the security measures
                                                                                                            that must be taken
                                                                                                            in connection with
                                                                                                            protecting that information
                                                                                                            and related systems,
                                                                                                            as well as similar
                                                                                                            or more stringent
                                                                                                            state laws;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">federal
                                                                                                            and state laws that
                                                                                                            provide penalties
                                                                                                            for providers for
                                                                                                            billing and receiving
                                                                                                            payment from a governmental
                                                                                                            healthcare program
                                                                                                            for services unless
                                                                                                            the services are medically
                                                                                                            necessary and reasonable,
                                                                                                            adequately and accurately
                                                                                                            documented, and billed
                                                                                                            using codes that accurately
                                                                                                            reflect the type and
                                                                                                            level of services
                                                                                                            rendered; federal
                                                                                                            laws that provide
                                                                                                            for administrative
                                                                                                            sanctions, including
                                                                                                            civil monetary penalties
                                                                                                            for, among other violations,
                                                                                                            inappropriate billing
                                                                                                            of services to federal
                                                                                                            healthcare programs,
                                                                                                            payments by hospitals
                                                                                                            to physicians for
                                                                                                            reducing or limiting
                                                                                                            services to Medicare
                                                                                                            or Medicaid patients
                                                                                                            , or employing or
                                                                                                            contracting with individuals
                                                                                                            or entities who/which
                                                                                                            are excluded from
                                                                                                            participation in federal
                                                                                                            healthcare programs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">federal
                                                                                                            and state laws and
                                                                                                            policies that require
                                                                                                            healthcare providers
                                                                                                            to enroll in the Medicare
                                                                                                            and Medicaid programs
                                                                                                            before submitting
                                                                                                            any claims for services,
                                                                                                            to promptly report
                                                                                                            certain changes in
                                                                                                            their operations to
                                                                                                            the agencies that
                                                                                                            administer these programs,
                                                                                                            and to re-enroll in
                                                                                                            these programs when
                                                                                                            changes in direct
                                                                                                            or indirect ownership
                                                                                                            occur or in response
                                                                                                            to revalidation requests
                                                                                                            from Medicare and
                                                                                                            Medicaid;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">state
                                                                                                            laws that prohibit
                                                                                                            general business entities
                                                                                                            from practicing medicine,
                                                                                                            controlling physicians&rsquo;
                                                                                                            medical decisions
                                                                                                            or engaging in certain
                                                                                                            practices, such as
                                                                                                            splitting fees with
                                                                                                            physicians;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">laws
                                                                                                            that prohibit non-domiciled
                                                                                                            entities from owning
                                                                                                            and operating medical
                                                                                                            practices in their
                                                                                                            states;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">provisions
                                                                                                            of the Social Security
                                                                                                            Act (emanating from
                                                                                                            the Deficit Reduction
                                                                                                            Act of 2005) that
                                                                                                            require entities that
                                                                                                            make or receive annual
                                                                                                            Medicaid payments
                                                                                                            of $5 million or more
                                                                                                            from a single Medicaid
                                                                                                            program to provide
                                                                                                            their employees, contractors
                                                                                                            and agents with written
                                                                                                            policies and employee
                                                                                                            handbook materials
                                                                                                            on federal and state
                                                                                                            false claims acts
                                                                                                            and related statutes;
                                                                                                            that establish a new
                                                                                                            Medicaid Integrity
                                                                                                            Program designed to
                                                                                                            enhance federal and
                                                                                                            state efforts to detect
                                                                                                            Medicaid fraud, waste,
                                                                                                            and abuse; and that
                                                                                                            increase financial
                                                                                                            incentives for both
                                                                                                            states and individuals
                                                                                                            to bring fraud and
                                                                                                            abuse claims against
                                                                                                            healthcare companies;
                                                                                                            and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">federal
                                                                                                            and state laws and
                                                                                                            regulations restricting
                                                                                                            the techniques that
                                                                                                            may be used to collect
                                                                                                            past due accounts
                                                                                                            from consumers, such
                                                                                                            as our patients, for
                                                                                                            services provided
                                                                                                            to the consumer.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Providers in the healthcare industry are the subject
of federal and state investigations, as well as payer audits. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to our participation in government and private healthcare
programs, we are sometimes involved in inquiries, reviews, audits and investigations by governmental agencies and private payors
of our business practices, including assessments of our compliance with coding, billing and documentation requirements. Federal
and state government agencies have active civil and criminal enforcement efforts that include investigations of healthcare companies,
and their executives and managers. Under certain circumstances, these investigations can also be initiated by private individuals
under whistleblower provisions which may be incentivized by the possibility for private recoveries. The Deficit Reduction Act
of 2005 revised federal law to further encourage these federal, state and individually-initiated investigations against healthcare
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Responding to these audit and enforcement activities can be
costly and disruptive to our business operations, even when the allegations are without merit. If we are subject to an audit or
investigation and a finding is made that we were incorrectly reimbursed, we may be required to repay these agencies or private
payors, or we may be subjected to pre-payment reviews, which can be time-consuming and result in non-payment or delayed payment
for the services we provide. We also may be subject to other financial sanctions or be required to modify our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Economic conditions or changing consumer preferences
could adversely impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A downturn in economic conditions in one or more of the Company&rsquo;s
markets could have a material adverse effect on its results of operations, financial condition, business and prospects. Although
we attempt to stay informed of customer preferences, any sustained failure to identify and respond to trends could have a material
adverse effect on our results of operations, financial condition, business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be unable to scale our operations successfully.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our growth strategy will place significant demands on our management
and financial, administrative and other resources. Operating results will depend substantially on the ability of our officers
and key employees to manage changing business conditions and to implement and improve our financial, administrative and other
resources. If the Company is unable to respond to and manage changing business conditions, or the scale of its operations, then
the quality of its services, its ability to retain key personnel, and its business could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The Company&rsquo;s success depends upon the ability
to adapt to a changing market and continued development of additional services.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we expect to provide a broad and competitive
range of services, there can be no assurance of acceptance by the marketplace. The procurement of new contracts&nbsp;by the
Company may be dependent upon the continuing results achieved at the current facilities, upon pricing and operational
considerations, as well as the potential need for continuing improvement to existing services. Moreover, the markets for such
services may not develop as expected nor can there be any assurance that we will be successful in its marketing of any such
services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes associated with reimbursement by third-party
payers for the Company&rsquo;s services may adversely affect operating results and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The medical services industry is undergoing significant changes
with third-party payers that are taking measures to reduce reimbursement rates or in some cases, denying reimbursement altogether.
There is no assurance that third-party payers will continue to pay for the services provided by our affiliated medical groups.
Failure of third party payers to adequately cover the medical services so provided by the Company will have a material adverse
affect on our results of operations, financial condition, business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: windowtext"><B><I>Changes in the rates
or methods of third-party reimbursements may adversely affect our operations. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We derive the majority of our revenue from direct billings
to governmental healthcare programs, such as Medicare and Medicaid, and private health insurance companies. As a result, any negative
changes in the rates or methods of reimbursement for the services we provide would have a significant adverse impact on our revenue
and financial results. Government funding for healthcare programs, in particular, is subject to unpredictable statutory and regulatory
changes, administrative rulings, interpretations of policy and determinations by intermediaries, and governmental funding restrictions,
all of which could materially impact program coverage and reimbursements for our services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Medicare program reimburses for our services based upon
the rates set forth in the Medicare Physician Fee Schedule, which relies, in part, on a target-setting formula system called the
Sustainable Growth Rate ("SGR"). Each year on January&nbsp;1st, the Medicare program updates the Physician Fee Schedule
reimbursement rates. Many private payors use the Medicare Physician Fee Schedule to determine their own reimbursement rates. Based
on the SGR, the annual fee schedule update is adjusted to reflect the comparison of actual expenditures to target expenditures.
Because one of the factors for calculating the SGR is linked to the growth in the U.S. gross domestic product ("GDP"),
the SGR formula may result in a negative payment update if growth in Medicare beneficiaries&rsquo; use of services exceeds GDP
growth, a situation which has occurred every year since 2002 and the reoccurrence of which we cannot predict.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Center for Medicare &amp; Medicaid Services ("CMS")
has determined that, effective January&nbsp;1, 2012, the SGR formula results in a payment cut of approximately 27 percent. Congress,
however, enacted the Temporary Payroll Tax Cut Continuation Act of 2011, which blocks this cut through the end of February 2012.
In February 2012, Congress passed the Middle Class Tax Relief and Job Creation Act of 2012, which blocks the cut through the end
of 2012. While Congress has repeatedly intervened to mitigate the negative reimbursement impact associated with the SGR formula,
there is no guarantee that Congress will continue to do so in the future. Moreover, the existing methodology may result in significant
yearly fluctuations in the Physician Fee Schedule amounts, which may be unrelated to changes in the actual costs of providing
physician services. Unless Congress enacts a change in the SGR methodology, the uncertainty regarding reimbursement rates and
fluctuation will continue to exist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Another provision that affects physician payments is an adjustment
under the Medicare statute to reflect the geographic variation in the cost of delivering physician services, by comparing those
costs to the national average. This concerns the &ldquo;work&rdquo; component of the Geographic Practice Cost Indices (GPCI).
If Congress does not block this adjustment, payments would be decreased to any geographic area with an index of less than 1.0.
The Medicare and Medicaid Extenders Act of 2010 blocked cuts by providing a &ldquo;floor&rdquo; of 1.0 through the end of 2011,
and this protection was extended through the end of February 2012 by the Temporary Payroll Tax Cut Continuation Act of 2011. Congress
has convened a House / Senate conference committee whose duties include consideration of whether to block the adjustment for an
additional period. Providing an additional period is controversial because of disagreement on how to offset the costs so that
blocking the adjustment is deficit neutral. Although Congress has extended the work GPCI floor several times, there is no guarantee
that Congress will block the adjustment in the future, which could result in a decrease in payments we receive for physician services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Congress has a strong interest in reducing the federal debt,
which may lead to new proposals designed to achieve savings by altering payment policies. The Budget Control Act of 2011 (BCA)
established a Joint Select Committee on Deficit Reduction, which had the goal of achieving a reduction in the federal debt level
of at least $1.2 trillion. That Committee did not draft a proposal by the BCA&rsquo;s deadline, with the result that automatic
cuts in various federal programs will take place, beginning in January 2013. Although the Medicare program is generally exempt
from these cuts, Medicare payments to providers are not exempt. The BCA does, however, provide that the Medicare cuts to providers
may not exceed two percent. At this time it is unclear how this automatic reduction may be applied to various Medicare healthcare
programs, including physician reimbursement.&nbsp;Therefore it is not possible at this time to estimate what impact, if any, the
BCA will have on our business or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As noted, the cuts described above will occur automatically
as a matter of law. Many in Congress, however, want to achieve even greater reductions in the federal debt, and they want to change
entitlement programs, such as Medicare. It is difficult to assess whether and to what extent Congress will alter Medicare payment
policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Because governmental healthcare programs generally reimburse
on a fee schedule basis rather than on a charge-related basis, we generally cannot increase our revenues from these programs by
increasing the amount we charge for our services. If our costs increase, we may not be able to recover our increased costs from
these programs. Government and private payors have taken and may continue to take steps to control the cost, eligibility for,
use and delivery of healthcare services as a result of budgetary constraints, cost containment pressures and other reasons. We
believe that these trends in cost containment will continue. These cost containment measures and other market changes in non-governmental
insurance plans have generally restricted our ability to recover, or shift to non-governmental payors, any increased costs that
we experience. Our business and financial operations may be materially affected by these developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be impacted by eligibility changes to government
and private insurance programs. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to potential decreased availability of healthcare through
private employers, the number of patients who are uninsured or participate in governmental programs may increase. A shift in payor
mix from managed care and other private payors to government payors or the uninsured may result in a reduction in our rates of
reimbursement or an increase in our uncollectible receivables or uncompensated care, with a corresponding decrease in our net
revenue. Changes in the eligibility requirements for governmental programs also could increase the number of patients who participate
in such programs or the number of uninsured patients. Even for those patients who remain with private insurance, changes in those
programs could increase patient responsibility amounts, resulting in a greater risk for us of uncollectible receivables. These
factors and events could have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may have difficulty collecting payments from third-party
payors in a timely manner. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We derive significant revenue from third-party payors, and
delays in payment or audits leading to refunds to payors may impact our net revenue. We assume the financial risks relating to
uncollectible and delayed payments. In the current healthcare environment, payors are continuing their efforts to control expenditures
for healthcare, including proposals to revise coverage and reimbursement policies. We may experience difficulties in collecting
our revenue because third-party payors may seek to reduce or delay payment to which we believe we are entitled. If we are not
paid fully and in a timely manner for such services or there is a finding that we were incorrectly paid, our revenues, cash flows,
and financial condition could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to effectively adapt to changes in the
healthcare industry, our business may be harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to the importance of the healthcare industry in the lives
of all Americans, federal, state, and local legislative bodies frequently pass legislation and promulgate regulations relating
to healthcare reform. It is reasonable to believe that there may be increased federal oversight and regulation of the healthcare
industry in the future. We cannot assure you as to the ultimate content, timing or effect of any healthcare reform legislation,
nor is it possible at this time to estimate the impact of potential legislation on our business. It is possible that future legislation
enacted by Congress or state legislatures could adversely affect our business or could change the operating environment of our
targeted customers. It is possible that the changes to the Medicare or other governmental healthcare program reimbursements may
serve as precedent to possible changes in other payors&rsquo; reimbursement policies in a manner adverse to us. Similarly, changes
in private payor reimbursements could lead to adverse changes in Medicare and other governmental healthcare programs which could
have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Compliance with changing regulation of corporate governance
and public disclosure, once the Company is subject to such requirements, will result in significant additional expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changing laws, regulations, and standards relating to corporate
governance and public disclosure for public companies, including the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform
and Consumer Protection Act,&nbsp;and various rules and regulations adopted by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;),
are creating uncertainty for public companies. The Company's management will continue to invest significant time and financial
resources to comply with both existing and evolving requirements for public companies, which will lead, among other things, to
significantly increased general and administrative expenses and a certain diversion of management time and attention from revenue
generating activities to compliance activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to remain current in our SEC reporting obligations,
we could be removed from the OTCQB, which would adversely affect the market liquidity for our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies trading on the OTCQB, such as us, must be reporting
issuers under Section 12 of the Securities Exchange Act of 1934, as amended, and must be current in their reports under Section
13, in order to maintain price quotation privileges on the OTCQB. If we fail to remain current in our reporting requirements,
we could be removed from the OTCQB. As a result, the market liquidity for our securities could be severely adversely affected
by limiting the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the
secondary market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our common stock is subject to the &ldquo;penny stock&rdquo;
rules of the SEC, and trading in our securities is very limited, which makes transactions in our common stock cumbersome and may
reduce the value of an investment in our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC has adopted Rule 3a51-1 of the Securities and Exchange
Act of 1934, as amended, which establishes the definition of a "penny stock," for the purposes relevant to us, as any
equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject
to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15g-9 requires:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>that a broker or dealer approve a person's account for
                                                                      transactions in penny stocks; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>the broker or dealer receives from the investor a written
                                                                      agreement to the transaction, setting forth the identity
                                                                      and quantity of the penny stock to be purchased.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to approve a person's account for transactions in
penny stocks, the broker or dealer must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>obtain financial information and investment experience
                                                                      objectives of the person; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>make a reasonable determination that the transactions
                                                                      in penny stocks are suitable for that person and the person
                                                                      has sufficient knowledge and experience in financial matters
                                                                      to be capable of evaluating the risks of transactions in
                                                                      penny stocks.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The broker or dealer must also deliver, prior to any transaction
in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>sets forth the basis on which the broker or dealer made
                                                                      the suitability determination; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD>that the broker or dealer received a signed, written
                                                                      agreement from the investor prior to the transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disclosure also has to be made about the risks of investing
in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer
and the registered representative, current quotations for the securities and the rights and remedies available to an investor
in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information
for the penny stock held in the account and information on the limited market in penny stocks. Generally, brokers may be less
willing to execute transactions in securities subject to the &ldquo;penny stock&rdquo; rules. This may make it more difficult
for investors to dispose of our common stock and cause a decline in the market value of our stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Trading on the OTCQB may be volatile and sporadic, which
could depress the market price of our common stock and make it difficult for our stockholders to resell their shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on the OTCQB. Trading in stock quoted
on the OTCQB is often thin and characterized by wide fluctuations in trading prices due to many factors that may have little to
do with our operations or business prospects. This volatility could depress the market price of our common stock for reasons unrelated
to operating performance. Moreover, the OTCQB is not a stock exchange, and trading of securities on the OTCQB is often more sporadic
than the trading of securities listed on a&nbsp;stock exchange&nbsp;like NASDAQ or a&nbsp;New York&nbsp;Stock Exchange. Accordingly,
our shareholders may have difficulty reselling any of their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We might need to raise additional capital, which might
not be available. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may require additional equity or debt financing for additional
working capital for expansion, to consummate acquisitions or if we suffer significant losses. In the event of additional financing
is unavailable to us, we may be unable to expand or make acquisitions and the price of our common stock may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may write off intangible assets, such as goodwill.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our intangible assets, which consist primarily of goodwill
related to our acquisitions, are subject to annual impairment testing. Under current accounting standards, goodwill is tested
for impairment on an annual basis and we may be subject to impairment losses as circumstances change after an acquisition. If
we record an impairment loss related to our goodwill, it could have a material adverse effect on our results of operations for
the year in which the impairment is recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 1B. UNRESOLVED STAFF COMMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 2. DESCRIPTION OF PROPERTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s corporate headquarters is located at 700
North Brand Boulevard, Suite 450, Glendale, California. The lease on our present corporate headquarters expires on December 31,
2013. We believe our present facilities are adequate to meet our current and projected needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM&nbsp;3. LEGAL&nbsp;PROCEEDINGS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the ordinary course of our business, we become involved
in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical
services provided by our affiliated hospitalists. We may also become subject to other lawsuits which could involve significant
claims and/or significant defense costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe, based upon our review of pending actions and proceedings,
that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition,
results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty
and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition,
results of operations, or cash flows in a future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM&nbsp;4. MINE SAFETY DISCLOSURE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.6in"><B>ITEM&nbsp;5.</B></TD><TD><B>MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER
                                                                           MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is traded on the OTCQB under the symbol "AMEH".
Following is a table presenting the closing sale prices for a share of our common stock by fiscal quarter for the fiscal years
2012 and 2011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Fiscal Year ended January 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt; width: 74%">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.26</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.16</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Fiscal Year ended January 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt; width: 74%">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.07</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of April 30, 2012, as reported by the Company&rsquo;s stock
transfer agent, there were 325 holders of record of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date we have not paid any cash dividends on our common stock
and we do not contemplate the payment of cash dividends in the foreseeable future. Our future dividend policy will depend on our
earnings, capital requirements, financial condition, and other factors considered relevant to our ability to pay dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Securities Authorized for Issuance Under Equity Compensation
Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the twelve months ended January 31, 2012, the Company did
not grant any stock options to management, employees or consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 4, 2010, the Board of Directors of Apollo Medical
Holdings, Inc. and three members of our Board that own, in the aggregate, approximately 70% of the outstanding shares of our common
stock, approved the adoption of the Apollo Medical Holdings Inc., 2010 Equity Incentive Plan (the &ldquo;Plan&rdquo;). Subject
to the adjustment provisions of the Plan that are applicable in the event of a stock dividend, stock split, reverse stock split
or similar transaction, up to 5,000,000 shares of common stock may be issued under the Plan. As of January 31, 2012, 883,332
shares had vested under the Plan and 266,668 remained unvested. See "Item 12" for more information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have issued and sold securities of
the Company as disclosed below within the last three years. Unless otherwise noted, the following sales of securities were effected
in reliance on the exemption from registration contained in Section&nbsp;4(2) of the Act and Regulation&nbsp;D promulgated there
under, and such securities may not be reoffered or sold in the United States by the holders in the absence of an effective registration
statement, or valid exemption from the registration requirements, under the Securities Act of 1933 (as amended, the &ldquo; Act
&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the fiscal year ended January 31, 2012, the Company
issued 350,000 restricted shares to Kaneohe Advisors LLC (Kyle Francis) pursuant to a consulting contract dated October 22, 2008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM&nbsp;6. SELECTED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM&nbsp;7. MANAGEMENTS&rsquo; DISCUSSION AND ANALYSIS
OR PLAN OF OPERATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE FOLLOWING DISCUSSION OF OUR FINANCIAL
CONDITION AND RESULTS OF OPERATIONS SHOULD BE READ IN CONJUNCTION WITH OUR CONSOLIDATED FINANCIAL STATEMENTS AND THE NOTES TO
THOSE STATEMENTS INCLUDED ELSEWHERE IN THIS REPORT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CRITICAL ACCOUNTING POLICIES AND ESTIMATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our consolidated financial statements have been prepared in
accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements
requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses.
Note 1 of Notes to Consolidated Financial Statements describes the significant accounting policies used in the preparation of
the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting
policies, as defined below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A critical accounting policy is defined as one that is both
material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments
that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates
have the following attributes: (i) we are required to make assumptions about matters that are uncertain at the time of the estimate;
and (ii) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would
have a material effect on our financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimates and assumptions about future events and their effects
cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed
to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information
is obtained and as our operating environment changes. These changes have historically been minor and have been included in the
consolidated financial statements as soon as they became known. Based on a critical assessment of our accounting policies and
the underlying judgments and uncertainties affecting the application of those policies, management believes that our consolidated
financial statements are fairly stated in accordance with accounting principles generally accepted in the United States, and meaningfully
present our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe the following critical accounting policies reflect
our more significant estimates and assumptions used in the preparation of our consolidated financial statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Revenue Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue consists of contracted and fee-for-service revenue.
Revenue is recorded in the period in which services are rendered. Our revenue is principally derived from the provision of healthcare
staffing services to patients within healthcare facilities. The form of billing and related risk of collection for such services
may vary by customer. The following is a summary of the principal forms of our billing arrangements and how net revenue is recognized
for each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contracted revenue represents revenue generated
under contracts in which we provide physician and other healthcare staffing and administrative services in return for
a contractually negotiated fee. Contracted revenue represented 80.7% of our revenues in the twelve months ended January
31, 2012. Contract revenue consists primarily of billings on a per admission or based on hours of healthcare staffing
provided at agreed-to hourly rates. Hourly revenue is recognized as the hours are worked by our staff and contractors.
Additionally, contracted revenue also includes supplemental revenue from hospitals where we may have a fee-for-service
contract arrangement or provide physician advisory services to the medical staff at specific facility. Contract revenue for
the supplemental billing in such cases is recognized based on the terms of each individual contract. Such contract terms
generally either provides for a fixed monthly dollar amount or a variable amount based upon measurable monthly activity, such
as hours staffed, patient visits or collections per visit compared to a minimum activity threshold. Such supplemental
revenues based on variable arrangements are usually contractually fixed on a monthly, quarterly or annual calculation basis
considering the variable factors negotiated in each such arrangement. Such supplemental revenues are recognized as revenue in
the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer
under the terms of the respective agreement. Additionally, we derive a portion of our revenue as a contractual bonus from
collections received by our partners and such revenue is contingent upon the collection of third-party billings. These
revenues are not considered earned and therefore not recognized as revenue until actual cash collections are achieved in
accordance with the contractual arrangements for such services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fee-for-service revenue represents revenue earned under contracts
in which we bill and collect the professional component of charges for medical services rendered by our contracted and employed
physicians. Under the fee-for-service arrangements, we bill patients for services provided and receive payment from patients or
their third-party payers. Fee-for-service revenue is reported net of contractual allowances and policy discounts. All services
provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fee-for-service revenue is recognized in the period in which
the services are rendered to specific patients and reduced immediately for the estimated impact of contractual allowances in the
case of those patients having third-party payer coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The recognition of net revenue (gross charges less contractual
allowances) from such visits is dependent on such factors as proper completion of medical charts following a patient visit, the
forwarding of such charts to our billing center for medical coding and entering into our billing system and the verification of
each patient&rsquo;s submission or representation at the time services are rendered as to the payer(s) responsible for payment
of such services. Revenue is recorded based on the information known at the time of entering of such information into our billing
systems as well as an estimate of the revenue associated with medical services provided.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Direct Costs of Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Direct Costs include the direct salaries and contract payments
to physicians employed by the Company that serve as hospitalists, all employment related taxes, medical and disability insurance
costs, premiums for malpractice insurance provided to these physicians, and costs associated with establishing physician privileges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Management Fees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our affiliated medical groups are responsible for the provision
of medical care to patients. For financial reporting purposes, we consolidate the revenues and expenses of all our practice groups
that we own or manage because we have a controlling financial interest in these practices based on applicable accounting rules
as described in our accompanying consolidated financial statements. We provide all of the non-medical, administrative and management
services necessary for the operations of each of our affiliated medical groups under comprehensive long-term management agreements.
Under the terms of these agreements, we are paid for the provision of these non-medical management services based upon either the
financial performance of the applicable practice group or a fixed fee. Each agreement is for a term of 20 years with 10 year automatic
renewal periods.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FISCAL YEAR ENDED JANUARY 31, 2012 COMPARED TO FISCAL YEAR
ENDED JANUARY 31, 2011</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net revenue increased to $5,110,806 or 31.2% for the twelve
months ended January 31, 2012, compared to revenues of $3,896,584 for the comparable twelve months ended January 31, 2011. The
increase was directly attributable to an increase in new contracts during the year and the acquisition of PCCM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of services totaled $4,132,399 for the twelve months
ended January 31, 2012, compared to $3,314,722 for the corresponding twelve months ended January 31, 2011. Cost of services
were 80.9% of net revenues for the twelve months ended January 31, 2012, down from 85.1% of revenues for the comparable
twelve month period ended January 31, 2011. Cost of services includes the payroll and consulting costs of the physicians, all
payroll related costs, costs for all medical malpractice insurance and physician privileges. The reduction in the cost of
services as percentage of revenue is primarily due to new hospital contracts for 2011, increased volume at existing hospitals
and leveraging of fixed costs. Total physician compensation increased to $3,814,698 or 74.6% of revenues for the twelve
months ended January 31, 2012, up 26.7% compared to $3,010,716 or 77.3% of revenues for the twelve month period ended January
31, 2011. The increases in physician costs are directly related to new contracts started in the period, offset by increased
revenue per physician.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses increased $812,504, or
143.4%, to $1,379,153 or 27% of net revenue, for the twelve months ended January 31, 2012, as compared to $566,649,of 15% of net
revenue, for the twelve months ended January 31, 2011. For the twelve months ended January 31, 2012, bad debt expense was $118,077
compared to a reversal of $76,231 for the twelve month period ended January 31, 2011. The increase in bad debt expense was due
to a write off of historical accounts receivable amounts deemed uncollectible at January 31, 2012, compared to the reversal of
a previous recorded provision for doubtful accounts at January 31, 2011. The Company recorded stock compensation expense of $181,733
for the twelve months ended January 31, 2012, compared with $119,530 in the year ended January 31, 2011. The Company incurred
expenses of $189,610 associated with Aligned Healthcare transaction which closed on February 15, 2011. The Company recognized
an impairment loss of $210,000 relating to our investment in Aligned Healthcare Group Inc. based upon the completion of the Company&rsquo;s
annual goodwill impairment test. The cause of the impairment was due to contracts not materializing as anticipated at the
time of closing the Acquisition and management has decided to focus its energies on new higher growth initiatives. Additionally
the Company incurred higher legal, salary and consulting expenses and overhead costs related to the continuing growth of our
operations in the 12 months ended January 31, 2012 as compared to 12 months ended January 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation and amortization expense was $12,589 and $11,198
for the twelve months ended January 31, 2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company reported a loss from operations of $413,335 for
the twelve months ended January 31, 2012, compared to income from operations of $4,015 in the fiscal year ended January 31, 2011.
The decrease in income from operations was primarily due to write off of accounts receivable, expenses associated with the acquisition
of Aligned Healthcare Group, higher legal costs associated with acquisitions and new growth opportunities and consulting expenses
during the year ended January 31, 2012 as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest expense and financing costs were $304,034 for the
twelve months ended January 31, 2012, compared to interest and financing expenses of $163,931 for the twelve months ended January&nbsp;31,
2011. Interest expense in 2012 included $131,534 of interest expense related to our 10% Senior Subordinated Callable Convertible
Notes. Financing fees included the amortization of pre-paid commissions of $37,500 that were paid to the placement agent and a
charge of $120,000 related to an exercise price adjustment pertaining to the warrants that were issued in connection with our
10% Senior Subordinated Callable Convertible Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company reported a net loss of $720,346 for the twelve
months ended January&nbsp;31, 2012, compared to a net loss of $156,331 reported for the twelve months ended January 31, 2011.
The increase in net loss was primarily due to an impairment loss of $210,000 recognized relating to the our investment in
Aligned Healthcare Group, Inc., a $120,000 charge related to the increase in the Company&rsquo;s warrant liability and a
write off of accounts receivable, expenses associated with the acquisition of Aligned Healthcare Group, higher legal
costs associated with acquisitions and new growth opportunities and consulting expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At January 31, 2012, the Company had cash and cash
equivalents of $164,361, compared to cash and cash equivalents of $397,101 at the beginning of the fiscal year at January 31,
2011. The cash balance at January 31, 2012 included $27,407 in a money market brokerage account. Total borrowings were
$1,399,392 as of January 31, 2012, compared to total borrowings of $1,248,588 on January 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash used in operating activities for the
twelve months ended January 31, 2012 was $385,455 and included a net loss of $720,346 for the twelve month period.
Adjustments for non-cash charges which include depreciation, bad debt expense, the value of shares issued for services,
option expense, amortization of warrant discount and impairment loss on our investment in Aligned Healthcare Group, Inc.,
totaled $643,203. In addition, net changes in operating assets and liabilities, primarily due to an increase in outstanding
receivables, used cash of $308,311.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by investing activities totaled $157,005
for the twelve months ended January 31, 2012, compared to net cash used in operations of $21,165 in the comparable twelvemonths
ended January 31, 2011. The increase in net cash provided by operating activities was primarily due to cash received from the
consolidation of a variable interest entity ("VIE") during the year ended January 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the twelve months ended January 31, 2012, net cash used
in financing activities totaled $4,290, compared to $2,440 used in financing activities for the same period in 2011. During the
year ended January 31, 2012, the Company issued convertible notes payable in the amount of $150,000 and made distributions of
$154,290 to a non-controlling interest shareholder. During the year ended January 31, 2011, the Company did not issue any debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company's financial statements are prepared using the generally
accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of
liabilities in the normal course of business. However, the Company continues to incur operating losses and has an accumulated
deficit of $2,117,708 as of January 31, 2012. In addition, the Company has a total stockholders&rsquo; deficit of $421,220 and
generated a negative net cash flow operating activities for the twelve months ended January 31, 2012 of $385,455.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements do not include any adjustments relating
to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a
going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date the Company has funded its operations from both internally
generated cash flow and external sources, and the proceeds available from the private placement of convertible notes which have
provided funds for near-term operations and growth. The Company will pursue additional external capitalization opportunities,
as necessary, to fund its long-term goals and objectives. We may seek to raise additional capital through public or private equity
financings, partnerships, joint ventures, disposition of assets, debt financings, bank borrowings or other sources of financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No assurances can be made that management will be successful
in achieving its plan. If the Company is not able to raise substantial additional capital in a timely manner, the Company may
be forced to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company had no off-balance sheet arrangements during the
period ended January 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s financial statements for the fiscal year
ended January 31, 2012 are included in this annual report, beginning on page F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9A.</B> <B>CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the end of the period covered by this report, the Company
has carried out an evaluation under the supervision and with the participation of its management, including its Chief Executive
Officer and its Chief Financial Officer, of the effectiveness of the design and operation of its disclosure controls and procedures
as defined in Rules 13a-15(e) and 15d- 15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that, at January&nbsp;31, 2012, the Company&rsquo;s disclosure controls
and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) were not effective, at
a reasonable assurance level, in ensuring that information required to be disclosed in the reports the Company files and submits
under the Securities Exchange Act of 1934 are recorded, processed, summarized and reported as and when required. For a discussion
of the reasons on which this conclusion was based, see &ldquo;Management&rsquo;s Annual Report on Internal Control over Financial
Reporting&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Management&rsquo;s Report on Internal Control Over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our management is responsible for establishing and maintaining
adequate internal control over financial reporting, as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act. Management
must evaluate&nbsp;its internal controls over financial reporting, as required by Sarbanes-Oxley Act. The Company's&nbsp;internal
control&nbsp;over financial&nbsp;reporting is a process designed under the supervision of the Company's management to provide
reasonable&nbsp;assurance regarding the reliability of financial reporting and the preparation&nbsp;of the Company's financial
statements for external purposes in&nbsp;accordance&nbsp;with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;).
Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the criteria&nbsp;for
effective&nbsp;internal control over financial reporting established in Internal Control-Integrated Framework issued by the Committee
of&nbsp;Sponsoring Organizations&nbsp;of the Treadway Commission&nbsp;(&ldquo;COSO&rdquo;)&nbsp;and SEC guidance on conducting&nbsp;such&nbsp;assessments.
Based on this evaluation, our management concluded that there were material weaknesses in our internal control over financial
reporting as of January&nbsp;31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A material weakness is a significant control deficiency (within
the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of significant control
deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements
will not be prevented or detected. Management has identified the following three material weaknesses in our disclosure controls
and procedures, and internal controls over financial reporting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">1. We do not have written documentation
of our internal control policies and procedures.&nbsp; Written documentation of key internal controls over financial reporting
is a requirement of Section 404 of the Sarbanes-Oxley Act.&nbsp; Management evaluated the impact of our failure to have written
documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures, and concluded
that the control deficiency that resulted represented a material weakness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">2. We do not have sufficient segregation
of duties within accounting functions, which is a basic internal control.&nbsp; Due to our size and nature, segregation of all
conflicting duties may not always be possible and may not be economically feasible.&nbsp; However, to the extent possible, the
initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals.&nbsp;
Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and
procedures, and concluded that the control deficiency that resulted represented a material weakness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">3.We do not have review and supervision
procedures for financial reporting functions. The review and supervision function of internal control relates to the accuracy
of financial information reported. The failure to review and supervise could allow the reporting of inaccurate or incomplete financial
information. Due to our size and nature, review and supervision may not always be possible or economically feasible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the foregoing material weaknesses, we have determined
that, as of January 31, 2012, our internal controls over our financial reporting are not effective. The Company is taking remediating
steps to address each material weakness. We continue to add employees and consultants to address these issues and we will continue
to broaden the scope of our accounting and billing capabilities and realigning responsibilities in our financial and accounting
review functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It should be noted that any system of controls, however well
designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition,
the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of
these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions, regardless of how remote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Annual Report on Form 10-K does not include an attestation
report of our independent registered public accounting firm regarding internal control over financial reporting. Management&rsquo;s
report was not subject to attestation by our independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Internal Controls Over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There has been no change in our internal controls over financial
reporting during our most recently completed fiscal quarter (i.e., the three-month period ended January&nbsp;31, 2012) that has
materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9B.</B> <B>OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 10.</B> &nbsp;&nbsp; <B>DIRECTORS, EXECUTIVE OFFICERS
AND CORPORATE GOVERNANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-right: 0.8pt; font-weight: bold; text-align: left"><B>Name</B></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>Age</B></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 48%; padding-right: 0.8pt; font-weight: bold; text-align: left"><B>Title</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Warren&nbsp;Hosseinion,&nbsp;M.D.</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">39</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Chief&nbsp;Executive&nbsp;Officer,&nbsp;Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Kyle Francis</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">38</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Executive Vice President and Chief&nbsp;Financial&nbsp;Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Ted Schreck</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">66</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Chairman, Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Suresh&nbsp;Nihalani</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">58</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Gary Augusta</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">45</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warren Hosseinion, M.D.</B> Dr. Hosseinion has been a director,
and our Company&rsquo;s Chief Executive Officer since July 2008. In 2001, Dr. Hosseinion founded ApolloMed Hospitalists in Los
Angeles with Dr. Vazquez. Dr. Hosseinion received his medical degree from Georgetown University and is a Diplomat of the American
Board of Internal Medicine. Dr. Hosseinion's qualifications to serve on our Board of Directors include his position as our chief
executive officer since the inception of the Company, his background as founder of the Company and leading physician within the
medical community in Los Angeles. In addition, Dr. Hosseinion is currently a practicing hospitalist physician and brings to our
Board of Directors and our Company a depth of understanding of physician culture and strong knowledge of the healthcare market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Kyle Francis.</B> Mr. Francis was appointed as Chief Financial
Officer, effective December 31, 2010. Prior to being appointed Chief Financial Officer, Mr. Francis served as the Executive Vice
President of Business Development and Strategy. Mr. Francis will continue to serve in that function as well as Chief Financial
Officer. Prior to joining ApolloMed, he was a member of the Healthcare Services Investment Banking Division of Oppenheimer &amp;
Co. and CIBC World Markets. Prior to joining CIBC World Markets, Mr. Francis worked at Enron Corporation. Mr. Francis holds a
Bachelor of Commerce with a major in finance and accounting degree from McGill University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ted Schreck.</B> Mr. Schreck is a senior healthcare executive
with over 37 years of ealthcare experience in both the public and private sector . In 1998, he joined Tenet Healthcare Corporation
and served in a number of senior executive roles including, CEO of USC University Hospital and USC/Norris Cancer Hospital, Regional
Vice President of Operations, charged with leading a group of ten Los Angeles-area hospitals and finally Senior Vice President
of Operations. Prior to joining Tenet, Mr. Schreck worked for the St. Joseph Health System, serving as CEO of Santa Rosa General
Hospital and Senior Vice President of Santa Rosa Memorial Hospital, and for Sutter Health System as CEO of Delta Memorial Hospital.
He also served as CEO of the Eden Township District Hospitals. Mr. Schreck retired in 2006 but returned to work as a consultant
for Portland-based Legacy Health System, which operates five hospitals, a research facility, a hospice agency, and specialty and
primary care clinics. Most recently, he served on the board of Los Angeles Orthopedic Hospital, a member of the UCLA Health System.
Mr. Schreck brings to our Company a significant amount of healthcare experience and will be tremendous resource to our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Suresh Nihalani.</B> As a Business consultant and advisor,
Mr. Nihalani is currently involved with many early stage ventures in the area of Cloud Computing, Data Centers, Next Generation
Storage and 4G Backhaul wireless radios, consulting them in technology direction, business development and strategic business
planning.Mr. Nihalani was President and CEO of ClearMesh Network from 2005 to 2007. He also co-founded Nevis Networks, where he
served as CEO from 2002 through 2005. Prior to Nevis Networks, he co-founded Accelerated Networks and ACT Networks. Mr. Nihalani
holds a BS in Electrical Engineering from ITT Bombay and MSEE and MBA degrees from the Florida Institute of Technology. Mr. Nihalani
has over 35 years of corporate experience working as a senior executive and director. Mr. Nihalani&rsquo;s qualifications to serve
on our Board of Directors includes his many years of experience as a senior corporate executive with both public and private organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mr. Augusta</B> brings more than 20 years of experience
as an executive focused on private equity, growth strategy and operations, corporate development and M&amp;A. He is also an experienced
investor and operator of growth businesses. Mr. Augusta currently serves as President of SpaGus Ventures LLC and SpaGus Capital
Partners, growth funds that invest in life sciences and technology companies. Previously, Mr. Augusta was CEO of OCTANe, an innovation
development company, AT Kearney, a leading consulting firm, and Corporate Development/M&amp;A Officer at Fluor Inc., a Fortune
500 company. He earned a BS in Mechanical Engineering from the University of Rhode Island and a Master of Science and Management
(MSM) from Georgia Tech.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 16(a) Beneficial Ownership Reporting Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 16(a) of the Securities Exchange Act of 1934, as amended,
requires our directors and executive officers, and persons who beneficially own more than 10% of our outstanding common stock,
to file with the SEC, initial reports of ownership and reports of changes in ownership of our equity securities. Such persons
are required by SEC regulations to furnish us with copies of all such reports they file. To our knowledge, based solely on our
review of the copies of such forms received by us, or written representations from our officers, directors and greater than 10%
beneficial owners, we believe that our insiders complied with all applicable Section 16(a) filing requirements during fiscal year
ending January 31, 2012, except as follows: Warren Hosseinion, Kyle Francis, Ted Schreck, Gary Augusta, Suresh Nihalani have not
filed Forms 3 or Forms 4 to reflect their holdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has not yet adopted a code of ethics, in part because
we recently commenced business operations and have a limited number of employees. As the Company grows its business, and hires
additional employees, we expect to adopt a code of ethics applicable to the conduct of our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Committees of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Our common stock is currently
quoted on the OTCQB electronic trading platform, which does not maintain any standards requiring us to establish or maintain an
Audit, Nominating or Compensation committee. As of January 31, 2012, our Board of directors did not maintain an audit committee
established in accordance with Section 3(a)(58)(A) of the Exchange Act, a nominating committee, or a compensation committee. The
entire Board of Directors is acting as the Company's audit committee</FONT> <FONT STYLE="font-size: 10pt">as specified in section
3(a)(58)(B) of the Exchange Act, and the Board of Directors has determined that no current director is an &ldquo;audit committee
financial expert&rdquo; as defined by item 407 of Regulation S-K</FONT> due to the <FONT STYLE="font-size: 10pt">limited number
of directors currently on our board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 11.</B> <B>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table discloses the compensation awarded to,
earned by, or paid to our executive officers for the fiscal years ended January 31, 2011, 2010 and 2009, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Non- <BR>Qualified</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">Name&nbsp;and</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Stock</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Non-Equity</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Deferred</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Principal <BR>Position</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Salary</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Bonus</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>Awards</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><I>(1)</I></FONT></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Incentive&nbsp;Plan<BR>Compensation</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Compensation<BR>Earnings</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="width: 25%; text-align: left"><FONT STYLE="font-size: 8pt">Warren Hosseinion, M. D.</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">349,999</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">349,999</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="font-style: italic; text-align: left"><FONT STYLE="font-size: 8pt">Chief Executive Officer(2)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">385,013</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">12,619</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">397,632</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">353,285</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">353,285</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Adrian Vazquez, M.D. <I>(2)(3)</I></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">300,074</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">300,074</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">382,920</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">12,619</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">395,539</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">361,097</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">361,097</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Kyle Francis</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">142,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">63,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">205,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Chief Financial Officer<I>(4)</I></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">11,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">33,761</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">44,761</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) The amount shown in this column reflects the aggregate
grant date fair value computed in accordance with FASB ASC Topic 718.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) The reported compensation for Dr. Hosseinion and Dr. Vazquez
is a fixed annual amount and is generated from patient care activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) Adrian Vazquez, M.D., resigned his positions as Chairman
of the Board, President and a director of Apollo Medical Holdings, Inc., in each case effective December 9, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) Mr. Francis was appointed as Chief Financial Officer, effective
December 31, 2010. Prior to being appointed Chief Financial Officer, Mr. Francis served as the Executive Vice President of Business
Development and Strategy. Mr. Francis will continue to serve in that function as well as Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the outstanding equity awards
held by each of our named executive officers as of January 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2012 Outstanding Equity Awards at Fiscal
Year End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="12" STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">Option&nbsp;Awards</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: left; vertical-align: bottom">Name</TD>
    <TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Grant&nbsp;Date</TD>
    <TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number&nbsp;of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Underlying</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Unexercised</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Options</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercisable&nbsp;(#)</B></P></TD>
    <TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number&nbsp;of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Underlying</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Options</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Unexercisable</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(#)(1)</B></P></TD>
    <TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: windowtext 1pt solid; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercise&nbsp;Price</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>($)&nbsp;(2)</B></P></TD>
    <TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; text-align: center; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Expiration</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warren Hosseinion, M.D.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%">12/9/2010</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%">200,000</TD>
    <TD STYLE="text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%">100,000</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 10%">0.15</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%">12/8/2020</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Adrian Vazquez, M.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">12/9/2010</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">200,000</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">100,000</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">0.15</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">12/8/2020</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kyle W. D. Francis</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Chief Financial Officer</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">12/9/2010</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">100,000</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">50,000</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">0.15</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">12/8/2020</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) The shares underlying these options vest 33% immediately
on the grant date and in equal installments on the first and second anniversary.<BR>
(2) All options have been issued with an exercise price equal to the closing price of our common stock on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No options were exercised during the fiscal year ended January
31, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hospitalist Participation Service Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warren Hosseinion, M.D. In February 2009, the Company entered
into a Second Amended and Restated Hospitalist Participation Agreement with Dr. Hosseinion, pursuant to which he provides physician
services for ApolloMed Hospitalists. Effective February 2009, Dr.Hosseinion&rsquo;s annual base salary was set at $360,000 payable
in bimonthly installments. Dr. Hosseinion's salary is for physician services only and he does not receive any compensation to
serve as Chief Executive Officer or for his services as a Director. He is eligible to receive equity awards, in each case as determined
by the Board of Directors in accordance with the 2010 Equity Incentive Plan. The Company maintains Dr. Hosseinion&rsquo;s professional
liability insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adrian Vazquez, M.D. In February 2009, the Company entered
into a Second Amended and Restated Hospitalist Participation Agreement with Dr. Vazquez, pursuant to which he provides physician
services for ApolloMed Hospitalists. Effective February 2009, Dr.Vazquez&rsquo;s annual base salary was set at $360,000 payable
in bi-monthly installments. Dr. Vazquez's salary for physician services only and he does not receive any compensation to serve
as President or as Chairman of our Board of Directors. He is eligible to receive equity awards, in each case as determined by
the Board of Directors in accordance with the 2010 Equity Incentive Plan. The Company maintains Dr. Vazquez&rsquo;s professional
liability insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 15, 2009, the Company entered into a Consulting Agreement
with Kaneohe Advisors LLC (Kyle Francis) under which Mr. Francis became the Company&rsquo;s Executive Vice President, Business
Development and Strategy. Under the terms of the Agreement, Mr. Francis is compensated at a rate of $8,000 per month. In addition,
Mr. Francis received 350,000 shares of restricted stock at the date of the Agreement and is entitled to 350,000 additional restricted
shares on the first and second anniversaries of the Agreement, provided the Agreement is not terminated. The initial 350,000 shares,
along with 50,000 shares granted to Mr. Francis in the year ended January 2009, were issued in the third quarter ended October
31, 2009. On March 15, 2011, the second anniversary of the Consulting Agreement, Mr. Francis was granted an additional 350,000
shares. Mr. Francis was named Chief Financial Officer on December 31, 2010. Mr. Francis' compensation&nbsp;has been increased
to $11,000 per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards at Fiscal Year-End</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 4, 2010, the Board of Directors of Apollo Medical
Holdings, Inc. and three members of our Board that owned, in the aggregate, approximately 65% of the outstanding shares of our common
stock, approved the adoption of the Apollo Medical Holdings, Inc., 2010 Equity Incentive Plan. Subject to the adjustment provisions
of the Plan that are applicable in the event of a stock dividend, stock split, reverse stock split or similar transaction, up
to 5,000,000 shares of common stock may be issued under the Plan. During the fiscal year ended January 31, 2011, 1,150,000 options
were granted to management, directors and independent contractors of which 883,332 were exercisable as of January 31, 2012 at
an exercise price of $0.15 per stock option.&nbsp; There were no stock options granted during the year ended January 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of March 7, 2012, Gary Augusta was appointed to
the Company&rsquo;s Board of Directors. In connection with his service to the Company as a director, Mr. Augusta entered into
the Company&rsquo;s form of Director Agreement, which provides for Mr. Augusta to be a director and entitles Mr. Augusta to receive
a restricted stock grant of 400,000 shares of the Company's Common Stock. The shares will vest monthly at a rate of 1/36 per month
over a three year time period. In connection with Mr. Augusta&rsquo;s service as a consultant to the Company, Mr. Augusta, through
his entity, Augusta Advisors, entered into a Consulting Agreement with the Company which became effective December 1, 2011, and
which terminates on June 30, 2012. Pursuant to that agreement, various consulting services were provided to the Company in return
for $10,000 a month in cash compensation and 100,000 shares of common stock issued in the name of Gary Augusta monthly over the
term of the agreement (totaling 700,000 shares of common stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 7, 2012, an entity affiliated with Mr. Augusta,
SpaGus Capital Partners, LLC, had provided a $270,000 seven-month loan to the Company. The Company prepaid interest expenses of
$15,000 and closing costs of $5,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of February 15, 2012, Edward &ldquo;Ted&rdquo;
Schreck was appointed to the Company&rsquo;s Board of Directors was also appointed as the Chairman of the Board of Directors.
In connection with his service to the Company as a director and Chairman, Mr. Schreck entered into the Company&rsquo;s form of
Director Agreement which entitles such director to receive a combined $30,000 annual cash retainer for his board service as well
as an initial option grant of 1,000,000 options. These options will vest evenly over a 3 year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with his service to the Company as a director,
Mr. Nihalani entered into the Company&rsquo;s form of Director Agreement, which provides for Mr. Nihalani to be a director and
entitles Mr. Nihalani to receive a restricted stock grant of 400,000 shares of the Company's common stock. The shares will vest
monthly at a rate of 1/36 per month over a three year time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of our remaining directors are named executive officers
whose compensation is fully reflected in the Summary Compensation Table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Name</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Fees
    <BR>Earned<BR>or&nbsp;Paid<BR>in&nbsp;Cash<BR>($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock
    <BR>Awards<BR>($)(1)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    <BR>Awards <BR>($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Non-Equity
    <BR>Incentive&nbsp;Plan<BR>Compensation<BR>($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Nonqualified
    <BR>Deferred<BR>Compensation<BR>Earnings</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">All&nbsp;Other
    <BR>Compensation<BR>($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Total
    <BR>($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Suresh Nihalani</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;The amount shown in this column reflects the aggregate
grant date fair value computed in accordance with FASB ASC Topic&nbsp;718 for the year of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 12.</B> <B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth certain information as of&nbsp;April
30, 2012, with respect to (i) those persons known to us to beneficially own more than 5% of our voting securities, (ii) each of
our directors, (iii) each of our executive officers, and (iv) all directors and executive officers as a group. The information
is determined in accordance with Rule 13d-3 promulgated under the Exchange Act. Except as indicated below, the beneficial owners
have sole voting and dispositive power with respect to the shares beneficially owned. As of April 30, 2012, there were 30,635,774
shares of the Company&rsquo;s common stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Name&nbsp;and&nbsp;Address&nbsp;of&nbsp;Beneficial&nbsp;Owner&nbsp;(1)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Shares&nbsp;Beneficially<BR>Owned&nbsp;(2)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Percent<BR>of&nbsp;Class<BR>(3)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Certain Beneficial Owners:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Directors/Named Executive Officers:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Warren Hosseinion, M.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">9,123,387</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">30.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Adrian Vazquez, M.D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,123,387</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Kyle Francis</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Suresh Nihalani</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gary Augusta</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.9</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: justify">All Named Executive Officers and Directors as a group (4 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,046,774</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68.7</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) Unless otherwise indicated, the business address of each
person listed is c/o Apollo Medical Holdings, Inc., 700 N. Brand Blvd., Suite 450, Glendale, California 91203.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) For purposes of this table, shares are considered beneficially
owned if the person directly or indirectly has the sole or shared power to vote or direct the voting of the securities or the
sole or shared power to dispose of or direct the disposition of the securities. Shares are also considered beneficially owned
if a person has the right to acquire beneficial ownership of the shares within 60 days of April 30, 2012. AMH is 100% owned by
Dr Hosseinion and Dr. Vazquez. Dr. Hosseinion is an officer and Director of Apollo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) The percentages are calculated based on the actual number
of shares issued and outstanding as of April 30, 2012, which is 30,635,774.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides information, as of January 31,
2012, with respect to all of our compensation plans under which equity securities are authorized for issuance :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number&nbsp;of&nbsp;securities</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining&nbsp;available</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number&nbsp;of&nbsp;securities</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">for&nbsp;future&nbsp;issuance</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">to&nbsp;be&nbsp;issued&nbsp;upon</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted-average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">under&nbsp;equity</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise&nbsp;of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise&nbsp;price&nbsp;of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">compensation&nbsp;plans</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">outstanding&nbsp;options,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">outstanding&nbsp;options,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(excluding&nbsp;securities</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Plan&nbsp;category</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">warrants&nbsp;and&nbsp;rights</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">warrants&nbsp;and&nbsp;rights</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">reflected&nbsp;in&nbsp;column&nbsp;(a))</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(a)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(b)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(c)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: left">Equity compensation plans approved by stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Equity compensation plans not approved by stockholders </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,850,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,850,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 13.</B> <B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the twelve months ended January 31, 2012 and 2011, the
Company generated revenue of $514,000 and $577,000, respectively, by providing management services to ApolloMed Hospitalists,
an affiliated company with common ownership interest. Commencing August 1, 2008, the management services fee income reported by
AMM was eliminated in consolidation against similar costs recorded at AMH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on the OTCQB electronic trading
platform, which does not maintain any standards regarding the &ldquo;independence&rdquo; of the directors on our Company&rsquo;s
Board, and we are not otherwise subject to the requirements of any national securities exchange or an inter-dealer quotation system
with respect to the need to have a majority of our directors be independent. In the absence of such requirements, we have elected
to use the definition for director independence under the NASDAQ stock market&rsquo;s listing standards, which defines an independent
director as &ldquo;a person other than an officer or employee of the Company or its subsidiaries or any other individual having
a relationship, which in the opinion of our Board, would interfere with the exercise of independent judgment in carrying out the
responsibilities of a director.&rdquo; The definition further provides that, among others, employment of a director by us (or
any parent or subsidiary of ours) at any time during the past three years is considered a bar to independence regardless of the
determination of our Board. Based on the foregoing standards, we have determined that Ted Schreck, Suresh Nihalani and Gary Augusta
are &ldquo;independent&rdquo; directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 14.</B> <B>PRINCIPAL ACCOUNTING FEES AND SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate fees for professional services rendered by Kabani
and Company to us for the fiscal years ended January&nbsp;31, 2012 and January 31, 2011 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Black"><B>Fiscal&nbsp;Year</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Black"><B>Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Black"><B>1/31/2012</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="color: Black">Fiscal&nbsp;Year
    <BR>Ended <BR>1/31/2011</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left"><FONT STYLE="color: Black">Audit fees</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: Black">48,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: Black">47,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: Black">Audit-related fees</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="color: Black">Tax fees(1)</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">3,050</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: Black">1,200</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: Black">All other fees</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: Black">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"><FONT STYLE="color: Black">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: Black">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: Black">51,050</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: Black">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: Black">48,200</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">(1) Tax Returns for the Company
were completed by a local CPA firm. The Company paid $3,050 to such firm for 2012 and $1,200 for 2011.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Notes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">(A) Audit fees represent fees for
professional services provided in connection with the audit of our annual financial statements and the review of our financial
statements included in our Forms 10-Q quarterly reports and services that are normally provided in connection with statutory or
regulatory filings for the 2012 and 2011 fiscal years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">(B) Audit-related fees represent
fees for assurance and related services that are reasonably related to the performance of the audit or review of our financial
statements and not reported above under &ldquo;Audit Fees.&rdquo;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">(C) Tax fees represent fees for
professional services related to tax compliance, tax advice and tax planning</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 15.</B> <B>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>Please see the Report of our Independent Registered Public
                                                                 Accounting Firm, and related financial statements for our fiscal
                                                                 year ended January 31, 2012, beginning on page F-1 of this Form
                                                                 10-K.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>Exhibits Index</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; font-weight: bold; text-align: center">Number</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid; font-weight: bold; text-align: center">Exhibit</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">3.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certificate of Incorporation (filed as an exhibit to Registration Statement on Form 10-SB filed on April 19, 1999, and
    incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">3.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certificate of Ownership (filed as an exhibit to Current Report on Form 8-K filed on July 15, 2008, and incorporated herein
    by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">3.3</TD>
    <TD>&nbsp;</TD>
    <TD>Second Amended and Restated Bylaws (filed as an exhibit to Form 10-Q filed on September 14, 2011, and incorporated herein
    by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">4.1</TD>
    <TD>&nbsp;</TD>
    <TD>Form of 10% Senior Subordinated Convertible Note, dated October 16, 2009 (filed as an exhibit on Annual Report on Form
    10-K on May 14, 2010, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">4.2</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Investor Warrant, dated October 16, 2009, for the purchase of 25,000 shares of common stock (filed as an exhibit
    on Annual Report on Form 10-K/A on March 28, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Agreement and Plan of Merger among Siclone Industries, Inc. and Apollo Acquisition Co., Inc. and Apollo Medical Management,
    Inc (filed as an exhibit to Current Report on Form 8-K filed on June 19, 2008 and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.2</TD>
    <TD>&nbsp;</TD>
    <TD>Management Services Agreement dated August 1, 2008, between Apollo Medical Management and ApolloMed Hospitalists (filed
    as an exhibit on Annual Report on Form 10-K/A on March 28, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.3</TD>
    <TD>&nbsp;</TD>
    <TD>Director Agreement, dated October 27, 2008, between the Company and Suresh Nihalani (filed as an exhibit on Annual Report
    on Form 10-K/A on March 28, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.4</TD>
    <TD>&nbsp;</TD>
    <TD>Management Services Agreement dated March 20, 2009, between Apollo Medical Management and ApolloMed Hospitalists (filed
    as an exhibit on Annual Report on Form 10-K/A on April 10, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.5</TD>
    <TD>&nbsp;</TD>
    <TD>2010 Equity Compensation Plan (filed as an exhibit to Current Report on Form 8-K filed on March 9, 2010, and incorporated
    herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.6</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement with A. Noel DeWinter (filed as an exhibit to Current Report on Form 8-K filed on September 11, 2008,
    and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.7</TD>
    <TD>&nbsp;</TD>
    <TD>Amendment to Suresh Nihalani's Director Agreement dated July 16, 2010 (filed as an exhibit on Annual Report on Form 10-K/A
    on April 10, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.8</TD>
    <TD>&nbsp;</TD>
    <TD>2010 Equity Incentive Plan (filed as Appendix A to Schedule 14C Information Statement filed on August 17, 2010 and incorporated
    herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.9</TD>
    <TD>&nbsp;</TD>
    <TD>Stock Purchase Agreement, dated as of February 15, 2011, among the Company, Aligned Healthcare Group LLC, Aligned Healthcare
    Group - California, Inc., Raouf Khalil, Jamie McReynolds, M.D., BJ Reese &amp; Associates, LLC and BJ Reese (filed as an exhibit
    on Annual Report on Form 10-K/A on April 10, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.10</TD>
    <TD>&nbsp;</TD>
    <TD>First Amendment to Stock Purchase Agreement entered into by Apollo Medical Holdings, Inc. and Aligned Healthcare Group
    LLC, Aligned Healthcare Group - California, Inc., Raouf Khalil, Jamie McReynolds, M.D., BJ Reese &amp; Associates&nbsp;&nbsp;LLC
    and BJ Reese dated July 8, 2011 (filed as an exhibit on Annual Report on Form 10-K/A on April 10, 2012, and incorporated herein
    by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.11</TD>
    <TD>&nbsp;</TD>
    <TD>Services Agreement entered into by Apollo Medical Holdings, Inc. and Aligned Healthcare Group LLC, Aligned Healthcare
    Group - California, Inc., Raouf Khalil, Jamie McReynolds, M.D., BJ Reese &amp; Associates&nbsp;&nbsp;LLC and BJ Reese dated
    July 8, 2011 (filed as an exhibit on Annual Report on Form 10-K/A on April 10, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.12</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement with Jilbert Issai, M.D. dated September 4, 2008 (filed as an exhibit on Annual Report on Form 10-K/A
    on April 10, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.13</TD>
    <TD>&nbsp;</TD>
    <TD>Consulting Agreement with Kyle Francis dated March 22, 2009 (filed as an exhibit on Annual Report on Form 10-K/A on April
    10, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.14</TD>
    <TD>&nbsp;</TD>
    <TD>Hospitalist Participation Service Agreement with Warren Hosseinion, M.D. dated May 1, 2009 (filed as an exhibit on Annual
    Report on Form 10-K/A on April 10, 2012, and incorporated herein by reference).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.15</TD>
    <TD>&nbsp;</TD>
    <TD>Hospitalist Participation Service Agreement with Adrian C. Vazquez, M.D. dated May 1, 2009 (filed as an exhibit on Annual
    Report on Form 10-K/A on April 10, 2012, and incorporated herein by reference).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: center">21.1</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%">Subsidiaries of Apollo Medical Holdings, Inc.*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">23.1</TD>
    <TD>&nbsp;</TD>
    <TD>Consent of Kabani and Company.*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">31.1</TD>
    <TD>&nbsp;</TD>
    <TD>Rule 13a-14(a) Certification, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">31.2</TD>
    <TD>&nbsp;</TD>
    <TD>Rule 13a-14(a) Certification, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">32.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">32.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">101</TD>
    <TD>&nbsp;</TD>
    <TD>Financial statements from the quarterly report on Form 10-K of&nbsp; Apollo Medical Holdings, Inc. for the year ended
    January 31, 2012, formatted in XBRL, are filed herewith and include: (i) the Condensed Consolidated Balance Sheets, (ii) the
    Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) the Notes
    to Condensed Consolidated Financial Statements tagged as blocks of text.*</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 15.</B> <B>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">APOLLO&nbsp;MEDICAL&nbsp;HOLDINGS,&nbsp;INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 52%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Date: May 15, 2012</TD>
    <TD STYLE="padding-right: 0.8pt">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt">/s/ WARREN&nbsp;HOSSEINION,&nbsp;M.D</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Warren&nbsp;Hosseinion,&nbsp;M.D.,&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Chief Executive&nbsp;Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the
dates indicated.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-right: 0.8pt">SIGNATURE</TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 0.8pt">TITLE</TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 24%; padding-right: 0.8pt">DATE</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt"><BR>
    /S/ KYLE FRANCIS</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Chief Financial Officer (Principal Financial and Accounting Officer)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">May 15, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Kyle Francis</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>FINANCIAL STATEMENTS - TABLE OF CONTENTS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 88%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 12%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Report of independent registered public accounting firm</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Financial statements:</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Consolidated balance sheets</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Consolidated statements of operations</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Consolidated statements of changes in stockholders&rsquo; deficit</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Consolidated statements of cash flows</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">F-6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Notes to consolidated financial statements</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">F-7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board of Directors and Stockholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Apollo Medical Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Apollo Medical Holdings, Inc as of January 31, 2012 and 2011 and the related consolidated statements of operations,
stockholders' deficit, and cash flows for the years then ended. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance
with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the financial position of Apollo Medical Holdings, Inc
as of January 31, 2012 and 2011, and the results of their operations and their cash flows for each of the years then ended, in
conformity with U.S. generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's consolidated financial
statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. The Company has accumulated
deficit of $2,117,708 as of January 31, 2012, negative working capital of $266,044 and cash flows used in operating
activities of $385,455. These factors, as discussed in Note 3 to the financial statements raises substantial doubt about the
Company's ability to continue as a going concern. Management's plans in regard to the matter are also described in Note 3.
The statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Kabani &amp; Company, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Los Angeles, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 15, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FOR THE YEARS ENDED JANUARY 31, 2012 AND
2011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">January&nbsp;31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">164,361</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">397,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">994,118</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">704,971</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Advances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Receivable from officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,873</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Due from affiliate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,504</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,601</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid financing cost, current</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 27pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,249,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,197,483</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Prepaid financing cost, long term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Property and equipment &ndash; net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,261</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,593</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,364,048</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,258,139</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;LIABILITIES AND STOCKHOLDERS' DEFICIT:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">163,476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">92,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes, net of $653,026 debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">596,366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">653,026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Shares to be issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Due to officers</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,400</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 27pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,515,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,248,588</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Warrant liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,785,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,341,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">STOCKHOLDERS' DEFICIT:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Preferred stock, par value $0.001 ;&nbsp;5,000,000 shares authorized; none
    issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Common Stock, par value $0.001; 100,000,000 shares authorized,&nbsp;29,335,774
    and 27,635,774 shares issued and outstanding as on January 31, 2012 and 2011, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,336</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,636</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,429,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,058,418</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,117,708</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,397,363</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 27pt">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(659,321</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(311,309</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">Non-controlling interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">238,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">228,115</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt">Total stockholders' deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(421,220</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(83,194</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,364,048</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,258,139</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FOR THE YEARS ENDED JANUARY 31, 2012 AND
2011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">For&nbsp;the&nbsp;years&nbsp;ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">January&nbsp;31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%">REVENUES</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,110,806</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,896,584</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">COST OF SERVICES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,132,399</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,314,722</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">GROSS REVENUE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">978,407</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">581,862</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,379,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">566,649</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,589</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,198</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,391,742</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">577,847</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(LOSS) INCOME FROM OPERATIONS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(413,335</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">OTHER EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(131,534</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(126,431</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Financing cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,500</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,842</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,185</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(301,192</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">158,746</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">LOSS BEFORE INCOME TAXES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(714,527</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(154,731</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Provision for income tax</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">5,819</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,600</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">NET LOSS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(720,346</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(156,331</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,078,925</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,490,476</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">*BASIC AND DILUTED NET LOSS PER SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Weighted average number of shares used to compute basic and
diluted loss per share is the same since the effect of dilutive securities is anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF STOCKHOLDERS'
DEFICIT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FOR THE YEARS ENDED JANUARY 31, 2012 AND
2011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Common&nbsp;Stock</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Non- <BR>controlling</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Accumulated</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Stockholder's</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">APIC</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Interest</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Deficit</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Deficit</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 8pt">Balance at January 31, 2010</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">27,041,328</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">27,041</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">939,483</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">228,115</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">(1,241,031</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">(46,393</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Shares issued for service</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">594,446</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">595</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">46,783</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">47,378</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Non-cash stock-based compensation charges</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">72,152</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">72,152</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Net Loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(156,331</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(156,331</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 8pt">Balance at January 31, 2011</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">27,635,774</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">27,636</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,058,418</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">228,115</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1,397,362</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(83,194</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Shares issued in connection with acquisitions of AHI and PCCM</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,350,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,350</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">278,650</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">280,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Acquisition related non-controlling interest</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">164,276</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">164,276</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Distributions to non-controlling interest shareholder</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(154,290</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(154,290</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Non-cash stock-based compensation charges</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">350,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">350</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">62,650</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">63,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Stock option expense</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">29,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">29,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Net Loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(720,346</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(720,346</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Balance at January 31, 2012</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">29,335,774</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">29,336</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1,429,051</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">238,101</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(2,117,708</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(421,220</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FOR THE YEARS ENDED JANUARY 31, 2012 AND
2011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Years&nbsp;ended&nbsp;January&nbsp;31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(720,346</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(156,331</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,589</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,198</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Bad debt expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">118,077</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,908</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Issuance of shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,378</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Stock option expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,152</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Amortization of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">804</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,006</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Increase in warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Impairment loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(407,224</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(290,363</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Due from / to officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,953</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Due from affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,604</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Prepaid financing cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,668</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,027</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,731</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,507</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 27pt">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(385,455</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(245,031</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Cash paid for purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,205</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,165</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Cash received from consolidation of VIE</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">164,210</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Net cash provided by (used) in financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">157,005</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Due from related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,440</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Proceeds from/(payment to) convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Distribution to non-controlling interest shareholder</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(154,290</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt">Net cash used in financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,290</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,440</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">NET DECREASE IN CASH &amp; CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(232,740</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(268,636</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">CASH &amp; CASH EQUIVALENTS, BEGINNING BALANCE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">397,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">665,737</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">CASH &amp; CASH EQUIVALENTS, ENDING BALANCE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">164,361</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">397,101</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Interest paid during the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">129,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">125,425</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Taxes paid during the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,400</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,600</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">NON-CASH FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Fair value of common stock issued in connection
    with acquisitions (Note 17)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">280,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Shares to be issued for services (Note 15)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1. Organization and Summary of Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc. (&ldquo;Apollo&rdquo; or the
&ldquo;Company&rdquo;) is a leading provider of hospitalist services in the Greater Los Angeles, California area. Hospitalist
medicine is organized around the admission and care of patients in an inpatient facility such as a hospital or skilled nursing
facility and is focused on providing, managing and coordinating the care of hospitalized patients. Apollo Medical Holdings, Inc.
operates as a medical management holding company that focuses on managing the provision of hospital-based medicine through a wholly
owned subsidiary-management companies, Apollo Medical Management, Inc. (&ldquo;AMM&rdquo;) and Pulmonary Critical Care Management,
Inc. (&ldquo;PCCM&rdquo;). Through AMM and PCCM, the Company manages affiliated medical groups, which primarily consists of ApolloMed
Hospitalists (&ldquo;AMH and Los Angeles Lung Center (&ldquo;LALC&rdquo;). AMM and PCCM operate as a Physician Practice Management
Company (PPM) and is in the business of providing management services to Physician Practice Companies (PPC) under Management Service
Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Principles of Consolidation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our consolidated financial statements include the accounts
of Apollo Medical Holdings, Inc. and its wholly owned subsidiaries AMM, , Aligned Healthcare Group (&ldquo;AHI&rdquo;) and PCCM
as well as Professional Medical Corporations managed under long-term management agreements including AMH and LALC. Some states
have laws that prohibit business entities, such as ApolloMed, from practicing medicine, employing physicians to practice medicine,
exercising control over medical decisions by physicians (collectively known as the corporate practice of medicine), or engaging
in certain arrangements with physicians, such as fee-splitting. In California, we operate by maintaining long-term management
contracts with the Professional Medical Corporations, which are each owned and operated by physicians, and which employ or contract
with additional physicians to provide hospitalist services. Under the management agreements, we provide and perform all non-medical
management and administrative services, including financial management, information systems, marketing, risk management and administrative
support. The management agreements have an initial term of 20 years unless terminated by either party for cause. The management
agreements are not terminable by the Professional Medical Corporations, except in the case of gross negligence, fraud, or other
illegal acts by us, or bankruptcy of ApolloMed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through the management agreements and our relationship with
the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related
to the ongoing business operations of the Professional Medical Corporations. Consequently, we consolidate the revenue and expenses
of the Professional Medical Corporations from the date of execution of the management agreements. All intercompany balances and
transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All intercompany balances and transactions are eliminated in
consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-controlling Interest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-controlling interest represents the portion of equity that
is not attributable to the Company. The non-controlling interest recorded in our consolidated financial statements represents
the pre-acquisition equity of those entities which we have determined that we have a controlling financial interest and that consolidation
is required as a result of management contracts entered into with these entities. The nature of these contracts provide us with
a monthly management fee to provide the services described above, and as such, the only adjustments to non-controlling interests
in any period subsequent to initial consolidation would relate to either capital contributions or withdrawals by the non-controlling
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fair Value of Financial Instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our accounting for Fair Value Measurement and Disclosures,
defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on
the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and
unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data
(observable inputs) and an entity&rsquo;s own assumptions (unobservable inputs). The hierarchy consists of three levels:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level one &mdash; Quoted market prices in active markets for
identical assets or liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level two &mdash; Inputs other than level one inputs that are
either directly or indirectly observable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level three &mdash; Unobservable inputs developed using estimates
and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Determining which category an asset or liability falls within
the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company currently
records warrants using level two in the hierarchy.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying values of cash and cash equivalents, trade and
other receivables, trade and other payables approximate their fair values due to the short maturities of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fair Value of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for free-standing warrants for shares
of common stock by first determining whether the instruments require liability treatment based on the provision in the warrant
agreements. Generally, when the agreement may require future performance obligations on the part of the Company (other than the
issuance of common shares in connection with notice of exercise) or the exercise price of warrants is not fixed or determinable,
then the warrants are treated as liabilities and recorded at their relative fair value as of each reporting period. If the warrants
are determined to be equity-classified instruments, then the warrants are recorded as an increase in additional paid-in capital
with a corresponding discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants included with convertible
notes by first allocating the proceeds of issuance among the convertible instrument and the stock warrants based on their relative
fair values, as there are two separate instruments involved. Following this, it is then further determined whether the embedded
conversion option has an intrinsic value. The fair value of the warrants is recorded as an increase to additional paid-in capital
with a corresponding discount on the related notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent adjustments to the exercise price of the warrants
are recorded at the date of the change. Warrants that are classified as liabilities, are re-measured at each reporting period
and changes in the fair value are reported in the Company&rsquo;s statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Concentrations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the twelve month period ended January 31, 2012, the
Company had three major customers, which contributed 34%, 17% and 7.6% of revenue. As of January 31, 2012, the total receivables
from these customers amounted to $140,000, $89,099 and $41,900, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the twelve month period ended January 31, 2011, the
Company had three major customers, which contributed 36%, 20% and 12% of revenue. As of January 31, 2011, the total receivables
from these customers amounted to $170,638, $167,799 and $88,580, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employee Stock Options and Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All share-based payments to employees, including grants of
employee stock options, are recognized in the financial statements based on their fair values. There were no stock options granted
during the year ended January 31, 2012. For options granted during the year ended January 31, 2011, the fair value of each option
award was estimated using the Black-Scholes option pricing model and the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center">Year&nbsp;ended</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center">January&nbsp;31,</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center">2012</P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%">Weighted average risk-free interest rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.9</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Volatility factor of the expected market price of the Company's common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average live</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.0 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expected volatility is based on the historical volatility of
the Company&rsquo;s stock. The Company also uses historical data to estimate the expected term of options granted and employee
termination rates. The risk-free rate for periods within the expected useful life of the options is based on the U.S. Treasury
yield curve in effect at the time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The estimated weighted average fair value of options granted
during the year ended January 31, 2011, was $ $0.011. As of January 31, 2012 and 2011, there was approximately $25,015 and $54,348,
respectively, of total unrecognized compensation cost related to non-vested share-based employee compensation arrangements. The
remaining unrecognized expense at January 31, 2012, is expected to be recognized during the fiscal year end January 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock options and warrants issued to non-employees as compensation
for services to be provided to the Company are accounted for based upon the fair value of the services provided or the estimated
fair value of the option or warrant, whichever can be more clearly determined. The Company recognizes this expense over the period
in which the services are provided. During the years ended January 31. 2012 and 2011, the Company&rsquo;s operating results included
$29,333 and $72,152, respectively, for non-cash stock-based compensation for options issued to consultants and other non-employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company issues new shares to satisfy stock option and warrant
exercises. There were no options exercised during the years ended January 31, 2012 or 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basic and Diluted Earnings Per Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic net loss per share is calculated using the weighted average
number of shares of the Company&rsquo;s common stock issued and outstanding during a certain period, and is calculated by dividing
net loss by the weighted average number of shares of the Company&rsquo;s common stock issued and outstanding during such period.
Diluted net loss per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding
during the period, using the as-if converted method for secured convertible notes, and the treasury stock method for options and
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cash and Cash Equivalents and Concentration of Cash</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company considers all short-term investments with an original
maturity of three months or less to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and cash equivalents at January 31, 2012, include cash
in bank representing the Company&rsquo;s current operating account and $27,407 in a brokerage money market account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accounts Receivable and Allowance for Doubtful Accounts&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts receivable primarily consists of amounts due from
third-party payors, including government sponsored Medicare and Medicaid programs, and insurance companies, and amounts due from
hospitals, and patients. Accounts receivable are recorded and stated at the amount expected to be collected</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company maintains reserves for potential credit losses
on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer
concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy
of these reserves. Reserves are recorded primarily on a specific identification basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Property and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
Property and Equipment is recorded at cost and depreciated using the straight- line method over the estimated useful lives of
the respective assets. Cost and related accumulated depreciation on assets retired or disposed of are removed from the accounts
and any resulting gains or losses are credited or charged to income. Computers and Software are depreciated over 3 years. Furniture
and Fixtures are depreciated over 8 years. Machinery and Equipment are depreciated over 5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for income taxes using an asset and liability
approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax
benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income
tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either
expire before the Company is able to realize their benefits, or that future deductibility is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A tax position is recognized as a benefit only if it is &ldquo;more
likely than not&rdquo; that the tax position would be sustained in a tax examination, with a tax examination being presumed to
occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not
that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on
the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold
to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed
to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold
is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the
first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to
underpayment of income tax are classified as income tax expense in the year incurred.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Revenue Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue consists of contracted and fee-for-service revenue.
Revenue is recorded in the period in which services are rendered. Our revenue is principally derived from the provision of healthcare
staffing services to patients within healthcare facilities. The form of billing and related risk of collection for such services
may vary by customer. The following is a summary of the principal forms of our billing arrangements and how net revenue is recognized
for each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contracted revenue represents revenue generated under contracts
in which we provide physician and other healthcare staffing and administrative services in return for a contractually negotiated
fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates.
Revenue in such cases is recognized as the hours are worked by our staff and contractors. Additionally, contract revenue also
includes supplemental revenue from hospitals where we may have a fee-for-service contract arrangement or provide physician advisory
services to the medical staff at specific facility. Contract revenue for the supplemental billing in such cases is recognized
based on the terms of each individual contract. Such contract terms generally either provides for a fixed monthly dollar amount
or a variable amount based upon measurable monthly activity, such as hours staffed, patient visits or collections per visit compared
to a minimum activity threshold. Such supplemental revenues based on variable arrangements are usually contractually fixed on
a monthly, quarterly or annual calculation basis considering the variable factors negotiated in each such arrangement. Such supplemental
revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated
as payable by the customer under the terms of the respective agreement. Additionally, we derive a portion of our revenue as a
contractual bonus from collections received by our partners and such revenue is contingent upon the collection of third-party
billings. These revenues are not considered earned and therefore not recognized as revenue until actual cash collections are achieved
in accordance with the contractual arrangements for such services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fee-for-service revenue represents revenue earned under contracts
in which we bill and collect the professional component of charges for medical services rendered by our contracted and employed
physicians. Under the fee-for-service arrangements, we bill patients for services provided and receive payment from patients or
their third-party payers. Fee-for-service revenue is reported net of contractual allowances and policy discounts. All services
provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. Fee-for-service
revenue is recognized in the period in which the services are rendered to specific patients and reduced immediately for the estimated
impact of contractual allowances in the case of those patients having third-party payer coverage. The recognition of net revenue
(gross charges less contractual allowances) from such visits is dependent on such factors as proper completion of medical charts
following a patient visit, the forwarding of such charts to our billing center for medical coding and entering into our billing
system and the verification of each patient&rsquo;s submission or representation at the time services are rendered as to the payer(s)
responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information
into our billing systems as well as an estimate of the revenue associated with medical services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Adopted Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2010, the Financial Accounting Standards Board
issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2010-29, <I>Business Combinations, Disclosure of Supplementary Pro
Forma Information for Business Combinations</I> (&ldquo;ASU 2010-29&rdquo;), which provides clarification regarding pro forma
revenue and earnings disclosure requirements for business combinations. The amendments in this ASU specify that if a public entity
presents comparative financial statements, the entity should disclose only revenue and earnings of the combined entity as though
the business combination(s) that occurred during the current year had occurred as of the beginning of the comparable prior annual
reporting period. The amendments also expand the supplemental pro forma disclosures to include a description of the nature and
amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported
pro forma revenue and earnings. The amendments are effective prospectively for business combinations for which the acquisition
date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2010. Early adoption
is permitted. The Company adopted ASU 2010-29 during the first interim reporting period of 2011 as it relates to pro-forma disclosure
of the Company&rsquo;s acquisitions. The adoption of ASU 2010-29 did not have a material impact on the Company&rsquo;s consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ASU No. 2010-28, <I>Intangibles &mdash; Goodwill and Other,
When to Perform Step 2 of the Goodwill Impairment Test for Reporting Units with Zero or Negative Carrying Amounts</I> (&ldquo;ASU
2010-28&rdquo;) was issued in December 2010. The amendments in this ASU modify Step 1 of the goodwill impairment test for reporting
units with zero or negative carrying amounts. For those reporting units, an entity is required to perform Step 2 of the goodwill
impairment test if it is more likely than not that a goodwill impairment exists. In determining whether it is more likely than
not that impairment to goodwill exists, an entity should consider whether there are any events or circumstances that would more
likely than not reduce the fair value of a reporting unit below its carrying amount. The amendments in this ASU are effective
for fiscal years, and interim periods within those years, beginning after December 15, 2010. Early adoption is not permitted.
The Company adopted ASU 2010-28 for the quarter ending March 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">In December
2011, the FASB issued guidance on offsetting (netting) assets and liabilities. Entities are required to disclose both gross information
and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments
and transactions subject to an agreement similar to a master netting arrangement. The new guidance is effective for annual periods
beginning after January 1, 2013. </FONT>We do not expect the adoption of this revised GAAP to have a material effect on our financial
position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2011, the FASB issued a GAAP update on goodwill
to allow an entity the option of performing a qualitative assessment before calculating the fair value of the reporting unit when
testing goodwill for impairment. If the qualitative assessment concludes that it is more likely than not that the fair value of
a reporting unit is less than its carrying value, the entity shall perform the quantitative two-step goodwill impairment test.
Otherwise, the two-step goodwill impairment test is not required. This revised GAAP will be effective for fiscal years beginning
after December 15, 2011, with early adoption permitted. We do not expect the adoption of this revised GAAP to have a material
effect on our financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
June 2011, the FASB issued guidance on presentation of comprehensive income. The new guidance eliminates the current option to
report other comprehensive income and its components in the statement of changes in equity. Instead, an entity will be required
to present either a continuous statement of net income and other comprehensive income or in two separate but consecutive statements.
The new guidance is effective for annual periods beginning after December 15, 2011. In December 2011, the FASB issued a deferral
of certain portion of this guidance</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">We do not expect the adoption
of this revised GAAP to have a material effect on our financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2011, the FASB issued a GAAP update on fair value measurement,
which eliminates differences between U.S. GAAP and International Financial Reporting Standards (IFRS), resulting in a consistent
definition of fair value and common requirements for measurement of and disclosure about fair value between GAAP and IFRS. It
also expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This
revised GAAP will be effective for annual and interim periods beginning after December 15, 2011. We do not expect the adoption
of this revised GAAP to have a material effect on our financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3. Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company's financial statements are prepared using the generally
accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of
liabilities in the normal course of business. However, the Company continues to incur operating losses and has an accumulated
deficit of $2,117,708 as of January 31, 2012. In addition, at January 31, 2012, the Company has a total stockholders&rsquo; deficit
of $659,321 and generated a negative net cash flow operating activities of $385,455 for the year then ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements do not include any adjustments relating
to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a
going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date the Company has funded its operations from both internally
generated cash flow and external sources, and the proceeds available from the private placement of convertible notes which have
provided funds for near-term operations and growth. The Company will pursue additional external capitalization opportunities,
as necessary, to fund its long-term goals and objectives. We may seek to raise additional capital through public or private equity
financings, partnerships, joint ventures, disposition of assets, debt financings, bank borrowings or other sources of financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No assurances can be made that management will be successful
in achieving its plan. If the Company is not able to raise substantial additional capital in a timely manner, the Company may
be forced to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4. Accounts Receivable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts Receivable is stated at the amount management
expects to collect from outstanding balances. An allowance for doubtful accounts is provided for those accounts receivable
considered to be uncollectible, based upon historical experience and management's evaluation of outstanding accounts
receivable at each quarter end. As of January 31, 2012, Accounts Receivable was $994,118, net of a provision for bad debt of
$42,576, and represents amounts invoiced by AMH and LALC. Accounts Receivable was $704,971, net of the provision for bad debt of
$34,746, on January 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5. Receivable from officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receivable from officers represent compensation
payments made in fiscal year 2010 above contractual amounts. These amounts were expensed in fiscal year 2012 in exchange for
additional physical services provided to the company.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6. Due from Affiliate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amounts due from affiliate represents advances made by the
Company to Apollo Medical Associates (&ldquo;AMA&rdquo;). These balances are due on demand, non-interest bearing and are unsecured.
AMA is an unconsolidated affiliate of the Company and currently has no operations and is inactive. No management agreement currently
exists between AMM and AMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>7. Prepaid Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepaid Expenses represent amounts paid in advance for medical
malpractice insurance, software licenses and Director&rsquo;s and Officer&rsquo;s insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8.&nbsp;&nbsp;Prepaid financing cost</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepaid financing cost represents unamortized financing cost
associated with 10% Senior Subordinated Callable Convertible Notes due January 31, 2013 paid by the Company on the closing of
the placement on October 16, 2009 (see Note 11).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>9.</B> <B>Property and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and Equipment consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">January&nbsp;31, <BR>2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">January&nbsp;31, <BR>2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%">Website</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,568</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,568</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Computers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,912</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,912</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Software</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,039</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,039</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Machinery and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,815</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Furniture and fixtures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,302</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,198</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Gross Property and Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">258,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,334</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Less accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(215,311</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(202,741</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 2.5pt">Net Property and Equipment</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">43,261</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">21,593</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense was $12,589 and $11,198 for the twelve
month periods ended January 31, 2012 and 2011, respectively.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10. Accounts Payable and Accrued&nbsp;Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts payable and accrued liabilities consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">January&nbsp;31,<BR> 2012</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">January&nbsp;31,<BR> 2011</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Accounts payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">109,704</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">35,815</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">D&amp;O insurance payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,444</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,913</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Income taxes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Accrued professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,483</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accrued payroll and income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,609</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,534</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">163,476</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,745</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>11.&nbsp;&nbsp;Convertible Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s long-term debt consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">January&nbsp;31,<BR>2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">January&nbsp;31,<BR>2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Subordinated Borrowings:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: -9.35pt; padding-left: 18.7pt; padding-bottom: 1pt">10% Senior Subordinated Convertible Notes, net of debt discount of $653,026, due January 31, 2013</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">596,366</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">1,248,588</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.7pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 18.7pt">8% Senior Subordinated Convertible Notes due February 1, 2015</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total Convertible Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">746,366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,248,588</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: Current Portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">596,366</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">150,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,248,588</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subordinated Borrowings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>10% Senior Subordinated Callable Convertible Notes due January
31, 2013</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 16, 2009, the Company issued $1,250,000 of its 10%
Senior Subordinated Callable Convertible Notes. The net proceeds of $1,100,000 will be used for the repayment of existing debt,
acquisitions, physician recruitment and other general corporate purposes. The notes bear interest at a rate of 10% annually, payable
semi annually on January 31 and July 31. The Notes mature and become due and payable on January 31, 2013 and rank senior to all
other unsecured debt of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 10% Notes were sold through an Agent in the form of a Unit.
Each Unit was comprised of one 10% Senior Subordinated Callable Note with a par value $25,000, and one five-year warrant to purchase
25,000 shares of the Company&rsquo;s common stock. The purchase price of each Unit was $25,000, resulting in gross proceeds of
$1,250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the placement of the subordinated notes,
the Company paid a commission of $125,000 and $25,000 of other direct expenses. The agent also received five-year warrants to
purchase up to 250,000 shares of the Common Stock at an initial exercise price of $0.25 per share adjustable pursuant to changes
in public value of our shares and cash flow of the Company from July 31, 2011 until the note is paid in full. The agent also received
100,000 shares of restricted common stock for pre-transaction advisory services and due diligence. A commission of $125,000 paid
at closing, is accounted for as prepaid expense and will be amortized over a forty-month period through January 31, 2013, the
maturity date of the notes. The $25,000 of other direct expenses were paid at closing and reported as financing costs in the Operating
Statement. In addition, financing costs included $4,000 related to the value of the 100,000 shares granted to the placement agent.
Interest expense of $36,458 was recorded in the year ended January 31, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 10% Notes are convertible any time prior to January 31,
2013. The initial conversion rate is 200,000 shares of the Company&rsquo;s common stock per $25,000 principal amount of the 10%
Notes adjustable pursuant to changes in public value of our shares and cash flow of the Company. This represents an initial conversion
price of $0.125 per share of the Company&rsquo;s common stock. The note is fixed from August 1, 2009 through July 31, 2011. After
July 31, 2011, the conversion price will equal to the lesser of $0.125 per share or the average of the monthly high stock price
and low stock price as reported by Bloomberg multiplied by 110%. The minimum conversion price is the greater of $0.05 per share
or 8 times cash EPS.&nbsp; On or after January 31, 2012, the Company may, at its option, upon 60 days notice to both the Note-holder&rsquo;s
and the placement agent, redeem all or a portion of the notes at a redemption price in cash equal to 102% of the principal amount
of the notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At January 31, 2012, the Company has recorded a derivative
liability and an off-setting debt discount in the amount of $653,026 as the result of the change in the conversion price. At January
31, 2012, the conversion price reset to $0.11485. The Company&rsquo;s calculation of the derivative liability was made using the
Black-Scholes option-pricing model with the following assumptions: expected life of 1 year; 80.0% stock price volatility; risk-free
interest rate of 0.30% and no dividends during the expected term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrants attached to the Units are exercisable into shares
of Common Stock at an initial exercise price of $0.125. The Warrants have a five-year term and expire on October 31, 2014. The
Company&rsquo;s calculations were made using the Black-Scholes option-pricing model with the following assumptions: expected life
of 5 years; 48.0% stock price volatility; risk-free interest rate of 2.16% and no dividends during the expected term. These warrants
were estimated to have a fair value of $2,653 using the Black-Scholes pricing model which was recorded as unamortized warrant
discount on the grant date and $2,418 as of January 31, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with this offering, the Company also issued warrants
to purchase 250,000 shares of our common stock to the placement agent at an exercise price of $0.25 per share, and are exercisable
immediately upon issuance and expire five years after the date of issuance. The Company&rsquo;s calculations were made using the
Black-Scholes option-pricing model with the following assumptions: expected life of 5 years; 48.0% stock price volatility; risk-free
interest rate of 2.16% and no dividends during the expected term. These warrants were estimated to have a fair value of $2,200,
which was recorded as unamortized warrant discount on the grant date. The exercise price of the warrants are adjustable according
to the same terms as the 10% Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At January 31, 2012, the warrant exercise price reset to $0.11485.
As the result, the Company has recorded a warrant liability of $120,000 and recognized additional financing costs of $120,000
for the year ended January 31, 2012. The fair value of the warrant liability was determined using the Black-Scholes model option
pricing model with the following assumptions: expected life of 2.75 years; 30% stock price volatility; risk-free interest rate
of 0.30% and no dividends during the expected term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>8% Senior Subordinated Convertible Promissory Notes due
February 1, 2015</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 1, 2011, the Company issued $150,000 of its 8%
Senior Subordinated Promissory Convertible Notes. The net proceeds will be used for working capital to support organic growth
including the expansion to new hospitals and hiring of new physicians, acquisitions of physician practices and/or care management
businesses and for general corporate purposes. The notes bear interest at a rate of 8% annually, payable semi annually on December
31 and June 30. The Notes mature and become due and payable on January 31, 2013 and rank senior to all other subordinated debt
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 8% Notes are convertible any time prior to February 1,
2015. The initial conversion rate is 100,000 shares of the Company&rsquo;s common stock per $25,000 principal amount of the 8%
Notes, which represents an initial conversion price of $0.25 per share of the Company&rsquo;s common stock. The conversion price
of the 8% Notes will be adjusted on a weighted average basis if the Company issues certain additional shares of common stock (or
warrants or rights to purchase share of common stock or securities convertible into common stock) for a consideration per share
which is less than the then applicable conversion price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company may require the holders of the 8% Notes to convert
to common stock at the then applicable conversion rate at any time after June 30, 2013 if: i) our 10% Notes have been fully repaid
or converted and ii) the closing price of our common stock has exceeded 150% of the then applicable Conversion Price for no less
than 30 consecutive trading days prior to giving notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At any time on or after June 30, 2014, the Company may, at
its sole option redeem all of the Notes at redemption price in cash equal to 108% of the principal amount of the Notes to be redeemed
plus any accrued and unpaid interest to, but excluding the redemption rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Interest expense was $130,000 and
$125,000 for the years ended January 31, 2012 and 2011, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table represents the principal repayments of
all the outstanding debt as of January 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ending&nbsp;January&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; text-align: center">2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 25%; text-align: right">1,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>12. Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company uses the liability method of accounting for income
taxes as set forth in ASC 740 (formerly Statement of Financial Accounting Standards No. 109, &ldquo;Accounting for Income Taxes&rdquo;
(&ldquo;SFAS 109&rdquo;)). Under the liability method, deferred taxes are determined based on differences between the financial
statement and tax bases of assets and liabilities using enacted tax rates. As of January 31, 2012, the Company had federal and
California tax net operating loss carryforwards of approximately $1,981,000 and $2,060,000, respectively. The federal and California
net operating loss carryforwards will expire at various dates from 2028 through 2031.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s effective tax rate is different from the
federal statutory rate of 34% due primarily to operating losses that receive no tax benefit as a result of a valuation allowance
recorded for such losses.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Internal Revenue Code Sections 382 and 383, use
of the Company&rsquo;s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than
50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these
Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net
operating loss and tax credit carryforwards until the time that it projects it will be able to utilize these tax attributes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant components of the Company&rsquo;s deferred tax assets
as of January 31, 2012 and January 31, 2011 are shown below. A valuation allowance of $933,420 and $232,700 as of January 31, 2012
and 2011, respectively, has been established against the Company&rsquo;s deferred tax assets as realization of such assets is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">January 31,</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">January 31,</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2012</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2011</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: left">NOL carry forward</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">849,591</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">212,800</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stock Option - exercisabe</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">81,775</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,800</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Contribution carryforward</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,970</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">51,408</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">State income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,247</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrual to cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(76,500</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">State income taxes, deferred</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(71,035</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Impairment loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">89,964</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">9,100</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net Deferred Tax Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">933,420</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">232,700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation Allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">(933,420</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">(232,700</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provision for income taxes for the year ended January 31,
2012 differs from the amount computed by applying the federal income tax rate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left">Tax computed at the statutory rate (34%)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.34</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stock options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.01</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Accrual to cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.01</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.05</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Impairment Loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.08</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Non-cash stock compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.06</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Change in valuation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.15</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of January 31, 2012, the Company does not have any unrecognized
tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties
related to unrecognized tax benefits in income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is subject to U.S. federal income tax as well as
income tax of multiple state tax jurisdictions. The Company and its subsidiaries&rsquo; state income tax returns are open to audit
under the statute of limitations for the years ended January 31, 2009 through 2012. The Company does not anticipate any material
amount of unrecognized tax benefits within the next 12 months.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>13. Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the twelve months ended January 31, 2012 and 2011, the
Company generated revenue of $514,000 and $577,000, respectively, by providing management services to ApolloMed Hospitalists (AMH),
an affiliated company with common ownership interest. Commencing August 1, 2008, the management services fee income reported by
AMM was eliminated in consolidation against similar costs recorded at AMH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>14&nbsp;&nbsp;Non-Controlling Interest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Activity within non-controlling interest for the twelve-months
ended January 31, 2012 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 82%">Beginning balance as of January 31, 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">228,115</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Acquisition-related non-controlling interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164,276</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Distributions to non-controlling interest shareholder</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(154,290</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Ending balance as of January 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">238,101</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>15. Stockholder&rsquo;s Deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company issued a total of 1,350,000 common shares during
the twelve months ended January 31, 2012 related to acquisitions (see Note 17).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company authorized the issuance 600,000 shares of common
stock for compensation related to consulting and directors fees during the twelve months ended January 31, 2012. The shares were
valued at $90,000 based on the fair values of the shares at the issuance dates. These shares were not issued as January 31, 2012
and as such have been recorded as shares to be issued in current liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company issued 350,000 shares of common stock for compensation
to the CFO during the twelve months ended January 31, 2012. The shares were valued at $63,000 based on the fair value of the shares
at the issuance date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company issued a total of 594,446 common shares in the
twelve months ended January 31, 2011, including 244,446 shares issued to officers and directors and 350,000 shares issued to Kanehoe
Advisors related to professional services related to the issuances. The total shares were valued at $47,378 based on the fair
value of the shares at the issuance dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants outstanding:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Aggregate<BR>intrinsic<BR>value</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;warrants<BR>issued</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%">Outstanding at January 31, 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,655,333</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">,</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Lapsed</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(155,333</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding at January 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">-</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,500,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Warrants <BR>outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted <BR>average <BR>remaining <BR>contractual&nbsp;life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Warrants <BR>exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Weighted</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">average</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">exercise&nbsp;price</P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">0.114850</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">2.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 17%; text-align: right">0.114850</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.114850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.114850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In conjunction with the completion of the private placement
on October 16, 2009, as described in Note 11, the Company issued a total of 1,500,000 warrants. Of this amount, 1,250,000 warrants
were issued to the holders of the Convertible Notes and 250,000 warrants were granted to the placement agent. The 1,250,000 warrants
held by the note holders are exercisable into shares of Common Stock at an initial exercise price of $0.11485. The Warrants have
a five-year term and expire on October 31, 2014. The 250,000 warrants conveyed to the placement agent also have a five-year term,
expire on October 31, 2014, and are exercisable at $0.11485 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2010 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 4, 2010, the Company&rsquo;s Board of Directors approved
the 2010 Equity Incentive Plan (the &ldquo;Plan&rdquo;). The Plan provides for the granting of the following types of awards to
persons who are employees, officers, consultants, advisors, or directors of our Company or any of its affiliates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Plan, the Company may issue a variety of equity vehicles
to provide flexibility in implementing equity awards, including incentive stock options, nonqualified stock options, restricted
stock grants and stock appreciation rights. The exercise price of stock options offered under the Plan shall not be less than
the fair market value of the Company&rsquo;s common stock on the date of the grant. The exercise price of an ISO granted to any
person who owns, directly or by attribution under the Code (currently Section 424(d)), stock possessing more than 10% of the total
combined voting power of all classes of stock of the Company or of any affiliate (a &ldquo;10% Stockholder&rdquo;) shall in no
event be less than 110% of the fair market value (determined in accordance with Section 6.1.10) of the stock covered by the option
at the time the option is granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the adjustment provisions of the Plan that are applicable
in the event of a stock dividend, stock split, reverse stock split or similar transaction, up to 5,000,000 shares of common stock
may be issued under the Plan. Options granted under the Plan generally vest over a three-year period and generally expire five
years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of January 31, 2012, options to purchase an aggregate of
883,332 shares of common stock were exercisable under the Company&rsquo;s stock option Plan. During the year ended January 31,
2012, the Company did not issue options to purchase shares of common stock with exercise prices below the fair market value of
the common stock on the dates of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock option transactions under the Company&rsquo;s stock option
plans for the year ended January 31, 2012 are summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Per&nbsp;Share<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;Average<BR> Remaining<BR> Contractual&nbsp;Term</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic&nbsp;Value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Balance, January 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; padding-left: 9pt">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,150,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Balance, January 31, 2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,150,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">8.9 years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Vested and expected to vest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.9 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercisable, January 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">883,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.9 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As January 31, 2012, options available for future grant under
the Plan amounted to 3,850,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information regarding stock options outstanding at January
31, 2012 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="text-align: center">Options&nbsp;Outstanding</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center">Options&nbsp;Exercisable</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Range&nbsp;of&nbsp;exercise<BR> prices</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number<BR> outstanding&nbsp;at<BR> January&nbsp;31,<BR> 2012</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted<BR> average<BR> remaining<BR> contractual&nbsp;life</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted<BR> average<BR> exercise&nbsp;price</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number<BR> exercisable&nbsp;at<BR> January&nbsp;31,<BR> 2012</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted<BR> average<BR> exercise<BR> price</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">1,150,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">8.9 years</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">883,332</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>16.</B> <B>Commitments and Contingency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 15, 2009, the Company entered into a Consulting Agreement
with Kaneohe Advisors LLC (Kyle Francis) under which Mr. Francis became the Company&rsquo;s Executive Vice President, Business
Development and Strategy. Under the terms of the Agreement, Mr. Francis is compensated at a rate of $8,000 per month. In addition,
Mr. Francis received 350,000 shares of restricted stock at the date of the Agreement and is entitled to 350,000 additional restricted
shares on the first and second anniversaries of the Agreement, provided the Agreement is not terminated. The initial 350,000 shares,
along with 50,000 shares granted to Mr. Francis in the year ended January 2009, were issued in the third quarter ended October
31, 2009. On March 15, 2010, the second anniversary of the Consulting Agreement, Mr. Francis was granted an additional 350,000
shares. On March 15, 2011, Mr. Francis was granted an additional 350,000 shares on the third anniversary of the before mentioned
Consulting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 4, 2008, Apollo Medical Management, Inc. executed
an employment agreement with Jilbert Issai, M.D., to provide services as Senior Vice President. The agreement is for an initial
one-year term with provision for successive one-year periods. Under the agreement, Dr. Issai is entitled to a nominal salary and
may be granted options to purchase an aggregate of 300,000 shares of the Company&rsquo;s common stock at an exercise price of
$0.15 per share when and if the Company is to adopt a stock compensation plan. The Company granted Dr. Issai 300,000 options on
December 9, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of January 1, 2012, Suresh Nihalani was re-elected
to the Company&rsquo;s Board of Directors. In connection with his service to the Company as a director, In connection with his
service to the Company as a director, Mr. Nihalani entered into the Company&rsquo;s form of Director Agreement, which provides
for Mr. Nihalani to be a director and Mr. Nihalani received a restricted stock grant of 400,000 shares of the Company's Common
Stock. The shares will vest monthly at a rate of 1/36 per month over a three year time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>17. Acquisitions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Aligned Healthcare Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 15, 2011, Apollo Medical Holdings, Inc. (the &ldquo;Company&rdquo;)
entered into a Stock Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Aligned Healthcare Group &ndash; California,
Inc., Raouf Khalil, Jamie McReynolds, M.D. BJ Reese and BJ Reese &amp; Associates, LLC, under which the Company acquired all of
the issued and outstanding shares of capital stock and associated Intellectual property and related intangibles (the &ldquo;Acquisition&rdquo;)
of Aligned Healthcare, Inc., a California corporation (&ldquo;AHI&rdquo;), from AHI&rsquo;s shareholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon the signing of the Purchase Agreement, 1,000,000
shares of the Company&rsquo;s common stock became issuable (the &ldquo;Initial Shares&rdquo;) and are included in the number
of shares outstanding. In addition, if the gross revenues of AHI and an affiliated entity (the &ldquo;Aligned
Division&rdquo;) had exceeded $1,000,000 on or before February 1, 2012, then the Company would have been obligated to issue
an additional 1,000,000 shares of common stock (the &ldquo;Contingent Shares&rdquo;). Moreover, the Company would be
obligated to issue up to an additional 3,500,000 shares of common stock (the &ldquo;Earn-Out Shares&rdquo; and, collectively
with the Initial Shares and the Contingent Shares, the &ldquo;Shares&rdquo;) over a three year period following closing based
on the EBITDA generated by the Aligned Division during that time. Under the agreement, ApolloMed would issue twelve shares of
its Common stock for each dollar of Actual EBITDA earned in the first 12-month period. In subsequent periods, ApolloMed would
be required to issue twelve shares of its common stock for each dollar of Actual EBITDA in excess of the maximum EBITDA
earned in either the first 12-month period or first 12-month period and second 12 month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, in Accordance with the Purchase Agreement,
if prior to February 15, 2012, AHI had not entered into an agreement for the provision of certain services to a hospital or
certain other health organizations that has a term of at least one year and provides aggregate net revenues to AHI of at
least $1,000,000, the Company would have the right to repurchase all of the Initial Shares for $0.05 per share, at which time
the Company&rsquo;s obligation to issue any further Shares would terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on our initial internal estimate of
contingent shares to be issued as part of this agreement, we had estimated that the total fair value of the common stock
shares issued and contingently issuable for this transaction on the acquisition date was $367,500 (1,750,000 shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company originally recognized a liability based on the
acquisition date fair value of the acquisition-related contingent consideration based on the probability of the achievement
of the targets stipulated in the Purchase Agreement. Based on the Company&rsquo;s estimation, an initial liability of
$367,500 was recorded.  Subsequently, we have reassessed our estimates and have determined that the initial terms of the
agreement have not be met, and as the result, we have determined that there will be no additional shares contingently
issuable under the terms of the Purchase Agreement and we have recorded an adjustment to revise our initial estimate of the
purchase price in contemplation that no  contingent consideration as was previously reported in our
interim financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the preliminary and final determination
of the purchase price and fair value of AHI&rsquo;s assets acquired at the date of acquisition:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">Preliminary</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">Final</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Purchase price calculation:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 10pt">Common stock issued (1,000,000 shares)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">210,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">210,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Contingent consideration (1,750,000 shares of common stock)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">367,500</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 20pt">Fair value of total consideration</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">577,500</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">210,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Allocation of purchase price:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Intellectual property and technical know-how</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">577,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Goodwill</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">210,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">577,500</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">210,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of January, 31, 2012, based upon the completion of the
Company&rsquo;s annual goodwill impairment test, it was determined that the goodwill associated with the AHI acquisition has
been impaired, and as the result, the Company has recorded an impairment loss of $210,000. The cause of the impairment was
the result of contracts that were anticipated to result from this acquisition that have not materialized and management has
decided to focus its energies on new initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pulmonary Critical Care Management, Inc</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 2, 2011, Apollo Medical Holdings, Inc. entered into
a stock purchase agreement (the &ldquo;PCCM Purchase Agreement&rdquo;) with the sole shareholder of Pulmonary Critical Care Management,
Inc. ("PCCM"), a provider of management services to the Los Angeles Lung Center (&ldquo;LALC&rdquo;), under which the
Company acquired (the &ldquo;PCCM Acquisition&rdquo;) all of the issued and outstanding shares of capital stock of PCCM and the
associated intangible asset in the management services agreement that PCCM has with LALC (the &ldquo;PCCM Services Agreement&rdquo;).
Upon the signing of the PCCM Purchase Agreement, the Company issued 350,000 common shares to the sole shareholder of PCCM, which
was valued as of the date of issuance at $70,000, based on the fair market value of our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the time of the acquisition, the assets of PCCM consisted
only of the PCCM Services Agreement with LALC. Through this PCCM Services Agreement, our wholly-owned subsidiary, PCCM, has exclusive
authority over all non-medical decision-making related to the ongoing business operations of LALC. Based on the provisions of
the PCCM Purchase Agreement, we have determined that LALC is a variable interest entity (VIE), and that we are the primary beneficiary
because we have control over the operations of the VIE. Consequently, we consolidated the accounts of LALC beginning on the PCCM
Acquisition date. As a result of this consolidation, we recorded additional non-controlling interest of $164,276.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the fair value of LALC&rsquo;s
assets acquired and liabilities at the date of acquisition of PCCM and consolidation of LALC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%">Purchase Price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">70,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Fair value of net assets acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">164,210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,472</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,041</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Management services agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,447</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Due from officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Non-controlling interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(164,276</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Net assets acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">38,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Goodwill</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proforma financial information is not presented as PCCM did
not exist in the comparative period herein presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>18. Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 7, 2012, an entity affiliated with Mr. Augusta,
SpaGus Capital Partners, LLC, had provided a $270,000 seven-month loan to the Company. The Company prepaid interest expenses of
$15,000 and closing costs of $5,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>v312954_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 21.1&nbsp;&nbsp;&nbsp;Subsidiaries of Apollo Medical
Holdings, Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; border-bottom: black 1.5pt solid; padding-right: 0.8pt">Name</TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 53%; border-bottom: black 1.5pt solid; padding-right: 0.8pt">Jurisdiction of Operations</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Apollo Medical Management, Inc</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">California</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Pulmonary Critical Care Management, Inc.</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">California</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Aligned Healthcare, Inc</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">California</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>v312954_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF RULE 13A-14(A)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302(A) OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Warren Hosseinion, M.D., Chief Executive Officer of Apollo
Medical Holdings, Inc., certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD>I have reviewed this annual report on Form 10-K of Apollo Medical
                                                          Holdings, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement
                                                          of a material fact or omit to state a material fact necessary to make
                                                          the statements made, in light of the circumstances under which such
                                                          statements were made, not misleading with respect to the period covered
                                                          by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial
                                                          information included in this report, fairly present in all material
                                                          respects the financial condition, results of operations and cash flows
                                                          of the registrant as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible
                                                          for establishing and maintaining disclosure controls and procedures
                                                          (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
                                                          control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                                          and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused
                                                               such disclosure controls and procedures to be designed under our
                                                               supervision, to ensure that material information relating to the
                                                               registrant, including its consolidated subsidiaries, is made known
                                                               to us by others within those entities, particularly during the
                                                               period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or
                                                               caused such internal control over financial reporting to be designed
                                                               under our supervision, to provide reasonable assurance regarding
                                                               the reliability of financial reporting and the preparation of financial
                                                               statements for external purposes in accordance with generally accepted
                                                               accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure
                                                               controls and procedures and presented in this report our conclusions
                                                               about the effectiveness of the disclosure controls and procedures,
                                                               as of the end of the period covered by this report based on such
                                                               evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s
                                                               internal control over financial reporting that occurred during
                                                               the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                                               fourth fiscal quarter in the case of an annual report) that has
                                                               materially affected, or is reasonably likely to materially affect,
                                                               the registrant&rsquo;s internal control over financial reporting;
                                                               and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed,
                                                          based on our most recent evaluation of internal control over financial
                                                          reporting, to the registrant&rsquo;s auditors and the audit committee
                                                          of the registrant&rsquo;s board of directors (or persons performing
                                                          the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>All significant deficiencies and material weaknesses in the
                                                               design or operation of internal control over financial reporting
                                                               which are reasonably likely to adversely affect the registrant&rsquo;s
                                                               ability to record, process, summarize and report financial information;
                                                               and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Any fraud, whether or not material, that involves management
                                                               or other employees who have a significant role in the registrant&rsquo;s
                                                               internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 15, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; border-bottom: black 1.5pt solid; padding-right: 0.8pt">/s/&nbsp;WARREN&nbsp;HOSSEINION,&nbsp;M.D.</TD>
    <TD STYLE="width: 61%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">WARREN HOSSEINION, M.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><I>&nbsp;</I> Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>v312954_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF RULE 13A-14(A)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302(A) OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I,&nbsp;Kyle Francis, Chief Financial Officer of Apollo Medical
Holdings, Inc., certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD>I have reviewed this annual report on Form 10-K of Apollo Medical
                                                          Holdings, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement
                                                          of a material fact or omit to state a material fact necessary to make
                                                          the statements made, in light of the circumstances under which such
                                                          statements were made, not misleading with respect to the period covered
                                                          by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial
                                                          information included in this report, fairly present in all material
                                                          respects the financial condition, results of operations and cash flows
                                                          of the registrant as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible
                                                          for establishing and maintaining disclosure controls and procedures
                                                          (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
                                                          control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                                          and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused
                                                               such disclosure controls and procedures to be designed under our
                                                               supervision, to ensure that material information relating to the
                                                               registrant, including its consolidated subsidiaries, is made known
                                                               to us by others within those entities, particularly during the
                                                               period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or
                                                               caused such internal control over financial reporting to be designed
                                                               under our supervision, to provide reasonable assurance regarding
                                                               the reliability of financial reporting and the preparation of financial
                                                               statements for external purposes in accordance with generally accepted
                                                               accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure
                                                               controls and procedures and presented in this report our conclusions
                                                               about the effectiveness of the disclosure controls and procedures,
                                                               as of the end of the period covered by this report based on such
                                                               evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s
                                                               internal control over financial reporting that occurred during
                                                               the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                                               fourth fiscal quarter in the case of an annual report) that has
                                                               materially affected, or reasonably likely to materially affect,
                                                               registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed,
                                                          based on our most recent evaluation of internal control over financial
                                                          reporting, to the registrant&rsquo;s auditors and the audit committee
                                                          of the registrant&rsquo;s board of directors (or persons performing
                                                          the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 15, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; border-bottom: black 1.5pt solid; padding-right: 0.8pt">/s/&nbsp;KYLE FRANCIS</TD>
    <TD STYLE="width: 61%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">KYLE FRANCIS</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Chief&nbsp;Financial&nbsp;Officer</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>v312954_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to 18 U.S.C. Section 1350, as
created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Apollo Medical Holdings, Inc. (the &ldquo;Company&rdquo;)
hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in">(i)</TD><TD>The Annual Report on Form 10-K of the Company for the year
                                                                 ended January 31, 2012 (the &ldquo; <U>Report</U> &rdquo;), fully
                                                                 complies with the requirements of Section 13(a) or Section 15(d),
                                                                 as applicable, of the Securities Exchange Act of 1934, as amended;
                                                                 and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in">(ii)</TD><TD>The information contained in the Report fairly presents,
                                                                  in all material respects, the financial condition and results
                                                                  of operations of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">Dated: May 15, 2012</TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; padding-right: 0.8pt">/s/&nbsp;WARREN&nbsp;HOSSEINION,&nbsp;M.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">WARREN HOSSEINION, M.D.&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Chief Executive Officer&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>v312954_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to 18 U.S.C. Section 1350, as created by Section 906
of the Sarbanes-Oxley Act of 2002, the undersigned officer of Apollo Medical Holdings, Inc.(the &ldquo;Company&rdquo;) hereby
certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in">(i)</TD><TD>The Annual Report on Form 10-K of the Company for the year
                                                                 ended January 31, 2012 (the &ldquo; <U>Report</U> &rdquo;), fully
                                                                 complies with the requirements of Section 13(a) or Section 15(d),
                                                                 as applicable, of the Securities Exchange Act of 1934, as amended;
                                                                 and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in">(ii)</TD><TD>The information contained in the Report fairly presents,
                                                                  in all material respects, the financial condition and results
                                                                  of operations of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">Dated: May 15, 2012</TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; padding-right: 0.8pt">/s/&nbsp;KYLE FRANCIS</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-left: 9pt">&nbsp; KYLE FRANCIS</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Chief&nbsp;Financial&nbsp;Officer&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>ameh-20120131.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.14.9 -->
<!-- Round: 78e78d3c-9523-426b-a0b4-c45cd75b162c -->
<!-- Creation date: 2012-05-14T14:40:59Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ameh="http://www.apollomed.net/20120131" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="ameh-20120131.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE61543---1210-K0001_STD_0_20120430_0" unitRef="shares" decimals="INF" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_2_500008">30635774</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat contextRef="eol_PE61543---1210-K0001_STD_0_20110731_0" unitRef="iso4217_USD" decimals="0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_3_600009">988413</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE61543---1210-K0001_STD_0_20100131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2001_28">665737</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20100131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_1006_900001">-46393</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x440920" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_1005_800001">-1241031</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x443747" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_1004_700001">228115</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding contextRef="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x444581" unitRef="shares" decimals="INF" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_1001_400001">27041328</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x444581" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_1001_500001">27041</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x453698" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_1003_600001">939483</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:DeferredFinanceCostsCurrentNet contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_7">37500</us-gaap:DeferredFinanceCostsCurrentNet>
  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_9">39500</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_22">92745</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_23">1248588</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_37">-1397363</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_2">704971</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_13">1258139</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_31">27636</us-gaap:CommonStockValue>
  <us-gaap:MinorityInterest contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_39">228115</us-gaap:MinorityInterest>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="shares" decimals="INF" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_35">27635774</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="shares" decimals="INF" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_29">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_8">1197483</us-gaap:AssetsCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_6">29138</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_1">397101</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_32">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_36">1058418</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DueFromOfficersOrStockholdersCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_4">24873</us-gaap:DueFromOfficersOrStockholdersCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_16">92745</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_41">1258139</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="shares" xsi:nil="true" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_30" />
  <us-gaap:PreferredStockValue contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" xsi:nil="true" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_27" />
  <us-gaap:StockholdersEquity contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_38">-311309</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="shares" decimals="INF" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_34">27635774</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_28">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_10">21593</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="shares" decimals="INF" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_33">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_25">1341333</us-gaap:Liabilities>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_40">-83194</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:DueFromAffiliateCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_2_5">3900</us-gaap:DueFromAffiliateCurrent>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x440920" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_3005_800005">-1397362</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x443747" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_3004_700005">228115</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x444581" unitRef="shares" decimals="INF" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_3001_400005">27635774</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x444581" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_3001_500005">27636</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x453698" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_3003_600005">1058418</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:DeferredFinanceCostsCurrentNet contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_7">37500</us-gaap:DeferredFinanceCostsCurrentNet>
  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_9">1563</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_22">1515268</us-gaap:LiabilitiesCurrent>
  <us-gaap:AdvancesOnInventoryPurchases contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_3">2140</us-gaap:AdvancesOnInventoryPurchases>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_23">150000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_19">653026</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_37">-2117708</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_2">994118</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_13">1364048</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_31">29336</us-gaap:CommonStockValue>
  <us-gaap:MinorityInterest contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_39">238101</us-gaap:MinorityInterest>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_20">90000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="shares" decimals="INF" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_35">29335774</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="shares" decimals="INF" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_29">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:AssetsCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_8">1249224</us-gaap:AssetsCurrent>
  <us-gaap:Goodwill contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_12">32000</us-gaap:Goodwill>
  <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_21">12400</us-gaap:DueToOfficersOrStockholdersCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_6">45601</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_1">164361</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_24">120000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_17">596366</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_32">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_36">1429051</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_16">163476</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_41">1364048</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="shares" xsi:nil="true" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_30" />
  <us-gaap:PreferredStockValue contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" xsi:nil="true" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_27" />
  <us-gaap:StockholdersEquity contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_38">-659321</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="shares" decimals="INF" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_34">29335774</us-gaap:CommonStockSharesIssued>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_11">38000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_28">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_10">43261</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="shares" decimals="INF" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_33">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_25">1785268</us-gaap:Liabilities>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_40">-421220</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:DueFromAffiliateCurrent contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_5">5504</us-gaap:DueFromAffiliateCurrent>
  <ameh:ConvertibleNotesCurrentUnamortizedDiscount contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_F6D01787-5F36-480C-833D-21197790BAE5_1_18">653026</ameh:ConvertibleNotesCurrentUnamortizedDiscount>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x440920" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_6005_800012">-2117708</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x443747" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_6004_700012">238101</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x444581" unitRef="shares" decimals="INF" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_6001_400012">29335774</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x444581" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_6001_500012">29336</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x453698" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_6003_600012">1429051</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:GrossProfit contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_2">581862</us-gaap:GrossProfit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_4006_900003">72152</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_21">-21165</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_11">290363</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_32">1600</us-gaap:IncomeTaxesPaid>
  <us-gaap:Revenues contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_0">3896584</us-gaap:Revenues>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_17">-245031</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_7">1006</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_5">47378</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_13">-154731</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_15">-1027</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:Depreciation contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_5">11198</us-gaap:Depreciation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_16">-11507</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_9">126431</us-gaap:InterestExpense>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_4">42908</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:NetIncomeLoss contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_15">-156331</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_12">158746</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:StockOptionPlanExpense contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_6">72152</us-gaap:StockOptionPlanExpense>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_19">21165</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_7">4015</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_11">5185</us-gaap:OtherNonoperatingIncome>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_14">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_27">-268636</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_23">2440</us-gaap:RepaymentsOfRelatedPartyDebt>
  <us-gaap:InterestPaid contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_31">125425</us-gaap:InterestPaid>
  <us-gaap:OperatingExpenses contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_6">577847</us-gaap:OperatingExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_4">566649</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_26">-2440</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_10">37500</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:CostOfServices contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_1">3314722</us-gaap:CostOfServices>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_2_14">-37500</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_17">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
  <ameh:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0" unitRef="shares" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_16">27490476</ameh:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:NetIncomeLoss contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x440920" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_4005_800004">-156331</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x444581_455296x455803" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_5001_500002">595</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x444581_455296x455803" unitRef="shares" decimals="INF" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_5001_400002">594446</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x453698" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_4003_600003">72152</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x453698_455296x455803" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_5003_600002">46783</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE61543---1210-K0001_STD_365_20110131_0_455296x455803" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_5006_900002">47378</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_79C53FBC-DB41-419E-A88C-949885381FEB_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityVoluntaryFilers contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_1_400006">No</dei:EntityVoluntaryFilers>
  <dei:TradingSymbol contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_1_400000">AMEH</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_1_400001">APOLLO MEDICAL HOLDINGS, INC.</dei:EntityRegistrantName>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_1_400005">Yes</dei:EntityCurrentReportingStatus>
  <dei:AmendmentFlag contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_79C53FBC-DB41-419E-A88C-949885381FEB_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_1_400007">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_79C53FBC-DB41-419E-A88C-949885381FEB_1_3">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_79C53FBC-DB41-419E-A88C-949885381FEB_1_0">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_79C53FBC-DB41-419E-A88C-949885381FEB_1_2">2012-01-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_1_400002">0001083446</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_1_400004">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_73A1FC4D-B0C0-467B-A793-0B410F4128F6_1_400003">--01-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:GrossProfit contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_2">978407</us-gaap:GrossProfit>
  <us-gaap:StockIssued1 contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_34">280000</us-gaap:StockIssued1>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_24">150000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_12">-14953</us-gaap:IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_0495D065-F42B-45D0-ABED-CB1618DBFA26_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;15.
Stockholder&amp;#x2019;s Deficit&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The
Company issued a total of 1,350,000 common shares during the twelve
months ended January 31, 2012 related to acquisitions (see Note
17).&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The
Company authorized the issuance 600,000 shares of common stock for
compensation related to consulting and directors fees during the
twelve months ended January 31, 2012. The shares were valued at
$90,000 based on the fair values of the shares at the issuance
dates. These shares were not issued as January 31, 2012 and as such
have been recorded as shares to be issued in current
liabilities.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The
Company issued 350,000 shares of common stock for compensation to
the CFO during the twelve months ended January 31, 2012. The shares
were valued at $63,000 based on the fair value of the shares at the
issuance date.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The
Company issued a total of 594,446 common shares in the twelve
months ended January 31, 2011, including 244,446 shares issued to
officers and directors and 350,000 shares issued to Kanehoe
Advisors related to professional services related to the issuances.
The total shares were valued at $47,378 based on the fair value of
the shares at the issuance dates.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Warrants outstanding:&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Aggregate&lt;br /&gt;
intrinsic&lt;br /&gt;
value&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Number&amp;#xA0;of&amp;#xA0;warrants&lt;br /&gt;
issued&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="WIDTH: 62%"&gt;Outstanding at January 31, 2011&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 16%"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 16%"&gt;1,655,333&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;,&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;Lapsed&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(155,333&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;Outstanding at January 31,
2012&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,500,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#xA0;Price&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Warrants&lt;br /&gt;
outstanding&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Weighted&lt;br /&gt;
average&lt;br /&gt;
remaining&lt;br /&gt;
contractual&amp;#xA0;life&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Warrants&lt;br /&gt;
exercisable&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Weighted&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
average&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
exercise&amp;#xA0;price&lt;/p&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 18%"&gt;0.114850&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt;1,250,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt;2.75&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt;1,250,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt;0.114850&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0.114850&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;250,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2.75&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;250,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0.114850&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;In
conjunction with the completion of the private placement on October
16, 2009, as described in Note 11, the Company issued a total of
1,500,000 warrants. Of this amount, 1,250,000 warrants were issued
to the holders of the Convertible Notes and 250,000 warrants were
granted to the placement agent. The 1,250,000 warrants held by the
note holders are exercisable into shares of Common Stock at an
initial exercise price of $0.11485. The Warrants have a five-year
term and expire on October 31, 2014. The 250,000 warrants conveyed
to the placement agent also have a five-year term, expire on
October 31, 2014, and are exercisable at $0.11485 per share.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2010
Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On
March 4, 2010, the Company&amp;#x2019;s Board of Directors approved the
2010 Equity Incentive Plan (the &amp;#x201C;Plan&amp;#x201D;). The Plan
provides for the granting of the following types of awards to
persons who are employees, officers, consultants, advisors, or
directors of our Company or any of its affiliates:&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Under
the Plan, the Company may issue a variety of equity vehicles to
provide flexibility in implementing equity awards, including
incentive stock options, nonqualified stock options, restricted
stock grants and stock appreciation rights. The exercise price of
stock options offered under the Plan shall not be less than the
fair market value of the Company&amp;#x2019;s common stock on the date
of the grant. The exercise price of an ISO granted to any person
who owns, directly or by attribution under the Code (currently
Section 424(d)), stock possessing more than 10% of the total
combined voting power of all classes of stock of the Company or of
any affiliate (a &amp;#x201C;10% Stockholder&amp;#x201D;) shall in no event
be less than 110% of the fair market value (determined in
accordance with Section 6.1.10) of the stock covered by the option
at the time the option is granted.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Subject
to the adjustment provisions of the Plan that are applicable in the
event of a stock dividend, stock split, reverse stock split or
similar transaction, up to 5,000,000 shares of common stock may be
issued under the Plan. Options granted under the Plan generally
vest over a three-year period and generally expire five years from
the date of grant.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;As of
January 31, 2012, options to purchase an aggregate of 883,332
shares of common stock were exercisable under the Company&amp;#x2019;s
stock option Plan. During the year ended January 31, 2012, the
Company did not issue options to purchase shares of common stock
with exercise prices below the fair market value of the common
stock on the dates of grant.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Stock
option transactions under the Company&amp;#x2019;s stock option plans
for the year ended January 31, 2012 are summarized below:&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Shares&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Per&amp;#xA0;Share&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
Remaining&lt;br /&gt;
Contractual&amp;#xA0;Term&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Aggregate&lt;br /&gt;
Intrinsic&amp;#xA0;Value&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;Balance, January 31, 2011&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt; WIDTH: 48%"&gt;Granted&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,150,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;0.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Expired&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;Forfeited&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;Balance, January 31, 2012&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,150,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;8.9 years&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Vested and expected to vest&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,150,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.9 years&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;Exercisable, January 31, 2012&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;883,332&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.9 years&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;As
January 31, 2012, options available for future grant under the Plan
amounted to 3,850,000.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Information regarding stock options outstanding at January 31, 2012
is as follows:&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td colspan="2" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="10" nowrap="nowrap"&gt;
Options&amp;#xA0;Outstanding&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;
Options&amp;#xA0;Exercisable&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;
Range&amp;#xA0;of&amp;#xA0;exercise&lt;br /&gt;
prices&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;
Number&lt;br /&gt;
outstanding&amp;#xA0;at&lt;br /&gt;
January&amp;#xA0;31,&lt;br /&gt;
2012&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;
Weighted&lt;br /&gt;
average&lt;br /&gt;
remaining&lt;br /&gt;
contractual&amp;#xA0;life&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;
Weighted&lt;br /&gt;
average&lt;br /&gt;
exercise&amp;#xA0;price&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;
Number&lt;br /&gt;
exercisable&amp;#xA0;at&lt;br /&gt;
January&amp;#xA0;31,&lt;br /&gt;
2012&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;
Weighted&lt;br /&gt;
average&lt;br /&gt;
exercise&lt;br /&gt;
price&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%"&gt;0.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%"&gt;1,150,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%"&gt;8.9 years&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%"&gt;0.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%"&gt;883,332&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 13%"&gt;0.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_6BCF0065-319F-4EC2-8356-108C3E391B8B_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;6. Due from Affiliate&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Amounts due from affiliate represents advances made by the Company
to Apollo Medical Associates (&amp;#x201C;AMA&amp;#x201D;). These balances
are due on demand, non-interest bearing and are unsecured. AMA is
an unconsolidated affiliate of the Company and currently has no
operations and is inactive. No management agreement currently
exists between AMM and AMA.&lt;/p&gt;
&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_21">157005</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8006_900008">-154290</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_11">407224</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_32">2400</us-gaap:IncomeTaxesPaid>
  <us-gaap:MinorityInterestDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_D1E2D7BD-A0CE-4837-B5B9-9409663BD9A2_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;14&amp;#xA0;&amp;#xA0;Non-Controlling Interest&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Activity within non-controlling interest for the twelve-months
ended January 31, 2012 consisted of the following:&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.3in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="WIDTH: 82%"&gt;Beginning balance as of January 31,
2011&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;228,115&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;Acquisition-related non-controlling interest&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;164,276&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Distributions to
non-controlling interest shareholder&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(154,290&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;Ending balance as of January 31,
2012&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
238,101&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
  <us-gaap:Revenues contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_0">5110806</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseDueFromAffiliates contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_13">1604</us-gaap:IncreaseDecreaseDueFromAffiliates>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_DFC500AE-7FB4-4CAA-AC01-2F2B9A9F9F08_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;16.&lt;/b&gt; &lt;b&gt;Commitments and Contingency&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
On March 15, 2009, the Company entered into a Consulting Agreement
with Kaneohe Advisors LLC (Kyle Francis) under which Mr. Francis
became the Company&amp;#x2019;s Executive Vice President, Business
Development and Strategy. Under the terms of the Agreement, Mr.
Francis is compensated at a rate of $8,000 per month. In addition,
Mr. Francis received 350,000 shares of restricted stock at the date
of the Agreement and is entitled to 350,000 additional restricted
shares on the first and second anniversaries of the Agreement,
provided the Agreement is not terminated. The initial 350,000
shares, along with 50,000 shares granted to Mr. Francis in the year
ended January 2009, were issued in the third quarter ended October
31, 2009. On March 15, 2010, the second anniversary of the
Consulting Agreement, Mr. Francis was granted an additional 350,000
shares. On March 15, 2011, Mr. Francis was granted an additional
350,000 shares on the third anniversary of the before mentioned
Consulting Agreement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
On September 4, 2008, Apollo Medical Management, Inc. executed an
employment agreement with Jilbert Issai, M.D., to provide services
as Senior Vice President. The agreement is for an initial one-year
term with provision for successive one-year periods. Under the
agreement, Dr. Issai is entitled to a nominal salary and may be
granted options to purchase an aggregate of 300,000 shares of the
Company&amp;#x2019;s common stock at an exercise price of $0.15 per
share when and if the Company is to adopt a stock compensation
plan. The Company granted Dr. Issai 300,000 options on December 9,
2010.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Effective as of January 1, 2012, Suresh Nihalani was re-elected to
the Company&amp;#x2019;s Board of Directors. In connection with his
service to the Company as a director, In connection with his
service to the Company as a director, Mr. Nihalani entered into the
Company&amp;#x2019;s form of Director Agreement, which provides for Mr.
Nihalani to be a director and Mr. Nihalani received a restricted
stock grant of 400,000 shares of the Company&apos;s Common Stock. The
shares will vest monthly at a rate of 1/36 per month over a three
year time period.&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_17">-385455</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_7">804</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_5">152400</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_13">-714527</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_15">22668</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:Depreciation contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_5">12589</us-gaap:Depreciation>
  <us-gaap:PaymentsToMinorityShareholders contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_25">154290</us-gaap:PaymentsToMinorityShareholders>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_16">70731</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:MinorityInterestIncreaseFromStockIssuance contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8006_900007">164276</us-gaap:MinorityInterestIncreaseFromStockIssuance>
  <us-gaap:InterestExpense contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_9">131534</us-gaap:InterestExpense>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_527450DD-7136-4A49-AABE-6BC5E1CAC4A5_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;18.
Subsequent Events&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;As of
March 7, 2012, an entity affiliated with Mr. Augusta, SpaGus
Capital Partners, LLC, had provided a $270,000 seven-month loan to
the Company. The Company prepaid interest expenses of $15,000 and
closing costs of $5,000.&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_4">118077</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:NetIncomeLoss contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_15">-720346</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_12">-301192</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_8242EAC8-8F4C-483F-980E-B22057D1B078_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Our consolidated financial statements include the accounts of
Apollo Medical Holdings, Inc. and its wholly owned subsidiaries
AMM, , Aligned Healthcare Group (&amp;#x201C;AHI&amp;#x201D;) and PCCM as
well as Professional Medical Corporations managed under long-term
management agreements including AMH and LALC. Some states have laws
that prohibit business entities, such as ApolloMed, from practicing
medicine, employing physicians to practice medicine, exercising
control over medical decisions by physicians (collectively known as
the corporate practice of medicine), or engaging in certain
arrangements with physicians, such as fee-splitting. In California,
we operate by maintaining long-term management contracts with the
Professional Medical Corporations, which are each owned and
operated by physicians, and which employ or contract with
additional physicians to provide hospitalist services. Under the
management agreements, we provide and perform all non-medical
management and administrative services, including financial
management, information systems, marketing, risk management and
administrative support. The management agreements have an initial
term of 20 years unless terminated by either party for cause. The
management agreements are not terminable by the Professional
Medical Corporations, except in the case of gross negligence,
fraud, or other illegal acts by us, or bankruptcy of ApolloMed.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Through the management agreements and our relationship with the
stockholders of the Professional Medical Corporations, we have
exclusive authority over all non-medical decision making related to
the ongoing business operations of the Professional Medical
Corporations. Consequently, we consolidate the revenue and expenses
of the Professional Medical Corporations from the date of execution
of the management agreements. All intercompany balances and
transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
All intercompany balances and transactions are eliminated in
consolidation.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Non-controlling Interest&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Non-controlling interest represents the portion of equity that is
not attributable to the Company. The non-controlling interest
recorded in our consolidated financial statements represents the
pre-acquisition equity of those entities which we have determined
that we have a controlling financial interest and that
consolidation is required as a result of management contracts
entered into with these entities. The nature of these contracts
provide us with a monthly management fee to provide the services
described above, and as such, the only adjustments to
non-controlling interests in any period subsequent to initial
consolidation would relate to either capital contributions or
withdrawals by the non-controlling parties.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The preparation of financial statements in conformity with
generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting
period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Our accounting for Fair Value Measurement and Disclosures, defines
fair value as the exchange price that would be received for an
asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in
an orderly transaction between market participants on the
measurement date. This topic also establishes a fair value
hierarchy which requires classification based on observable and
unobservable inputs when measuring fair value. The fair value
hierarchy distinguishes between assumptions based on market data
(observable inputs) and an entity&amp;#x2019;s own assumptions
(unobservable inputs). The hierarchy consists of three levels:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Level one &amp;#x2014; Quoted market prices in active markets for
identical assets or liabilities;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Level two &amp;#x2014; Inputs other than level one inputs that are
either directly or indirectly observable; and&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Level three &amp;#x2014; Unobservable inputs developed using estimates
and assumptions, which are developed by the reporting entity and
reflect those assumptions that a market participant would use.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Determining which category an asset or liability falls within the
hierarchy requires significant judgment. The Company evaluates its
hierarchy disclosures each quarter. The Company currently records
warrants using level two in the hierarchy.&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The carrying values of cash and cash equivalents, trade and other
receivables, trade and other payables approximate their fair values
due to the short maturities of these instruments.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Fair Value of Warrants&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company accounts for free-standing warrants for shares of
common stock by first determining whether the instruments require
liability treatment based on the provision in the warrant
agreements. Generally, when the agreement may require future
performance obligations on the part of the Company (other than the
issuance of common shares in connection with notice of exercise) or
the exercise price of warrants is not fixed or determinable, then
the warrants are treated as liabilities and recorded at their
relative fair value as of each reporting period. If the warrants
are determined to be equity-classified instruments, then the
warrants are recorded as an increase in additional paid-in capital
with a corresponding discount.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company accounts for warrants included with convertible notes
by first allocating the proceeds of issuance among the convertible
instrument and the stock warrants based on their relative fair
values, as there are two separate instruments involved. Following
this, it is then further determined whether the embedded conversion
option has an intrinsic value. The fair value of the warrants is
recorded as an increase to additional paid-in capital with a
corresponding discount on the related notes.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Subsequent adjustments to the exercise price of the warrants are
recorded at the date of the change. Warrants that are classified as
liabilities, are re-measured at each reporting period and changes
in the fair value are reported in the Company&amp;#x2019;s statement of
operations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Concentrations&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
During the twelve month period ended January 31, 2012, the Company
had three major customers, which contributed 34%, 17% and 7.6% of
revenue. As of January 31, 2012, the total receivables from these
customers amounted to $140,000, $89,099 and $41,900,
respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
During the twelve month period ended January 31, 2011, the Company
had three major customers, which contributed 36%, 20% and 12% of
revenue. As of January 31, 2011, the total receivables from these
customers amounted to $170,638, $167,799 and $88,580,
respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Employee Stock Options and Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
All share-based payments to employees, including grants of employee
stock options, are recognized in the financial statements based on
their fair values. There were no stock options granted during the
year ended January 31, 2012. For options granted during the year
ended January 31, 2011, the fair value of each option award was
estimated using the Black-Scholes option pricing model and the
following assumptions:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"&gt;
Year&amp;#xA0;ended&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"&gt;
January&amp;#xA0;31,&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"&gt;
2012&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 87%"&gt;Weighted average risk-free interest
rate&lt;/td&gt;
&lt;td style="width: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;1.9&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;0&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left"&gt;Volatility factor of the expected
market price of the Company&apos;s common stock&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;80&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td&gt;Weighted average live&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;10.0 years&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Expected volatility is based on the historical volatility of the
Company&amp;#x2019;s stock. The Company also uses historical data to
estimate the expected term of options granted and employee
termination rates. The risk-free rate for periods within the
expected useful life of the options is based on the U.S. Treasury
yield curve in effect at the time of grant.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The estimated weighted average fair value of options granted during
the year ended January 31, 2011, was $ $0.011. As of January 31,
2012 and 2011, there was approximately $25,015 and $54,348,
respectively, of total unrecognized compensation cost related to
non-vested share-based employee compensation arrangements. The
remaining unrecognized expense at January 31, 2012, is expected to
be recognized during the fiscal year end January 31, 2013.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Stock options and warrants issued to non-employees as compensation
for services to be provided to the Company are accounted for based
upon the fair value of the services provided or the estimated fair
value of the option or warrant, whichever can be more clearly
determined. The Company recognizes this expense over the period in
which the services are provided. During the years ended January 31.
2012 and 2011, the Company&amp;#x2019;s operating results included
$29,333 and $72,152, respectively, for non-cash stock-based
compensation for options issued to consultants and other
non-employees.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company issues new shares to satisfy stock option and warrant
exercises. There were no options exercised during the years ended
January 31, 2012 or 2011.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Basic and Diluted Earnings Per Share&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Basic net loss per share is calculated using the weighted average
number of shares of the Company&amp;#x2019;s common stock issued and
outstanding during a certain period, and is calculated by dividing
net loss by the weighted average number of shares of the
Company&amp;#x2019;s common stock issued and outstanding during such
period. Diluted net loss per share is calculated using the weighted
average number of common and potentially dilutive common shares
outstanding during the period, using the as-if converted method for
secured convertible notes, and the treasury stock method for
options and warrants.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Cash and Cash Equivalents and Concentration of Cash&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company considers all short-term investments with an original
maturity of three months or less to be cash equivalents.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Cash and cash equivalents at January 31, 2012, include cash in bank
representing the Company&amp;#x2019;s current operating account and
$27,407 in a brokerage money market account.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;
&amp;#xA0;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Accounts Receivable and Allowance for Doubtful
Accounts&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Accounts receivable primarily consists of amounts due from
third-party payors, including government sponsored Medicare and
Medicaid programs, and insurance companies, and amounts due from
hospitals, and patients. Accounts receivable are recorded and
stated at the amount expected to be collected&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company maintains reserves for potential credit losses on
accounts receivable. Management reviews the composition of accounts
receivable and analyzes historical bad debts, customer
concentrations, customer credit worthiness, current economic trends
and changes in customer payment patterns to evaluate the adequacy
of these reserves. Reserves are recorded primarily on a specific
identification basis.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;br /&gt;
Property and Equipment is recorded at cost and depreciated using
the straight- line method over the estimated useful lives of the
respective assets. Cost and related accumulated depreciation on
assets retired or disposed of are removed from the accounts and any
resulting gains or losses are credited or charged to income.
Computers and Software are depreciated over 3 years. Furniture and
Fixtures are depreciated over 8 years. Machinery and Equipment are
depreciated over 5 years.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company accounts for income taxes using an asset and liability
approach which allows for the recognition and measurement of
deferred tax assets based upon the likelihood of realization of tax
benefits in future years. Under the asset and liability approach,
deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income
tax purposes. A valuation allowance is provided for deferred tax
assets if it is more likely than not these items will either expire
before the Company is able to realize their benefits, or that
future deductibility is uncertain.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
A tax position is recognized as a benefit only if it is &amp;#x201C;more
likely than not&amp;#x201D; that the tax position would be sustained in
a tax examination, with a tax examination being presumed to occur.
The evaluation of a tax position is a two-step process. The first
step is to determine whether it is more-likely-than-not that a tax
position will be sustained upon examination, including the
resolution of any related appeals or litigations based on the
technical merits of that position. The second step is to measure a
tax position that meets the more-likely-than-not threshold to
determine the amount of benefit to be recognized in the financial
statements. A tax position is measured at the largest amount of
benefit that is greater than 50 percent likely of being realized
upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be
recognized in the first subsequent period in which the threshold is
met. Previously recognized tax positions that no longer meet the
more-likely-than-not criteria should be de-recognized in the first
subsequent financial reporting period in which the threshold is no
longer met. Penalties and interest incurred related to underpayment
of income tax are classified as income tax expense in the year
incurred.&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Revenue consists of contracted and fee-for-service revenue. Revenue
is recorded in the period in which services are rendered. Our
revenue is principally derived from the provision of healthcare
staffing services to patients within healthcare facilities. The
form of billing and related risk of collection for such services
may vary by customer. The following is a summary of the principal
forms of our billing arrangements and how net revenue is recognized
for each.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Contracted revenue represents revenue generated under contracts in
which we provide physician and other healthcare staffing and
administrative services in return for a contractually negotiated
fee. Contract revenue consists primarily of billings based on hours
of healthcare staffing provided at agreed-to hourly rates. Revenue
in such cases is recognized as the hours are worked by our staff
and contractors. Additionally, contract revenue also includes
supplemental revenue from hospitals where we may have a
fee-for-service contract arrangement or provide physician advisory
services to the medical staff at specific facility. Contract
revenue for the supplemental billing in such cases is recognized
based on the terms of each individual contract. Such contract terms
generally either provides for a fixed monthly dollar amount or a
variable amount based upon measurable monthly activity, such as
hours staffed, patient visits or collections per visit compared to
a minimum activity threshold. Such supplemental revenues based on
variable arrangements are usually contractually fixed on a monthly,
quarterly or annual calculation basis considering the variable
factors negotiated in each such arrangement. Such supplemental
revenues are recognized as revenue in the period when such amounts
are determined to be fixed and therefore contractually obligated as
payable by the customer under the terms of the respective
agreement. Additionally, we derive a portion of our revenue as a
contractual bonus from collections received by our partners and
such revenue is contingent upon the collection of third-party
billings. These revenues are not considered earned and therefore
not recognized as revenue until actual cash collections are
achieved in accordance with the contractual arrangements for such
services.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Fee-for-service revenue represents revenue earned under contracts
in which we bill and collect the professional component of charges
for medical services rendered by our contracted and employed
physicians. Under the fee-for-service arrangements, we bill
patients for services provided and receive payment from patients or
their third-party payers. Fee-for-service revenue is reported net
of contractual allowances and policy discounts. All services
provided are expected to result in cash flows and are therefore
reflected as net revenue in the financial statements.
Fee-for-service revenue is recognized in the period in which the
services are rendered to specific patients and reduced immediately
for the estimated impact of contractual allowances in the case of
those patients having third-party payer coverage. The recognition
of net revenue (gross charges less contractual allowances) from
such visits is dependent on such factors as proper completion of
medical charts following a patient visit, the forwarding of such
charts to our billing center for medical coding and entering into
our billing system and the verification of each patient&amp;#x2019;s
submission or representation at the time services are rendered as
to the payer(s) responsible for payment of such services. Revenue
is recorded based on the information known at the time of entering
of such information into our billing systems as well as an estimate
of the revenue associated with medical services.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
In December 2010, the Financial Accounting Standards Board issued
Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) No. 2010-29,
&lt;i&gt;Business Combinations, Disclosure of Supplementary Pro Forma
Information for Business Combinations&lt;/i&gt; (&amp;#x201C;ASU
2010-29&amp;#x201D;), which provides clarification regarding pro forma
revenue and earnings disclosure requirements for business
combinations. The amendments in this ASU specify that if a public
entity presents comparative financial statements, the entity should
disclose only revenue and earnings of the combined entity as though
the business combination(s) that occurred during the current year
had occurred as of the beginning of the comparable prior annual
reporting period. The amendments also expand the supplemental pro
forma disclosures to include a description of the nature and amount
of material, nonrecurring pro forma adjustments directly
attributable to the business combination included in the reported
pro forma revenue and earnings. The amendments are effective
prospectively for business combinations for which the acquisition
date is on or after the beginning of the first annual reporting
period beginning on or after December 15, 2010. Early adoption is
permitted. The Company adopted ASU 2010-29 during the first interim
reporting period of 2011 as it relates to pro-forma disclosure of
the Company&amp;#x2019;s acquisitions. The adoption of ASU 2010-29 did
not have a material impact on the Company&amp;#x2019;s consolidated
financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
ASU No. 2010-28, &lt;i&gt;Intangibles &amp;#x2014; Goodwill and Other, When to
Perform Step 2 of the Goodwill Impairment Test for Reporting Units
with Zero or Negative Carrying Amounts&lt;/i&gt; (&amp;#x201C;ASU
2010-28&amp;#x201D;) was issued in December 2010. The amendments in this
ASU modify Step 1 of the goodwill impairment test for reporting
units with zero or negative carrying amounts. For those reporting
units, an entity is required to perform Step 2 of the goodwill
impairment test if it is more likely than not that a goodwill
impairment exists. In determining whether it is more likely than
not that impairment to goodwill exists, an entity should consider
whether there are any events or circumstances that would more
likely than not reduce the fair value of a reporting unit below its
carrying amount. The amendments in this ASU are effective for
fiscal years, and interim periods within those years, beginning
after December 15, 2010. Early adoption is not permitted. The
Company adopted ASU 2010-28 for the quarter ending March 31,
2011.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&lt;font style="color: black"&gt;In December 2011, the FASB issued
guidance on offsetting (netting) assets and liabilities. Entities
are required to disclose both gross information and net information
about both instruments and transactions eligible for offset in the
statement of financial position and instruments and transactions
subject to an agreement similar to a master netting arrangement.
The new guidance is effective for annual periods beginning after
January 1, 2013.&lt;/font&gt; We do not expect the adoption of this
revised GAAP to have a material effect on our financial
position.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
In September 2011, the FASB issued a GAAP update on goodwill to
allow an entity the option of performing a qualitative assessment
before calculating the fair value of the reporting unit when
testing goodwill for impairment. If the qualitative assessment
concludes that it is more likely than not that the fair value of a
reporting unit is less than its carrying value, the entity shall
perform the quantitative two-step goodwill impairment test.
Otherwise, the two-step goodwill impairment test is not required.
This revised GAAP will be effective for fiscal years beginning
after December 15, 2011, with early adoption permitted. We do not
expect the adoption of this revised GAAP to have a material effect
on our financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;font style="font-family: Times New Roman, Times, Serif"&gt;In June
2011, the FASB issued guidance on presentation of comprehensive
income. The new guidance eliminates the current option to report
other comprehensive income and its components in the statement of
changes in equity. Instead, an entity will be required to present
either a continuous statement of net income and other comprehensive
income or in two separate but consecutive statements. The new
guidance is effective for annual periods beginning after December
15, 2011. In December 2011, the FASB issued a deferral of certain
portion of this guidance&lt;/font&gt;. &lt;font style="font-family: Times New Roman, Times, Serif"&gt;We do not expect the
adoption of this revised GAAP to have a material effect on our
financial position.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
In May 2011, the FASB issued a GAAP update on fair value
measurement, which eliminates differences between U.S. GAAP and
International Financial Reporting Standards (IFRS), resulting in a
consistent definition of fair value and common requirements for
measurement of and disclosure about fair value between GAAP and
IFRS. It also expands the disclosures for fair value measurements
that are estimated using significant unobservable (Level 3) inputs.
This revised GAAP will be effective for annual and interim periods
beginning after December 15, 2011. We do not expect the adoption of
this revised GAAP to have a material effect on our financial
position, results of operations or cash flows.&lt;/p&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_9">210000</us-gaap:AssetImpairmentCharges>
  <us-gaap:StockOptionPlanExpense contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_6">29333</us-gaap:StockOptionPlanExpense>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_19">7205</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NatureOfOperations contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_E2333796-5EEF-4CBA-B0EE-CF3FA9CFB72C_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;1.
Organization and Summary of Critical Accounting Policies&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Apollo
Medical Holdings, Inc. (&amp;#x201C;Apollo&amp;#x201D; or the
&amp;#x201C;Company&amp;#x201D;) is a leading provider of hospitalist
services in the Greater Los Angeles, California area. Hospitalist
medicine is organized around the admission and care of patients in
an inpatient facility such as a hospital or skilled nursing
facility and is focused on providing, managing and coordinating the
care of hospitalized patients. Apollo Medical Holdings, Inc.
operates as a medical management holding company that focuses on
managing the provision of hospital-based medicine through a wholly
owned subsidiary-management companies, Apollo Medical Management,
Inc. (&amp;#x201C;AMM&amp;#x201D;) and Pulmonary Critical Care Management,
Inc. (&amp;#x201C;PCCM&amp;#x201D;). Through AMM and PCCM, the Company
manages affiliated medical groups, which primarily consists of
ApolloMed Hospitalists (&amp;#x201C;AMH and Los Angeles Lung Center
(&amp;#x201C;LALC&amp;#x201D;). AMM and PCCM operate as a Physician Practice
Management Company (PPM) and is in the business of providing
management services to Physician Practice Companies (PPC) under
Management Service Agreements.&lt;/p&gt;
&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_7">-413335</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_11">2842</us-gaap:OtherNonoperatingIncome>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_A4BE5731-654C-4153-9E7C-34F2A24E889A_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;9.&lt;/b&gt; &lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Property and Equipment consisted of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;
January&amp;#xA0;31,&lt;br /&gt;
2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;
January&amp;#xA0;31,&lt;br /&gt;
2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 74%"&gt;Website&lt;/td&gt;
&lt;td style="width: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;4,568&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;4,568&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td&gt;Computers&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;13,912&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;13,912&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td&gt;Software&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;155,039&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;155,039&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;71,553&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;50,815&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;5,302&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;-&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold
improvements&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;
8,198&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;
-&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left; padding-left: 9pt"&gt;Gross Property and
Equipment&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;258,572&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;224,334&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in"&gt;Less
accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;
(215,311&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;
(202,741&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left; padding-left: 9pt; padding-bottom: 2.5pt"&gt;Net
Property and Equipment&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;
$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;
43,261&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;
$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;
21,593&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Depreciation expense was $12,589 and $11,198 for the twelve month
periods ended January 31, 2012 and 2011, respectively.&lt;/p&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_14">5819</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_27">-232740</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_AB9E5F3F-BB66-483D-9D99-E114DB75BA07_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;12. Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company uses the liability method of accounting for income
taxes as set forth in ASC 740 (formerly Statement of Financial
Accounting Standards No. 109, &amp;#x201C;Accounting for Income
Taxes&amp;#x201D; (&amp;#x201C;SFAS 109&amp;#x201D;)). Under the liability method,
deferred taxes are determined based on differences between the
financial statement and tax bases of assets and liabilities using
enacted tax rates. As of January 31, 2012, the Company had federal
and California tax net operating loss carryforwards of
approximately $1,981,000 and $2,060,000, respectively. The federal
and California net operating loss carryforwards will expire at
various dates from 2028 through 2031.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company&amp;#x2019;s effective tax rate is different from the
federal statutory rate of 34% due primarily to operating losses
that receive no tax benefit as a result of a valuation allowance
recorded for such losses.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Pursuant to Internal Revenue Code Sections 382 and 383, use of the
Company&amp;#x2019;s net operating loss and credit carryforwards may be
limited if a cumulative change in ownership of more than 50% occurs
within any three-year period since the last ownership change. The
Company may have had a change in control under these Sections.
However, the Company does not anticipate performing a complete
analysis of the limitation on the annual use of the net operating
loss and tax credit carryforwards until the time that it projects
it will be able to utilize these tax attributes.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Significant components of the Company&amp;#x2019;s deferred tax assets
as of January 31, 2012 and January 31, 2011 are shown below. A
valuation allowance of $933,420 and $232,700 as of January 31, 2012
and 2011, respectively, has been established against the
Company&amp;#x2019;s deferred tax assets as realization of such assets
is uncertain.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Deferred tax assets consist of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"&gt;
&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
January 31,&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"&gt;
January 31,&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;2012&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;2011&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 62%; font-size: 10pt; text-align: left"&gt;NOL carry
forward&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 15%; font-size: 10pt; text-align: right"&gt;
849,591&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 15%; font-size: 10pt; text-align: right"&gt;
212,800&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Stock Option -
exercisabe&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;81,775&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;10,800&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Contribution
carryforward&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;6,970&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Warrant
liability&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;51,408&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;State income
taxes&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;1,247&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Accrual to cash&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(76,500&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;State income taxes,
deferred&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(71,035&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Impairment loss&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;89,964&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
Other, net&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
9,100&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Net Deferred Tax
Assets&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;933,420&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;232,700&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
Valuation Allowance&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
(933,420&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
(232,700&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double"&gt;
-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double"&gt;
-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The provision for income taxes for the year ended January 31, 2012
differs from the amount computed by applying the federal income tax
rate as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 86%; font-size: 10pt; text-align: left"&gt;Tax
computed at the statutory rate (34%)&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
0.34&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Stock options&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(0.01&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Accrual to cash&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;0.01&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Warrant
liability&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(0.05&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Impairment Loss&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(0.08&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Non-cash stock
compensation&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(0.06&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;Change in
valuation&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;(0.15&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
As of January 31, 2012, the Company does not have any unrecognized
tax benefits related to various federal and state income tax
matters. The Company will recognize accrued interest and penalties
related to unrecognized tax benefits in income tax expense.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company is subject to U.S. federal income tax as well as income
tax of multiple state tax jurisdictions. The Company and its
subsidiaries&amp;#x2019; state income tax returns are open to audit
under the statute of limitations for the years ended January 31,
2009 through 2012. The Company does not anticipate any material
amount of unrecognized tax benefits within the next 12 months.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_31">129000</us-gaap:InterestPaid>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_0E4D372E-1715-4D9E-BBCF-59BF225ED51D_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;17. Acquisitions&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Aligned Healthcare Group&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
On February 15, 2011, Apollo Medical Holdings, Inc. (the
&amp;#x201C;Company&amp;#x201D;) entered into a Stock Purchase Agreement (the
&amp;#x201C;Purchase Agreement&amp;#x201D;) with Aligned Healthcare Group
&amp;#x2013; California, Inc., Raouf Khalil, Jamie McReynolds, M.D. BJ
Reese and BJ Reese &amp;amp; Associates, LLC, under which the Company
acquired all of the issued and outstanding shares of capital stock
and associated Intellectual property and related intangibles (the
&amp;#x201C;Acquisition&amp;#x201D;) of Aligned Healthcare, Inc., a
California corporation (&amp;#x201C;AHI&amp;#x201D;), from AHI&amp;#x2019;s
shareholders.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Upon the signing of the Purchase Agreement, 1,000,000 shares of the
Company&amp;#x2019;s common stock became issuable (the &amp;#x201C;Initial
Shares&amp;#x201D;) and are included in the number of shares
outstanding. In addition, if the gross revenues of AHI and an
affiliated entity (the &amp;#x201C;Aligned Division&amp;#x201D;) had exceeded
$1,000,000 on or before February 1, 2012, then the Company would
have been obligated to issue an additional 1,000,000 shares of
common stock (the &amp;#x201C;Contingent Shares&amp;#x201D;). Moreover, the
Company would be obligated to issue up to an additional 3,500,000
shares of common stock (the &amp;#x201C;Earn-Out Shares&amp;#x201D; and,
collectively with the Initial Shares and the Contingent Shares, the
&amp;#x201C;Shares&amp;#x201D;) over a three year period following closing
based on the EBITDA generated by the Aligned Division during that
time. Under the agreement, ApolloMed would issue twelve shares of
its Common stock for each dollar of Actual EBITDA earned in the
first 12-month period. In subsequent periods, ApolloMed would be
required to issue twelve shares of its common stock for each dollar
of Actual EBITDA in excess of the maximum EBITDA earned in either
the first 12-month period or first 12-month period and second 12
month period.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Additionally, in Accordance with the Purchase Agreement, if prior
to February 15, 2012, AHI had not entered into an agreement for the
provision of certain services to a hospital or certain other health
organizations that has a term of at least one year and provides
aggregate net revenues to AHI of at least $1,000,000, the Company
would have the right to repurchase all of the Initial Shares for
$0.05 per share, at which time the Company&amp;#x2019;s obligation to
issue any further Shares would terminate.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Based on our initial internal estimate of contingent shares to be
issued as part of this agreement, we had estimated that the total
fair value of the common stock shares issued and contingently
issuable for this transaction on the acquisition date was $367,500
(1,750,000 shares).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company originally recognized a liability based on the
acquisition date fair value of the acquisition-related contingent
consideration based on the probability of the achievement of the
targets stipulated in the Purchase Agreement. Based on the
Company&amp;#x2019;s estimation, an initial liability of $367,500 was
recorded. Subsequently, we have reassessed our estimates and have
determined that the initial terms of the agreement have not be met,
and as the result, we have determined that there will be no
additional shares contingently issuable under the terms of the
Purchase Agreement and we have recorded an adjustment to revise our
initial estimate of the purchase price in contemplation that no
contingent consideration as was previously reported in our interim
financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The following table summarizes the preliminary and final
determination of the purchase price and fair value of AHI&amp;#x2019;s
assets acquired at the date of acquisition:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;Preliminary&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;Final&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font-size: 10pt"&gt;Purchase price calculation:&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 72%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;
Common stock issued (1,000,000 shares)&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
210,000&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;
210,000&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;
Contingent consideration (1,750,000 shares of common stock)&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
367,500&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 20pt"&gt;Fair
value of total consideration&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double"&gt;
577,500&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double"&gt;
210,000&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt"&gt;Allocation of purchase price:&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;
Intellectual property and technical know-how&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;577,500&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;
Goodwill&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
-&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid"&gt;
210,000&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double"&gt;
577,500&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double"&gt;
210,000&lt;/td&gt;
&lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
As of January, 31, 2012, based upon the completion of the
Company&amp;#x2019;s annual goodwill impairment test, it was determined
that the goodwill associated with the AHI acquisition has been
impaired, and as the result, the Company has recorded an impairment
loss of $210,000. The cause of the impairment was the result of
contracts that were anticipated to result from this acquisition
that have not materialized and management has decided to focus its
energies on new initiatives.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;Pulmonary Critical Care Management, Inc&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
On August 2, 2011, Apollo Medical Holdings, Inc. entered into a
stock purchase agreement (the &amp;#x201C;PCCM Purchase
Agreement&amp;#x201D;) with the sole shareholder of Pulmonary Critical
Care Management, Inc. ("PCCM"), a provider of management services
to the Los Angeles Lung Center (&amp;#x201C;LALC&amp;#x201D;), under which
the Company acquired (the &amp;#x201C;PCCM Acquisition&amp;#x201D;) all of
the issued and outstanding shares of capital stock of PCCM and the
associated intangible asset in the management services agreement
that PCCM has with LALC (the &amp;#x201C;PCCM Services
Agreement&amp;#x201D;). Upon the signing of the PCCM Purchase Agreement,
the Company issued 350,000 common shares to the sole shareholder of
PCCM, which was valued as of the date of issuance at $70,000, based
on the fair market value of our shares.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
At the time of the acquisition, the assets of PCCM consisted only
of the PCCM Services Agreement with LALC. Through this PCCM
Services Agreement, our wholly-owned subsidiary, PCCM, has
exclusive authority over all non-medical decision-making related to
the ongoing business operations of LALC. Based on the provisions of
the PCCM Purchase Agreement, we have determined that LALC is a
variable interest entity (VIE), and that we are the primary
beneficiary because we have control over the operations of the VIE.
Consequently, we consolidated the accounts of LALC beginning on the
PCCM Acquisition date. As a result of this consolidation, we
recorded additional non-controlling interest of $164,276.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The following table summarizes the fair value of LALC&amp;#x2019;s
assets acquired and liabilities at the date of acquisition of PCCM
and consolidation of LALC:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="width: 87%"&gt;Purchase Price&lt;/td&gt;
&lt;td style="width: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;70,000&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left"&gt;Fair value of net assets acquired&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td&gt;Cash&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;164,210&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,472&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;26,041&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left"&gt;Management services agreement&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;38,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="text-align: left"&gt;Accounts payable and accrued
liabilities&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(1,447&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left"&gt;Due from officer&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(34,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-bottom: 1pt"&gt;Non-controlling interest&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;
(164,276&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="text-align: left"&gt;Net assets acquired&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;38,000&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,204)"&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;Goodwill&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;
$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;
32,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Proforma financial information is not presented as PCCM did not
exist in the comparative period herein presented.&lt;/p&gt;
&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_F04FF20C-E151-4EF2-98E0-D74ACDF27E6C_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;10.
Accounts Payable and Accrued&amp;#xA0;Liabilities&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Accounts payable and accrued liabilities consisted of the
following:&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;January&amp;#xA0;31,&lt;br /&gt;
2012&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;January&amp;#xA0;31,&lt;br /&gt;
2011&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt;Accounts payable&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;109,704&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;35,815&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;D&amp;amp;O insurance payable&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;11,444&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;10,913&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Income taxes payable&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,219&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Accrued interest&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Accrued professional fees&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;27,500&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;5,483&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Accrued payroll
and income taxes&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
9,609&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
40,534&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;Total&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
163,476&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
92,745&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:OperatingExpenses contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_6">1391742</us-gaap:OperatingExpenses>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8006_900009">63000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_8">120000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_9FB4386F-4DDB-43FE-854E-85DF3E7C3EDA_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;13.
Related Party Transactions&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;During
the twelve months ended January 31, 2012 and 2011, the Company
generated revenue of $514,000 and $577,000, respectively, by
providing management services to ApolloMed Hospitalists (AMH), an
affiliated company with common ownership interest. Commencing
August 1, 2008, the management services fee income reported by AMM
was eliminated in consolidation against similar costs recorded at
AMH.&lt;/p&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_4">1379153</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_20">164210</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_26">-4290</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_10">172500</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:CostOfServices contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_1">4132399</us-gaap:CostOfServices>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_14">-37500</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_17">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <ameh:CompensationExpenseRelatedStockOptions contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8006_900010">29333</ameh:CompensationExpenseRelatedStockOptions>
  <ameh:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="shares" decimals="0" id="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_16">29078925</ameh:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <ameh:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_E5896406-42AF-4A62-B539-3E1BD5AC1F01_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;7. Prepaid Expenses&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Prepaid Expenses represent amounts paid in advance for medical
malpractice insurance, software licenses and Director&amp;#x2019;s and
Officer&amp;#x2019;s insurance.&lt;/p&gt;
&lt;/div&gt;</ameh:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock>
  <ameh:InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_7810EE4D-8E97-4BD7-B075-FDD5C46F704C_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;8.&amp;#xA0;&amp;#xA0;Prepaid financing cost&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
Prepaid financing cost represents unamortized financing cost
associated with 10% Senior Subordinated Callable Convertible Notes
due January 31, 2013 paid by the Company on the closing of the
placement on October 16, 2009 (see Note 11).&lt;/p&gt;
&lt;/div&gt;</ameh:InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock>
  <ameh:GoingConcernDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_6CEACE26-8D28-4532-B8C2-41F555199FDD_1_0">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&lt;b&gt;3. Going Concern&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The Company&apos;s financial statements are prepared using the generally
accepted accounting principles applicable to a going concern, which
contemplates the realization of assets and liquidation of
liabilities in the normal course of business. However, the Company
continues to incur operating losses and has an accumulated deficit
of $2,117,708 as of January 31, 2012. In addition, at January 31,
2012, the Company has a total stockholders&amp;#x2019; deficit of
$659,321 and generated a negative net cash flow operating
activities of $385,455 for the year then ended.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
The financial statements do not include any adjustments relating to
the recoverability and classification of liabilities that might be
necessary should the Company be unable to continue as a going
concern.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
To date the Company has funded its operations from both internally
generated cash flow and external sources, and the proceeds
available from the private placement of convertible notes which
have provided funds for near-term operations and growth. The
Company will pursue additional external capitalization
opportunities, as necessary, to fund its long-term goals and
objectives. We may seek to raise additional capital through public
or private equity financings, partnerships, joint ventures,
disposition of assets, debt financings, bank borrowings or other
sources of financing.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;
No assurances can be made that management will be successful in
achieving its plan. If the Company is not able to raise substantial
additional capital in a timely manner, the Company may be forced to
cease operations.&lt;/p&gt;
&lt;/div&gt;</ameh:GoingConcernDisclosureTextBlock>
  <ameh:IssuanceOfCommonStockValueForStockBasedCompensation contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" unitRef="iso4217_USD" decimals="0" id="id_23189_9F289E07-84E9-4EAD-8F96-4B63550DFB8F_1_35">90000</ameh:IssuanceOfCommonStockValueForStockBasedCompensation>
  <ameh:ConvertibleDebtDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0" id="id_23189_B38C06D3-A4BA-450B-93C4-3EA6C9C188D5_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;11.&amp;#xA0;&amp;#xA0;Convertible Notes&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The
Company&amp;#x2019;s long-term debt consists of the following:&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;January&amp;#xA0;31,&lt;br /&gt;
2012&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;January&amp;#xA0;31,&lt;br /&gt;
2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Subordinated Borrowings:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -9.35pt; PADDING-LEFT: 18.7pt; WIDTH: 74%"&gt;
10% Senior Subordinated Convertible Notes, net of debt discount of
$653,026, due January 31, 2013&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
596,366&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
1,248,588&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -9.35pt; PADDING-LEFT: 18.7pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -9.35pt; PADDING-LEFT: 18.7pt"&gt;
8% Senior Subordinated Convertible Notes due February 1, 2015&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
150,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Total Convertible Notes&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;746,366&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,248,588&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Less: Current
Portion&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
596,366&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;Total&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
150,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,248,588&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Subordinated Borrowings&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;10%
Senior Subordinated Callable Convertible Notes due January 31,
2013&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On
October 16, 2009, the Company issued $1,250,000 of its 10% Senior
Subordinated Callable Convertible Notes. The net proceeds of
$1,100,000 will be used for the repayment of existing debt,
acquisitions, physician recruitment and other general corporate
purposes. The notes bear interest at a rate of 10% annually,
payable semi annually on January 31 and July 31. The Notes mature
and become due and payable on January 31, 2013 and rank senior to
all other unsecured debt of the Company.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The 10%
Notes were sold through an Agent in the form of a Unit. Each Unit
was comprised of one 10% Senior Subordinated Callable Note with a
par value $25,000, and one five-year warrant to purchase 25,000
shares of the Company&amp;#x2019;s common stock. The purchase price of
each Unit was $25,000, resulting in gross proceeds of
$1,250,000.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;In
connection with the placement of the subordinated notes, the
Company paid a commission of $125,000 and $25,000 of other direct
expenses. The agent also received five-year warrants to purchase up
to 250,000 shares of the Common Stock at an initial exercise price
of $0.25 per share adjustable pursuant to changes in public value
of our shares and cash flow of the Company from July 31, 2011 until
the note is paid in full. The agent also received 100,000 shares of
restricted common stock for pre-transaction advisory services and
due diligence. A commission of $125,000 paid at closing, is
accounted for as prepaid expense and will be amortized over a
forty-month period through January 31, 2013, the maturity date of
the notes. The $25,000 of other direct expenses were paid at
closing and reported as financing costs in the Operating Statement.
In addition, financing costs included $4,000 related to the value
of the 100,000 shares granted to the placement agent. Interest
expense of $36,458 was recorded in the year ended January 31,
2010.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The 10%
Notes are convertible any time prior to January 31, 2013. The
initial conversion rate is 200,000 shares of the Company&amp;#x2019;s
common stock per $25,000 principal amount of the 10% Notes
adjustable pursuant to changes in public value of our shares and
cash flow of the Company. This represents an initial conversion
price of $0.125 per share of the Company&amp;#x2019;s common stock. The
note is fixed from August 1, 2009 through July 31, 2011. After July
31, 2011, the conversion price will equal to the lesser of $0.125
per share or the average of the monthly high stock price and low
stock price as reported by Bloomberg multiplied by 110%. The
minimum conversion price is the greater of $0.05 per share or 8
times cash EPS.&amp;#xA0; On or after January 31, 2012, the Company
may, at its option, upon 60 days notice to both the
Note-holder&amp;#x2019;s and the placement agent, redeem all or a
portion of the notes at a redemption price in cash equal to 102% of
the principal amount of the notes to be redeemed plus accrued and
unpaid interest to, but excluding, the redemption date.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;At
January 31, 2012, the Company has recorded a derivative liability
and an off-setting debt discount in the amount of $653,026 as the
result of the change in the conversion price. At January 31, 2012,
the conversion price reset to $0.11485. The Company&amp;#x2019;s
calculation of the derivative liability was made using the
Black-Scholes option-pricing model with the following assumptions:
expected life of 1 year; 80.0% stock price volatility; risk-free
interest rate of 0.30% and no dividends during the expected
term.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The
Warrants attached to the Units are exercisable into shares of
Common Stock at an initial exercise price of $0.125. The Warrants
have a five-year term and expire on October 31, 2014. The
Company&amp;#x2019;s calculations were made using the Black-Scholes
option-pricing model with the following assumptions: expected life
of 5 years; 48.0% stock price volatility; risk-free interest rate
of 2.16% and no dividends during the expected term. These warrants
were estimated to have a fair value of $2,653 using the
Black-Scholes pricing model which was recorded as unamortized
warrant discount on the grant date and $2,418 as of January 31,
2010.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;In
connection with this offering, the Company also issued warrants to
purchase 250,000 shares of our common stock to the placement agent
at an exercise price of $0.25 per share, and are exercisable
immediately upon issuance and expire five years after the date of
issuance. The Company&amp;#x2019;s calculations were made using the
Black-Scholes option-pricing model with the following assumptions:
expected life of 5 years; 48.0% stock price volatility; risk-free
interest rate of 2.16% and no dividends during the expected term.
These warrants were estimated to have a fair value of $2,200, which
was recorded as unamortized warrant discount on the grant date. The
exercise price of the warrants are adjustable according to the same
terms as the 10% Notes.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;At
January 31, 2012, the warrant exercise price reset to $0.11485. As
the result, the Company has recorded a warrant liability of
$120,000 and recognized additional financing costs of $120,000 for
the year ended January 31, 2012. The fair value of the warrant
liability was determined using the Black-Scholes model option
pricing model with the following assumptions: expected life of 2.75
years; 30% stock price volatility; risk-free interest rate of 0.30%
and no dividends during the expected term.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;8%
Senior Subordinated Convertible Promissory Notes due February 1,
2015&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On
September 1, 2011, the Company issued $150,000 of its 8% Senior
Subordinated Promissory Convertible Notes. The net proceeds will be
used for working capital to support organic growth including the
expansion to new hospitals and hiring of new physicians,
acquisitions of physician practices and/or care management
businesses and for general corporate purposes. The notes bear
interest at a rate of 8% annually, payable semi annually on
December 31 and June 30. The Notes mature and become due and
payable on January 31, 2013 and rank senior to all other
subordinated debt of the Company.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The 8%
Notes are convertible any time prior to February 1, 2015. The
initial conversion rate is 100,000 shares of the Company&amp;#x2019;s
common stock per $25,000 principal amount of the 8% Notes, which
represents an initial conversion price of $0.25 per share of the
Company&amp;#x2019;s common stock. The conversion price of the 8% Notes
will be adjusted on a weighted average basis if the Company issues
certain additional shares of common stock (or warrants or rights to
purchase share of common stock or securities convertible into
common stock) for a consideration per share which is less than the
then applicable conversion price.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The
Company may require the holders of the 8% Notes to convert to
common stock at the then applicable conversion rate at any time
after June 30, 2013 if: i) our 10% Notes have been fully repaid or
converted and ii) the closing price of our common stock has
exceeded 150% of the then applicable Conversion Price for no less
than 30 consecutive trading days prior to giving notice.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;At any
time on or after June 30, 2014, the Company may, at its sole option
redeem all of the Notes at redemption price in cash equal to 108%
of the principal amount of the Notes to be redeemed plus any
accrued and unpaid interest to, but excluding the redemption
rate.&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="COLOR: black"&gt;Interest expense was $130,000 and
$125,000 for the years ended January 31, 2012 and 2011,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The
following table represents the principal repayments of all the
outstanding debt as of January 31, 2012:&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 40%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.5in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"&gt;
Year&amp;#xA0;ending&amp;#xA0;January&amp;#xA0;31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; WIDTH: 72%"&gt;2013&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 25%"&gt;1,250,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;2014&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;2015&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;2016&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;150,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</ameh:ConvertibleDebtDisclosureTextBlock>
  <us-gaap:NetIncomeLoss contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x440920" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8005_800011">-720346</us-gaap:NetIncomeLoss>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x443747" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8004_700008">-154290</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestIncreaseFromStockIssuance contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x443747" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8004_700007">164276</us-gaap:MinorityInterestIncreaseFromStockIssuance>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x444581" unitRef="shares" decimals="INF" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8001_400009">350000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x444581" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8001_500009">350</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x444581_455296x442897" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_9001_500006">1350</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x444581_455296x442897" unitRef="shares" decimals="INF" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_9001_400006">1350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x453698" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8003_600009">62650</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <ameh:CompensationExpenseRelatedStockOptions contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x453698" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_8003_600010">29333</ameh:CompensationExpenseRelatedStockOptions>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x453698_455296x442897" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_9003_600006">278650</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_455296x441878" id="id_23189_F8900C95-54EE-4B12-937A-9BBEC106E1A4_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;4.
Accounts Receivable&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Accounts Receivable is stated at the amount management expects to
collect from outstanding balances. An allowance for doubtful
accounts is provided for those accounts receivable considered to be
uncollectible, based upon historical experience and management&apos;s
evaluation of outstanding accounts receivable at each quarter end.
As of January 31, 2012, Accounts Receivable was $994,118, net of a
provision for bad debt of $42,576, and represents amounts invoiced
by AMH and LALC. Accounts Receivable was $704,971, net of the
provision for bad debt of $34,746, on January 31, 2011.&lt;/p&gt;
&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_455296x442897" unitRef="iso4217_USD" decimals="0" id="id_23189_5D0E9419-A4C6-43E4-AA1C-B8EE0AAD7818_9006_900006">280000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="eol_PE61543---1210-K0001_STD_365_20120131_0_455296x451883" id="id_23189_0E3E484A-2111-420C-A37B-940FE4250E25_1_0">&lt;div style="FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;5.
Receivable from officers&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Receivable from officers represent compensation payments made in
fiscal year 2010 above contractual amounts. These amounts were
expensed in fiscal year 2012 in exchange for additional physical
services provided to the company.&lt;/p&gt;
&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_455296x451883">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_455296x442897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:AcquisitionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_455296x441878">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x453698_455296x442897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:AcquisitionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x444581_455296x442897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:AcquisitionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x443747">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20120131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20110131_0_455296x455803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-02-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x453698_455296x455803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-02-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-02-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x444581_455296x455803">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-02-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20110131_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-02-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_365_20110131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
    </entity>
    <period>
      <startDate>2010-02-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x443747">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20120131_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20120131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x443747">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20110131_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20110131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
    </entity>
    <period>
      <instant>2011-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x443747">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20100131_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20100131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
    </entity>
    <period>
      <instant>2010-01-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20110731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
    </entity>
    <period>
      <instant>2011-07-31</instant>
    </period>
  </context>
  <context id="eol_PE61543---1210-K0001_STD_0_20120430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
    </entity>
    <period>
      <instant>2012-04-30</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_17" xlink:label="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_17" xlink:type="locator" />
    <xbrll:loc xlink:href="#id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_17" xlink:label="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_17" xlink:type="locator" />
    <xbrll:footnote xlink:label="footnote_55838054" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Weighted average number of shares used to compute basic and diluted loss per share is the same since the effect of dilutive securities is anti-dilutive.</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_1_17" xlink:to="footnote_55838054" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc" />
    <xbrll:footnoteArc xlink:from="id_23189_44B9AC6D-BE51-405F-8963-2EFD6D548C34_2_17" xlink:to="footnote_55838054" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc" />
  </xbrll:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ameh-20120131.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.14.9 -->
<!-- Round: 78e78d3c-9523-426b-a0b4-c45cd75b162c -->
<!-- Creation date: 2012-05-14T14:40:59Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31"
  xmlns:us-types="http://fasb.org/us-types/2011-01-31"
  xmlns:ameh="http://www.apollomed.net/20120131"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2011-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31"
  targetNamespace="http://www.apollomed.net/20120131"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/DocumentDocumentandEntityInformation" id="DocumentDocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsNatureOfOperations" id="Role_NotesToFinancialStatementsNatureOfOperations">
        <link:definition>108 - Disclosure - Organization and Summary of Critical Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock" id="Role_NotesToFinancialStatementsGoingConcernDisclosureTextBlock">
        <link:definition>110 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Role_NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
        <link:definition>111 - Disclosure - Receivable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Due from Affiliate</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
        <link:definition>113 - Disclosure - Prepaid Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" id="Role_NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock">
        <link:definition>114 - Disclosure - Prepaid financing cost</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>115 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <link:definition>116 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock">
        <link:definition>117 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>118 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>119 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsMinorityInterestDisclosureTextBlock" id="Role_NotesToFinancialStatementsMinorityInterestDisclosureTextBlock">
        <link:definition>120 - Disclosure - Non-Controlling Interest</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>121 - Disclosure - Stockholder's Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>122 - Disclosure - Commitments and Contingency</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" id="Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
        <link:definition>123 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>124 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="ameh-20120131_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="ameh-20120131_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="ameh-20120131_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="ameh-20120131_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
  <element name="CompensationExpenseRelatedStockOptions" id="ameh_CompensationExpenseRelatedStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleDebtDisclosureTextBlock" id="ameh_ConvertibleDebtDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleNotesCurrentUnamortizedDiscount" id="ameh_ConvertibleNotesCurrentUnamortizedDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentDocumentandEntityInformationAbstract" id="ameh_DocumentDocumentandEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GoingConcernDisclosureTextBlock" id="ameh_GoingConcernDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" id="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockValueForStockBasedCompensation" id="ameh_IssuanceOfCommonStockValueForStockBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NotesToFinancialStatementsAbstract" id="ameh_NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" id="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberBasicDilutedSharesOutstanding" id="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ameh-20120131_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.14.9 -->
<!-- Round: 78e78d3c-9523-426b-a0b4-c45cd75b162c -->
<!-- Creation date: 2012-05-14T14:40:59Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.apollomed.net/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfIncome" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsGoingConcernDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsMinorityInterestDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsMinorityInterestDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/DocumentDocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="us-gaap_DueFromAffiliateCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueFromOfficersOrStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AdvancesOnInventoryPurchases" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromOfficersOrStockholdersCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromAffiliateCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="1.2700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfServices" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_Depreciation" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0600" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1.1900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsToMinorityShareholders" order="1.2100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseDueFromAffiliates" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsMinorityInterestDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ameh-20120131_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.14.9 -->
<!-- Round: 78e78d3c-9523-426b-a0b4-c45cd75b162c -->
<!-- Creation date: 2012-05-14T14:40:59Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.apollomed.net/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfIncome" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsGoingConcernDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsMinorityInterestDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsMinorityInterestDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="us-gaap_DueFromAffiliateCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueFromOfficersOrStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AdvancesOnInventoryPurchases" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromOfficersOrStockholdersCurrent" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromAffiliateCurrent" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.1400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_ConvertibleNotesCurrentUnamortizedDiscount" xlink:label="ameh_ConvertibleNotesCurrentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_ConvertibleNotesCurrentUnamortizedDiscount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_Depreciation" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfServices" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AcquisitionMember" xlink:label="us-gaap_AcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_CompensationExpenseRelatedStockOptions" xlink:label="ameh_CompensationExpenseRelatedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestIncreaseFromStockIssuance" xlink:label="us-gaap_MinorityInterestIncreaseFromStockIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_AcquisitionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestIncreaseFromStockIssuance" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_CompensationExpenseRelatedStockOptions" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_IssuanceOfCommonStockValueForStockBasedCompensation" xlink:label="ameh_IssuanceOfCommonStockValueForStockBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ameh_IssuanceOfCommonStockValueForStockBasedCompensation" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseDueFromAffiliates" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsToMinorityShareholders" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NatureOfOperations" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_GoingConcernDisclosureTextBlock" xlink:label="ameh_GoingConcernDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_GoingConcernDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_OfficerMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" xlink:label="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_ConvertibleDebtDisclosureTextBlock" xlink:label="ameh_ConvertibleDebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_ConvertibleDebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsMinorityInterestDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ameh-20120131_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.14.9 -->
<!-- Round: 78e78d3c-9523-426b-a0b4-c45cd75b162c -->
<!-- Creation date: 2012-05-14T14:40:59Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_23189_452127_1_1">Accounts Payable And Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_23189_452127_2_1">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_454109_1_1">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_454109_2_1">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="id_23189_441878_1_1">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="id_23189_441878_2_1">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_23189_445011_1_1">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_23189_445011_2_1">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AcquisitionMember" xlink:label="us-gaap_AcquisitionMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquisitionMember_lbl" xml:lang="en-US" id="id_23189_442897_1_1">Acquisition [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquisitionMember_lbl" xml:lang="en-US" id="id_23189_442897_2_1">AHI and PCCM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionMember" xlink:to="us-gaap_AcquisitionMember_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_23189_450188_1_1">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_23189_450188_2_1">Additional paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_23189_453698_1_1">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_23189_453698_2_1">APIC</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_23189_441073_1_1">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_23189_441073_2_1">Non-cash stock-based compensation charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_23189_456429_1_1">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_23189_456429_2_1">Adjustments to reconcile net loss to net cash (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xml:lang="en-US" id="id_23189_442375_1_1">Advances On Inventory Purchases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xml:lang="en-US" id="id_23189_442375_2_1">Advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_23189_440685_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_23189_440685_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_23189_444354_1_1">Amortization Of Debt Discount Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_23189_444354_2_1">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" id="id_23189_455678_1_1">Amortization Of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" id="id_23189_455678_8_1">Financing cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_23189_449411_1_1">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_23189_449411_2_1">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_23189_445113_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_23189_445113_6_1">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_23189_447705_1_1">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_23189_447705_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_23189_448471_1_1">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_23189_448471_2_1">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_454030_1_1">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_454030_2_1">Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_23189_449216_1_1">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_23189_449216_4_1">CASH &amp; CASH EQUIVALENTS, ENDING BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_23189_449216_5_1">CASH &amp; CASH EQUIVALENTS, BEGINNING BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_23189_449216_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_23189_452867_1_1">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_23189_452867_6_1">NET DECREASE IN CASH &amp; CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_23189_448139_1_1">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_23189_448139_2_1">NON-CASH FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_443397_1_1">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_443397_2_1">Commitments and Contingency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_23189_444581_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_23189_444581_2_1">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_23189_449974_1_1">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_23189_449974_2_1">Common Stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_23189_454829_1_1">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_23189_454829_2_1">Common Stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_23189_453540_1_1">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_23189_453540_2_1">Common Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_23189_447408_1_1">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_23189_447408_2_1">Common Stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_23189_445860_1_1">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_23189_445860_2_1">Common Stock, par value $0.001; 100,000,000 shares authorized, 29,335,774 and 27,635,774 shares issued and outstanding as on January 31, 2012 and 2011, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_CompensationExpenseRelatedStockOptions" xlink:label="ameh_CompensationExpenseRelatedStockOptions" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_CompensationExpenseRelatedStockOptions_lbl" xml:lang="en-US" id="id_23189_458851_3_1">Value of stock option compensation expense recorded during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_CompensationExpenseRelatedStockOptions_lbl" xml:lang="en-US" id="id_23189_458851_1_1">Compensation Expense Related Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_CompensationExpenseRelatedStockOptions_lbl" xml:lang="en-US" id="id_23189_458851_2_1">Stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_CompensationExpenseRelatedStockOptions" xlink:to="ameh_CompensationExpenseRelatedStockOptions_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_ConvertibleDebtDisclosureTextBlock" xlink:label="ameh_ConvertibleDebtDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_484917_3_1">Convertible Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_484917_1_1">Convertible Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_484917_2_1">Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_ConvertibleDebtDisclosureTextBlock" xlink:to="ameh_ConvertibleDebtDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" id="id_23189_442639_1_1">Convertible Long Term Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" id="id_23189_442639_2_1">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_ConvertibleNotesCurrentUnamortizedDiscount" xlink:label="ameh_ConvertibleNotesCurrentUnamortizedDiscount" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_ConvertibleNotesCurrentUnamortizedDiscount_lbl" xml:lang="en-US" id="id_23189_465827_3_1">Convertible Notes, Current, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_ConvertibleNotesCurrentUnamortizedDiscount_lbl" xml:lang="en-US" id="id_23189_465827_1_1">Convertible Notes Current Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_ConvertibleNotesCurrentUnamortizedDiscount_lbl" xml:lang="en-US" id="id_23189_465827_2_1">Convertible notes, debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_ConvertibleNotesCurrentUnamortizedDiscount" xlink:to="ameh_ConvertibleNotesCurrentUnamortizedDiscount_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US" id="id_23189_449563_1_1">Convertible Notes Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US" id="id_23189_449563_2_1">Convertible notes, net of $653,026 debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfServices_lbl" xml:lang="en-US" id="id_23189_456100_1_1">Cost Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfServices_lbl" xml:lang="en-US" id="id_23189_456100_2_1">COST OF SERVICES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfServices" xlink:to="us-gaap_CostOfServices_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_23189_440743_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_23189_440743_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US" id="id_23189_440944_1_1">Deferred Finance Costs Current Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US" id="id_23189_440944_2_1">Prepaid financing cost, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" id="id_23189_441136_1_1">Deferred Finance Costs Noncurrent Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" id="id_23189_441136_2_1">Prepaid financing cost, long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_23189_446238_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_23189_446238_2_1">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_23189_443179_1_1">Derivative Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_23189_443179_2_1">Derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_23189_449547_1_1">Derivative Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_23189_449547_2_1">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_DocumentDocumentandEntityInformationAbstract" xlink:label="ameh_DocumentDocumentandEntityInformationAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US" id="id_23189_544950_3_1">Document - Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US" id="id_23189_544950_1_1">Document Documentand Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US" id="id_23189_544950_2_1">Document - Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_DocumentDocumentandEntityInformationAbstract" xlink:to="ameh_DocumentDocumentandEntityInformationAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_23189_440619_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_23189_440619_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_23189_440713_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_23189_440713_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" id="id_23189_440663_1_1">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" id="id_23189_440663_2_1">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_23189_440728_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_23189_440728_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_23189_440723_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_23189_440723_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="us-gaap_DueFromAffiliateCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromAffiliateCurrent_lbl" xml:lang="en-US" id="id_23189_456379_1_1">Due From Affiliate Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromAffiliateCurrent_lbl" xml:lang="en-US" id="id_23189_456379_2_1">Due from affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromAffiliateCurrent" xlink:to="us-gaap_DueFromAffiliateCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueFromOfficersOrStockholdersCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOfficersOrStockholdersCurrent_lbl" xml:lang="en-US" id="id_23189_450516_1_1">Due From Officers Or Stockholders Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOfficersOrStockholdersCurrent_lbl" xml:lang="en-US" id="id_23189_450516_2_1">Receivable from officers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueFromOfficersOrStockholdersCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xml:lang="en-US" id="id_23189_448374_1_1">Due To Officers Or Stockholders Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xml:lang="en-US" id="id_23189_448374_2_1">Due to officers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_23189_456407_1_1">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_23189_456407_2_1">BASIC AND DILUTED NET LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US" id="id_23189_440683_1_1">Entities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US" id="id_23189_440683_2_1">Entities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_23189_440736_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_23189_440736_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_23189_440642_1_1">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_23189_440642_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_23189_440680_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_23189_440680_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_23189_440709_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_23189_440709_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_23189_440693_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_23189_440693_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_23189_440732_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_23189_440732_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_23189_440675_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_23189_440675_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_23189_440627_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_23189_440627_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_23189_440742_1_1">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_23189_440742_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_23189_447770_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_23189_447770_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_23189_454032_1_1">Finite Lived Intangible Assets Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_23189_454032_2_1">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_23189_455205_1_1">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_23189_455205_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_GoingConcernDisclosureTextBlock" xlink:label="ameh_GoingConcernDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_GoingConcernDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_476810_3_1">Going Concern Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_GoingConcernDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_476810_1_1">Going Concern Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_GoingConcernDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_476810_2_1">Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_GoingConcernDisclosureTextBlock" xlink:to="ameh_GoingConcernDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember_lbl" xml:lang="en-US" id="id_23189_455803_1_1">Goods And Services Exchanged For Equity Instrument [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember_lbl" xml:lang="en-US" id="id_23189_455803_2_1">Service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" xlink:to="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_23189_447873_1_1">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_23189_447873_2_1">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" id="id_23189_440915_1_1">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" id="id_23189_440915_6_1">GROSS REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="id_23189_445103_1_1">Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="id_23189_445103_6_1">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_23189_446071_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_23189_446071_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_453581_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_453581_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" id="id_23189_443197_1_1">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" id="id_23189_443197_2_1">Taxes paid during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_23189_452757_1_1">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_23189_452757_2_1">Provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates_lbl" xml:lang="en-US" id="id_23189_443367_1_1">Increase Decrease Due From Affiliates</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates_lbl" xml:lang="en-US" id="id_23189_443367_8_1">Due from affiliates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:to="us-gaap_IncreaseDecreaseDueFromAffiliates_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="id_23189_446370_1_1">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="id_23189_446370_2_1">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_23189_442949_1_1">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_23189_442949_8_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" id="id_23189_455136_1_1">Increase Decrease In Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" id="id_23189_455136_2_1">Increase in warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent_lbl" xml:lang="en-US" id="id_23189_441679_1_1">Increase Decrease In Due From Officers And Stockholders Current</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent_lbl" xml:lang="en-US" id="id_23189_441679_8_1">Due from / to officers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_23189_449791_1_1">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_23189_449791_2_1">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_23189_456140_1_1">Increase Decrease In Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_23189_456140_8_1">Prepaid financing cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_23189_445984_1_1">Increase Decrease In Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_23189_445984_8_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_23189_446767_1_1">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_23189_446767_8_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" xlink:label="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_475529_3_1">Interest Income (Expense) and Other Financial Costs Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_475529_1_1">Interest Income Expense And Other Financial Costs Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_475529_2_1">Prepaid financing cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" xlink:to="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_23189_453757_1_1">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_23189_453757_2_1">Interest paid during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_IssuanceOfCommonStockValueForStockBasedCompensation" xlink:label="ameh_IssuanceOfCommonStockValueForStockBasedCompensation" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_IssuanceOfCommonStockValueForStockBasedCompensation_lbl" xml:lang="en-US" id="id_23189_484147_3_1">Issuance of Common Stock Value for Stock-Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_IssuanceOfCommonStockValueForStockBasedCompensation_lbl" xml:lang="en-US" id="id_23189_484147_1_1">Issuance Of Common Stock Value For Stock Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_IssuanceOfCommonStockValueForStockBasedCompensation_lbl" xml:lang="en-US" id="id_23189_484147_2_1">Shares to be issued for services (Note 15)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_IssuanceOfCommonStockValueForStockBasedCompensation" xlink:to="ameh_IssuanceOfCommonStockValueForStockBasedCompensation_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="id_23189_444473_1_1">Issuance Of Stock And Warrants For Services Or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="id_23189_444473_2_1">Issuance of shares for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_23189_440692_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_23189_440692_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_23189_454926_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_23189_454926_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_23189_452563_1_1">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_23189_452563_6_1">TOTAL LIABILITIES AND STOCKHOLDERS&apos; DEFICIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_23189_445804_1_1">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_23189_445804_2_1">LIABILITIES AND STOCKHOLDERS&apos; DEFICIT:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_23189_442283_1_1">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_23189_442283_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_23189_453630_1_1">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_23189_453630_2_1">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_448381_1_1">Loans Notes Trade And Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_448381_2_1">Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US" id="id_23189_446163_1_1">Minority Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US" id="id_23189_446163_2_1">Non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_443310_1_1">Minority Interest Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_443310_2_1">Non-Controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestIncreaseFromStockIssuance" xlink:label="us-gaap_MinorityInterestIncreaseFromStockIssuance" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestIncreaseFromStockIssuance_lbl" xml:lang="en-US" id="id_23189_446410_1_1">Minority Interest Increase From Stock Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestIncreaseFromStockIssuance_lbl" xml:lang="en-US" id="id_23189_446410_2_1">Acquisition related non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestIncreaseFromStockIssuance" xlink:to="us-gaap_MinorityInterestIncreaseFromStockIssuance_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_23189_442709_1_1">Minority Interest Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_23189_442709_2_1">Distributions to non-controlling interest shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" id="id_23189_450968_1_1">Nature Of Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" id="id_23189_450968_2_1">Organization and Summary of Critical Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_23189_455588_1_1">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_23189_455588_6_1">Net cash used in financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_23189_441258_1_1">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_23189_441258_2_1">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_23189_442115_1_1">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_23189_442115_6_1">Net cash provided by (used) in financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_23189_446874_1_1">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_23189_446874_2_1">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_23189_444138_1_1">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_23189_444138_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_23189_455701_1_1">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_23189_455701_2_1">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_23189_448373_1_1">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_23189_448373_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_23189_448373_6_1">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US" id="id_23189_443747_1_1">Noncontrolling Interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US" id="id_23189_443747_2_1">Non- controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_23189_448410_1_1">Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_23189_448410_6_1">Total other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_23189_451121_1_1">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_23189_451121_2_1">OTHER EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_23189_457102_3_1">Notes to Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_23189_457102_1_1">Notes To Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_23189_457102_2_1">Notes to Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="ameh_NotesToFinancialStatementsAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficerMember_lbl" xml:lang="en-US" id="id_23189_451883_1_1">Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficerMember_lbl" xml:lang="en-US" id="id_23189_451883_2_1">Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficerMember" xlink:to="us-gaap_OfficerMember_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_23189_454286_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_23189_454286_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_23189_446526_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_23189_446526_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_23189_451396_1_1">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_23189_451396_6_1">(LOSS) INCOME FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_23189_447022_1_1">Other Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_23189_447022_2_1">Shares to be issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_442043_1_1">Other Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_442043_2_1">Due from Affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="id_23189_452415_1_1">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="id_23189_452415_2_1">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_23189_450798_1_1">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_23189_450798_8_1">Cash paid for purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xml:lang="en-US" id="id_23189_446278_1_1">Payments To Minority Shareholders</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xml:lang="en-US" id="id_23189_446278_8_1">Distribution to non-controlling interest shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToMinorityShareholders" xlink:to="us-gaap_PaymentsToMinorityShareholders_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_23189_454155_1_1">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_23189_454155_2_1">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_23189_447581_1_1">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_23189_447581_2_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_23189_452714_1_1">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_23189_452714_2_1">Preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_23189_452720_1_1">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_23189_452720_2_1">Preferred stock, par value $0.001 ; 5,000,000 shares authorized; none issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_23189_449033_1_1">Prepaid Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_23189_449033_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_475297_3_1">The disclosure describes the Company&apos;s prepaid and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_475297_1_1">Prepaid Expenses And Other Current Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_475297_2_1">Prepaid Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_lbl" xml:lang="en-US" id="id_23189_455579_1_1">Proceeds From Divestiture Of Interest In Consolidated Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_lbl" xml:lang="en-US" id="id_23189_455579_2_1">Cash received from consolidation of VIE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:to="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_23189_441056_1_1">Proceeds From Repayments Of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_23189_441056_2_1">Proceeds from/(payment to) convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_452562_1_1">Property Plant And Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_452562_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_23189_454339_1_1">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_23189_454339_2_1">Property and equipment - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" id="id_23189_447808_1_1">Provision For Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" id="id_23189_447808_2_1">Bad debt expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_455167_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_455167_2_1">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US" id="id_23189_453409_1_1">Repayments Of Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US" id="id_23189_453409_8_1">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_23189_443900_1_1">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_23189_443900_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_23189_440920_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_23189_440920_2_1">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_23189_443349_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_23189_443349_2_1">REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_23189_455613_1_1">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_23189_455613_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_23189_451274_1_1">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_23189_451274_4_1">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_23189_451274_5_1">Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_23189_449007_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_23189_449007_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_23189_452905_1_1">Statement Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_23189_452905_2_1">Statement, Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_23189_442947_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_23189_442947_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_23189_444291_1_1">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_23189_444291_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_23189_445234_1_1">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_23189_445234_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_23189_454336_1_1">Statement Of Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_23189_454336_2_1">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_23189_455296_1_1">Statement Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_23189_455296_2_1">Statement, Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_23189_447352_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_23189_447352_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_23189_453525_1_1">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_23189_453525_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="id_23189_456188_1_1">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="id_23189_456188_4_1">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="id_23189_456188_5_1">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="id_23189_456188_6_1">Total stockholders&apos; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" id="id_23189_452930_1_1">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" id="id_23189_452930_2_1">STOCKHOLDERS&apos; DEFICIT:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_441733_1_1">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_23189_441733_2_1">Stockholder&apos;s Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="id_23189_440980_1_1">Stock Issued 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="id_23189_440980_2_1">Fair value of common stock issued in connection with acquisitions (Note 17)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_23189_451622_1_1">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_23189_451622_2_1">Shares issued (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_23189_447790_1_1">Stock Issued During Period Shares Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_23189_447790_2_1">Non-cash stock-based compensation charges (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_23189_450789_1_1">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_23189_450789_2_1">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" id="id_23189_454375_1_1">Stock Issued During Period Value Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" id="id_23189_454375_2_1">Non-cash stock-based compensation charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US" id="id_23189_450706_1_1">Stock Option Plan Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US" id="id_23189_450706_2_1">Stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_23189_447520_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_23189_447520_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_23189_445733_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_23189_445733_2_1">SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_23189_440666_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_23189_440666_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_23189_466530_3_1">Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_23189_466530_1_1">Weighted Average Number Basic Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_23189_466530_2_1">WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:to="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" />
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ameh-20120131_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.14.9 -->
<!-- Round: 78e78d3c-9523-426b-a0b4-c45cd75b162c -->
<!-- Creation date: 2012-05-14T14:40:59Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.apollomed.net/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfIncome" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.apollomed.net/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsGoingConcernDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsMinorityInterestDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsMinorityInterestDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ameh-20120131.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_DocumentDocumentandEntityInformationAbstract" xlink:label="ameh_DocumentDocumentandEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_DocumentDocumentandEntityInformationAbstract" xlink:to="dei_EntitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="us-gaap_DueFromAffiliateCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueFromOfficersOrStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AdvancesOnInventoryPurchases" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromOfficersOrStockholdersCurrent" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromAffiliateCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_ConvertibleNotesCurrentUnamortizedDiscount" xlink:label="ameh_ConvertibleNotesCurrentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_ConvertibleNotesCurrentUnamortizedDiscount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.1300" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1.1400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_Depreciation" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfServices" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AcquisitionMember" xlink:label="us-gaap_AcquisitionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_CompensationExpenseRelatedStockOptions" xlink:label="ameh_CompensationExpenseRelatedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" xlink:label="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestIncreaseFromStockIssuance" xlink:label="us-gaap_MinorityInterestIncreaseFromStockIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_GoodsAndServicesExchangedForEquityInstrumentMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_AcquisitionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestIncreaseFromStockIssuance" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_CompensationExpenseRelatedStockOptions" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0525" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0550" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_IssuanceOfCommonStockValueForStockBasedCompensation" xlink:label="ameh_IssuanceOfCommonStockValueForStockBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ameh_IssuanceOfCommonStockValueForStockBasedCompensation" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent" order="1.0800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseDueFromAffiliates" order="1.0900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.1100" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1.1300" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsToMinorityShareholders" order="1.1500" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NatureOfOperations" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_GoingConcernDisclosureTextBlock" xlink:label="ameh_GoingConcernDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_GoingConcernDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_OfficerMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" xlink:label="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_ConvertibleDebtDisclosureTextBlock" xlink:label="ameh_ConvertibleDebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ameh_ConvertibleDebtDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsMinorityInterestDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ameh-20120131.xsd#ameh_NotesToFinancialStatementsAbstract" xlink:label="ameh_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ameh_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Going Concern<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_GoingConcernDisclosureTextBlock', window );">Going Concern</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>3. Going Concern</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company's financial statements are prepared using the generally
accepted accounting principles applicable to a going concern, which
contemplates the realization of assets and liquidation of
liabilities in the normal course of business. However, the Company
continues to incur operating losses and has an accumulated deficit
of $2,117,708 as of January 31, 2012. In addition, at January 31,
2012, the Company has a total stockholders&#x2019; deficit of
$659,321 and generated a negative net cash flow operating
activities of $385,455 for the year then ended.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The financial statements do not include any adjustments relating to
the recoverability and classification of liabilities that might be
necessary should the Company be unable to continue as a going
concern.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
To date the Company has funded its operations from both internally
generated cash flow and external sources, and the proceeds
available from the private placement of convertible notes which
have provided funds for near-term operations and growth. The
Company will pursue additional external capitalization
opportunities, as necessary, to fund its long-term goals and
objectives. We may seek to raise additional capital through public
or private equity financings, partnerships, joint ventures,
disposition of assets, debt financings, bank borrowings or other
sources of financing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
No assurances can be made that management will be successful in
achieving its plan. If the Company is not able to raise substantial
additional capital in a timely manner, the Company may be forced to
cease operations.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_GoingConcernDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Going Concern Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ameh_GoingConcernDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ameh_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\U9C%C.#)A-E\P83EC7S0Y9C!?.#0T.%]B93%F
M-&9D8SDX,3(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?4U1//"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?0T%3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]3=6UM87)Y7V]F7T-R
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R
M>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^1V]I;F=?0V]N8V5R;CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E8V5I=F%B;&4\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$=65?9G)O;5]!9F9I;&EA
M=&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F5P
M86ED7T5X<&5N<V5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4')E<&%I9%]F:6YA;F-I;F=?8V]S=#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G0\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8V-O=6YT
M<U]087EA8FQE7V%N9%]!8V-R=65D7TP\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y#;VYV97)T:6)L95].;W1E<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R
M='E?5')A;G-A8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^3F]N0V]N=')O;&QI;F=?26YT97)E<W0\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?1&5F:6-I
M=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI
M=&UE;G1S7V%N9%]#;VYT:6YG96YC>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D%C<75I<VET:6]N<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$
M(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP
M/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E
M/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A
M;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*
M/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^
M5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC
M96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-68Q8S@R839?,&$Y8U\T.68P7S@T-#A?8F4Q9C1F
M9&,Y.#$R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S5F,6,X,F$V
M7S!A.6-?-#EF,%\X-#0X7V)E,68T9F1C.3@Q,B]7;W)K<VAE971S+U-H965T
M,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5654%%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C
M=6UE;G0@26YF;W)M871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P+4L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&
M;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C
M=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y*86X@,S$L#0H)"3(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R
M($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M;V-U;65N="!&:7-C86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y&63QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3>6UB;VP\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/D%-14@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA
M;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D%03TQ,3R!-141)
M0T%,($A/3$1)3D=3+"!)3D,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#$P.#,T-#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U
M<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/BTM,#$M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!796QL+6MN;W=N(%-E87-O
M;F5D($ES<W5E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3F\\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE
M<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/E-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O
M8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S`L-C,U+#<W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%!U8FQI8R!&;&]A=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y.#@L-#$S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%/04<^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0Q/CQS=')O;F<^0T].4T],241!5$5$($)!3$%.0T4@4TA%1513
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2F%N+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*86XN(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-54E)%3E0@05-31513/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,38T+#,V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,SDW+#$P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L92P@;F5T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.30L,3$X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`T+#DW
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^061V86YC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y296-E:79A8FQE(&9R;VT@;V9F:6-E<G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(T+#@W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1'5E(&9R;VT@869F:6QI871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#4P-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P
M86ED(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-2PV,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.2PQ,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R97!A:60@9FEN86YC:6YG(&-O<W0L(&-U<G)E;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#4P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#4P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(T.2PR,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#$Y-RPT.#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@9FEN86YC:6YG
M(&-O<W0L(&QO;F<@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PU-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS.2PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@+2!N970\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+#(V,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#4Y,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1/5$%,($%34T544SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PS-C0L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-3@L,3,Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-5
M4E)%3E0@3$E!0DE,251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@
M;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M,RPT-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY,BPW-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO=&5S+"!N970@;V8@)#8U,RPP
M,C8@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3DV+#,V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8U,RPP,C8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!T;R!B92!I<W-U
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1'5E
M('1O(&]F9FEC97)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,BPT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4Q-2PR-C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,BPW-#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I
M8FQE(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PR-#@L-3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y787)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<X-2PR-C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T
M,2PS,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!$149)0TE4.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL('!A<B!V86QU92`D,"XP,#$@.R`U+#`P,"PP,#`@<VAA<F5S(&%U
M=&AO<FEZ960[(&YO;F4@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C
M:RP@<&%R('9A;'5E("0P+C`P,3L@,3`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO
M<FEZ960L(#(Y+#,S-2PW-S0@86YD(#(W+#8S-2PW-S0@<VAA<F5S(&ES<W5E
M9"!A;F0@;W5T<W1A;F1I;F<@87,@;VX@2F%N=6%R>2`S,2P@,C`Q,B!A;F0@
M,C`Q,2P@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.2PS,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-RPV,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;BUC87!I=&%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0R.2PP-3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`U
M."PT,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L,3$W+#<P."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,Y-RPS-C,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8U.2PS,C$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S$Q+#,P.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYO;BUC;VYT<F]L;&EN9R!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C,X+#$P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(R."PQ,34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:VAO;&1E
M<G,G(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0R
M,2PR,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH.#,L,3DT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1/5$%,($Q)04))3$E42453($%.1"!35$]#2TA/
M3$1%4E,G($1%1DE#250\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,2PS-C0L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+#(U."PQ,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S5F,6,X,F$V7S!A.6-?-#EF,%\X-#0X7V)E
M,68T9F1C.3@Q,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U9C%C
M.#)A-E\P83EC7S0Y9C!?.#0T.%]B93%F-&9D8SDX,3(O5V]R:W-H965T<R]3
M:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%34U!0SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%!A<F5N=&AE=&EC
M86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2F%N+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!N;W1E<RP@9&5B="!D:7-C
M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V-3,L,#(V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K+"!P87(@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@4W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@4W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Y+#,S-2PW-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-RPV,S4L-S<T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL
M('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CDL,S,U+#<W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(W+#8S-2PW-S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S5F,6,X,F$V7S!A.6-?-#EF,%\X-#0X
M7V)E,68T9F1C.3@Q,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U
M9C%C.#)A-E\P83EC7S0Y9C!?.#0T.%]B93%F-&9D8SDX,3(O5V]R:W-H965T
M<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%-5%!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!/4$52051)3TY3
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#0^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/DIA;BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^2F%N+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D5614Y515,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PQ,3`L.#`V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#@Y-BPU.#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-/4U0@3T8@4T525DE#15,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,3,R+#,Y.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L,S$T+#<R,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=23U-3(%)%5D5.544\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDW."PT,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU.#$L.#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]P97)A=&EN9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,S<Y+#$U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4V-BPV-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E
M8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-3@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,3DX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,Y,2PW-#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S<L.#0W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^*$Q/4U,I($E.0T]-12!&4D]-($]0
M15)!5$E/3E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0Q,RPS
M,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3U1(15(@15A014Y3
M15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$S,2PU,S0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3(V+#0S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9I;F%N8VEN9R!C;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-S(L-3`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,W+#4P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R
M(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX-#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$X-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]T:&5R(&5X<&5N<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,#$L,3DR*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U."PW-#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,3U-3($)%1D]212!)3D-/344@5$%815,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<Q-"PU,C<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,34T+#<S,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX,3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#8P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DY%5"!,3U-3/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#<R,"PS-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q-38L,S,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5T5)
M1TA4140@059%4D%'12!32$%215,@3T8@0T]-34].(%-43T-+($]55%-404Y$
M24Y'+"!"05-)0R!!3D0@1$E,551%1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CDL,#<X+#DR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(W+#0Y,"PT-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)!4TE#($%.1"!$24Q55$5$($Y%5"!,3U-3(%!%4B!32$%213PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO
M<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&0@8V]L<W!A;CTS1#4^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$
M=&]P/ELQ73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX]
M,T1T;W`^5V5I9VAT960@879E<F%G92!N=6UB97(@;V8@<VAA<F5S('5S960@
M=&\@8V]M<'5T92!B87-I8R!A;F0@9&EL=71E9"!L;W-S('!E<B!S:&%R92!I
M<R!T:&4@<V%M92!S:6YC92!T:&4@969F96-T(&]F(&1I;'5T:79E('-E8W5R
M:71I97,@:7,@86YT:2UD:6QU=&EV92X\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-68Q8S@R839?,&$Y8U\T.68P7S@T-#A?8F4Q9C1F9&,Y.#$R#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S5F,6,X,F$V7S!A.6-?-#EF
M,%\X-#0X7V)E,68T9F1C.3@Q,B]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4T44-)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3E-/3$E$
M051%1"!35$%414U%3E13($]&(%-43T-+2$],1$524R<@1$5&24-)5"`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E1O=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<G9I
M8V4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^04A)(&%N9"!0
M0T--/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3
M=&]C:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@
M4W1O8VL\8G(^4V5R=FEC93QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y#;VUM;VX@4W1O8VL\8G(^04A)(&%N9"!00T--/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D%024,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^05!)0SQB<CY397)V:6-E/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%024,\8G(^04A)(&%N9"!00T--/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO;BT@8V]N=')O;&QI;F<@
M26YT97)E<W0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^06-C
M=6UU;&%T960@1&5F:6-I=#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%L86YC92!A="!*86XN(#,Q+"`R,#$P/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#0V+#,Y,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W+#`T,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3,Y+#0X
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C(X+#$Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,2PR-#$L,#,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@<VAA<F5S*2!A
M="!*86XN(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-RPP-#$L,S(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D("AI;B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.30L-#0V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S
M=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RPS-S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-BPW.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYO;BUC87-H('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!C:&%R
M9V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,BPQ-3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,BPQ
M-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-38L,S,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$U-BPS,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($IA;BX@,S$L(#(P,3$\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@S+#$Y-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPV,S8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`U
M."PT,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,C@L,3$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PS.3<L,S8R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@<VAA<F5S*2!A
M="!*86XN(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-RPV,S4L-S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D("AI;B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#,U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(W."PV-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C<75I<VET:6]N(')E;&%T960@;F]N+6-O;G1R;VQL
M:6YG(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-C0L,C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,38T+#(W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&ES=')I8G5T:6]N<R!T;R!N;VXM8V]N=')O;&QI
M;F<@:6YT97)E<W0@<VAA<F5H;VQD97(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$U-"PR.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,34T+#(Y,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H('-T;V-K+6)A
M<V5D(&-O;7!E;G-A=&EO;B!C:&%R9V5S("AI;B!S:&%R97,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@8VAA<F=E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L-C4P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VX@
M97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL,S,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,CDL,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-S(P+#,T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@W,C`L,S0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!*86XN(#,Q+"`R,#$R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0R,2PR,C`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M.2PS,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$L-#(Y+#`U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C,X+#$P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPQ,3<L-S`X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC
M92`H:6X@<VAA<F5S*2!A="!*86XN(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR.2PS,S4L-S<T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P135304<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0T].4T],241!5$5$(%-4051%345.5%,@3T8@0T%32"!&3$]7
M4R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M86XN(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIA;BX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($]015)!5$E.1R!!0U1)
M5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@W,C`L,S0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,34V+#,S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@
M<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H("AU<V5D(&EN*2!O<&5R
M871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,BPU.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PQ.3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A9"!D96)T(&5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q."PP-S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPY,#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F('-H87)E<R!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$U,BPT,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RPS-S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO
M;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PS
M,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW,BPQ-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!D96)T(&1I<V-O=6YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A<V4@
M:6X@=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEM<&%I<FUE;G0@;&]S<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN
M(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P-RPR,C0I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDP+#,V,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1U92!F<F]M("\@=&\@;V9F:6-E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+#DU,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1'5E(&9R;VT@869F:6QI871E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV,#0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&9I;F%N
M8VEN9R!C;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RPU
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(R+#8V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`R-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A
M;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S`L-S,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3$L-3`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E
M<F%T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,X-2PT-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C0U+#`S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-
M($E.5D535$E.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R('!U<F-H87-E(&]F
M('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<L,C`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(Q+#$V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<F5C96EV960@9G)O;2!C
M;VYS;VQI9&%T:6]N(&]F(%9)13PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,38T+#(Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D*2!I
M;B!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34W+#`P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(Q+#$V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&
M4D]-($9)3D%.0TE.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$=64@9G)O;2!R96QA=&5D('!A<G1I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-#0P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2\H<&%Y;65N="!T;RD@8V]N=F5R=&EB;&4@;F]T97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I<W1R:6)U
M=&EO;B!T;R!N;VXM8V]N=')O;&QI;F<@:6YT97)E<W0@<VAA<F5H;VQD97(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U-"PR.3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&-A<V@@=7-E9"!I;B!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-"PR.3`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPT-#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($1%0U)%
M05-%($E.($-!4T@@)F%M<#L@0T%32"!%455)5D%,14Y44SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C,R+#<T,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-C@L-C,V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T%32"`F
M86UP.R!#05-(($5154E604Q%3E13+"!"14=)3DY)3D<@0D%,04Y#13PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDW+#$P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V-2PW,S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-!
M4T@@)F%M<#L@0T%32"!%455)5D%,14Y44RP@14Y$24Y'($)!3$%.0T4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V-"PS-C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3<L,3`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-54%!,14U%3E1!4ED@1$E30TQ/4U5215,@3T8@0T%32"!&3$]7
M($E.1D]234%424]./"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=&5R97-T('!A:60@9'5R:6YG('1H92!Y96%R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,CDL,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#0R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&%X
M97,@<&%I9"!D=7)I;F<@=&AE('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PV,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3D].+4-!4T@@1DE.04Y#
M24Y'($%#5$E6251)15,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!C;VUM;VX@<W1O8VL@:7-S=65D
M(&EN(&-O;FYE8W1I;VX@=VET:"!A8W%U:7-I=&EO;G,@*$YO=&4@,3<I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@
M=&\@8F4@:7-S=65D(&9O<B!S97)V:6-E<R`H3F]T92`Q-2D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O9B!#<FET:6-A
M;"!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@
M0W)I=&EC86P@06-C;W5N=&EN9R!0;VQI8VEE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
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M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D%P;VQL;PT*365D:6-A;"!(;VQD:6YG<RP@26YC+B`H
M)B-X,C`Q0SM!<&]L;&\F(W@R,#%$.R!O<B!T:&4-"B8C>#(P,4,[0V]M<&%N
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M>#(P,4,[04U-)B-X,C`Q1#LI(&%N9"!0=6QM;VYA<GD@0W)I=&EC86P@0V%R
M92!-86YA9V5M96YT+`T*26YC+B`H)B-X,C`Q0SM00T--)B-X,C`Q1#LI+B!4
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M=&\@4&AY<VEC:6%N(%!R86-T:6-E($-O;7!A;FEE<R`H4%!#*2!U;F1E<@T*
M36%N86=E;65N="!397)V:6-E($%G<F5E;65N=',N/"]P/@T*/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2F%N+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\8CXR+B!3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CQB/E!R:6YC:7!L97,@;V8@0V]N
M<V]L:61A=&EO;CPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-
M"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*3W5R(&-O
M;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E('1H92!A
M8V-O=6YT<R!O9@T*07!O;&QO($UE9&EC86P@2&]L9&EN9W,L($EN8RX@86YD
M(&ET<R!W:&]L;'D@;W=N960@<W5B<VED:6%R:65S#0I!34TL("P@06QI9VYE
M9"!(96%L=&AC87)E($=R;W5P("@F(W@R,#%#.T%(228C>#(P,40[*2!A;F0@
M4$-#32!A<PT*=V5L;"!A<R!0<F]F97-S:6]N86P@365D:6-A;"!#;W)P;W)A
M=&EO;G,@;6%N86=E9"!U;F1E<B!L;VYG+71E<FT-"FUA;F%G96UE;G0@86=R
M965M96YT<R!I;F-L=61I;F<@04U((&%N9"!,04Q#+B!3;VUE('-T871E<R!H
M879E(&QA=W,-"G1H870@<')O:&EB:70@8G5S:6YE<W,@96YT:71I97,L('-U
M8V@@87,@07!O;&QO365D+"!F<F]M('!R86-T:6-I;F<-"FUE9&EC:6YE+"!E
M;7!L;WEI;F<@<&AY<VEC:6%N<R!T;R!P<F%C=&EC92!M961I8VEN92P@97AE
M<F-I<VEN9PT*8V]N=')O;"!O=F5R(&UE9&EC86P@9&5C:7-I;VYS(&)Y('!H
M>7-I8VEA;G,@*&-O;&QE8W1I=F5L>2!K;F]W;B!A<PT*=&AE(&-O<G!O<F%T
M92!P<F%C=&EC92!O9B!M961I8VEN92DL(&]R(&5N9V%G:6YG(&EN(&-E<G1A
M:6X-"F%R<F%N9V5M96YT<R!W:71H('!H>7-I8VEA;G,L('-U8V@@87,@9F5E
M+7-P;&ET=&EN9RX@26X@0V%L:69O<FYI82P-"G=E(&]P97)A=&4@8GD@;6%I
M;G1A:6YI;F<@;&]N9RUT97)M(&UA;F%G96UE;G0@8V]N=')A8W1S('=I=&@@
M=&AE#0I0<F]F97-S:6]N86P@365D:6-A;"!#;W)P;W)A=&EO;G,L('=H:6-H
M(&%R92!E86-H(&]W;F5D(&%N9`T*;W!E<F%T960@8GD@<&AY<VEC:6%N<RP@
M86YD('=H:6-H(&5M<&QO>2!O<B!C;VYT<F%C="!W:71H#0IA9&1I=&EO;F%L
M('!H>7-I8VEA;G,@=&\@<')O=FED92!H;W-P:71A;&ES="!S97)V:6-E<RX@
M56YD97(@=&AE#0IM86YA9V5M96YT(&%G<F5E;65N=',L('=E('!R;W9I9&4@
M86YD('!E<F9O<FT@86QL(&YO;BUM961I8V%L#0IM86YA9V5M96YT(&%N9"!A
M9&UI;FES=')A=&EV92!S97)V:6-E<RP@:6YC;'5D:6YG(&9I;F%N8VEA;`T*
M;6%N86=E;65N="P@:6YF;W)M871I;VX@<WES=&5M<RP@;6%R:V5T:6YG+"!R
M:7-K(&UA;F%G96UE;G0@86YD#0IA9&UI;FES=')A=&EV92!S=7!P;W)T+B!4
M:&4@;6%N86=E;65N="!A9W)E96UE;G1S(&AA=F4@86X@:6YI=&EA;`T*=&5R
M;2!O9B`R,"!Y96%R<R!U;FQE<W,@=&5R;6EN871E9"!B>2!E:71H97(@<&%R
M='D@9F]R(&-A=7-E+B!4:&4-"FUA;F%G96UE;G0@86=R965M96YT<R!A<F4@
M;F]T('1E<FUI;F%B;&4@8GD@=&AE(%!R;V9E<W-I;VYA;`T*365D:6-A;"!#
M;W)P;W)A=&EO;G,L(&5X8V5P="!I;B!T:&4@8V%S92!O9B!G<F]S<R!N96=L
M:6=E;F-E+`T*9G)A=60L(&]R(&]T:&5R(&EL;&5G86P@86-T<R!B>2!U<RP@
M;W(@8F%N:W)U<'1C>2!O9B!!<&]L;&]-960N/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P)SX-"E1H<F]U9V@@=&AE(&UA;F%G96UE;G0@86=R965M96YT<R!A;F0@
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M(&)A;&%N8V5S(&%N9`T*=')A;G-A8W1I;VYS(&AA=F4@8F5E;B!E;&EM:6YA
M=&5D(&EN(&-O;G-O;&ED871I;VXN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-
M"D%L;"!I;G1E<F-O;7!A;GD@8F%L86YC97,@86YD('1R86YS86-T:6]N<R!A
M<F4@96QI;6EN871E9"!I;@T*8V]N<V]L:61A=&EO;BX\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`G/@T*/&(^3F]N+6-O;G1R;VQL:6YG($EN=&5R97-T/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,"<^#0I.;VXM8V]N=')O;&QI;F<@:6YT97)E
M<W0@<F5P<F5S96YT<R!T:&4@<&]R=&EO;B!O9B!E<75I='D@=&AA="!I<PT*
M;F]T(&%T=')I8G5T86)L92!T;R!T:&4@0V]M<&%N>2X@5&AE(&YO;BUC;VYT
M<F]L;&EN9R!I;G1E<F5S=`T*<F5C;W)D960@:6X@;W5R(&-O;G-O;&ED871E
M9"!F:6YA;F-I86P@<W1A=&5M96YT<R!R97!R97-E;G1S('1H90T*<')E+6%C
M<75I<VET:6]N(&5Q=6ET>2!O9B!T:&]S92!E;G1I=&EE<R!W:&EC:"!W92!H
M879E(&1E=&5R;6EN960-"G1H870@=V4@:&%V92!A(&-O;G1R;VQL:6YG(&9I
M;F%N8VEA;"!I;G1E<F5S="!A;F0@=&AA=`T*8V]N<V]L:61A=&EO;B!I<R!R
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M('-U8G-E<75E;G0@=&\@:6YI=&EA;`T*8V]N<V]L:61A=&EO;B!W;W5L9"!R
M96QA=&4@=&\@96ET:&5R(&-A<&ET86P@8V]N=')I8G5T:6]N<R!O<@T*=VET
M:&1R87=A;',@8GD@=&AE(&YO;BUC;VYT<F]L;&EN9R!P87)T:65S+CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,"<^#0H\8CY5<V4@;V8@17-T:6UA=&5S/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,"<^#0I4:&4@<')E<&%R871I;VX@;V8@9FEN
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M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX-"CQB/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L
M($EN<W1R=6UE;G1S/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I/=7(@
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M(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I,
M979E;"!O;F4@)B-X,C`Q-#L@475O=&5D(&UA<FME="!P<FEC97,@:6X@86-T
M:79E(&UA<FME=',@9F]R#0II9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET
M:65S.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I,979E;"!T=V\@)B-X,C`Q
M-#L@26YP=71S(&]T:&5R('1H86X@;&5V96P@;VYE(&EN<'5T<R!T:&%T(&%R
M90T*96ET:&5R(&1I<F5C=&QY(&]R(&EN9&ER96-T;'D@;V)S97)V86)L93L@
M86YD/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"DQE=F5L('1H<F5E("8C>#(P
M,30[(%5N;V)S97)V86)L92!I;G!U=',@9&5V96QO<&5D('5S:6YG(&5S=&EM
M871E<PT*86YD(&%S<W5M<'1I;VYS+"!W:&EC:"!A<F4@9&5V96QO<&5D(&)Y
M('1H92!R97!O<G1I;F<@96YT:71Y(&%N9`T*<F5F;&5C="!T:&]S92!A<W-U
M;7!T:6]N<R!T:&%T(&$@;6%R:V5T('!A<G1I8VEP86YT('=O=6QD('5S92X\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*1&5T97)M:6YI;F<@=VAI8V@@8V%T
M96=O<GD@86X@87-S970@;W(@;&EA8FEL:71Y(&9A;&QS('=I=&AI;B!T:&4-
M"FAI97)A<F-H>2!R97%U:7)E<R!S:6=N:69I8V%N="!J=61G;65N="X@5&AE
M($-O;7!A;GD@979A;'5A=&5S(&ET<PT*:&EE<F%R8VAY(&1I<V-L;W-U<F5S
M(&5A8V@@<75A<G1E<BX@5&AE($-O;7!A;GD@8W5R<F5N=&QY(')E8V]R9',-
M"G=A<G)A;G1S('5S:6YG(&QE=F5L('1W;R!I;B!T:&4@:&EE<F%R8VAY+B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I4:&4@8V%R<GEI;F<@=F%L
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M:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,"<^#0H\8CY&86ER(%9A;'5E(&]F(%=A<G)A;G1S/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*/&(^)B-X03`[/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*5&AE($-O;7!A;GD@86-C
M;W5N=',@9F]R(&9R964M<W1A;F1I;F<@=V%R<F%N=',@9F]R('-H87)E<R!O
M9@T*8V]M;6]N('-T;V-K(&)Y(&9I<G-T(&1E=&5R;6EN:6YG('=H971H97(@
M=&AE(&EN<W1R=6UE;G1S(')E<75I<F4-"FQI86)I;&ET>2!T<F5A=&UE;G0@
M8F%S960@;VX@=&AE('!R;W9I<VEO;B!I;B!T:&4@=V%R<F%N=`T*86=R965M
M96YT<RX@1V5N97)A;&QY+"!W:&5N('1H92!A9W)E96UE;G0@;6%Y(')E<75I
M<F4@9G5T=7)E#0IP97)F;W)M86YC92!O8FQI9V%T:6]N<R!O;B!T:&4@<&%R
M="!O9B!T:&4@0V]M<&%N>2`H;W1H97(@=&AA;B!T:&4-"FES<W5A;F-E(&]F
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M=&EO;F%L('!A:60M:6X@8V%P:71A;`T*=VET:"!A(&-O<G)E<W!O;F1I;F<@
M9&ES8V]U;G0N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"E1H92!#;VUP86YY
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M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I3=6)S97%U96YT(&%D:G5S=&UE
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M86YY)B-X,C`Q.3MS('-T871E;65N="!O9@T*;W!E<F%T:6]N<RX\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`G/@T*/&(^0V]N8V5N=')A=&EO;G,\+V(^/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX-"D1U<FEN9R!T:&4@='=E;'9E(&UO;G1H('!E
M<FEO9"!E;F1E9"!*86YU87)Y(#,Q+"`R,#$R+"!T:&4@0V]M<&%N>0T*:&%D
M('1H<F5E(&UA:F]R(&-U<W1O;65R<RP@=VAI8V@@8V]N=')I8G5T960@,S0E
M+"`Q-R4@86YD(#<N-B4@;V8-"G)E=F5N=64N($%S(&]F($IA;G5A<GD@,S$L
M(#(P,3(L('1H92!T;W1A;"!R96-E:79A8FQE<R!F<F]M('1H97-E#0IC=7-T
M;VUE<G,@86UO=6YT960@=&\@)#$T,"PP,#`L("0X.2PP.3D@86YD("0T,2PY
M,#`L#0IR97-P96-T:79E;'DN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*1'5R:6YG('1H92!T=V5L
M=F4@;6]N=&@@<&5R:6]D(&5N9&5D($IA;G5A<GD@,S$L(#(P,3$L('1H92!#
M;VUP86YY#0IH860@=&AR964@;6%J;W(@8W5S=&]M97)S+"!W:&EC:"!C;VYT
M<FEB=71E9"`S-B4L(#(P)2!A;F0@,3(E(&]F#0IR979E;G5E+B!!<R!O9B!*
M86YU87)Y(#,Q+"`R,#$Q+"!T:&4@=&]T86P@<F5C96EV86)L97,@9G)O;2!T
M:&5S90T*8W5S=&]M97)S(&%M;W5N=&5D('1O("0Q-S`L-C,X+"`D,38W+#<Y
M.2!A;F0@)#@X+#4X,"P-"G)E<W!E8W1I=F5L>2X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P)SX-"B8C>$$P.R8C>$$P.R8C>$$P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`G/@T*/&(^4W1O8VLM0F%S960@0V]M<&5N<V%T
M:6]N/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\8CY%;7!L;WEE92!3
M=&]C:R!/<'1I;VYS(&%N9"!3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"D%L;"!S:&%R92UB87-E9"!P87EM
M96YT<R!T;R!E;7!L;WEE97,L(&EN8VQU9&EN9R!G<F%N=',@;V8@96UP;&]Y
M964-"G-T;V-K(&]P=&EO;G,L(&%R92!R96-O9VYI>F5D(&EN('1H92!F:6YA
M;F-I86P@<W1A=&5M96YT<R!B87-E9"!O;@T*=&AE:7(@9F%I<B!V86QU97,N
M(%1H97)E('=E<F4@;F\@<W1O8VL@;W!T:6]N<R!G<F%N=&5D(&1U<FEN9R!T
M:&4-"GEE87(@96YD960@2F%N=6%R>2`S,2P@,C`Q,BX@1F]R(&]P=&EO;G,@
M9W)A;G1E9"!D=7)I;F<@=&AE('EE87(-"F5N9&5D($IA;G5A<GD@,S$L(#(P
M,3$L('1H92!F86ER('9A;'5E(&]F(&5A8V@@;W!T:6]N(&%W87)D('=A<PT*
M97-T:6UA=&5D('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC
M:6YG(&UO9&5L(&%N9"!T:&4-"F9O;&QO=VEN9R!A<W-U;7!T:6]N<SH\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`G/@T*/"]P/@T*/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@=VED=&@Z(#DW)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`N,#5I;B`P<'0@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"EEE87(F(WA!
M,#ME;F1E9#PO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`N,#5I;B`P<'0@
M,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX-"DIA;G5A<GDF(WA!,#LS,2P\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P+C`U:6X@,'!T(#`[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^#0HR,#$R/"]P/@T*/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=W:61T:#H@
M.#<E)SY796EG:'1E9"!A=F5R86=E(')I<VLM9G)E92!I;G1E<F5S=`T*<F%T
M93PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L:6=N
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M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U
M+#(P-"DG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/E9O;&%T
M:6QI='D@9F%C=&]R(&]F('1H92!E>'!E8W1E9`T*;6%R:V5T('!R:6-E(&]F
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M93PO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXQ,"XP('EE87)S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`G/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,"<^#0I%>'!E8W1E9"!V;VQA=&EL:71Y(&ES(&)A<V5D(&]N('1H92!H:7-T
M;W)I8V%L('9O;&%T:6QI='D@;V8@=&AE#0I#;VUP86YY)B-X,C`Q.3MS('-T
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M;V8@9W)A;G0N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"E1H92!E<W1I;6%T
M960@=V5I9VAT960@879E<F%G92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A
M;G1E9"!D=7)I;F<-"G1H92!Y96%R(&5N9&5D($IA;G5A<GD@,S$L(#(P,3$L
M('=A<R`D("0P+C`Q,2X@07,@;V8@2F%N=6%R>2`S,2P-"C(P,3(@86YD(#(P
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M:&4@9FES8V%L('EE87(@96YD($IA;G5A<GD@,S$L(#(P,3,N/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G
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M#0HR,#$R(&%N9"`R,#$Q+"!T:&4@0V]M<&%N>28C>#(P,3D[<R!O<&5R871I
M;F<@<F5S=6QT<R!I;F-L=61E9`T*)#(Y+#,S,R!A;F0@)#<R+#$U,BP@<F5S
M<&5C=&EV96QY+"!F;W(@;F]N+6-A<V@@<W1O8VLM8F%S960-"F-O;7!E;G-A
M=&EO;B!F;W(@;W!T:6]N<R!I<W-U960@=&\@8V]N<W5L=&%N=',@86YD(&]T
M:&5R#0IN;VXM96UP;&]Y965S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"E1H92!#;VUP86YY(&ES
M<W5E<R!N97<@<VAA<F5S('1O('-A=&ES9GD@<W1O8VL@;W!T:6]N(&%N9"!W
M87)R86YT#0IE>&5R8VES97,N(%1H97)E('=E<F4@;F\@;W!T:6]N<R!E>&5R
M8VES960@9'5R:6YG('1H92!Y96%R<R!E;F1E9`T*2F%N=6%R>2`S,2P@,C`Q
M,B!O<B`R,#$Q+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X
M03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\8CY"87-I8R!A
M;F0@1&EL=71E9"!%87)N:6YG<R!097(@4VAA<F4\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P)SX-"D)A<VEC(&YE="!L;W-S('!E<B!S:&%R92!I<R!C86QC
M=6QA=&5D('5S:6YG('1H92!W96EG:'1E9"!A=F5R86=E#0IN=6UB97(@;V8@
M<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!I
M<W-U960@86YD#0IO=71S=&%N9&EN9R!D=7)I;F<@82!C97)T86EN('!E<FEO
M9"P@86YD(&ES(&-A;&-U;&%T960@8GD@9&EV:61I;F<-"FYE="!L;W-S(&)Y
M('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE
M#0I#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!I<W-U960@86YD(&]U
M='-T86YD:6YG(&1U<FEN9R!S=6-H#0IP97)I;V0N($1I;'5T960@;F5T(&QO
M<W,@<&5R('-H87)E(&ES(&-A;&-U;&%T960@=7-I;F<@=&AE('=E:6=H=&5D
M#0IA=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@86YD('!O=&5N=&EA;&QY(&1I
M;'5T:79E(&-O;6UO;B!S:&%R97,-"F]U='-T86YD:6YG(&1U<FEN9R!T:&4@
M<&5R:6]D+"!U<VEN9R!T:&4@87,M:68@8V]N=F5R=&5D(&UE=&AO9"!F;W(-
M"G-E8W5R960@8V]N=F5R=&EB;&4@;F]T97,L(&%N9"!T:&4@=')E87-U<GD@
M<W1O8VL@;65T:&]D(&9O<@T*;W!T:6]N<R!A;F0@=V%R<F%N=',N/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX-"CQB/D-A<V@@86YD($-A<V@@17%U:79A;&5N
M=',@86YD($-O;F-E;G1R871I;VX@;V8@0V%S:#PO8CX\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`G/@T*5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!S:&]R="UT
M97)M(&EN=F5S=&UE;G1S('=I=&@@86X@;W)I9VEN86P-"FUA='5R:71Y(&]F
M('1H<F5E(&UO;G1H<R!O<B!L97-S('1O(&)E(&-A<V@@97%U:79A;&5N=',N
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"D-A<V@@86YD(&-A<V@@97%U:79A
M;&5N=',@870@2F%N=6%R>2`S,2P@,C`Q,BP@:6YC;'5D92!C87-H(&EN(&)A
M;FL-"G)E<')E<V5N=&EN9R!T:&4@0V]M<&%N>28C>#(P,3D[<R!C=7)R96YT
M(&]P97)A=&EN9R!A8V-O=6YT(&%N9`T*)#(W+#0P-R!I;B!A(&)R;VME<F%G
M92!M;VYE>2!M87)K970@86-C;W5N="X\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P.R!T97AT+6%L:6=N.B!C96YT97(G/@T*)B-X03`[/&(^)B-X03`[
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*/&(^06-C;W5N
M=',@4F5C96EV86)L92!A;F0@06QL;W=A;F-E(&9O<B!$;W5B=&9U;`T*06-C
M;W5N=',F(WA!,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^
M#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"D%C8V]U
M;G1S(')E8V5I=F%B;&4@<')I;6%R:6QY(&-O;G-I<W1S(&]F(&%M;W5N=',@
M9'5E(&9R;VT-"G1H:7)D+7!A<G1Y('!A>6]R<RP@:6YC;'5D:6YG(&=O=F5R
M;FUE;G0@<W!O;G-O<F5D($UE9&EC87)E(&%N9`T*365D:6-A:60@<')O9W)A
M;7,L(&%N9"!I;G-U<F%N8V4@8V]M<&%N:65S+"!A;F0@86UO=6YT<R!D=64@
M9G)O;0T*:&]S<&ET86QS+"!A;F0@<&%T:65N=',N($%C8V]U;G1S(')E8V5I
M=F%B;&4@87)E(')E8V]R9&5D(&%N9`T*<W1A=&5D(&%T('1H92!A;6]U;G0@
M97AP96-T960@=&\@8F4@8V]L;&5C=&5D/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P
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M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X
M03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\8CY0<F]P97)T
M>2!A;F0@17%U:7!M96YT/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`G/@T*/&)R("\^#0I0<F]P97)T>2!A;F0@17%U:7!M96YT(&ES(')E8V]R
M9&5D(&%T(&-O<W0@86YD(&1E<')E8VEA=&5D('5S:6YG#0IT:&4@<W1R86EG
M:'0M(&QI;F4@;65T:&]D(&]V97(@=&AE(&5S=&EM871E9"!U<V5F=6P@;&EV
M97,@;V8@=&AE#0IR97-P96-T:79E(&%S<V5T<RX@0V]S="!A;F0@<F5L871E
M9"!A8V-U;75L871E9"!D97!R96-I871I;VX@;VX-"F%S<V5T<R!R971I<F5D
M(&]R(&1I<W!O<V5D(&]F(&%R92!R96UO=F5D(&9R;VT@=&AE(&%C8V]U;G1S
M(&%N9"!A;GD-"G)E<W5L=&EN9R!G86EN<R!O<B!L;W-S97,@87)E(&-R961I
M=&5D(&]R(&-H87)G960@=&\@:6YC;VUE+@T*0V]M<'5T97)S(&%N9"!3;V9T
M=V%R92!A<F4@9&5P<F5C:6%T960@;W9E<B`S('EE87)S+B!&=7)N:71U<F4@
M86YD#0I&:7AT=7)E<R!A<F4@9&5P<F5C:6%T960@;W9E<B`X('EE87)S+B!-
M86-H:6YE<GD@86YD($5Q=6EP;65N="!A<F4-"F1E<')E8VEA=&5D(&]V97(@
M-2!Y96%R<RX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#`G/@T*/&(^26YC;VUE(%1A>&5S/"]B/CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,"<^#0I4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@:6YC;VUE('1A>&5S
M('5S:6YG(&%N(&%S<V5T(&%N9"!L:6%B:6QI='D-"F%P<')O86-H('=H:6-H
M(&%L;&]W<R!F;W(@=&AE(')E8V]G;FET:6]N(&%N9"!M96%S=7)E;65N="!O
M9@T*9&5F97)R960@=&%X(&%S<V5T<R!B87-E9"!U<&]N('1H92!L:6ME;&EH
M;V]D(&]F(')E86QI>F%T:6]N(&]F('1A>`T*8F5N969I=',@:6X@9G5T=7)E
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M=&EO;B!A;&QO=V%N8V4@:7,@<')O=FED960@9F]R(&1E9F5R<F5D('1A>`T*
M87-S971S(&EF(&ET(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1H97-E(&ET
M96US('=I;&P@96ET:&5R(&5X<&ER90T*8F5F;W)E('1H92!#;VUP86YY(&ES
M(&%B;&4@=&\@<F5A;&EZ92!T:&5I<B!B96YE9FET<RP@;W(@=&AA=`T*9G5T
M=7)E(&1E9'5C=&EB:6QI='D@:7,@=6YC97)T86EN+CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"<^#0I!('1A>"!P;W-I=&EO;B!I<R!R96-O9VYI>F5D(&%S(&$@
M8F5N969I="!O;FQY(&EF(&ET(&ES("8C>#(P,4,[;6]R90T*;&EK96QY('1H
M86X@;F]T)B-X,C`Q1#L@=&AA="!T:&4@=&%X('!O<VET:6]N('=O=6QD(&)E
M('-U<W1A:6YE9"!I;@T*82!T87@@97AA;6EN871I;VXL('=I=&@@82!T87@@
M97AA;6EN871I;VX@8F5I;F<@<')E<W5M960@=&\@;V-C=7(N#0I4:&4@979A
M;'5A=&EO;B!O9B!A('1A>"!P;W-I=&EO;B!I<R!A('1W;RUS=&5P('!R;V-E
M<W,N(%1H92!F:7)S=`T*<W1E<"!I<R!T;R!D971E<FUI;F4@=VAE=&AE<B!I
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M86X@-3`@<&5R8V5N="!L:6ME;'D@;V8@8F5I;F<@<F5A;&EZ960-"G5P;VX@
M=6QT:6UA=&4@<V5T=&QE;65N="X@5&%X('!O<VET:6]N<R!T:&%T('!R979I
M;W5S;'D@9F%I;&5D('1O#0IM965T('1H92!M;W)E+6QI:V5L>2UT:&%N+6YO
M="!R96-O9VYI=&EO;B!T:')E<VAO;&0@<VAO=6QD(&)E#0IR96-O9VYI>F5D
M(&EN('1H92!F:7)S="!S=6)S97%U96YT('!E<FEO9"!I;B!W:&EC:"!T:&4@
M=&AR97-H;VQD(&ES#0IM970N(%!R979I;W5S;'D@<F5C;V=N:7IE9"!T87@@
M<&]S:71I;VYS('1H870@;F\@;&]N9V5R(&UE970@=&AE#0IM;W)E+6QI:V5L
M>2UT:&%N+6YO="!C<FET97)I82!S:&]U;&0@8F4@9&4M<F5C;V=N:7IE9"!I
M;B!T:&4@9FER<W0-"G-U8G-E<75E;G0@9FEN86YC:6%L(')E<&]R=&EN9R!P
M97)I;V0@:6X@=VAI8V@@=&AE('1H<F5S:&]L9"!I<R!N;PT*;&]N9V5R(&UE
M="X@4&5N86QT:65S(&%N9"!I;G1E<F5S="!I;F-U<G)E9"!R96QA=&5D('1O
M('5N9&5R<&%Y;65N=`T*;V8@:6YC;VUE('1A>"!A<F4@8VQA<W-I9FEE9"!A
M<R!I;F-O;64@=&%X(&5X<&5N<V4@:6X@=&AE('EE87(-"FEN8W5R<F5D+B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P)SX-"CQB/E)E=F5N=64@4F5C;V=N:71I;VX\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P)SX-"E)E=F5N=64@8V]N<VES=',@;V8@8V]N
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M('!R:6YC:7!A;`T*9F]R;7,@;V8@;W5R(&)I;&QI;F<@87)R86YG96UE;G1S
M(&%N9"!H;W<@;F5T(')E=F5N=64@:7,@<F5C;V=N:7IE9`T*9F]R(&5A8V@N
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"D-O;G1R86-T960@<F5V96YU92!R
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M<'!L96UE;G1A;`T*<F5V96YU97,@87)E(')E8V]G;FEZ960@87,@<F5V96YU
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M960@8GD@;W5R('!A<G1N97)S(&%N9`T*<W5C:"!R979E;G5E(&ES(&-O;G1I
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M(&9O<B!S=6-H#0IS97)V:6-E<RX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*
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M<BUS97)V:6-E(&%R<F%N9V5M96YT<RP@=V4@8FEL;`T*<&%T:65N=',@9F]R
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M<W5C:`T*8VAA<G1S('1O(&]U<B!B:6QL:6YG(&-E;G1E<B!F;W(@;65D:6-A
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M97)V:6-E<RX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P
M.R8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*/&(^4F5C
M96YT;'D@061O<'1E9"!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,"<^#0I);B!$96-E;6)E<B`R,#$P+"!T:&4@
M1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D(&ES<W5E9`T*
M06-C;W5N=&EN9R!3=&%N9&%R9',@57!D871E("@F(W@R,#%#.T%3528C>#(P
M,40[*2!.;RX@,C`Q,"TR.2P-"CQI/D)U<VEN97-S($-O;6)I;F%T:6]N<RP@
M1&ES8VQO<W5R92!O9B!3=7!P;&5M96YT87)Y(%!R;R!&;W)M80T*26YF;W)M
M871I;VX@9F]R($)U<VEN97-S($-O;6)I;F%T:6]N<SPO:3X@*"8C>#(P,4,[
M05-5#0HR,#$P+3(Y)B-X,C`Q1#LI+"!W:&EC:"!P<F]V:61E<R!C;&%R:69I
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M<B!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q,"X@16%R;'D@861O<'1I;VX@:7,-
M"G!E<FUI='1E9"X@5&AE($-O;7!A;GD@861O<'1E9"!!4U4@,C`Q,"TR.2!D
M=7)I;F<@=&AE(&9I<G-T(&EN=&5R:6T-"G)E<&]R=&EN9R!P97)I;V0@;V8@
M,C`Q,2!A<R!I="!R96QA=&5S('1O('!R;RUF;W)M82!D:7-C;&]S=7)E(&]F
M#0IT:&4@0V]M<&%N>28C>#(P,3D[<R!A8W%U:7-I=&EO;G,N(%1H92!A9&]P
M=&EO;B!O9B!!4U4@,C`Q,"TR.2!D:60-"FYO="!H879E(&$@;6%T97)I86P@
M:6UP86-T(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;G-O;&ED871E9`T*
M9FEN86YC:6%L('-T871E;65N=',N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-
M"CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*05-5($YO+B`R,#$P
M+3(X+"`\:3Y);G1A;F=I8FQE<R`F(W@R,#$T.R!';V]D=VEL;"!A;F0@3W1H
M97(L(%=H96X@=&\-"E!E<F9O<FT@4W1E<"`R(&]F('1H92!';V]D=VEL;"!)
M;7!A:7)M96YT(%1E<W0@9F]R(%)E<&]R=&EN9R!5;FET<PT*=VET:"!:97)O
M(&]R($YE9V%T:79E($-A<G)Y:6YG($%M;W5N=',\+VD^("@F(W@R,#%#.T%3
M50T*,C`Q,"TR."8C>#(P,40[*2!W87,@:7-S=65D(&EN($1E8V5M8F5R(#(P
M,3`N(%1H92!A;65N9&UE;G1S(&EN('1H:7,-"D%352!M;V1I9GD@4W1E<"`Q
M(&]F('1H92!G;V]D=VEL;"!I;7!A:7)M96YT('1E<W0@9F]R(')E<&]R=&EN
M9PT*=6YI=',@=VET:"!Z97)O(&]R(&YE9V%T:79E(&-A<G)Y:6YG(&%M;W5N
M=',N($9O<B!T:&]S92!R97!O<G1I;F<-"G5N:71S+"!A;B!E;G1I='D@:7,@
M<F5Q=6ER960@=&\@<&5R9F]R;2!3=&5P(#(@;V8@=&AE(&=O;V1W:6QL#0II
M;7!A:7)M96YT('1E<W0@:68@:70@:7,@;6]R92!L:6ME;'D@=&AA;B!N;W0@
M=&AA="!A(&=O;V1W:6QL#0II;7!A:7)M96YT(&5X:7-T<RX@26X@9&5T97)M
M:6YI;F<@=VAE=&AE<B!I="!I<R!M;W)E(&QI:V5L>2!T:&%N#0IN;W0@=&AA
M="!I;7!A:7)M96YT('1O(&=O;V1W:6QL(&5X:7-T<RP@86X@96YT:71Y('-H
M;W5L9"!C;VYS:61E<@T*=VAE=&AE<B!T:&5R92!A<F4@86YY(&5V96YT<R!O
M<B!C:7)C=6US=&%N8V5S('1H870@=V]U;&0@;6]R90T*;&EK96QY('1H86X@
M;F]T(')E9'5C92!T:&4@9F%I<B!V86QU92!O9B!A(')E<&]R=&EN9R!U;FET
M(&)E;&]W(&ET<PT*8V%R<GEI;F<@86UO=6YT+B!4:&4@86UE;F1M96YT<R!I
M;B!T:&ES($%352!A<F4@969F96-T:79E(&9O<@T*9FES8V%L('EE87)S+"!A
M;F0@:6YT97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!Y96%R<RP@8F5G:6YN
M:6YG#0IA9G1E<B!$96-E;6)E<B`Q-2P@,C`Q,"X@16%R;'D@861O<'1I;VX@
M:7,@;F]T('!E<FUI='1E9"X@5&AE#0I#;VUP86YY(&%D;W!T960@05-5(#(P
M,3`M,C@@9F]R('1H92!Q=6%R=&5R(&5N9&EN9R!-87)C:"`S,2P-"C(P,3$N
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CQB/E)E8V5N=&QY($ES<W5E9"!!
M8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]B/CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^#0H\9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VLG/DEN($1E8V5M8F5R
M(#(P,3$L('1H92!&05-"(&ES<W5E9`T*9W5I9&%N8V4@;VX@;V9F<V5T=&EN
M9R`H;F5T=&EN9RD@87-S971S(&%N9"!L:6%B:6QI=&EE<RX@16YT:71I97,-
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M;V1S(&)E9VEN;FEN9R!A9G1E<@T*2F%N=6%R>2`Q+"`R,#$S+CPO9F]N=#X@
M5V4@9&\@;F]T(&5X<&5C="!T:&4@861O<'1I;VX@;V8@=&AI<PT*<F5V:7-E
M9"!'04%0('1O(&AA=F4@82!M871E<FEA;"!E9F9E8W0@;VX@;W5R(&9I;F%N
M8VEA;`T*<&]S:71I;VXN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P)SX-"DEN(%-E<'1E;6)E<B`R,#$Q+"!T:&4@1D%30B!I
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M;`T*<&5R9F]R;2!T:&4@<75A;G1I=&%T:79E('1W;RUS=&5P(&=O;V1W:6QL
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M:&4@861O<'1I;VX@;V8@=&AI<R!R979I<V5D($=!05`@=&\@:&%V92!A(&UA
M=&5R:6%L(&5F9F5C=`T*;VX@;W5R(&9I;F%N8VEA;"!P;W-I=&EO;BP@<F5S
M=6QT<R!O9B!O<&5R871I;VYS(&]R(&-A<V@@9FQO=W,N/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P)SX-"CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^26X@2G5N90T*,C`Q,2P@=&AE
M($9!4T(@:7-S=65D(&=U:61A;F-E(&]N('!R97-E;G1A=&EO;B!O9B!C;VUP
M<F5H96YS:79E#0II;F-O;64N(%1H92!N97<@9W5I9&%N8V4@96QI;6EN871E
M<R!T:&4@8W5R<F5N="!O<'1I;VX@=&\@<F5P;W)T#0IO=&AE<B!C;VUP<F5H
M96YS:79E(&EN8V]M92!A;F0@:71S(&-O;7!O;F5N=',@:6X@=&AE('-T871E
M;65N="!O9@T*8VAA;F=E<R!I;B!E<75I='DN($EN<W1E860L(&%N(&5N=&ET
M>2!W:6QL(&)E(')E<75I<F5D('1O('!R97-E;G0-"F5I=&AE<B!A(&-O;G1I
M;G5O=7,@<W1A=&5M96YT(&]F(&YE="!I;F-O;64@86YD(&]T:&5R(&-O;7!R
M96AE;G-I=F4-"FEN8V]M92!O<B!I;B!T=V\@<V5P87)A=&4@8G5T(&-O;G-E
M8W5T:79E('-T871E;65N=',N(%1H92!N97<-"F=U:61A;F-E(&ES(&5F9F5C
M=&EV92!F;W(@86YN=6%L('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M
M8F5R#0HQ-2P@,C`Q,2X@26X@1&5C96UB97(@,C`Q,2P@=&AE($9!4T(@:7-S
M=65D(&$@9&5F97)R86P@;V8@8V5R=&%I;@T*<&]R=&EO;B!O9B!T:&ES(&=U
M:61A;F-E/"]F;VYT/BX@/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY792!D;R!N;W0@97AP96-T
M('1H90T*861O<'1I;VX@;V8@=&AI<R!R979I<V5D($=!05`@=&\@:&%V92!A
M(&UA=&5R:6%L(&5F9F5C="!O;B!O=7(-"F9I;F%N8VEA;"!P;W-I=&EO;BX\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"DEN($UA>2`R,#$Q+"!T
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M:6-A;G0@=6YO8G-E<G9A8FQE("A,979E;"`S*2!I;G!U=',N#0I4:&ES(')E
M=FES960@1T%!4"!W:6QL(&)E(&5F9F5C=&EV92!F;W(@86YN=6%L(&%N9"!I
M;G1E<FEM('!E<FEO9',-"F)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q-2P@
M,C`Q,2X@5V4@9&\@;F]T(&5X<&5C="!T:&4@861O<'1I;VX@;V8-"G1H:7,@
M<F5V:7-E9"!'04%0('1O(&AA=F4@82!M871E<FEA;"!E9F9E8W0@;VX@;W5R
M(&9I;F%N8VEA;`T*<&]S:71I;VXL(')E<W5L=',@;V8@;W!E<F%T:6]N<R!O
M<B!C87-H(&9L;W=S+CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-68Q8S@R839?,&$Y8U\T.68P7S@T-#A?
M8F4Q9C1F9&,Y.#$R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S5F
M,6,X,F$V7S!A.6-?-#EF,%\X-#0X7V)E,68T9F1C.3@Q,B]7;W)K<VAE971S
M+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY';VEN9R!#;VYC97)N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y';VEN9R!#;VYC97)N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,"<^#0H\8CXS+B!';VEN9R!#;VYC97)N/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"<^#0I4:&4@0V]M<&%N>2=S(&9I;F%N8VEA;"!S=&%T96UE;G1S
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M(&AA<R!A;B!A8V-U;75L871E9"!D969I8VET#0IO9B`D,BPQ,3<L-S`X(&%S
M(&]F($IA;G5A<GD@,S$L(#(P,3(N($EN(&%D9&ET:6]N+"!A="!*86YU87)Y
M(#,Q+`T*,C`Q,BP@=&AE($-O;7!A;GD@:&%S(&$@=&]T86P@<W1O8VMH;VQD
M97)S)B-X,C`Q.3L@9&5F:6-I="!O9@T*)#8U.2PS,C$@86YD(&=E;F5R871E
M9"!A(&YE9V%T:79E(&YE="!C87-H(&9L;W<@;W!E<F%T:6YG#0IA8W1I=FET
M:65S(&]F("0S.#4L-#4U(&9O<B!T:&4@>65A<B!T:&5N(&5N9&5D+CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,"<^#0I4:&4@9FEN86YC:6%L('-T871E;65N=',@
M9&\@;F]T(&EN8VQU9&4@86YY(&%D:G5S=&UE;G1S(')E;&%T:6YG('1O#0IT
M:&4@<F5C;W9E<F%B:6QI='D@86YD(&-L87-S:69I8V%T:6]N(&]F(&QI86)I
M;&ET:65S('1H870@;6EG:'0@8F4-"FYE8V5S<V%R>2!S:&]U;&0@=&AE($-O
M;7!A;GD@8F4@=6YA8FQE('1O(&-O;G1I;G5E(&%S(&$@9V]I;F<-"F-O;F-E
M<FXN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"E1O(&1A=&4@=&AE($-O;7!A
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M(&]R(&]T:&5R#0IS;W5R8V5S(&]F(&9I;F%N8VEN9RX\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`G/@T*3F\@87-S=7)A;F-E<R!C86X@8F4@;6%D92!T:&%T(&UA
M;F%G96UE;G0@=VEL;"!B92!S=6-C97-S9G5L(&EN#0IA8VAI979I;F<@:71S
M('!L86XN($EF('1H92!#;VUP86YY(&ES(&YO="!A8FQE('1O(')A:7-E('-U
M8G-T86YT:6%L#0IA9&1I=&EO;F%L(&-A<&ET86P@:6X@82!T:6UE;'D@;6%N
M;F5R+"!T:&4@0V]M<&%N>2!M87D@8F4@9F]R8V5D('1O#0IC96%S92!O<&5R
M871I;VYS+CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-68Q8S@R839?,&$Y8U\T.68P7S@T-#A?8F4Q9C1F
M9&,Y.#$R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S5F,6,X,F$V
M7S!A.6-?-#EF,%\X-#0X7V)E,68T9F1C.3@Q,B]7;W)K<VAE971S+U-H965T
M,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-0T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E)E8V5I=F%B;&4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIA;BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8V]U;G1S(%)E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&(^-"X-"D%C8V]U;G1S(%)E8V5I=F%B;&4\+V(^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
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M,3$X+"!N970@;V8@80T*<')O=FES:6]N(&9O<B!B860@9&5B="!O9B`D-#(L
M-3<V+"!A;F0@<F5P<F5S96YT<R!A;6]U;G1S(&EN=F]I8V5D#0IB>2!!34@@
M86YD($Q!3$,N($%C8V]U;G1S(%)E8V5I=F%B;&4@=V%S("0W,#0L.3<Q+"!N
M970@;V8@=&AE#0IP<F]V:7-I;VX@9F]R(&)A9"!D96)T(&]F("0S-"PW-#8L
M(&]N($IA;G5A<GD@,S$L(#(P,3$N/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9I8V5R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5I=F%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/C4N#0I296-E:79A8FQE(&9R;VT@
M;V9F:6-E<G,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.SPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"E)E8V5I=F%B;&4@9G)O;2!O9F9I8V5R<R!R97!R97-E
M;G0@8V]M<&5N<V%T:6]N('!A>6UE;G1S(&UA9&4@:6X-"F9I<V-A;"!Y96%R
M(#(P,3`@86)O=F4@8V]N=')A8W1U86P@86UO=6YT<RX@5&AE<V4@86UO=6YT
M<R!W97)E#0IE>'!E;G-E9"!I;B!F:7-C86P@>65A<B`R,#$R(&EN(&5X8VAA
M;F=E(&9O<B!A9&1I=&EO;F%L('!H>7-I8V%L#0IS97)V:6-E<R!P<F]V:61E
M9"!T;R!T:&4@8V]M<&%N>2X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^1'5E(&9R;VT@069F:6QI871E/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$=64@9G)O;2!!9F9I;&EA=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P)SX-"CQB/C8N($1U92!F<F]M($%F9FEL:6%T
M93PO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*06UO=6YT<R!D=64@9G)O
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-68Q8S@R839?
M,&$Y8U\T.68P7S@T-#A?8F4Q9C1F9&,Y.#$R#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S5F,6,X,F$V7S!A.6-?-#EF,%\X-#0X7V)E,68T9F1C
M.3@Q,B]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F5P86ED($5X<&5N<V5S/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED($5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\8CXW+B!0<F5P86ED($5X
M<&5N<V5S/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X
M03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I0<F5P86ED($5X
M<&5N<V5S(')E<')E<V5N="!A;6]U;G1S('!A:60@:6X@861V86YC92!F;W(@
M;65D:6-A;`T*;6%L<')A8W1I8V4@:6YS=7)A;F-E+"!S;V9T=V%R92!L:6-E
M;G-E<R!A;F0@1&ER96-T;W(F(W@R,#$Y.W,@86YD#0I/9F9I8V5R)B-X,C`Q
M.3MS(&EN<W5R86YC92X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4')E<&%I9"!F:6YA;F-I;F<@8V]S=#QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!F:6YA;F-I;F<@8V]S
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*/&(^."XF(WA!,#LF(WA!,#M0
M<F5P86ED(&9I;F%N8VEN9R!C;W-T/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,"<^#0I0<F5P86ED(&9I;F%N8VEN9R!C;W-T(')E<')E<V5N=',@=6YA;6]R
M=&EZ960@9FEN86YC:6YG(&-O<W0-"F%S<V]C:6%T960@=VET:"`Q,"4@4V5N
M:6]R(%-U8F]R9&EN871E9"!#86QL86)L92!#;VYV97)T:6)L92!.;W1E<PT*
M9'5E($IA;G5A<GD@,S$L(#(P,3,@<&%I9"!B>2!T:&4@0V]M<&%N>2!O;B!T
M:&4@8VQO<VEN9R!O9B!T:&4-"G!L86-E;65N="!O;B!/8W1O8F5R(#$V+"`R
M,#`Y("AS964@3F]T92`Q,2DN/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CQB/CDN/"]B/B`\8CY0
M<F]P97)T>2!A;F0@17%U:7!M96YT/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,"<^#0I0<F]P97)T>2!A;F0@17%U:7!M96YT(&-O;G-I<W1E9"!O9B!T:&4@
M9F]L;&]W:6YG.CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X
M03`[/"]P/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z
M(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B-X03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S
M;VQI9"<^#0I*86YU87)Y)B-X03`[,S$L/&)R("\^#0HR,#$R/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*2F%N=6%R>28C
M>$$P.S,Q+#QB<B`O/@T*,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#<T)2<^
M5V5B<VET93PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$P)3L@=&5X="UA;&EG
M;CH@<FEG:'0G/C0L-38X/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
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M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^,3,L.3$R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,3,L.3$R/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9#Y3;V9T=V%R93PO=&0^
M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXQ-34L,#,Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^,34U+#`S.3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/DUA8VAI;F5R>2!A;F0@97%U:7!M96YT/"]T9#X-"CQT9#XF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C<Q+#4U,SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/C4P+#@Q-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L
M,C`T*2<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^1G5R;FET
M=7)E(&%N9"!F:7AT=7)E<SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU+#,P,CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!
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M;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SX-"C@L,3DX/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
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M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I
M)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE
M9G0Z(#EP="<^1W)O<W,@4')O<&5R='D@86YD#0I%<75I<&UE;G0\+W1D/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^,C4X+#4W,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
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M861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#`N,C5I;B<^3&5S
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M*#(Q-2PS,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L
M969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^#0HH,C`R
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M/DYE=`T*4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H\=&0@<W1Y;&4]
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M.B!"
M;&%C:R`R+C5P="!D;W5B;&4G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O
M=6)L92<^#0HR,2PU.3,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"D1E<')E8VEA=&EO
M;B!E>'!E;G-E('=A<R`D,3(L-3@Y(&%N9"`D,3$L,3DX(&9O<B!T:&4@='=E
M;'9E(&UO;G1H#0IP97)I;V1S(&5N9&5D($IA;G5A<GD@,S$L(#(P,3(@86YD
M(#(P,3$L(')E<W!E8W1I=F5L>2X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S5F,6,X,F$V7S!A.6-?-#EF
M,%\X-#0X7V)E,68T9F1C.3@Q,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\U9C%C.#)A-E\P83EC7S0Y9C!?.#0T.%]B93%F-&9D8SDX,3(O5V]R
M:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B
M:6QI=&EE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!,:6%B:6QI=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^,3`N#0I!8V-O=6YT<R!087EA
M8FQE(&%N9"!!8V-R=65D)B-X03`[3&EA8FEL:71I97,\+V(^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0I!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R
M=65D(&QI86)I;&ET:65S(&-O;G-I<W1E9"!O9B!T:&4-"F9O;&QO=VEN9SH\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*
M/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97(G(&-O;'-P86X],T0R/DIA;G5A<GDF(WA!,#LS,2P\8G(@
M+SX-"C(P,3(\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G(&-O;'-P86X]
M,T0R/DIA;G5A<GDF(WA!,#LS,2P\8G(@+SX-"C(P,3$\+W1D/@T*/'1D/B8C
M>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`W-"4G
M/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q
M)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!724142#H@,3`E)SXQ,#DL-S`T/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C,U+#@Q
M-3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^1"9A;7`[3R!I;G-U<F%N
M8V4@<&%Y86)L93PO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXQ,2PT-#0\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T
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M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/D%C
M8W)U960@:6YT97)E<W0\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^,2PP,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[
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M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^,C<L-3`P/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
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M3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0HY+#8P.3PO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^
M#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/@T*-#`L-3,T/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!
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M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HY,BPW-#4\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G9E<G1I8FQE($YO
M=&5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!.;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\
M8CXQ,2XF(WA!,#LF(WA!,#M#;VYV97)T:6)L92!.;W1E<SPO8CX\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY4:&4-"D-O;7!A;GDF(W@R,#$Y.W,@;&]N
M9RUT97)M(&1E8G0@8V]N<VES=',@;V8@=&AE(&9O;&QO=VEN9SH\+W`^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO<#X-
M"CQT86)L92!S='EL93TS1"=724142#H@.#4E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M2F%N=6%R>28C>$$P.S,Q+#QB<B`O/@T*,C`Q,CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y*86YU87)Y)B-X03`[,S$L
M/&)R("\^#0HR,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)R!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T
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M="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M24Y$14Y4.B`M.2XS-7!T.R!0041$
M24Y'+4Q%1E0Z(#$X+C=P=#L@5TE$5$@Z(#<T)2<^#0HQ,"4@4V5N:6]R(%-U
M8F]R9&EN871E9"!#;VYV97)T:6)L92!.;W1E<RP@;F5T(&]F(&1E8G0@9&ES
M8V]U;G0@;V8-"B0V-3,L,#(V+"!D=64@2F%N=6%R>2`S,2P@,C`Q,SPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5TE$5$@Z(#$E
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX-
M"B0\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/@T*-3DV
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M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/@T*,2PR-#@L
M-3@X/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!724142#H@,24G/@T*)B-X03`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR
M-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TY+C,U<'0[(%!!1$1)3D<M3$5&5#H@,3@N-W!T
M)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-
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M(#(P,34\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!R:6=H="<^#0HQ-3`L,#`P/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
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M9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT
M9#XF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^5&]T86P@0V]N=F5R=&EB;&4@3F]T97,\+W1D/@T*/'1D
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C<T-BPS
M-C8\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P
M.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^,2PR-#@L-3@X/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'
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M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T
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M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^5&]T86P\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G
M/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HQ-3`L,#`P/"]T
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M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C$L,C0X
M+#4X.#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CPO=&%B
M;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/&(^)B-X
M03`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\8CY3
M=6)O<F1I;F%T960@0F]R<F]W:6YG<SPO8CX\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\:3XQ,"4-"E-E;FEO<B!3=6)O<F1I;F%T960@0V%L;&%B;&4@
M0V]N=F5R=&EB;&4@3F]T97,@9'5E($IA;G5A<GD@,S$L#0HR,#$S/"]I/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3VX-"D]C=&]B97(@,38L
M(#(P,#DL('1H92!#;VUP86YY(&ES<W5E9"`D,2PR-3`L,#`P(&]F(&ET<R`Q
M,"4@4V5N:6]R#0I3=6)O<F1I;F%T960@0V%L;&%B;&4@0V]N=F5R=&EB;&4@
M3F]T97,N(%1H92!N970@<')O8V5E9',@;V8-"B0Q+#$P,"PP,#`@=VEL;"!B
M92!U<V5D(&9O<B!T:&4@<F5P87EM96YT(&]F(&5X:7-T:6YG(&1E8G0L#0IA
M8W%U:7-I=&EO;G,L('!H>7-I8VEA;B!R96-R=6ET;65N="!A;F0@;W1H97(@
M9V5N97)A;"!C;W)P;W)A=&4-"G!U<G!O<V5S+B!4:&4@;F]T97,@8F5A<B!I
M;G1E<F5S="!A="!A(')A=&4@;V8@,3`E(&%N;G5A;&QY+`T*<&%Y86)L92!S
M96UI(&%N;G5A;&QY(&]N($IA;G5A<GD@,S$@86YD($IU;'D@,S$N(%1H92!.
M;W1E<R!M871U<F4-"F%N9"!B96-O;64@9'5E(&%N9"!P87EA8FQE(&]N($IA
M;G5A<GD@,S$L(#(P,3,@86YD(')A;FL@<V5N:6]R('1O#0IA;&P@;W1H97(@
M=6YS96-U<F5D(&1E8G0@;V8@=&AE($-O;7!A;GDN/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQB/B8C
M>$$P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H92`Q
M,"4-"DYO=&5S('=E<F4@<V]L9"!T:')O=6=H(&%N($%G96YT(&EN('1H92!F
M;W)M(&]F(&$@56YI="X@16%C:"!5;FET#0IW87,@8V]M<')I<V5D(&]F(&]N
M92`Q,"4@4V5N:6]R(%-U8F]R9&EN871E9"!#86QL86)L92!.;W1E('=I=&@@
M80T*<&%R('9A;'5E("0R-2PP,#`L(&%N9"!O;F4@9FEV92UY96%R('=A<G)A
M;G0@=&\@<'5R8VAA<V4@,C4L,#`P#0IS:&%R97,@;V8@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,@8V]M;6]N('-T;V-K+B!4:&4@<'5R8VAA<V4@<')I8V4@;V8-
M"F5A8V@@56YI="!W87,@)#(U+#`P,"P@<F5S=6QT:6YG(&EN(&=R;W-S('!R
M;V-E961S(&]F#0HD,2PR-3`L,#`P+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DEN#0IC;VYN96-T:6]N('=I=&@@
M=&AE('!L86-E;65N="!O9B!T:&4@<W5B;W)D:6YA=&5D(&YO=&5S+"!T:&4-
M"D-O;7!A;GD@<&%I9"!A(&-O;6UI<W-I;VX@;V8@)#$R-2PP,#`@86YD("0R
M-2PP,#`@;V8@;W1H97(@9&ER96-T#0IE>'!E;G-E<RX@5&AE(&%G96YT(&%L
M<V\@<F5C96EV960@9FEV92UY96%R('=A<G)A;G1S('1O('!U<F-H87-E('5P
M#0IT;R`R-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M;6]N(%-T;V-K(&%T(&%N
M(&EN:71I86P@97AE<F-I<V4@<')I8V4-"F]F("0P+C(U('!E<B!S:&%R92!A
M9&IU<W1A8FQE('!U<G-U86YT('1O(&-H86YG97,@:6X@<'5B;&EC('9A;'5E
M#0IO9B!O=7(@<VAA<F5S(&%N9"!C87-H(&9L;W<@;V8@=&AE($-O;7!A;GD@
M9G)O;2!*=6QY(#,Q+"`R,#$Q('5N=&EL#0IT:&4@;F]T92!I<R!P86ED(&EN
M(&9U;&PN(%1H92!A9V5N="!A;'-O(')E8V5I=F5D(#$P,"PP,#`@<VAA<F5S
M(&]F#0IR97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!F;W(@<')E+71R86YS86-T
M:6]N(&%D=FES;W)Y('-E<G9I8V5S(&%N9`T*9'5E(&1I;&EG96YC92X@02!C
M;VUM:7-S:6]N(&]F("0Q,C4L,#`P('!A:60@870@8VQO<VEN9RP@:7,-"F%C
M8V]U;G1E9"!F;W(@87,@<')E<&%I9"!E>'!E;G-E(&%N9"!W:6QL(&)E(&%M
M;W)T:7IE9"!O=F5R(&$-"F9O<G1Y+6UO;G1H('!E<FEO9"!T:')O=6=H($IA
M;G5A<GD@,S$L(#(P,3,L('1H92!M871U<FET>2!D871E(&]F#0IT:&4@;F]T
M97,N(%1H92`D,C4L,#`P(&]F(&]T:&5R(&1I<F5C="!E>'!E;G-E<R!W97)E
M('!A:60@870-"F-L;W-I;F<@86YD(')E<&]R=&5D(&%S(&9I;F%N8VEN9R!C
M;W-T<R!I;B!T:&4@3W!E<F%T:6YG(%-T871E;65N="X-"DEN(&%D9&ET:6]N
M+"!F:6YA;F-I;F<@8V]S=',@:6YC;'5D960@)#0L,#`P(')E;&%T960@=&\@
M=&AE('9A;'5E#0IO9B!T:&4@,3`P+#`P,"!S:&%R97,@9W)A;G1E9"!T;R!T
M:&4@<&QA8V5M96YT(&%G96YT+B!);G1E<F5S=`T*97AP96YS92!O9B`D,S8L
M-#4X('=A<R!R96-O<F1E9"!I;B!T:&4@>65A<B!E;F1E9"!*86YU87)Y(#,Q
M+`T*,C`Q,"X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X
M03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4:&4@,3`E#0I.
M;W1E<R!A<F4@8V]N=F5R=&EB;&4@86YY('1I;64@<')I;W(@=&\@2F%N=6%R
M>2`S,2P@,C`Q,RX@5&AE#0II;FET:6%L(&-O;G9E<G-I;VX@<F%T92!I<R`R
M,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<PT*8V]M;6]N
M('-T;V-K('!E<B`D,C4L,#`P('!R:6YC:7!A;"!A;6]U;G0@;V8@=&AE(#$P
M)2!.;W1E<PT*861J=7-T86)L92!P=7)S=6%N="!T;R!C:&%N9V5S(&EN('!U
M8FQI8R!V86QU92!O9B!O=7(@<VAA<F5S(&%N9`T*8V%S:"!F;&]W(&]F('1H
M92!#;VUP86YY+B!4:&ES(')E<')E<V5N=',@86X@:6YI=&EA;"!C;VYV97)S
M:6]N#0IP<FEC92!O9B`D,"XQ,C4@<&5R('-H87)E(&]F('1H92!#;VUP86YY
M)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:RX@5&AE#0IN;W1E(&ES(&9I>&5D(&9R
M;VT@075G=7-T(#$L(#(P,#D@=&AR;W5G:"!*=6QY(#,Q+"`R,#$Q+B!!9G1E
M<B!*=6QY#0HS,2P@,C`Q,2P@=&AE(&-O;G9E<G-I;VX@<')I8V4@=VEL;"!E
M<75A;"!T;R!T:&4@;&5S<V5R(&]F("0P+C$R-0T*<&5R('-H87)E(&]R('1H
M92!A=F5R86=E(&]F('1H92!M;VYT:&QY(&AI9V@@<W1O8VL@<')I8V4@86YD
M(&QO=PT*<W1O8VL@<')I8V4@87,@<F5P;W)T960@8GD@0FQO;VUB97)G(&UU
M;'1I<&QI960@8GD@,3$P)2X@5&AE#0IM:6YI;75M(&-O;G9E<G-I;VX@<')I
M8V4@:7,@=&AE(&=R96%T97(@;V8@)#`N,#4@<&5R('-H87)E(&]R(#@-"G1I
M;65S(&-A<V@@15!3+B8C>$$P.R!/;B!O<B!A9G1E<B!*86YU87)Y(#,Q+"`R
M,#$R+"!T:&4@0V]M<&%N>0T*;6%Y+"!A="!I=',@;W!T:6]N+"!U<&]N(#8P
M(&1A>7,@;F]T:6-E('1O(&)O=&@@=&AE#0I.;W1E+6AO;&1E<B8C>#(P,3D[
M<R!A;F0@=&AE('!L86-E;65N="!A9V5N="P@<F5D965M(&%L;"!O<B!A#0IP
M;W)T:6]N(&]F('1H92!N;W1E<R!A="!A(')E9&5M<'1I;VX@<')I8V4@:6X@
M8V%S:"!E<75A;"!T;R`Q,#(E(&]F#0IT:&4@<')I;F-I<&%L(&%M;W5N="!O
M9B!T:&4@;F]T97,@=&\@8F4@<F5D965M960@<&QU<R!A8V-R=65D(&%N9`T*
M=6YP86ED(&EN=&5R97-T('1O+"!B=70@97AC;'5D:6YG+"!T:&4@<F5D96UP
M=&EO;B!D871E+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF
M(WA!,#LF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%T
M#0I*86YU87)Y(#,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!H87,@<F5C;W)D960@
M82!D97)I=F%T:79E(&QI86)I;&ET>0T*86YD(&%N(&]F9BUS971T:6YG(&1E
M8G0@9&ES8V]U;G0@:6X@=&AE(&%M;W5N="!O9B`D-C4S+#`R-B!A<R!T:&4-
M"G)E<W5L="!O9B!T:&4@8VAA;F=E(&EN('1H92!C;VYV97)S:6]N('!R:6-E
M+B!!="!*86YU87)Y(#,Q+"`R,#$R+`T*=&AE(&-O;G9E<G-I;VX@<')I8V4@
M<F5S970@=&\@)#`N,3$T.#4N(%1H92!#;VUP86YY)B-X,C`Q.3MS#0IC86QC
M=6QA=&EO;B!O9B!T:&4@9&5R:79A=&EV92!L:6%B:6QI='D@=V%S(&UA9&4@
M=7-I;F<@=&AE#0I";&%C:RU38VAO;&5S(&]P=&EO;BUP<FEC:6YG(&UO9&5L
M('=I=&@@=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N<SH-"F5X<&5C=&5D(&QI
M9F4@;V8@,2!Y96%R.R`X,"XP)2!S=&]C:R!P<FEC92!V;VQA=&EL:71Y.R!R
M:7-K+69R964-"FEN=&5R97-T(')A=&4@;V8@,"XS,"4@86YD(&YO(&1I=FED
M96YD<R!D=7)I;F<@=&AE(&5X<&5C=&5D#0IT97)M+CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#LF(WA!,#LF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H90T*5V%R<F%N=',@871T86-H
M960@=&\@=&AE(%5N:71S(&%R92!E>&5R8VES86)L92!I;G1O('-H87)E<R!O
M9@T*0V]M;6]N(%-T;V-K(&%T(&%N(&EN:71I86P@97AE<F-I<V4@<')I8V4@
M;V8@)#`N,3(U+B!4:&4@5V%R<F%N=',-"FAA=F4@82!F:79E+7EE87(@=&5R
M;2!A;F0@97AP:7)E(&]N($]C=&]B97(@,S$L(#(P,30N(%1H90T*0V]M<&%N
M>28C>#(P,3D[<R!C86QC=6QA=&EO;G,@=V5R92!M861E('5S:6YG('1H92!"
M;&%C:RU38VAO;&5S#0IO<'1I;VXM<')I8VEN9R!M;V1E;"!W:71H('1H92!F
M;VQL;W=I;F<@87-S=6UP=&EO;G,Z(&5X<&5C=&5D(&QI9F4-"F]F(#4@>65A
M<G,[(#0X+C`E('-T;V-K('!R:6-E('9O;&%T:6QI='D[(')I<VLM9G)E92!I
M;G1E<F5S="!R871E#0IO9B`R+C$V)2!A;F0@;F\@9&EV:61E;F1S(&1U<FEN
M9R!T:&4@97AP96-T960@=&5R;2X@5&AE<V4@=V%R<F%N=',-"G=E<F4@97-T
M:6UA=&5D('1O(&AA=F4@82!F86ER('9A;'5E(&]F("0R+#8U,R!U<VEN9R!T
M:&4-"D)L86-K+5-C:&]L97,@<')I8VEN9R!M;V1E;"!W:&EC:"!W87,@<F5C
M;W)D960@87,@=6YA;6]R=&EZ960-"G=A<G)A;G0@9&ES8V]U;G0@;VX@=&AE
M(&=R86YT(&1A=&4@86YD("0R+#0Q."!A<R!O9B!*86YU87)Y(#,Q+`T*,C`Q
M,"X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY);@T*8V]N;F5C=&EO;B!W:71H('1H:7,@;V9F97)I;F<L('1H92!#
M;VUP86YY(&%L<V\@:7-S=65D('=A<G)A;G1S('1O#0IP=7)C:&%S92`R-3`L
M,#`P('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K('1O('1H92!P;&%C96UE
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M#0IE>'!E8W1E9"!L:69E(&]F(#4@>65A<G,[(#0X+C`E('-T;V-K('!R:6-E
M('9O;&%T:6QI='D[(')I<VLM9G)E90T*:6YT97)E<W0@<F%T92!O9B`R+C$V
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M86)L92!A8V-O<F1I;F<@=&\@=&AE('-A;64-"G1E<FUS(&%S('1H92`Q,"4@
M3F]T97,N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P
M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^070-"DIA;G5A<GD@
M,S$L(#(P,3(L('1H92!W87)R86YT(&5X97)C:7-E('!R:6-E(')E<V5T('1O
M("0P+C$Q-#@U+B!!<PT*=&AE(')E<W5L="P@=&AE($-O;7!A;GD@:&%S(')E
M8V]R9&5D(&$@=V%R<F%N="!L:6%B:6QI='D@;V8-"B0Q,C`L,#`P(&%N9"!R
M96-O9VYI>F5D(&%D9&ET:6]N86P@9FEN86YC:6YG(&-O<W1S(&]F("0Q,C`L
M,#`P(&9O<@T*=&AE('EE87(@96YD960@2F%N=6%R>2`S,2P@,C`Q,BX@5&AE
M(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G0-"FQI86)I;&ET>2!W87,@9&5T
M97)M:6YE9"!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!M;V1E;"!O<'1I;VX-
M"G!R:6-I;F<@;6]D96P@=VET:"!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS
M.B!E>'!E8W1E9"!L:69E(&]F(#(N-S4-"GEE87)S.R`S,"4@<W1O8VL@<')I
M8V4@=F]L871I;&ET>3L@<FES:RUF<F5E(&EN=&5R97-T(')A=&4@;V8@,"XS
M,"4-"F%N9"!N;R!D:79I9&5N9',@9'5R:6YG('1H92!E>'!E8W1E9"!T97)M
M+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQI/C@E#0I396YI;W(@4W5B
M;W)D:6YA=&5D($-O;G9E<G1I8FQE(%!R;VUI<W-O<GD@3F]T97,@9'5E($9E
M8G)U87)Y(#$L#0HR,#$U/"]I/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D]N#0I397!T96UB97(@,2P@,C`Q,2P@=&AE($-O;7!A;GD@:7-S=65D("0Q
M-3`L,#`P(&]F(&ET<R`X)2!396YI;W(-"E-U8F]R9&EN871E9"!0<F]M:7-S
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M96UB97(@,S$@86YD($IU;F4@,S`N(%1H92!.;W1E<R!M871U<F4@86YD(&)E
M8V]M92!D=64@86YD#0IP87EA8FQE(&]N($IA;G5A<GD@,S$L(#(P,3,@86YD
M(')A;FL@<V5N:6]R('1O(&%L;"!O=&AE<@T*<W5B;W)D:6YA=&5D(&1E8G0@
M;V8@=&AE($-O;7!A;GDN/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE
M(#@E#0I.;W1E<R!A<F4@8V]N=F5R=&EB;&4@86YY('1I;64@<')I;W(@=&\@
M1F5B<G5A<GD@,2P@,C`Q-2X@5&AE#0II;FET:6%L(&-O;G9E<G-I;VX@<F%T
M92!I<R`Q,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<PT*
M8V]M;6]N('-T;V-K('!E<B`D,C4L,#`P('!R:6YC:7!A;"!A;6]U;G0@;V8@
M=&AE(#@E($YO=&5S+"!W:&EC:`T*<F5P<F5S96YT<R!A;B!I;FET:6%L(&-O
M;G9E<G-I;VX@<')I8V4@;V8@)#`N,C4@<&5R('-H87)E(&]F('1H90T*0V]M
M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VLN(%1H92!C;VYV97)S:6]N('!R
M:6-E(&]F('1H92`X)2!.;W1E<PT*=VEL;"!B92!A9&IU<W1E9"!O;B!A('=E
M:6=H=&5D(&%V97)A9V4@8F%S:7,@:68@=&AE($-O;7!A;GD@:7-S=65S#0IC
M97)T86EN(&%D9&ET:6]N86P@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R`H;W(@
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M,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H90T*0V]M<&%N
M>2!M87D@<F5Q=6ER92!T:&4@:&]L9&5R<R!O9B!T:&4@."4@3F]T97,@=&\@
M8V]N=F5R="!T;PT*8V]M;6]N('-T;V-K(&%T('1H92!T:&5N(&%P<&QI8V%B
M;&4@8V]N=F5R<VEO;B!R871E(&%T(&%N>2!T:6UE#0IA9G1E<B!*=6YE(#,P
M+"`R,#$S(&EF.B!I*2!O=7(@,3`E($YO=&5S(&AA=F4@8F5E;B!F=6QL>2!R
M97!A:60@;W(-"F-O;G9E<G1E9"!A;F0@:6DI('1H92!C;&]S:6YG('!R:6-E
M(&]F(&]U<B!C;VUM;VX@<W1O8VL@:&%S#0IE>&-E961E9"`Q-3`E(&]F('1H
M92!T:&5N(&%P<&QI8V%B;&4@0V]N=F5R<VEO;B!0<FEC92!F;W(@;F\@;&5S
M<PT*=&AA;B`S,"!C;VYS96-U=&EV92!T<F%D:6YG(&1A>7,@<')I;W(@=&\@
M9VEV:6YG(&YO=&EC92X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!="!A
M;GD-"G1I;64@;VX@;W(@869T97(@2G5N92`S,"P@,C`Q-"P@=&AE($-O;7!A
M;GD@;6%Y+"!A="!I=',@<V]L92!O<'1I;VX-"G)E9&5E;2!A;&P@;V8@=&AE
M($YO=&5S(&%T(')E9&5M<'1I;VX@<')I8V4@:6X@8V%S:"!E<75A;"!T;R`Q
M,#@E#0IO9B!T:&4@<')I;F-I<&%L(&%M;W5N="!O9B!T:&4@3F]T97,@=&\@
M8F4@<F5D965M960@<&QU<R!A;GD-"F%C8W)U960@86YD('5N<&%I9"!I;G1E
M<F5S="!T;RP@8G5T(&5X8VQU9&EN9R!T:&4@<F5D96UP=&EO;@T*<F%T92X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P+CAP="`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S
M='EL93TS1"=#3TQ/4CH@8FQA8VLG/DEN=&5R97-T(&5X<&5N<V4@=V%S("0Q
M,S`L,#`P(&%N9`T*)#$R-2PP,#`@9F]R('1H92!Y96%R<R!E;F1E9"!*86YU
M87)Y(#,Q+"`R,#$R(&%N9"`R,#$Q+`T*<F5S<&5C=&EV96QY+CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4:&4-"F9O;&QO=VEN9R!T86)L
M92!R97!R97-E;G1S('1H92!P<FEN8VEP86P@<F5P87EM96YT<R!O9B!A;&P@
M=&AE#0IO=71S=&%N9&EN9R!D96)T(&%S(&]F($IA;G5A<GD@,S$L(#(P,3(Z
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-
M"CQT86)L92!S='EL93TS1"=724142#H@-#`E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM3$5&5#H@,2XU:6XG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G/@T*665A<B8C>$$P.V5N
M9&EN9R8C>$$P.TIA;G5A<GDF(WA!,#LS,2P\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@8V]L<W!A
M;CTS1#(^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9#XF(WA!,#L\+W1D/@T*/'1D/B8C
M>$$P.SPO=&0^#0H\=&0@8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"CQT9#XF
M(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%=)1%1(.B`W
M,B4G/C(P,3,\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@
M,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,C4E)SXQ+#(U,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<B<^,C`Q-#PO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97(G/C(P,34\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^,C`Q
M-CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SXQ-3`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S5F
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CQB/C$R+B!);F-O;64@5&%X
M97,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,'!T(#`G/@T*5&AE($-O;7!A;GD@=7-E<R!T:&4@;&EA8FEL
M:71Y(&UE=&AO9"!O9B!A8V-O=6YT:6YG(&9O<B!I;F-O;64-"G1A>&5S(&%S
M('-E="!F;W)T:"!I;B!!4T,@-S0P("AF;W)M97)L>2!3=&%T96UE;G0@;V8@
M1FEN86YC:6%L#0I!8V-O=6YT:6YG(%-T86YD87)D<R!.;RX@,3`Y+"`F(W@R
M,#%#.T%C8V]U;G1I;F<@9F]R($EN8V]M90T*5&%X97,F(W@R,#%$.R`H)B-X
M,C`Q0SM31D%3(#$P.28C>#(P,40[*2DN(%5N9&5R('1H92!L:6%B:6QI='D@
M;65T:&]D+`T*9&5F97)R960@=&%X97,@87)E(&1E=&5R;6EN960@8F%S960@
M;VX@9&EF9F5R96YC97,@8F5T=V5E;B!T:&4-"F9I;F%N8VEA;"!S=&%T96UE
M;G0@86YD('1A>"!B87-E<R!O9B!A<W-E=',@86YD(&QI86)I;&ET:65S('5S
M:6YG#0IE;F%C=&5D('1A>"!R871E<RX@07,@;V8@2F%N=6%R>2`S,2P@,C`Q
M,BP@=&AE($-O;7!A;GD@:&%D(&9E9&5R86P-"F%N9"!#86QI9F]R;FEA('1A
M>"!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<R!O9@T*87!P<F]X
M:6UA=&5L>2`D,2PY.#$L,#`P(&%N9"`D,BPP-C`L,#`P+"!R97-P96-T:79E
M;'DN(%1H92!F961E<F%L#0IA;F0@0V%L:69O<FYI82!N970@;W!E<F%T:6YG
M(&QO<W,@8V%R<GEF;W)W87)D<R!W:6QL(&5X<&ER92!A=`T*=F%R:6]U<R!D
M871E<R!F<F]M(#(P,C@@=&AR;W5G:"`R,#,Q+CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
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M<RX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*4'5R<W5A;G0@=&\@26YT97)N
M86P@4F5V96YU92!#;V1E(%-E8W1I;VYS(#,X,B!A;F0@,S@S+"!U<V4@;V8@
M=&AE#0I#;VUP86YY)B-X,C`Q.3MS(&YE="!O<&5R871I;F<@;&]S<R!A;F0@
M8W)E9&ET(&-A<G)Y9F]R=V%R9',@;6%Y(&)E#0IL:6UI=&5D(&EF(&$@8W5M
M=6QA=&EV92!C:&%N9V4@:6X@;W=N97)S:&EP(&]F(&UO<F4@=&AA;B`U,"4@
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M;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,"<^#0I3:6=N:69I8V%N="!C;VUP;VYE;G1S(&]F('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&1E9F5R<F5D('1A>"!A<W-E=',-"F%S(&]F($IA;G5A<GD@,S$L
M(#(P,3(@86YD($IA;G5A<GD@,S$L(#(P,3$@87)E('-H;W=N(&)E;&]W+B!!
M#0IV86QU871I;VX@86QL;W=A;F-E(&]F("0Y,S,L-#(P(&%N9"`D,C,R+#<P
M,"!A<R!O9B!*86YU87)Y(#,Q+"`R,#$R#0IA;F0@,C`Q,2P@<F5S<&5C=&EV
M96QY+"!H87,@8F5E;B!E<W1A8FQI<VAE9"!A9V%I;G-T('1H90T*0V]M<&%N
M>28C>#(P,3D[<R!D969E<G)E9"!T87@@87-S971S(&%S(')E86QI>F%T:6]N
M(&]F('-U8V@@87-S971S#0II<R!U;F-E<G1A:6XN/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P)SX-"CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0H\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P)SX-"CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G
M/@T*1&5F97)R960@=&%X(&%S<V5T<R!C;VYS:7-T(&]F('1H92!F;VQL;W=I
M;F<Z/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P(#!P="`R,BXU<'0G/@T*/"]P/@T*
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4]
M,T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#@P)3L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M+6QE9G0Z(#`N-6EN)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/@T*2F%N=6%R>2`S,2P\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/@T*)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-
M"DIA;G5A<GD@,S$L/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/@T*
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@<FEG:'0G/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#8R)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SY.
M3TP@8V%R<GD-"F9O<G=A<F0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R
M)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HX-#DL-3DQ/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$U)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^#0HR
M,3(L.#`P/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SY3=&]C:R!/<'1I;VX@+0T*97AE
M<F-I<V%B93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXX,2PW-S4\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/C$P+#@P,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(U
M-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/D-O;G1R:6)U=&EO;@T*8V%R<GEF;W)W87)D/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@<FEG:'0G/C8L.3<P/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
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M>3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXU,2PT,#@\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SY3=&%T92!I;F-O;64-"G1A>&5S/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/C$L,C0W/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
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M9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXH-S8L-3`P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H
M="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R
M9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/E-T871E(&EN8V]M92!T87AE<RP-"F1E
M9F5R<F5D/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@W,2PP,S4\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
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M;G0@;&]S<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXX.2PY-C0\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/BT\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T
M*2<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SX-"D]T:&5R+"!N970\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60G/@T*+3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SX-"B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D
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M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,7!T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E
M)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/DYE="!$969E<G)E9"!487@-"D%S<V5T<SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(')I9VAT)SXY,S,L-#(P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M
M86QI9VXZ(')I9VAT)SXR,S(L-S`P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
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M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SX-"B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M)SX-"B@Y,S,L-#(P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/@T*
M*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG
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M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,7!T)SX-"BD\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4G/@T*+3PO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0HF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L
M92<^#0HM/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0HF(WA!
M,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*
M5&AE('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S(&9O<B!T:&4@>65A<B!E
M;F1E9"!*86YU87)Y(#,Q+"`R,#$R#0ID:69F97)S(&9R;VT@=&AE(&%M;W5N
M="!C;VUP=71E9"!B>2!A<'!L>6EN9R!T:&4@9F5D97)A;"!I;F-O;64@=&%X
M#0IR871E(&%S(&9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@
M,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CPO
M<#X-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T
M>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`W,"4[
M(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;BUL969T.B`P+C5I;B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T
M*2<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#@V)3L@9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SY487@-"F-O;7!U=&5D(&%T('1H92!S=&%T
M=71O<GD@<F%T92`H,S0E*3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E
M.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C`N,S0\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXE/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^4W1O8VL@;W!T:6]N<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXH
M,"XP,3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXI)3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R
M,#0L,C4U+#(P-"DG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^06-C<G5A;"!T;R!C87-H/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA
M;&EG;CH@<FEG:'0G/C`N,#$\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(%=H:71E)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/E=A<G)A;G0-"FQI86)I;&ET>3PO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(')I9VAT)SXH,"XP-3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXI)3PO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U+#(P-"DG/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^26UP86ER;65N
M="!,;W-S/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G/B@P+C`X/"]T9#X-"CQT
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M="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT
M)SXH,"XP-CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXI)3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G
M8B@R,#0L,C4U+#(P-"DG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^0VAA;F=E(&EN#0IV86QU871I;VX\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R!T97AT+6%L:6=N.B!R:6=H="<^*#`N,34\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^*24\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^+3PO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SXE/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P
M="`P)SX-"D%S(&]F($IA;G5A<GD@,S$L(#(P,3(L('1H92!#;VUP86YY(&1O
M97,@;F]T(&AA=F4@86YY('5N<F5C;V=N:7IE9`T*=&%X(&)E;F5F:71S(')E
M;&%T960@=&\@=F%R:6]U<R!F961E<F%L(&%N9"!S=&%T92!I;F-O;64@=&%X
M#0IM871T97)S+B!4:&4@0V]M<&%N>2!W:6QL(')E8V]G;FEZ92!A8V-R=65D
M(&EN=&5R97-T(&%N9"!P96YA;'1I97,-"G)E;&%T960@=&\@=6YR96-O9VYI
M>F5D('1A>"!B96YE9FET<R!I;B!I;F-O;64@=&%X(&5X<&5N<V4N/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#!P="`P)SX-"E1H92!#;VUP86YY(&ES('-U8FIE8W0@=&\@
M52Y3+B!F961E<F%L(&EN8V]M92!T87@@87,@=V5L;"!A<R!I;F-O;64-"G1A
M>"!O9B!M=6QT:7!L92!S=&%T92!T87@@:G5R:7-D:6-T:6]N<RX@5&AE($-O
M;7!A;GD@86YD(&ET<PT*<W5B<VED:6%R:65S)B-X,C`Q.3L@<W1A=&4@:6YC
M;VUE('1A>"!R971U<FYS(&%R92!O<&5N('1O(&%U9&ET#0IU;F1E<B!T:&4@
M<W1A='5T92!O9B!L:6UI=&%T:6]N<R!F;W(@=&AE('EE87)S(&5N9&5D($IA
M;G5A<GD@,S$L#0HR,#`Y('1H<F]U9V@@,C`Q,BX@5&AE($-O;7!A;GD@9&]E
M<R!N;W0@86YT:6-I<&%T92!A;GD@;6%T97)I86P-"F%M;W5N="!O9B!U;G)E
M8V]G;FEZ960@=&%X(&)E;F5F:71S('=I=&AI;B!T:&4@;F5X="`Q,B!M;VYT
M:',N/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\U9C%C.#)A-E\P83EC7S0Y9C!?.#0T.%]B93%F-&9D8SDX
M,3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-68Q8S@R839?,&$Y
M8U\T.68P7S@T-#A?8F4Q9C1F9&,Y.#$R+U=O<FMS:&5E=',O4VAE970Q."YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E;&%T
M960@4&%R='D@5')A;G-A8W1I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^,3,N#0I296QA=&5D(%!A<G1Y
M(%1R86YS86-T:6]N<SPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$
M=7)I;F<-"G1H92!T=V5L=F4@;6]N=&AS(&5N9&5D($IA;G5A<GD@,S$L(#(P
M,3(@86YD(#(P,3$L('1H92!#;VUP86YY#0IG96YE<F%T960@<F5V96YU92!O
M9B`D-3$T+#`P,"!A;F0@)#4W-RPP,#`L(')E<W!E8W1I=F5L>2P@8GD-"G!R
M;W9I9&EN9R!M86YA9V5M96YT('-E<G9I8V5S('1O($%P;VQL;TUE9"!(;W-P
M:71A;&ES=',@*$%-2"DL(&%N#0IA9F9I;&EA=&5D(&-O;7!A;GD@=VET:"!C
M;VUM;VX@;W=N97)S:&EP(&EN=&5R97-T+B!#;VUM96YC:6YG#0I!=6=U<W0@
M,2P@,C`P."P@=&AE(&UA;F%G96UE;G0@<V5R=FEC97,@9F5E(&EN8V]M92!R
M97!O<G1E9"!B>2!!34T-"G=A<R!E;&EM:6YA=&5D(&EN(&-O;G-O;&ED871I
M;VX@86=A:6YS="!S:6UI;&%R(&-O<W1S(')E8V]R9&5D(&%T#0I!34@N/"]P
M/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\U9C%C.#)A-E\P83EC7S0Y9C!?.#0T.%]B93%F-&9D8SDX,3(-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-68Q8S@R839?,&$Y8U\T.68P
M7S@T-#A?8F4Q9C1F9&,Y.#$R+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO;BU#;VYT<F]L
M;&EN9R!);G1E<F5S=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2F%N+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F]N+4-O;G1R;VQL:6YG($EN=&5R97-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)T9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"CQB/C$T)B-X03`[)B-X03`[3F]N+4-O;G1R;VQL
M:6YG($EN=&5R97-T/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M06-T:79I='D@=VET:&EN(&YO;BUC;VYT<F]L;&EN9R!I;G1E<F5S="!F;W(@
M=&AE('1W96QV92UM;VYT:',-"F5N9&5D($IA;G5A<GD@,S$L(#(P,3(@8V]N
M<VES=&5D(&]F('1H92!F;VQL;W=I;F<Z/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`P+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T
M>6QE/3-$)U=)1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3BU,1494.B`P+C-I;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,#X-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T
M+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL
M93TS1"=724142#H@.#(E)SY"96=I;FYI;F<@8F%L86YC92!A<R!O9B!*86YU
M87)Y(#,Q+`T*,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[(%=)1%1(.B`Q-24G/C(R."PQ,34\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D/D%C<75I<VET:6]N+7)E;&%T960@
M;F]N+6-O;G1R;VQL:6YG(&EN=&5R97-T/"]T9#X-"CQT9#XF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$V-"PR-S8\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
M/D1I<W1R:6)U=&EO;G,@=&\-"FYO;BUC;VYT<F]L;&EN9R!I;G1E<F5S="!S
M:&%R96AO;&1E<CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B@Q-30L,CDP/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXI/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^16YD:6YG(&)A;&%N8V4@
M87,@;V8@2F%N=6%R>2`S,2P-"C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HR
M,S@L,3`Q/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/"]T
M86)L93X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?-68Q8S@R839?,&$Y8U\T.68P7S@T-#A?8F4Q9C1F9&,Y.#$R
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S5F,6,X,F$V7S!A.6-?
M-#EF,%\X-#0X7V)E,68T9F1C.3@Q,B]7;W)K<VAE971S+U-H965T,C`N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO
M;&1E<B=S($1E9FEC:70\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIA;BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K:&]L9&5R)W,@1&5F:6-I=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&(^,34N#0I3=&]C:VAO;&1E<B8C>#(P,3D[<R!$969I
M8VET/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H90T*0V]M<&%N
M>2!I<W-U960@82!T;W1A;"!O9B`Q+#,U,"PP,#`@8V]M;6]N('-H87)E<R!D
M=7)I;F<@=&AE('1W96QV90T*;6]N=&AS(&5N9&5D($IA;G5A<GD@,S$L(#(P
M,3(@<F5L871E9"!T;R!A8W%U:7-I=&EO;G,@*'-E92!.;W1E#0HQ-RDN/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.R8C>$$P.SPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE#0I#;VUP86YY(&%U
M=&AO<FEZ960@=&AE(&ES<W5A;F-E(#8P,"PP,#`@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!F;W(-"F-O;7!E;G-A=&EO;B!R96QA=&5D('1O(&-O;G-U;'1I
M;F<@86YD(&1I<F5C=&]R<R!F965S(&1U<FEN9R!T:&4-"G1W96QV92!M;VYT
M:',@96YD960@2F%N=6%R>2`S,2P@,C`Q,BX@5&AE('-H87)E<R!W97)E('9A
M;'5E9"!A=`T*)#DP+#`P,"!B87-E9"!O;B!T:&4@9F%I<B!V86QU97,@;V8@
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M(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E1H90T*0V]M<&%N>2!I<W-U960@,S4P+#`P,"!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&9O<B!C;VUP96YS871I;VX@=&\-"G1H92!#1D\@
M9'5R:6YG('1H92!T=V5L=F4@;6]N=&AS(&5N9&5D($IA;G5A<GD@,S$L(#(P
M,3(N(%1H92!S:&%R97,-"G=E<F4@=F%L=65D(&%T("0V,RPP,#`@8F%S960@
M;VX@=&AE(&9A:7(@=F%L=64@;V8@=&AE('-H87)E<R!A="!T:&4-"FES<W5A
M;F-E(&1A=&4N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE#0I#;VUP
M86YY(&ES<W5E9"!A('1O=&%L(&]F(#4Y-"PT-#8@8V]M;6]N('-H87)E<R!I
M;B!T:&4@='=E;'9E#0IM;VYT:',@96YD960@2F%N=6%R>2`S,2P@,C`Q,2P@
M:6YC;'5D:6YG(#(T-"PT-#8@<VAA<F5S(&ES<W5E9"!T;PT*;V9F:6-E<G,@
M86YD(&1I<F5C=&]R<R!A;F0@,S4P+#`P,"!S:&%R97,@:7-S=65D('1O($MA
M;F5H;V4-"D%D=FES;W)S(')E;&%T960@=&\@<')O9F5S<VEO;F%L('-E<G9I
M8V5S(')E;&%T960@=&\@=&AE(&ES<W5A;F-E<RX-"E1H92!T;W1A;"!S:&%R
M97,@=V5R92!V86QU960@870@)#0W+#,W."!B87-E9"!O;B!T:&4@9F%I<B!V
M86QU92!O9@T*=&AE('-H87)E<R!A="!T:&4@:7-S=6%N8V4@9&%T97,N/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CQB/E=A<G)A;G1S(&]U='-T86YD:6YG.CPO
M8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&(^)B-X03`[
M/"]B/CPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@.3`E.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P(&%L:6=N/3-$8V5N=&5R/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/@T*/'1D(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^06=G<F5G871E/&)R("\^#0II;G1R
M:6YS:6,\8G(@+SX-"G9A;'5E/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/DYU;6)E<B8C>$$P.V]F)B-X03`[=V%R<F%N
M=',\8G(@+SX-"FES<W5E9#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U
M+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$
M)U=)1%1(.B`V,B4G/D]U='-T86YD:6YG(&%T($IA;G5A<GD@,S$L(#(P,3$\
M+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT
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M1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
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M>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXM/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX-"CQT9#Y%>&5R8VES960\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^+3PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
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M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M4$%$1$E.1RU"3U143TTZ(#%P="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T
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M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/BD\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T
M+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9#XF(WA!
M,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^3W5T<W1A;F1I;F<@870@2F%N=6%R>2`S,2P-"C(P,3(\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^+3PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HQ+#4P
M,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.R8C>$$P
M.SPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@,3`P)3L@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/D5X97)C:7-E)B-X03`[4')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^5V%R<F%N=',\8G(@+SX-"F]U='-T86YD
M:6YG/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)R!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/E=E:6=H=&5D/&)R("\^#0IA=F5R86=E/&)R("\^#0IR96UA:6YI;F<\
M8G(@+SX-"F-O;G1R86-T=6%L)B-X03`[;&EF93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y787)R86YT<SQB<B`O/@T*
M97AE<F-I<V%B;&4\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0I796EG:'1E9#PO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"F%V97)A9V4\+W`^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0IE>&5R8VES928C>$$P.W!R:6-E/"]P/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#$X)2<^,"XQ,30X-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=7
M24142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3<E)SXQ+#(U,"PP,#`\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C>$$P.SPO
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M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$W)2<^,2PR-3`L,#`P
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@
M,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)2<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M(%=)1%1(.B`Q-R4G/C`N,3$T.#4P/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,"XQ,30X-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SXR-3`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BXW-3PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
M9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/C(U,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^,"XQ,30X-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#LF(WA!,#LF(WA!,#LF
M(WA!,#LF(WA!,#LF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/DEN#0IC;VYJ=6YC=&EO;B!W:71H('1H92!C;VUP;&5T:6]N(&]F('1H
M92!P<FEV871E('!L86-E;65N="!O;B!/8W1O8F5R#0HQ-BP@,C`P.2P@87,@
M9&5S8W)I8F5D(&EN($YO=&4@,3$L('1H92!#;VUP86YY(&ES<W5E9"!A('1O
M=&%L(&]F#0HQ+#4P,"PP,#`@=V%R<F%N=',N($]F('1H:7,@86UO=6YT+"`Q
M+#(U,"PP,#`@=V%R<F%N=',@=V5R92!I<W-U960-"G1O('1H92!H;VQD97)S
M(&]F('1H92!#;VYV97)T:6)L92!.;W1E<R!A;F0@,C4P+#`P,"!W87)R86YT
M<R!W97)E#0IG<F%N=&5D('1O('1H92!P;&%C96UE;G0@86=E;G0N(%1H92`Q
M+#(U,"PP,#`@=V%R<F%N=',@:&5L9"!B>2!T:&4-"FYO=&4@:&]L9&5R<R!A
M<F4@97AE<F-I<V%B;&4@:6YT;R!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&%T
M(&%N#0II;FET:6%L(&5X97)C:7-E('!R:6-E(&]F("0P+C$Q-#@U+B!4:&4@
M5V%R<F%N=',@:&%V92!A(&9I=F4M>65A<@T*=&5R;2!A;F0@97AP:7)E(&]N
M($]C=&]B97(@,S$L(#(P,30N(%1H92`R-3`L,#`P('=A<G)A;G1S(&-O;G9E
M>65D#0IT;R!T:&4@<&QA8V5M96YT(&%G96YT(&%L<V\@:&%V92!A(&9I=F4M
M>65A<B!T97)M+"!E>'!I<F4@;VX-"D]C=&]B97(@,S$L(#(P,30L(&%N9"!A
M<F4@97AE<F-I<V%B;&4@870@)#`N,3$T.#4@<&5R('-H87)E+CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\8CXF(WA!,#L\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXR,#$P#0I%<75I
M='D@26YC96YT:79E(%!L86X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^3VX-"DUA<F-H(#0L(#(P,3`L('1H92!#;VUP86YY)B-X,C`Q.3MS($)O
M87)D(&]F($1I<F5C=&]R<R!A<'!R;W9E9"!T:&4-"C(P,3`@17%U:71Y($EN
M8V5N=&EV92!0;&%N("AT:&4@)B-X,C`Q0SM0;&%N)B-X,C`Q1#LI+B!4:&4@
M4&QA;@T*<')O=FED97,@9F]R('1H92!G<F%N=&EN9R!O9B!T:&4@9F]L;&]W
M:6YG('1Y<&5S(&]F(&%W87)D<R!T;PT*<&5R<V]N<R!W:&\@87)E(&5M<&QO
M>65E<RP@;V9F:6-E<G,L(&-O;G-U;'1A;G1S+"!A9'9I<V]R<RP@;W(-"F1I
M<F5C=&]R<R!O9B!O=7(@0V]M<&%N>2!O<B!A;GD@;V8@:71S(&%F9FEL:6%T
M97,Z/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
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M"F9A:7(@;6%R:V5T('9A;'5E(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O
M;6UO;B!S=&]C:R!O;B!T:&4@9&%T90T*;V8@=&AE(&=R86YT+B!4:&4@97AE
M<F-I<V4@<')I8V4@;V8@86X@25-/(&=R86YT960@=&\@86YY('!E<G-O;@T*
M=VAO(&]W;G,L(&1I<F5C=&QY(&]R(&)Y(&%T=')I8G5T:6]N('5N9&5R('1H
M92!#;V1E("AC=7)R96YT;'D-"E-E8W1I;VX@-#(T*&0I*2P@<W1O8VL@<&]S
M<V5S<VEN9R!M;W)E('1H86X@,3`E(&]F('1H92!T;W1A;`T*8V]M8FEN960@
M=F]T:6YG('!O=V5R(&]F(&%L;"!C;&%S<V5S(&]F('-T;V-K(&]F('1H92!#
M;VUP86YY(&]R(&]F#0IA;GD@869F:6QI871E("AA("8C>#(P,4,[,3`E(%-T
M;V-K:&]L9&5R)B-X,C`Q1#LI('-H86QL(&EN(&YO(&5V96YT#0IB92!L97-S
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M97)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E-U8FIE8W0-"G1O('1H92!A9&IU<W1M96YT('!R;W9I<VEO;G,@;V8@=&AE
M(%!L86X@=&AA="!A<F4@87!P;&EC86)L92!I;B!T:&4-"F5V96YT(&]F(&$@
M<W1O8VL@9&EV:61E;F0L('-T;V-K('-P;&ET+"!R979E<G-E('-T;V-K('-P
M;&ET(&]R#0IS:6UI;&%R('1R86YS86-T:6]N+"!U<"!T;R`U+#`P,"PP,#`@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!M87D@8F4-"FES<W5E9"!U;F1E<B!T
M:&4@4&QA;BX@3W!T:6]N<R!G<F%N=&5D('5N9&5R('1H92!0;&%N(&=E;F5R
M86QL>0T*=F5S="!O=F5R(&$@=&AR964M>65A<B!P97)I;V0@86YD(&=E;F5R
M86QL>2!E>'!I<F4@9FEV92!Y96%R<R!F<F]M#0IT:&4@9&%T92!O9B!G<F%N
M="X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!<R!O9@T*2F%N=6%R>2`S
M,2P@,C`Q,BP@;W!T:6]N<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@
M.#@S+#,S,@T*<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W97)E(&5X97)C:7-A
M8FQE('5N9&5R('1H92!#;VUP86YY)B-X,C`Q.3MS#0IS=&]C:R!O<'1I;VX@
M4&QA;BX@1'5R:6YG('1H92!Y96%R(&5N9&5D($IA;G5A<GD@,S$L(#(P,3(L
M('1H90T*0V]M<&%N>2!D:60@;F]T(&ES<W5E(&]P=&EO;G,@=&\@<'5R8VAA
M<V4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:PT*=VET:"!E>&5R8VES92!P<FEC
M97,@8F5L;W<@=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H92!C;VUM;VX-
M"G-T;V-K(&]N('1H92!D871E<R!O9B!G<F%N="X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[)B-X03`[/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/E-T;V-K#0IO<'1I;VX@=')A;G-A8W1I;VYS('5N9&5R('1H92!#;VUP
M86YY)B-X,C`Q.3MS('-T;V-K(&]P=&EO;B!P;&%N<PT*9F]R('1H92!Y96%R
M(&5N9&5D($IA;G5A<GD@,S$L(#(P,3(@87)E('-U;6UA<FEZ960@8F5L;W<Z
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-
M"CQT86)L92!S='EL93TS1"=724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%
M.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9#XF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/E-H
M87)E<SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$
M,CY796EG:'1E9#QB<B`O/@T*079E<F%G93QB<B`O/@T*4&5R)B-X03`[4VAA
M<F4\8G(@+SX-"D5X97)C:7-E/&)R("\^#0I0<FEC93PO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CY796EG:'1E9"8C>$$P.T%V
M97)A9V4\8G(@+SX-"E)E;6%I;FEN9SQB<B`O/@T*0V]N=')A8W1U86PF(WA!
M,#M497)M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X]
M,T0R/D%G9W)E9V%T93QB<B`O/@T*26YT<FEN<VEC)B-X03`[5F%L=64\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G
M8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D
M/D)A;&%N8V4L($IA;G5A<GD@,S$L(#(P,3$\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET
M93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU,1494.B`Y<'0[(%=)1%1(.B`T."4G/D=R86YT960\+W1D/@T*/'1D
M('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C$L
M,34P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q
M)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!724142#H@,3`E)SXP+C$U/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!72414
M2#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@5TE$5$@Z(#$P)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
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M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^+3PO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/BT\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-
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M+4Q%1E0Z(#EP="<^17AP:7)E9#PO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^+3PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@4$%$1$E.1RU,1494.B`Y<'0G/D9O<F9E:71E9#PO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX-"BT\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX-"BT\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0
M041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SY"86QA
M;F-E+"!*86YU87)Y(#,Q+"`R,#$R/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/@T*,2PQ-3`L
M,#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L
M969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C`N,34\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXX+CD@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M4$%$1$E.1RU"3U143TTZ(#%P="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0^
M)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
M9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/E9E<W1E
M9"!A;F0@97AP96-T960@=&\@=F5S=#PO=&0^#0H\=&0^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#$U,"PP,#`\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,"XQ-3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C@N.2!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9#Y%>&5R8VES86)L92P@2F%N
M=6%R>2`S,2P@,C`Q,CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXX.#,L,S,R/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C`N,34\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXX+CD@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^07,-"DIA;G5A<GD@,S$L(#(P,3(L(&]P=&EO;G,@
M879A:6QA8FQE(&9O<B!F=71U<F4@9W)A;G0@=6YD97(@=&AE(%!L86X-"F%M
M;W5N=&5D('1O(#,L.#4P+#`P,"X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"DEN9F]R;6%T:6]N(')E9V%R9&EN9R!S=&]C:R!O<'1I;VYS(&]U='-T
M86YD:6YG(&%T($IA;G5A<GD@,S$L(#(P,3(-"FES(&%S(&9O;&QO=W,Z/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQT
M86)L92!S='EL93TS1"=724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G(&-O
M;'-P86X],T0Q,"!N;W=R87`],T1N;W=R87`^#0I/<'1I;VYS)B-X03`[3W5T
M<W1A;F1I;F<\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#8@;F]W<F%P/3-$
M;F]W<F%P/@T*3W!T:6]N<R8C>$$P.T5X97)C:7-A8FQE/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M#0I286YG928C>$$P.V]F)B-X03`[97AE<F-I<V4\8G(@+SX-"G!R:6-E<SPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0I.
M=6UB97(\8G(@+SX-"F]U='-T86YD:6YG)B-X03`[870\8G(@+SX-"DIA;G5A
M<GDF(WA!,#LS,2P\8G(@+SX-"C(P,3(\+W1D/@T*/'1D(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P/@T*5V5I9VAT960\8G(@+SX-"F%V97)A
M9V4\8G(@+SX-"G)E;6%I;FEN9SQB<B`O/@T*8V]N=')A8W1U86PF(WA!,#ML
M:69E/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<#X-"E=E:6=H=&5D/&)R("\^#0IA=F5R86=E/&)R("\^#0IE>&5R8VES928C
M>$$P.W!R:6-E/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<#X-"DYU;6)E<CQB<B`O/@T*97AE<F-I<V%B;&4F(WA!,#MA=#QB
M<B`O/@T*2F%N=6%R>28C>$$P.S,Q+#QB<B`O/@T*,C`Q,CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0I796EG:'1E9#QB
M<B`O/@T*879E<F%G93QB<B`O/@T*97AE<F-I<V4\8G(@+SX-"G!R:6-E/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T
M*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$T)2<^,"XQ-3PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)
M1%1(.B`Q-"4G/C$L,34P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q-"4G/C@N.2!Y96%R
M<SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!72414
M2#H@,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!724142#H@,30E)SXP+C$U/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$T)2<^.#@S+#,S,CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@
M,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,3,E)SXP+C$U/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-68Q8S@R839?,&$Y8U\T.68P7S@T-#A?8F4Q9C1F9&,Y.#$R#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S5F,6,X,F$V7S!A.6-?-#EF
M,%\X-#0X7V)E,68T9F1C.3@Q,B]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8WD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIA;BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`G/@T*/&(^,38N/"]B/B`\8CY#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8WD\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-
M"D]N($UA<F-H(#$U+"`R,#`Y+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M82!#;VYS=6QT:6YG($%G<F5E;65N=`T*=VET:"!+86YE;VAE($%D=FES;W)S
M($Q,0R`H2WEL92!&<F%N8VES*2!U;F1E<B!W:&EC:"!-<BX@1G)A;F-I<PT*
M8F5C86UE('1H92!#;VUP86YY)B-X,C`Q.3MS($5X96-U=&EV92!6:6-E(%!R
M97-I9&5N="P@0G5S:6YE<W,-"D1E=F5L;W!M96YT(&%N9"!3=')A=&5G>2X@
M56YD97(@=&AE('1E<FUS(&]F('1H92!!9W)E96UE;G0L($UR+@T*1G)A;F-I
M<R!I<R!C;VUP96YS871E9"!A="!A(')A=&4@;V8@)#@L,#`P('!E<B!M;VYT
M:"X@26X@861D:71I;VXL#0I-<BX@1G)A;F-I<R!R96-E:79E9"`S-3`L,#`P
M('-H87)E<R!O9B!R97-T<FEC=&5D('-T;V-K(&%T('1H92!D871E#0IO9B!T
M:&4@06=R965M96YT(&%N9"!I<R!E;G1I=&QE9"!T;R`S-3`L,#`P(&%D9&ET
M:6]N86P@<F5S=')I8W1E9`T*<VAA<F5S(&]N('1H92!F:7)S="!A;F0@<V5C
M;VYD(&%N;FEV97)S87)I97,@;V8@=&AE($%G<F5E;65N="P-"G!R;W9I9&5D
M('1H92!!9W)E96UE;G0@:7,@;F]T('1E<FUI;F%T960N(%1H92!I;FET:6%L
M(#,U,"PP,#`-"G-H87)E<RP@86QO;F<@=VET:"`U,"PP,#`@<VAA<F5S(&=R
M86YT960@=&\@37(N($9R86YC:7,@:6X@=&AE('EE87(-"F5N9&5D($IA;G5A
M<GD@,C`P.2P@=V5R92!I<W-U960@:6X@=&AE('1H:7)D('%U87)T97(@96YD
M960@3V-T;V)E<@T*,S$L(#(P,#DN($]N($UA<F-H(#$U+"`R,#$P+"!T:&4@
M<V5C;VYD(&%N;FEV97)S87)Y(&]F('1H90T*0V]N<W5L=&EN9R!!9W)E96UE
M;G0L($UR+B!&<F%N8VES('=A<R!G<F%N=&5D(&%N(&%D9&ET:6]N86P@,S4P
M+#`P,`T*<VAA<F5S+B!/;B!-87)C:"`Q-2P@,C`Q,2P@37(N($9R86YC:7,@
M=V%S(&=R86YT960@86X@861D:71I;VYA;`T*,S4P+#`P,"!S:&%R97,@;VX@
M=&AE('1H:7)D(&%N;FEV97)S87)Y(&]F('1H92!B969O<F4@;65N=&EO;F5D
M#0I#;VYS=6QT:6YG($%G<F5E;65N="X\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G
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M<V4@86X@86=G<F5G871E(&]F(#,P,"PP,#`@<VAA<F5S(&]F('1H90T*0V]M
M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I
M8V4@;V8@)#`N,34@<&5R#0IS:&%R92!W:&5N(&%N9"!I9B!T:&4@0V]M<&%N
M>2!I<R!T;R!A9&]P="!A('-T;V-K(&-O;7!E;G-A=&EO;@T*<&QA;BX@5&AE
M($-O;7!A;GD@9W)A;G1E9"!$<BX@27-S86D@,S`P+#`P,"!O<'1I;VYS(&]N
M($1E8V5M8F5R(#DL#0HR,#$P+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I%
M9F9E8W1I=F4@87,@;V8@2F%N=6%R>2`Q+"`R,#$R+"!3=7)E<V@@3FEH86QA
M;FD@=V%S(')E+65L96-T960@=&\-"G1H92!#;VUP86YY)B-X,C`Q.3MS($)O
M87)D(&]F($1I<F5C=&]R<RX@26X@8V]N;F5C=&EO;B!W:71H(&AI<PT*<V5R
M=FEC92!T;R!T:&4@0V]M<&%N>2!A<R!A(&1I<F5C=&]R+"!);B!C;VYN96-T
M:6]N('=I=&@@:&ES#0IS97)V:6-E('1O('1H92!#;VUP86YY(&%S(&$@9&ER
M96-T;W(L($UR+B!.:6AA;&%N:2!E;G1E<F5D(&EN=&\@=&AE#0I#;VUP86YY
M)B-X,C`Q.3MS(&9O<FT@;V8@1&ER96-T;W(@06=R965M96YT+"!W:&EC:"!P
M<F]V:61E<R!F;W(@37(N#0I.:6AA;&%N:2!T;R!B92!A(&1I<F5C=&]R(&%N
M9"!-<BX@3FEH86QA;FD@<F5C96EV960@82!R97-T<FEC=&5D#0IS=&]C:R!G
M<F%N="!O9B`T,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>2=S($-O;6UO
M;B!3=&]C:RX@5&AE#0IS:&%R97,@=VEL;"!V97-T(&UO;G1H;'D@870@82!R
M871E(&]F(#$O,S8@<&5R(&UO;G1H(&]V97(@82!T:')E90T*>65A<B!T:6UE
M('!E<FEO9"X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M06-Q=6ES:71I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*86XN(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8W%U:7-I=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-
M"CQB/C$W+B!!8W%U:7-I=&EO;G,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P
M)SX-"CQB/D%L:6=N960@2&5A;'1H8V%R92!'<F]U<#PO8CX\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#`G/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^
M#0H\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"D]N($9E8G)U87)Y
M(#$U+"`R,#$Q+"!!<&]L;&\@365D:6-A;"!(;VQD:6YG<RP@26YC+B`H=&AE
M#0HF(W@R,#%#.T-O;7!A;GDF(W@R,#%$.RD@96YT97)E9"!I;G1O(&$@4W1O
M8VL@4'5R8VAA<V4@06=R965M96YT("AT:&4-"B8C>#(P,4,[4'5R8VAA<V4@
M06=R965M96YT)B-X,C`Q1#LI('=I=&@@06QI9VYE9"!(96%L=&AC87)E($=R
M;W5P#0HF(W@R,#$S.R!#86QI9F]R;FEA+"!);F,N+"!286]U9B!+:&%L:6PL
M($IA;6EE($UC4F5Y;F]L9',L($TN1"X@0DH-"E)E97-E(&%N9"!"2B!2965S
M92`F86UP.R!!<W-O8VEA=&5S+"!,3$,L('5N9&5R('=H:6-H('1H92!#;VUP
M86YY#0IA8W%U:7)E9"!A;&P@;V8@=&AE(&ES<W5E9"!A;F0@;W5T<W1A;F1I
M;F<@<VAA<F5S(&]F(&-A<&ET86P@<W1O8VL-"F%N9"!A<W-O8VEA=&5D($EN
M=&5L;&5C='5A;"!P<F]P97)T>2!A;F0@<F5L871E9"!I;G1A;F=I8FQE<R`H
M=&AE#0HF(W@R,#%#.T%C<75I<VET:6]N)B-X,C`Q1#LI(&]F($%L:6=N960@
M2&5A;'1H8V%R92P@26YC+BP@80T*0V%L:69O<FYI82!C;W)P;W)A=&EO;B`H
M)B-X,C`Q0SM!2$DF(W@R,#%$.RDL(&9R;VT@04A))B-X,C`Q.3MS#0IS:&%R
M96AO;&1E<G,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,'!T(#`G/@T*/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,"<^#0I5<&]N('1H92!S:6=N:6YG(&]F('1H92!0=7)C:&%S92!!9W)E
M96UE;G0L(#$L,#`P+#`P,"!S:&%R97,@;V8@=&AE#0I#;VUP86YY)B-X,C`Q
M.3MS(&-O;6UO;B!S=&]C:R!B96-A;64@:7-S=6%B;&4@*'1H92`F(W@R,#%#
M.TEN:71I86P-"E-H87)E<R8C>#(P,40[*2!A;F0@87)E(&EN8VQU9&5D(&EN
M('1H92!N=6UB97(@;V8@<VAA<F5S#0IO=71S=&%N9&EN9RX@26X@861D:71I
M;VXL(&EF('1H92!G<F]S<R!R979E;G5E<R!O9B!!2$D@86YD(&%N#0IA9F9I
M;&EA=&5D(&5N=&ET>2`H=&AE("8C>#(P,4,[06QI9VYE9"!$:79I<VEO;B8C
M>#(P,40[*2!H860@97AC965D960-"B0Q+#`P,"PP,#`@;VX@;W(@8F5F;W)E
M($9E8G)U87)Y(#$L(#(P,3(L('1H96X@=&AE($-O;7!A;GD@=V]U;&0-"FAA
M=F4@8F5E;B!O8FQI9V%T960@=&\@:7-S=64@86X@861D:71I;VYA;"`Q+#`P
M,"PP,#`@<VAA<F5S(&]F#0IC;VUM;VX@<W1O8VL@*'1H92`F(W@R,#%#.T-O
M;G1I;F=E;G0@4VAA<F5S)B-X,C`Q1#LI+B!-;W)E;W9E<BP@=&AE#0I#;VUP
M86YY('=O=6QD(&)E(&]B;&EG871E9"!T;R!I<W-U92!U<"!T;R!A;B!A9&1I
M=&EO;F%L(#,L-3`P+#`P,`T*<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R`H=&AE
M("8C>#(P,4,[16%R;BU/=70@4VAA<F5S)B-X,C`Q1#L@86YD+`T*8V]L;&5C
M=&EV96QY('=I=&@@=&AE($EN:71I86P@4VAA<F5S(&%N9"!T:&4@0V]N=&EN
M9V5N="!3:&%R97,L('1H90T*)B-X,C`Q0SM3:&%R97,F(W@R,#%$.RD@;W9E
M<B!A('1H<F5E('EE87(@<&5R:6]D(&9O;&QO=VEN9R!C;&]S:6YG#0IB87-E
M9"!O;B!T:&4@14))5$1!(&=E;F5R871E9"!B>2!T:&4@06QI9VYE9"!$:79I
M<VEO;B!D=7)I;F<@=&AA=`T*=&EM92X@56YD97(@=&AE(&%G<F5E;65N="P@
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M="`Q,BUM;VYT:"!P97)I;V0@;W(@9FER<W0@,3(M;6]N=&@@<&5R:6]D(&%N
M9"!S96-O;F0@,3(-"FUO;G1H('!E<FEO9"X\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`G/@T*061D:71I;VYA;&QY+"!I;B!!8V-O<F1A;F-E('=I=&@@=&AE(%!U
M<F-H87-E($%G<F5E;65N="P@:68@<')I;W(-"G1O($9E8G)U87)Y(#$U+"`R
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M<W0@)#$L,#`P+#`P,"P@=&AE($-O;7!A;GD-"G=O=6QD(&AA=F4@=&AE(')I
M9VAT('1O(')E<'5R8VAA<V4@86QL(&]F('1H92!);FET:6%L(%-H87)E<R!F
M;W(-"B0P+C`U('!E<B!S:&%R92P@870@=VAI8V@@=&EM92!T:&4@0V]M<&%N
M>28C>#(P,3D[<R!O8FQI9V%T:6]N('1O#0II<W-U92!A;GD@9G5R=&AE<B!3
M:&%R97,@=V]U;&0@=&5R;6EN871E+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^
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M:6]N(&]N('1H92!A8W%U:7-I=&EO;B!D871E('=A<R`D,S8W+#4P,`T**#$L
M-S4P+#`P,"!S:&%R97,I+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I4:&4@
M0V]M<&%N>2!O<FEG:6YA;&QY(')E8V]G;FEZ960@82!L:6%B:6QI='D@8F%S
M960@;VX@=&AE#0IA8W%U:7-I=&EO;B!D871E(&9A:7(@=F%L=64@;V8@=&AE
M(&%C<75I<VET:6]N+7)E;&%T960@8V]N=&EN9V5N=`T*8V]N<VED97)A=&EO
M;B!B87-E9"!O;B!T:&4@<')O8F%B:6QI='D@;V8@=&AE(&%C:&EE=F5M96YT
M(&]F('1H90T*=&%R9V5T<R!S=&EP=6QA=&5D(&EN('1H92!0=7)C:&%S92!!
M9W)E96UE;G0N($)A<V5D(&]N('1H90T*0V]M<&%N>28C>#(P,3D[<R!E<W1I
M;6%T:6]N+"!A;B!I;FET:6%L(&QI86)I;&ET>2!O9B`D,S8W+#4P,"!W87,-
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M(&]U<B!I;G1E<FEM#0IF:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,'!T(#`G/@T*5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S
M('1H92!P<F5L:6UI;F%R>2!A;F0@9FEN86P-"F1E=&5R;6EN871I;VX@;V8@
M=&AE('!U<F-H87-E('!R:6-E(&%N9"!F86ER('9A;'5E(&]F($%(228C>#(P
M,3D[<PT*87-S971S(&%C<75I<F5D(&%T('1H92!D871E(&]F(&%C<75I<VET
M:6]N.CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@.#4E.R!F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XM;&5F=#H@,"XU
M:6XG/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@<FEG:'0G/E!R96QI;6EN87)Y/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SY&:6YA;#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/E!U<F-H87-E
M('!R:6-E(&-A;&-U;&%T:6]N.CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=W:61T:#H@-S(E
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M;&5F=#H@,3!P="<^#0I#;VUM;VX@<W1O8VL@:7-S=65D("@Q+#`P,"PP,#`@
M<VAA<F5S*3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I
M>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C(Q,"PP,#`\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E
M.R!F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SX-"C(Q,"PP,#`\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P="<^#0I#;VYT:6YG
M96YT(&-O;G-I9&5R871I;VX@*#$L-S4P+#`P,"!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P
M861D:6YG+6)O='1O;3H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTZ
M($)L86-K(#%P="!S;VQI9"<^#0HS-C<L-3`P/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#L@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX-"BT\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^#0HF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@<&%D9&EN9RUL
M969T.B`R,'!T)SY&86ER#0IV86QU92!O9B!T;W1A;"!C;VYS:61E<F%T:6]N
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTZ($)L
M86-K(#(N-7!T(&1O=6)L92<^#0HU-S<L-3`P/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX-"B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R
M:6=H=#L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE)SX-"C(Q
M,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX-"B8C>$$P
M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I
M9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(U-2PR,#0I)SX-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G/D%L;&]C871I;VX@;V8@<'5R8VAA<V4@<')I8V4Z/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
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M:6-A;"!K;F]W+6AO=SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT)SXU-S<L-3`P
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
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M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX-"D=O;V1W:6QL
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,7!T('-O;&ED)SX-"BT\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60G/@T*,C$P+#`P,#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(%=H:71E)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0HF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L92<^#0HU
M-S<L-3`P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^#0HF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;3H@
M0FQA8VL@,BXU<'0@9&]U8FQE)SX-"C(Q,"PP,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P<'0@,"<^#0I!<R!O9B!*86YU87)Y+"`S,2P@,C`Q
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M;B!I;7!A:7)M96YT#0IL;W-S(&]F("0R,3`L,#`P+B!4:&4@8V%U<V4@;V8@
M=&AE(&EM<&%I<FUE;G0@=V%S('1H92!R97-U;'0@;V8-"F-O;G1R86-T<R!T
M:&%T('=E<F4@86YT:6-I<&%T960@=&\@<F5S=6QT(&9R;VT@=&AI<R!A8W%U
M:7-I=&EO;@T*=&AA="!H879E(&YO="!M871E<FEA;&EZ960@86YD(&UA;F%G
M96UE;G0@:&%S(&1E8VED960@=&\@9F]C=7,@:71S#0IE;F5R9VEE<R!O;B!N
M97<@:6YI=&EA=&EV97,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^
M#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*)B-X03`[/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P<'0@,"<^#0H\8CY0=6QM;VYA<GD@0W)I=&EC86P@0V%R
M92!-86YA9V5M96YT+"!);F,\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M<'0@,"<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-
M"D]N($%U9W5S="`R+"`R,#$Q+"!!<&]L;&\@365D:6-A;"!(;VQD:6YG<RP@
M26YC+B!E;G1E<F5D(&EN=&\@80T*<W1O8VL@<'5R8VAA<V4@86=R965M96YT
M("AT:&4@)B-X,C`Q0SM00T--(%!U<F-H87-E#0I!9W)E96UE;G0F(W@R,#%$
M.RD@=VET:"!T:&4@<V]L92!S:&%R96AO;&1E<B!O9B!0=6QM;VYA<GD@0W)I
M=&EC86P-"D-A<F4@36%N86=E;65N="P@26YC+B`H(E!#0TTB*2P@82!P<F]V
M:61E<B!O9B!M86YA9V5M96YT('-E<G9I8V5S#0IT;R!T:&4@3&]S($%N9V5L
M97,@3'5N9R!#96YT97(@*"8C>#(P,4,[3$%,0R8C>#(P,40[*2P@=6YD97(@
M=VAI8V@-"G1H92!#;VUP86YY(&%C<75I<F5D("AT:&4@)B-X,C`Q0SM00T--
M($%C<75I<VET:6]N)B-X,C`Q1#LI(&%L;"!O9@T*=&AE(&ES<W5E9"!A;F0@
M;W5T<W1A;F1I;F<@<VAA<F5S(&]F(&-A<&ET86P@<W1O8VL@;V8@4$-#32!A
M;F0@=&AE#0IA<W-O8VEA=&5D(&EN=&%N9VEB;&4@87-S970@:6X@=&AE(&UA
M;F%G96UE;G0@<V5R=FEC97,@86=R965M96YT#0IT:&%T(%!#0TT@:&%S('=I
M=&@@3$%,0R`H=&AE("8C>#(P,4,[4$-#32!397)V:6-E<PT*06=R965M96YT
M)B-X,C`Q1#LI+B!5<&]N('1H92!S:6=N:6YG(&]F('1H92!00T--(%!U<F-H
M87-E($%G<F5E;65N="P-"G1H92!#;VUP86YY(&ES<W5E9"`S-3`L,#`P(&-O
M;6UO;B!S:&%R97,@=&\@=&AE('-O;&4@<VAA<F5H;VQD97(@;V8-"E!#0TTL
M('=H:6-H('=A<R!V86QU960@87,@;V8@=&AE(&1A=&4@;V8@:7-S=6%N8V4@
M870@)#<P+#`P,"P@8F%S960-"F]N('1H92!F86ER(&UA<FME="!V86QU92!O
M9B!O=7(@<VAA<F5S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*
M)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P<'0@,"<^#0I!="!T:&4@
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M;&EN9R!I;G1E<F5S="!O9B`D,38T+#(W-BX\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T
M(#`G/@T*5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!F86ER
M('9A;'5E(&]F($Q!3$,F(W@R,#$Y.W,-"F%S<V5T<R!A8W%U:7)E9"!A;F0@
M;&EA8FEL:71I97,@870@=&AE(&1A=&4@;V8@86-Q=6ES:71I;VX@;V8@4$-#
M30T*86YD(&-O;G-O;&ED871I;VX@;V8@3$%,0SH\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#!P="`P)SX-"B8C>$$P.SPO<#X-"CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4[('=I9'1H.B`Y,B4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;BUL969T.B`P+C-I;B<^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#@W)2<^4'5R8VAA<V4@4')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0G/C<P+#`P,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0^)B-X03`[
M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M1F%I<B!V86QU92!O9B!N970@87-S971S(&%C<75I<F5D/"]T9#X-"CQT9#XF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B-X
M03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D/D-A<V@\
M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/C$V-"PR,3`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C4U
M+#(P-"DG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/E!R97!A
M:60@97AP96YS97,\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
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M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C(V+#`T,3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^36%N86=E;65N="!S97)V:6-E<R!A9W)E
M96UE;G0\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^,S@L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7
M:&ET92<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^06-C;W5N
M=',@<&%Y86)L92!A;F0@86-C<G5E9`T*;&EA8FEL:71I97,\+W1D/@T*/'1D
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M*#$L-#0W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXI
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^1'5E(&9R;VT@;V9F:6-E
M<CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXH,S0L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXI/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/DYO;BUC;VYT<F]L
M;&EN9R!I;G1E<F5S=#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SX-"B@Q-C0L,C<V/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N
M.B!L969T)SXI/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L
M,C`T*2<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^3F5T(&%S
M<V5T<R!A8W%U:7)E9#PO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^,S@L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!7:&ET92<^#0H\=&0^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B-X03`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR-34L,C`T*2<^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SY';V]D=VEL;#PO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@;&5F="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT)SX-"C,R+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXF(WA!,#L\+W1D/@T*
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`G/@T*4')O9F]R;6$@
M9FEN86YC:6%L(&EN9F]R;6%T:6]N(&ES(&YO="!P<F5S96YT960@87,@4$-#
M32!D:60@;F]T#0IE>&ES="!I;B!T:&4@8V]M<&%R871I=F4@<&5R:6]D(&AE
M<F5I;B!P<F5S96YT960N/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&(^,3@N#0I3=6)S97%U96YT($5V96YT<SPO
M8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!<R!O9@T*36%R8V@@-RP@
M,C`Q,BP@86X@96YT:71Y(&%F9FEL:6%T960@=VET:"!-<BX@075G=7-T82P@
M4W!A1W5S#0I#87!I=&%L(%!A<G1N97)S+"!,3$,L(&AA9"!P<F]V:61E9"!A
M("0R-S`L,#`P('-E=F5N+6UO;G1H(&QO86X@=&\-"G1H92!#;VUP86YY+B!4
M:&4@0V]M<&%N>2!P<F5P86ED(&EN=&5R97-T(&5X<&5N<V5S(&]F("0Q-2PP
M,#`@86YD#0IC;&]S:6YG(&-O<W1S(&]F("0U+#`P,"X\+W`^#0H\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S5F,6,X
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M2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(S+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\U
G9C%C.#)A-E\P83EC7S0Y9C!?.#0T.%]B93%F-&9D8SDX,3(M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>2. Summary of Significant Accounting Policies</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Principles of Consolidation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Our consolidated financial statements include the accounts of
Apollo Medical Holdings, Inc. and its wholly owned subsidiaries
AMM, , Aligned Healthcare Group (&#x201C;AHI&#x201D;) and PCCM as
well as Professional Medical Corporations managed under long-term
management agreements including AMH and LALC. Some states have laws
that prohibit business entities, such as ApolloMed, from practicing
medicine, employing physicians to practice medicine, exercising
control over medical decisions by physicians (collectively known as
the corporate practice of medicine), or engaging in certain
arrangements with physicians, such as fee-splitting. In California,
we operate by maintaining long-term management contracts with the
Professional Medical Corporations, which are each owned and
operated by physicians, and which employ or contract with
additional physicians to provide hospitalist services. Under the
management agreements, we provide and perform all non-medical
management and administrative services, including financial
management, information systems, marketing, risk management and
administrative support. The management agreements have an initial
term of 20 years unless terminated by either party for cause. The
management agreements are not terminable by the Professional
Medical Corporations, except in the case of gross negligence,
fraud, or other illegal acts by us, or bankruptcy of ApolloMed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Through the management agreements and our relationship with the
stockholders of the Professional Medical Corporations, we have
exclusive authority over all non-medical decision making related to
the ongoing business operations of the Professional Medical
Corporations. Consequently, we consolidate the revenue and expenses
of the Professional Medical Corporations from the date of execution
of the management agreements. All intercompany balances and
transactions have been eliminated in consolidation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
All intercompany balances and transactions are eliminated in
consolidation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Non-controlling Interest</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Non-controlling interest represents the portion of equity that is
not attributable to the Company. The non-controlling interest
recorded in our consolidated financial statements represents the
pre-acquisition equity of those entities which we have determined
that we have a controlling financial interest and that
consolidation is required as a result of management contracts
entered into with these entities. The nature of these contracts
provide us with a monthly management fee to provide the services
described above, and as such, the only adjustments to
non-controlling interests in any period subsequent to initial
consolidation would relate to either capital contributions or
withdrawals by the non-controlling parties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Use of Estimates</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The preparation of financial statements in conformity with
generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting
period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Fair Value of Financial Instruments</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Our accounting for Fair Value Measurement and Disclosures, defines
fair value as the exchange price that would be received for an
asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in
an orderly transaction between market participants on the
measurement date. This topic also establishes a fair value
hierarchy which requires classification based on observable and
unobservable inputs when measuring fair value. The fair value
hierarchy distinguishes between assumptions based on market data
(observable inputs) and an entity&#x2019;s own assumptions
(unobservable inputs). The hierarchy consists of three levels:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Level one &#x2014; Quoted market prices in active markets for
identical assets or liabilities;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Level two &#x2014; Inputs other than level one inputs that are
either directly or indirectly observable; and</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Level three &#x2014; Unobservable inputs developed using estimates
and assumptions, which are developed by the reporting entity and
reflect those assumptions that a market participant would use.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Determining which category an asset or liability falls within the
hierarchy requires significant judgment. The Company evaluates its
hierarchy disclosures each quarter. The Company currently records
warrants using level two in the hierarchy.&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The carrying values of cash and cash equivalents, trade and other
receivables, trade and other payables approximate their fair values
due to the short maturities of these instruments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Fair Value of Warrants</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>&#xA0;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company accounts for free-standing warrants for shares of
common stock by first determining whether the instruments require
liability treatment based on the provision in the warrant
agreements. Generally, when the agreement may require future
performance obligations on the part of the Company (other than the
issuance of common shares in connection with notice of exercise) or
the exercise price of warrants is not fixed or determinable, then
the warrants are treated as liabilities and recorded at their
relative fair value as of each reporting period. If the warrants
are determined to be equity-classified instruments, then the
warrants are recorded as an increase in additional paid-in capital
with a corresponding discount.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company accounts for warrants included with convertible notes
by first allocating the proceeds of issuance among the convertible
instrument and the stock warrants based on their relative fair
values, as there are two separate instruments involved. Following
this, it is then further determined whether the embedded conversion
option has an intrinsic value. The fair value of the warrants is
recorded as an increase to additional paid-in capital with a
corresponding discount on the related notes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Subsequent adjustments to the exercise price of the warrants are
recorded at the date of the change. Warrants that are classified as
liabilities, are re-measured at each reporting period and changes
in the fair value are reported in the Company&#x2019;s statement of
operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Concentrations</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
During the twelve month period ended January 31, 2012, the Company
had three major customers, which contributed 34%, 17% and 7.6% of
revenue. As of January 31, 2012, the total receivables from these
customers amounted to $140,000, $89,099 and $41,900,
respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
During the twelve month period ended January 31, 2011, the Company
had three major customers, which contributed 36%, 20% and 12% of
revenue. As of January 31, 2011, the total receivables from these
customers amounted to $170,638, $167,799 and $88,580,
respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;&#xA0;&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Stock-Based Compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Employee Stock Options and Stock-Based Compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
All share-based payments to employees, including grants of employee
stock options, are recognized in the financial statements based on
their fair values. There were no stock options granted during the
year ended January 31, 2012. For options granted during the year
ended January 31, 2011, the fair value of each option award was
estimated using the Black-Scholes option pricing model and the
following assumptions:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center">
Year&#xA0;ended</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center">
January&#xA0;31,</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center">
2012</p>
</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 87%">Weighted average risk-free interest
rate</td>
<td style="width: 1%">&#xA0;</td>
<td style="width: 1%; text-align: left">&#xA0;</td>
<td style="width: 10%; text-align: right">1.9</td>
<td style="width: 1%; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Dividend yield</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">0</td>
<td style="text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left">Volatility factor of the expected
market price of the Company's common stock</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">80</td>
<td style="text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Weighted average live</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">10.0 years</td>
<td style="text-align: left">&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Expected volatility is based on the historical volatility of the
Company&#x2019;s stock. The Company also uses historical data to
estimate the expected term of options granted and employee
termination rates. The risk-free rate for periods within the
expected useful life of the options is based on the U.S. Treasury
yield curve in effect at the time of grant.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The estimated weighted average fair value of options granted during
the year ended January 31, 2011, was $ $0.011. As of January 31,
2012 and 2011, there was approximately $25,015 and $54,348,
respectively, of total unrecognized compensation cost related to
non-vested share-based employee compensation arrangements. The
remaining unrecognized expense at January 31, 2012, is expected to
be recognized during the fiscal year end January 31, 2013.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Stock options and warrants issued to non-employees as compensation
for services to be provided to the Company are accounted for based
upon the fair value of the services provided or the estimated fair
value of the option or warrant, whichever can be more clearly
determined. The Company recognizes this expense over the period in
which the services are provided. During the years ended January 31.
2012 and 2011, the Company&#x2019;s operating results included
$29,333 and $72,152, respectively, for non-cash stock-based
compensation for options issued to consultants and other
non-employees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company issues new shares to satisfy stock option and warrant
exercises. There were no options exercised during the years ended
January 31, 2012 or 2011.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Basic and Diluted Earnings Per Share</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Basic net loss per share is calculated using the weighted average
number of shares of the Company&#x2019;s common stock issued and
outstanding during a certain period, and is calculated by dividing
net loss by the weighted average number of shares of the
Company&#x2019;s common stock issued and outstanding during such
period. Diluted net loss per share is calculated using the weighted
average number of common and potentially dilutive common shares
outstanding during the period, using the as-if converted method for
secured convertible notes, and the treasury stock method for
options and warrants.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Cash and Cash Equivalents and Concentration of Cash</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company considers all short-term investments with an original
maturity of three months or less to be cash equivalents.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Cash and cash equivalents at January 31, 2012, include cash in bank
representing the Company&#x2019;s current operating account and
$27,407 in a brokerage money market account.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&#xA0;<b>&#xA0;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Accounts Receivable and Allowance for Doubtful
Accounts&#xA0;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Accounts receivable primarily consists of amounts due from
third-party payors, including government sponsored Medicare and
Medicaid programs, and insurance companies, and amounts due from
hospitals, and patients. Accounts receivable are recorded and
stated at the amount expected to be collected</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company maintains reserves for potential credit losses on
accounts receivable. Management reviews the composition of accounts
receivable and analyzes historical bad debts, customer
concentrations, customer credit worthiness, current economic trends
and changes in customer payment patterns to evaluate the adequacy
of these reserves. Reserves are recorded primarily on a specific
identification basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Property and Equipment</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<br />
Property and Equipment is recorded at cost and depreciated using
the straight- line method over the estimated useful lives of the
respective assets. Cost and related accumulated depreciation on
assets retired or disposed of are removed from the accounts and any
resulting gains or losses are credited or charged to income.
Computers and Software are depreciated over 3 years. Furniture and
Fixtures are depreciated over 8 years. Machinery and Equipment are
depreciated over 5 years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Income Taxes</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company accounts for income taxes using an asset and liability
approach which allows for the recognition and measurement of
deferred tax assets based upon the likelihood of realization of tax
benefits in future years. Under the asset and liability approach,
deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income
tax purposes. A valuation allowance is provided for deferred tax
assets if it is more likely than not these items will either expire
before the Company is able to realize their benefits, or that
future deductibility is uncertain.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
A tax position is recognized as a benefit only if it is &#x201C;more
likely than not&#x201D; that the tax position would be sustained in
a tax examination, with a tax examination being presumed to occur.
The evaluation of a tax position is a two-step process. The first
step is to determine whether it is more-likely-than-not that a tax
position will be sustained upon examination, including the
resolution of any related appeals or litigations based on the
technical merits of that position. The second step is to measure a
tax position that meets the more-likely-than-not threshold to
determine the amount of benefit to be recognized in the financial
statements. A tax position is measured at the largest amount of
benefit that is greater than 50 percent likely of being realized
upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be
recognized in the first subsequent period in which the threshold is
met. Previously recognized tax positions that no longer meet the
more-likely-than-not criteria should be de-recognized in the first
subsequent financial reporting period in which the threshold is no
longer met. Penalties and interest incurred related to underpayment
of income tax are classified as income tax expense in the year
incurred.&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Revenue Recognition</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Revenue consists of contracted and fee-for-service revenue. Revenue
is recorded in the period in which services are rendered. Our
revenue is principally derived from the provision of healthcare
staffing services to patients within healthcare facilities. The
form of billing and related risk of collection for such services
may vary by customer. The following is a summary of the principal
forms of our billing arrangements and how net revenue is recognized
for each.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Contracted revenue represents revenue generated under contracts in
which we provide physician and other healthcare staffing and
administrative services in return for a contractually negotiated
fee. Contract revenue consists primarily of billings based on hours
of healthcare staffing provided at agreed-to hourly rates. Revenue
in such cases is recognized as the hours are worked by our staff
and contractors. Additionally, contract revenue also includes
supplemental revenue from hospitals where we may have a
fee-for-service contract arrangement or provide physician advisory
services to the medical staff at specific facility. Contract
revenue for the supplemental billing in such cases is recognized
based on the terms of each individual contract. Such contract terms
generally either provides for a fixed monthly dollar amount or a
variable amount based upon measurable monthly activity, such as
hours staffed, patient visits or collections per visit compared to
a minimum activity threshold. Such supplemental revenues based on
variable arrangements are usually contractually fixed on a monthly,
quarterly or annual calculation basis considering the variable
factors negotiated in each such arrangement. Such supplemental
revenues are recognized as revenue in the period when such amounts
are determined to be fixed and therefore contractually obligated as
payable by the customer under the terms of the respective
agreement. Additionally, we derive a portion of our revenue as a
contractual bonus from collections received by our partners and
such revenue is contingent upon the collection of third-party
billings. These revenues are not considered earned and therefore
not recognized as revenue until actual cash collections are
achieved in accordance with the contractual arrangements for such
services.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Fee-for-service revenue represents revenue earned under contracts
in which we bill and collect the professional component of charges
for medical services rendered by our contracted and employed
physicians. Under the fee-for-service arrangements, we bill
patients for services provided and receive payment from patients or
their third-party payers. Fee-for-service revenue is reported net
of contractual allowances and policy discounts. All services
provided are expected to result in cash flows and are therefore
reflected as net revenue in the financial statements.
Fee-for-service revenue is recognized in the period in which the
services are rendered to specific patients and reduced immediately
for the estimated impact of contractual allowances in the case of
those patients having third-party payer coverage. The recognition
of net revenue (gross charges less contractual allowances) from
such visits is dependent on such factors as proper completion of
medical charts following a patient visit, the forwarding of such
charts to our billing center for medical coding and entering into
our billing system and the verification of each patient&#x2019;s
submission or representation at the time services are rendered as
to the payer(s) responsible for payment of such services. Revenue
is recorded based on the information known at the time of entering
of such information into our billing systems as well as an estimate
of the revenue associated with medical services.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Recently Adopted Accounting Pronouncements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
In December 2010, the Financial Accounting Standards Board issued
Accounting Standards Update (&#x201C;ASU&#x201D;) No. 2010-29,
<i>Business Combinations, Disclosure of Supplementary Pro Forma
Information for Business Combinations</i> (&#x201C;ASU
2010-29&#x201D;), which provides clarification regarding pro forma
revenue and earnings disclosure requirements for business
combinations. The amendments in this ASU specify that if a public
entity presents comparative financial statements, the entity should
disclose only revenue and earnings of the combined entity as though
the business combination(s) that occurred during the current year
had occurred as of the beginning of the comparable prior annual
reporting period. The amendments also expand the supplemental pro
forma disclosures to include a description of the nature and amount
of material, nonrecurring pro forma adjustments directly
attributable to the business combination included in the reported
pro forma revenue and earnings. The amendments are effective
prospectively for business combinations for which the acquisition
date is on or after the beginning of the first annual reporting
period beginning on or after December 15, 2010. Early adoption is
permitted. The Company adopted ASU 2010-29 during the first interim
reporting period of 2011 as it relates to pro-forma disclosure of
the Company&#x2019;s acquisitions. The adoption of ASU 2010-29 did
not have a material impact on the Company&#x2019;s consolidated
financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
ASU No. 2010-28, <i>Intangibles &#x2014; Goodwill and Other, When to
Perform Step 2 of the Goodwill Impairment Test for Reporting Units
with Zero or Negative Carrying Amounts</i> (&#x201C;ASU
2010-28&#x201D;) was issued in December 2010. The amendments in this
ASU modify Step 1 of the goodwill impairment test for reporting
units with zero or negative carrying amounts. For those reporting
units, an entity is required to perform Step 2 of the goodwill
impairment test if it is more likely than not that a goodwill
impairment exists. In determining whether it is more likely than
not that impairment to goodwill exists, an entity should consider
whether there are any events or circumstances that would more
likely than not reduce the fair value of a reporting unit below its
carrying amount. The amendments in this ASU are effective for
fiscal years, and interim periods within those years, beginning
after December 15, 2010. Early adoption is not permitted. The
Company adopted ASU 2010-28 for the quarter ending March 31,
2011.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Recently Issued Accounting Pronouncements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<font style="color: black">In December 2011, the FASB issued
guidance on offsetting (netting) assets and liabilities. Entities
are required to disclose both gross information and net information
about both instruments and transactions eligible for offset in the
statement of financial position and instruments and transactions
subject to an agreement similar to a master netting arrangement.
The new guidance is effective for annual periods beginning after
January 1, 2013.</font> We do not expect the adoption of this
revised GAAP to have a material effect on our financial
position.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
In September 2011, the FASB issued a GAAP update on goodwill to
allow an entity the option of performing a qualitative assessment
before calculating the fair value of the reporting unit when
testing goodwill for impairment. If the qualitative assessment
concludes that it is more likely than not that the fair value of a
reporting unit is less than its carrying value, the entity shall
perform the quantitative two-step goodwill impairment test.
Otherwise, the two-step goodwill impairment test is not required.
This revised GAAP will be effective for fiscal years beginning
after December 15, 2011, with early adoption permitted. We do not
expect the adoption of this revised GAAP to have a material effect
on our financial position, results of operations or cash flows.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<font style="font-family: Times New Roman, Times, Serif">In June
2011, the FASB issued guidance on presentation of comprehensive
income. The new guidance eliminates the current option to report
other comprehensive income and its components in the statement of
changes in equity. Instead, an entity will be required to present
either a continuous statement of net income and other comprehensive
income or in two separate but consecutive statements. The new
guidance is effective for annual periods beginning after December
15, 2011. In December 2011, the FASB issued a deferral of certain
portion of this guidance</font>. <font style="font-family: Times New Roman, Times, Serif">We do not expect the
adoption of this revised GAAP to have a material effect on our
financial position.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
In May 2011, the FASB issued a GAAP update on fair value
measurement, which eliminates differences between U.S. GAAP and
International Financial Reporting Standards (IFRS), resulting in a
consistent definition of fair value and common requirements for
measurement of and disclosure about fair value between GAAP and
IFRS. It also expands the disclosures for fair value measurements
that are estimated using significant unobservable (Level 3) inputs.
This revised GAAP will be effective for annual and interim periods
beginning after December 15, 2011. We do not expect the adoption of
this revised GAAP to have a material effect on our financial
position, results of operations or cash flows.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 164,361<span></span></td>
        <td class="nump">$ 397,101<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
        <td class="nump">994,118<span></span></td>
        <td class="nump">704,971<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances</a></td>
        <td class="nump">2,140<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOfficersOrStockholdersCurrent', window );">Receivable from officers</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,873<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Due from affiliate</a></td>
        <td class="nump">5,504<span></span></td>
        <td class="nump">3,900<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">45,601<span></span></td>
        <td class="nump">29,138<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Prepaid financing cost, current</a></td>
        <td class="nump">37,500<span></span></td>
        <td class="nump">37,500<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">1,249,224<span></span></td>
        <td class="nump">1,197,483<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Prepaid financing cost, long term</a></td>
        <td class="nump">1,563<span></span></td>
        <td class="nump">39,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment - net</a></td>
        <td class="nump">43,261<span></span></td>
        <td class="nump">21,593<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
        <td class="nump">38,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">32,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump">1,364,048<span></span></td>
        <td class="nump">1,258,139<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">163,476<span></span></td>
        <td class="nump">92,745<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes, net of $653,026 debt discount</a></td>
        <td class="nump">596,366<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
        <td class="nump">653,026<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Shares to be issued</a></td>
        <td class="nump">90,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to officers</a></td>
        <td class="nump">12,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">1,515,268<span></span></td>
        <td class="nump">92,745<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes</a></td>
        <td class="nump">150,000<span></span></td>
        <td class="nump">1,248,588<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liability</a></td>
        <td class="nump">120,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">1,785,268<span></span></td>
        <td class="nump">1,341,333<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>STOCKHOLDERS' DEFICIT:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 ; 5,000,000 shares authorized; none issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, par value $0.001; 100,000,000 shares authorized, 29,335,774 and 27,635,774 shares issued and outstanding as on January 31, 2012 and 2011, respectively</a></td>
        <td class="nump">29,336<span></span></td>
        <td class="nump">27,636<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
        <td class="nump">1,429,051<span></span></td>
        <td class="nump">1,058,418<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(2,117,708)<span></span></td>
        <td class="num">(1,397,363)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total</a></td>
        <td class="num">(659,321)<span></span></td>
        <td class="num">(311,309)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
        <td class="nump">238,101<span></span></td>
        <td class="nump">228,115<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' deficit</a></td>
        <td class="num">(421,220)<span></span></td>
        <td class="num">(83,194)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</a></td>
        <td class="nump">$ 1,364,048<span></span></td>
        <td class="nump">$ 1,258,139<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdvancesOnInventoryPurchases</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of current deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 21<br><br><br><br> -Paragraph 16<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsCurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of long-term deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 21<br><br><br><br> -Paragraph 16<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsNoncurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FIN39-1<br><br><br><br> -Paragraph 10A, 10B<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 133<br><br><br><br> -Paragraph 4, 17<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 107<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FIN39-1<br><br><br><br> -Paragraph 10A, 10B<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 133<br><br><br><br> -Paragraph 4, 17<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 57<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 4<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueFromAffiliateCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOfficersOrStockholdersCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due from owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company, which are usually due within 1 year (or 1 business cycle).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 4<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 57<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueFromOfficersOrStockholdersCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 6<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 4<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 57<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToOfficersOrStockholdersCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Publisher AICPA<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet.  Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Publisher AICPA<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5SAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (720,346)<span></span></td>
        <td class="num">$ (156,331)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">12,589<span></span></td>
        <td class="nump">11,198<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
        <td class="nump">118,077<span></span></td>
        <td class="nump">42,908<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of shares for services</a></td>
        <td class="nump">152,400<span></span></td>
        <td class="nump">47,378<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
        <td class="nump">29,333<span></span></td>
        <td class="nump">72,152<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="nump">804<span></span></td>
        <td class="nump">1,006<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase in warrant liability</a></td>
        <td class="nump">120,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
        <td class="nump">210,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(407,224)<span></span></td>
        <td class="num">(290,363)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent', window );">Due from / to officers</a></td>
        <td class="nump">14,953<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseDueFromAffiliates', window );">Due from affiliates</a></td>
        <td class="num">(1,604)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Prepaid financing cost</a></td>
        <td class="nump">37,500<span></span></td>
        <td class="nump">37,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
        <td class="num">(22,668)<span></span></td>
        <td class="nump">1,027<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">70,731<span></span></td>
        <td class="num">(11,507)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(385,455)<span></span></td>
        <td class="num">(245,031)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash paid for purchase of property and equipment</a></td>
        <td class="num">(7,205)<span></span></td>
        <td class="num">(21,165)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries', window );">Cash received from consolidation of VIE</a></td>
        <td class="nump">164,210<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used) in financing activities</a></td>
        <td class="nump">157,005<span></span></td>
        <td class="num">(21,165)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Due from related parties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,440)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Proceeds from/(payment to) convertible notes</a></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distribution to non-controlling interest shareholder</a></td>
        <td class="num">(154,290)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
        <td class="num">(4,290)<span></span></td>
        <td class="num">(2,440)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH &amp; CASH EQUIVALENTS</a></td>
        <td class="num">(232,740)<span></span></td>
        <td class="num">(268,636)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH &amp; CASH EQUIVALENTS, BEGINNING BALANCE</a></td>
        <td class="nump">397,101<span></span></td>
        <td class="nump">665,737<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH &amp; CASH EQUIVALENTS, ENDING BALANCE</a></td>
        <td class="nump">164,361<span></span></td>
        <td class="nump">397,101<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid during the year</a></td>
        <td class="nump">129,000<span></span></td>
        <td class="nump">125,425<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid during the year</a></td>
        <td class="nump">2,400<span></span></td>
        <td class="nump">1,600<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH FINANCING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of common stock issued in connection with acquisitions (Note 17)</a></td>
        <td class="nump">280,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IssuanceOfCommonStockValueForStockBasedCompensation', window );">Shares to be issued for services (Note 15)</a></td>
        <td class="nump">$ 90,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IssuanceOfCommonStockValueForStockBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of Common Stock Value for Stock-Based Compensation</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ameh_IssuanceOfCommonStockValueForStockBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ameh_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense representing the noncash expenses charged against earnings in the period to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate caption: Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 21<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 8<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2420-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 45, 46, 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetImpairmentCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseDueFromAffiliates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in receivables to be collected from an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseDueFromAffiliates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in current receivables (due within one year or one operating cycle) to be collected from the reporting entity's executives and owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to return capital to noncontrolled interest, which generally occurs when noncontrolling shareholders reduce their ownership stake (in a subsidiary of the entity). This element does not include dividends paid to noncontrolling shareholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToMinorityShareholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from a long-term borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfRelatedPartyDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of stock issued in noncash financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockOptionPlanExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001144204-12-029578-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-029578-xbrl.zip
M4$L#!!0````(`,>"KT"P\VG0L7@``#=^`P`1`!P`86UE:"TR,#$R,#$S,2YX
M;6Q55`D``_:ZLD_VNK)/=7@+``$$)0X```0Y`0``[%U9<^,XDGYWA/\#5MO=
MT1UAV@1OVFU/Z*SVELMRV.YK7QP4"5F<H4@-2?G87[\)D)1X2:)L46;5U(L/
M"0`S$YF)S,0'\-=_O$P=]$3\P/;<\Q8^YEN(N*9GV>[C>6L><$9@VG8+!:'A
M6H;CN>2\]4J"UC\N#@]^_2^.0_W>I_8M&KJ.[1)TR7TAH6^_H+],XA#?".$C
MEW8U">IYYGQ*W/`(C8R`6,AST5^=VRLD'&.$)F$X.STY>7Y^/B;6H^%S'AOP
MV/2F)XCCDH?]$=%YBI!RC*5C/?75K3=WK5.D:D35+-'D=%D0.4E01IS!CR3.
ME&334N415@0SU:OK$R.$$9$%M)XB@<<"Q\L<ENZQ="KQI[+^O^G6WNS5MQ\G
M(?K9_`4:0TOH@3,R.`*.S6/4=AQT2YL&Z)8$Q'\BUG$\TLO(=Q!(W0W.6RF^
MZ<?'GO]X`N.*)W8LME;4\I1^ZZQI#X_^%Y7KHCW](-/^662ML:[K)^S;I*D=
M>)*`U77$1"T68P=VV<C0%)_\]>7JSIR0J<'E.3"F9)+I9LP\Q_&F(!B7A"=4
M]#P6<=+<A/D,_==%#T910,SC1^_I)/Z2=L(<C[EE-XO8Y5W@BY+FMOM$@K"\
M1_1=22?7<]WYM%Q>5NB?A*\S<@*-.&A%?-M<]-O<*=L!S._1,&:+3F,C&+$.
M\1<EM,$W=*2@M`_[IJ03)<3*R2V>4>4D^C+3-"QM*D=-PQ8H.4),S9W3@"G#
M+1DCIG.GE(3S5F!/9P[5#/:9X9N^YY!JVLUZ3'PR/F]1C>(2O3E^":PW*']U
MNSJ)V`(].NV[H1V^=KWIU'/O0L_\U]W$\$DPG(?,38+K1*;GAN0EO*5T$L]Y
MN.DK6)9$CN.P@'GN,P_&\G!WWWO@'Q@'DL@_@.N=NW;4)V`CMI!%3'MJ.#"?
ME]>#%K*M\Y9M/0@BUO0'56SC05?J<1V^RW.2HG:XMJJ+'-^1,#^0L*`-E`?A
M089G\5KK0N054595Z=>3:CSD^;V9CQS;'#B>$6[)'N95$6?8BSW*P^]WO32/
M_%LX%!\4RJ'>NM`U3<)BFK\4S1$[L>6<=HU@TG8M^JO_[[G]9#BP-`7ML&OX
M_BLP_X?AS,F6;/)4#]_"ICX0-+W/JYPF]75.ZK=[G#;0%4[JP(S)?&_0T08/
MU+T^"#"/BB*KHOKKR5:L9+EG$S[Q'`O64]HG?(5%RYG36;_Q?+H@MD-8QT?S
MT!@YY-Z[]EPJ"K!2L(?'2Q`*J,JV6O!F\<@]OJ]+6.?:4A>$(O8EKMW&7:ZC
M]?M\N]U3-:P]P/#*@TX5`;<N0%5$75R*:#?\-D>&#Y(LZ+S\(DF\+M0H4?E!
M2R2*!3`Y$?\GR%14);4^F4H/:BQ30=`PEFN6Z#M7IH)P)%G#6ZY3526#'Z1$
M,BH/CES04K(I7YV:I3@YV>Q8<7"TDB?B^0^P1%E4=*T^@<:!`PA4%W5)JWF]
MZ)$Q\7UB#6R7ID5=+PB#[AP^<<-KLGU$]<:U=*#T>*QJ*B</1)"-QG<Y311[
MG("QKJHZWVGW98@950@755"WI4C6D[^952JBIG(+H:.H;^0VPT&6X2O;&-F.
M'=HDD4G#.!0$4')!E5*K39'F7(3L0?X+N@X*?N6YC_?$GUY[(0ENC%>J]$UC
M4&Q=0(BBR5IJT=C`0I;?6Q(:MDNLON&[8,1!VS3GT[ECA,0";;!-NVES*JHT
M+!-U5512KFLS&UFVX7M:3`ENB4D@=P"Q@'8W5(E;%[#PZ6IJZ5M'?8[/("!A
MT#".,--:B!I$/<43HS1OC(L\_2V9:>VJR((21532MI>E.,O/%]OU?+:LOBE0
MJ)T?O1B=YTE>.4'O#;F+S%4)LJMR)D<S%16"JE"?Y?/&CU?&5./V/)R`:/Z/
M6$WB5(`Y9`%S>EU?3WZ9QVBF*]3`;\`'F:`U0V]AUF:&;?5?9L0-2#-94D`Q
M=2QJF<DJ4EU_&:]VIT^C316>\JX27LID;PQ_Z-^%=(EG#6^(SS1[EWP_S(C_
M4+1.\8U>")9R_IC/B&`S/SGSM"R;9F*&<P-*<NEVC9D=&D[#)EL$M<:\K$DX
MI=@K2,\E47,R\+WI<`Q!&Z2A5"++I+29)BR!"4N:FO))59@HCT?C&!VL`C[Q
MY\1J?(Z%E4*.M04S*Q-*Z%0L1S2,=0F7Q+&;>-@<6%P&P7R'0<5+8)^ZMG/>
M"F$*WFC._&(CL)SP&A:<'9`MJ`6R&Z]3(L0XG(BQR.OK"G,;PO`=J]`N(G"I
M4@0>$;Y.U;Z^99_N7N:6_6HLY<7@`5GAZXUCN"&X%JH(LVDC*XN8A\G&<GHO
M<AWU&Y2YF8F62(L8/)]/M=90OW*M:]CL"9`L8U'"HBB6+FL-V#*I?64'!88O
ML"[5O#L2!8IM"!0=&^R_F2&>3%.WS#Y!.=G-48R](`7$!5)`7I2DA6]P?[(@
MTQJ1`N("*2!_'4B!@G#J0@J("Z1`:2VSB4B!3;+9L>+$2`&Y4)3_9BVQ3J2`
MN$`*R"6UG,9#!81:UT3<,*A`W=SJH`)R>K]UWTB!NAFD2`$L8UE0M.I8@;;U
M1)D/ANZE^P3?>O[KS=PW)T:P=4Q?-W\B3<@D/EV,74U[G8B(VB>2IF5R/B?;
M`A#1([[]9(3V$VF\TF(P2T46>4%)&^9J\FM&?M2NPQ3Y`9^I*I\RT@]$?M2N
MRZT+'=;IS!Y*O<B/VC666J>H2+RDY7=P=XK\J%T5*?)#%_>&_*B='XK\$+7,
M[NQZY,<PG!"_\1X2<O\+/;L8K""\-EQ+D<6=%2%QA&L!/6P$KJ563C\4UU*W
MFFH,Q:D+@I3WBJ7:^<GSK&?;V7;3OW;G#NN5*&0F**&T4/6\]W:YPU^[&V$;
MO5*N!+J!A]UCD>IF4VE=2+*2VZ?Z""Q2[9H*TZE(HO(^+%)IJ+U,@AO&LR!1
M'<[ZSPT<K,P#T]E3,U490ZX@ZXJH**5I8`D#=>/,UG*\RPUGW""<6>UQ*\69
M2;08FD;'5\&9U0>XJEVU*<^***E*,2W\:,15W;PSQ%4^?_P@Q-7J</?=T"5<
M#^)JP^SL@.PZ$%>U^Q"*N%)D7136'BZM`W%5;VXH5<H-RQ!7`QOH@9C@B8#[
MA,3QD:Z944+2O+T)3)'E6B:N64__'M!E>USLFX<NJWW"><A31$')<+Q_=%F]
MQOMAZ++:\Q"ZG:QJ*W?:&K#-7GL40]%E,)X@\.M6G*;`R^H6!RB$+/-2IK:R
M&EY&K[\JI')QB]]=8TIE!>;0LP,6$C>,5ZPMM^RVY*0YAK$7=)V2H.MH6;&X
M[??-8'H*,JT17:<DZ#HJT_Q^3Q/1=07AU(6N4Q)T'9-,(6IN(KINDVQVK#@1
MNBX1S[>(KLL+M$YTG9*@ZZA`"Q6L.D3ZR?>"`.+D\3:X#E&1WP4PEZ2.WNXJ
M/:[3ES$G\?*`TW1%Y(3^H*?T9$GKBE)TQ07HKI9&3Z?(S1<F_SD/0AK;!_?>
MBE(?,U=VWRX$S'3K@MUV>TM`E`$DAG?$?[)-F@C9GG5+3._19:-L65-YKW`J
M*8JTN.`/,@)5P+*0+G36*XJLX"G0Q`@F,"=/MD6LSNOO`4VO+]E]L:!V;3.T
MG[;,.-XKPFI72++].QI"*"DP>75VLF(`2_0)R+-'HM^7;A&3TS@!8(97X3-7
MYE1AI,"Z-R7WQ@O=.[&WR)?WQ"7=]\!*.E_.49P'P#T1=[Y/=:WH#GE:T-(5
M64M%(`FQE6QR.*.WD#?;)C%#\TERYG;-ZOSD%H4H66*^;3CND5&89$TW/IG:
M\VGCV%=9?2>]A;.)A9PM!L&<`GB'8Q8LM%WK3\/W#;#>@>?'7CT8^EW'L*?-
MFWQ(^2555%/YW%;\E+FE*X@7:-4`$FK0E#DH2ZPUGAMTR-CS2<H9Y+%M\+CL
M*%'4]86$$\^*E@2VS#;.55!`)0<4J&DKVJ-`-JV-60!)X_00LY-[O*"N6Q:S
M/.0Q(#,?B(C>IM`TY:"55HQU+0WX6));-:Q9MZ?<O`E5Z(1BF5\[HU58RXLG
MLHN]*W+%J:8'=`1%RGJ!#,F%[9XGF[Y4!+QKSYN/PO'<2:32N$F58+6`Z#5S
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MYS8MP%!]PZ$!NC6U73L(?097;VK4`YY'5A1%2MW=MH&%2O6\Z)1]L^MY@L+J
M>6DSK,[-NFK>HCF[9*!Q4T[1:+F;(-;1GT>C!>%PG)2WFL<;L"9B215206Z6
MY$U%!!98+,NW6YY)WE=@*]$[%[-S6(V5+/O)$?0$8=DQ`ML$P^_9SCS<!E]8
MA>\5*%+AC3--XP?^.(T'V<!-"HWU)Z&O_"16^PF$\TBNY],1\5GSN.T[8"`K
M15%D_:U*3J_@5B6=9R<JWLA0#46'O:"LI,4=9M)VE0B6ZT;8\=[<I\`$%E:R
M?>-K\LR^V0'K%-,"_\&_R@O\TGBQ)D'(B_NC*!A!S]\ZMHG32L*)M&9?TMD9
M-DI>W#S&1`./S:-_-K+Z=4`X]H+\D1;W:GTTH&,_)LQDN2\3CB4+>BHI:N'5
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MH`T68#$K<(SM@^IWF2+(?PRNB43D9@C)"YAI>=<(R:/G;W'Z<V=RA=SF#MPH
M$($6DD1T]33<U[2T,W2N\GU_$\/_`,]':YPP1)GO6U!4)/G^=;8SVZQ&)T]Q
M3=SG+)V4C")QD<_N0T8)(M\OE4(D38['',UW5E)5<!70P#><2]<B+Y_)1^@R
MO=H!!N4UD87A*TG+4_XG<9S/KO?LWA$C\%QBL17>_P`.I/QJN(*T)0>Q%UQJ
M^XYU9@OB*=PJK36K2-L=]O[-)](JE3^B2P9534H#9E9B[U-!(]X?(Y6J>/%Y
M=RU[7C9-<`$`8Q)B,6Q;>KOH;5>;[HE%=H=/[G+3*HQLJM+FWE>5NT5CZU.C
M>Y(&.QB()5U>"VJOQ-NFTT=4F!2.ZWC!W"?W((6.`VUVY(!XX*''*S(WD(0.
M)\'?7+O3[W'=#E:PUNL,VH(2+:T_.>&993^A('QUR'EK,+R^/T68GX7HWIY"
M-@J9&[KUIH9[%'UPA.Y@.1NW?GH,SPX/:.]9TO=+^_;3Y?4IHIWYV<L9VFHP
M.M2(_H'EX\.#E,!^,J:SL_]^`4;ULP#%-[#2UB>CI-_);.?DP&#1<]M\78^X
MGY##@SAH1'9TVX>!0H]>BN2-$3X29?X(YAMT@I[11U'Y#5DLN4;AA*#PF3A/
M,`A\&TX"!`$S#/$_ACN'1!")^`A1!4%^M%\-(R/#C(HZ%+&+?@X(050/#P^P
M^LOQ/@2Y5Y$:RWL8J+#L&`^.%#X2:RQ/$'4B8*IT:.SYAP=FJA*6%B"89S!W
M6+AON!:R;)^8H><':$PR4W-X$,T-6CLUQP@(3NAX)CY!3[1:`FH0'A[\H$=D
MLLH<`C(H$V/#]J-&C/!PV=T(,UP>'EA`<\">$&2?X7KA0MV"HKI0ON#S8&Y.
M#@\F!O`P(H0*P?1\*^H3CP;R&)%D*-M%\25OAP?.$O2Z%[7:GWTF)KE:=U!&
M=4(/-`&FI3L8%@VWNG(<'F2U`_V@B.N4HU0W#@\6)D!UXQN;F93GE'7I"'*9
MG-^TW<H^$W[:R?%8)$C1:,DPT>/HQ'IQ!)!S!?2_G)XL.J'/ADLF'CR_;3U!
M\`+-4]YE!A$R"0)6HD=!LH>?:I"V\`"62:HA$=NE3@3](*E'HJJM49-(/<M]
M"(I<R->K)]^'K35`2B*VY%P5\I;;UZ?[B-`2`G**5/I4=K`]>?*?E[W[WTZ1
MSO]XACK#VU[_ENL.KZ[:-W?]4W`;CF/,`K(%/<@DCA/,#`K*8=D'_7]F6%;R
MO^'8C^YYRR04;)<B/_03DO[HW][3HC/7OKK\!$(9>6'H3=--+5BYGWUC=MZ*
M?K=*6`^M3(=X[)MVC]:QN<[P_G[X!3B:A:TW#Q;+*QEKY!BP\,&(*/`<VSI#
M]_V_[A,F8GZI2$$Z+@.3E#RW_?CHDT=P-FQ&?702/==V0U@Q`]O,?LQ<U[ZX
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M_(:U;I44?OD`?]=,3_&-.+Q:'KI'SR<<R[%JK@[-#P]HK7,+FU\.NB._^(X!
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M7"[%>",*:F1(U%6PR529#27(D6,TI(^V`V1,Z56H1VBQ.B[:1)C#:+C#@QBD
M&)]U2"A/O9.*41.!)$M'.CQXC/;2$[SCDEO(*-PP@L66D#$ACH5&KQ'2U:4L
M)T30MRVFDD\0"0R]1/!&K\!#[,@!K4X;+H4>V:$-8DF2"L1R"=KZAUCY(SH6
MT#<&E#;0V'XBW"LQ8#X@J9DR-LG+S`8*EG.50%*D:(P")R:5UFM*FCD1(,,)
MO,(3$7W@T?)IAP?YQQU%V.Z<-"A,-.8)S:`U$\R^0)^5X7N[/F4"\N`/#^+7
MQUZZ-`D%02)ZRVCM1!0*YKM_Q!"F_XOAFQ,DL;GG,\:?/5+3\0S?HJK=6T*8
M9S/?>XH.3K`=&AZ5B@K]3$==#M<]8P)<_-\[^R72<?KQX<$LNK<M8#AYVI.9
M.MT4BOW$V',<[YFAY%]GD74:8!96P/#6H)T!/;CR//$B+08'Z;T2RGD"Q3Y*
M3FA00P)]CT'6T``L<@G1AG&]N;_PA4`-^S5&-IB?D;PE,#C]>A7@=]>BBT(8
MRS[K^_^_O7?M;1M)^D??&_!W('*2@P00%5%WS>P&D"5YQKM)[!-G=L[_O`EH
MB;(Y(Y%:4K3C_?2G+GVE*%FR+4=R_`#/3FR3S>[JJNKJNOQJZ@O]#_KCVD_"
M8$Z+#WB+KX.K<#@)!,UYRYSQ)/@>4E''+1XI(9Y-J)%PK\1[O%-&ZCRJ4<DM
M7!\1$Y0Q/!/%T7\S?Q*.PV"4_QN"48*VG:,"Y#]=LEY$[<6_0/Y4(/EDEW"E
MRZ*^ED.(T9%1X)`9.1G2QY'D0:4WF5!ES$4`]DH*B[_R(V9_RI>?^LG?P=RN
MKBB4)JL>1&3<8QX]E@MHGE\R6UBB<W)^ZAA'(.X7,_[A`3)^?(,T8E:>$.O"
MF>>+YEU(#KVR7@P;]U94Y4QN#P_.`[8QZM7ZV]&[=R4QRUF<IEAV`%LYC4&N
M:.E>Y8U<)UD(5!-U$48PJ^N8MGT6PWE-DP;2#2<^#H(_BJ5;-,)YXF9079:4
M+^>M;^D._&1AX1^H$;%#P'I1[&#GFOGA@;55GC'AQ1U[.PKP>*3IAT!)?XC5
M3%3D0`:7I$RS[)6]RCM5/S/GFLQKXADV+@0KP1A<+3$'T3-^#X(EMV^/*R?.
MLXN_@"3*`O$5CI0SDTCYRKHC"8)-F)-6!MF<A$-A:+$$T7X1IPB*CD)4*M%(
M<F`*K\Q1\H'0:6#^DA1W&D[#"5HX0-?4IYTJ.=D,Q:.!IM.JDBS4=1>!3'O.
MR3W8MT(O2(G+Z85+QEI%X<$.)0YR`MK,5TD@K*X9H3N0;E(/2R,,;3,'GX(3
M+XFGK(Y1&>`L60_L+XMT4Y+H?-E:2:E:+&C*P`1!=&L@I2^3_''Q[7:M5*M5
M86N+=XWN%*:5:FJU1:UK:WFQM7U=;T<[55QF5V(6E7IJ%(YT@63A4HIG#,H9
M]8BMT5/@/+!GEN@D(3T\BEJ!/C'2I^62/2W&.F?JBYTW-$1Z!\]89@=>L2)@
M(VF8KF`84G)I-H6]I-IBVN(?82GN98+(VJZJ)\OU+`C5$E^1F&]K@C]Z=<5)
M$-VB)(@SL[R(J&+_7>7EV&_=(S=G_ZBGOE=(N2_%Z2.]HO21KV"=/E=R+2GO
M.U'E?6H>_[E':=]CA9WNG0-]Y$_P(E%:I^+LAX4=MO31E_6\K.=9Y:Y_'!R#
M?=29Z<AV7:3&+"_QV^&<AHK,:?!^MIR&BLII^!ES62I//9>?EP9/D_:WH)^L
MG/B7<M.79;P8%OMA6`C!10?QB]B^+.-%;)]`;!_EZ#6<#KJXT!;KXS@9!^'J
M6\*S*V)_`0!X_K3[<?`2/V)ZNS27G235#X!/6>9EW00[8._5Q?W\.'NF<E<Y
M?.Y+N(W=0#^C_FB7.YRM\NPHM:$/\8=!'?VL@#TOMYV7]>S]>IZZP/$_08H9
MBZ+$)!B*A&',4]PE6M_'9MDVZ]RKY.V9%"#>YY3?O?W82UA03-A;ZP+SXYB#
M\W+WFC5>1'6W]F-KHOH49<+XF6WDSJ]*G/>O_7!"R;V8CCS.YEDBRH9RY0F'
M!UR6RP=_K=3F@W:/BPHP*Q`6/96-ER[]A$`C<T5<*Y'>JUCL@4707$WX0ZKX
M]C(W^RZTJM5*8_LO%.B,A8Q3K[($:$L4^N@OG*Z&QMN-Y3377<U@-;C:HR!9
MW?/"LC86VA<_NC3@N\Q6%D%ADCD7V>SN[BU;J&C:,5F&U*@^[,_MAX2FTP^`
MRK.?6.81WVV"/#$FX[,AQBK,N[U:<Y%$F'B1+Q*Q!A,LZL:M'07[`6I8_ZES
M@.O[G_O]2"2X7V!K-TCPPOH/V/>-O5F[0H![[GIMV[N^TO_R?A1>XT^Z>?K:
M?<_M=NFG\ZL@^:B;"&^O47KSJ'=<P4;I-:]S[-8'O:K;KC6:KE=I]VJ#6L<[
M:A\5-DH?P^<W\128;H=UW_T5\0(NPT@X*(RA+O"?380X"`A9PNE*3!7:!_KS
M4J_'`S]_MPOH81_HDDL+FVF+M6F\F"28)4$:$!;0Z)J:X,(0HT`BLX@R?T(M
MZ<[0^^-\"D;AT)\XW32-AP3JY+P52R#,F>ZGKOY1PE6E,"*G&Z5@<R4!S26.
MG!'</1"T)(HC-T1##B%!+N!@D?W`\=DL2H,AL.JH[,#@3HA#("H/`E-AD@KU
M\M5KRN'DX"@*L<>Y\E/X&*(;@-TGG(/P0(C=C!'EX#HH.Y]CH$$$5J$`B$L"
M_I>!^Q-\#],Y@E',;["5=_?3)QH&IK?@*ER4X36$T9;>S\&\YZ=79XP<-3JZ
M_2,-1B?128212:!4%R=.0]U?B+,HY+?"-*Y7O=:W/\[[KV!_AN'4GZ3D$[/D
MO'-<;7<&E9;;K@\Z(.?=OML^[C3=^E&SUFA4^L='[6.0\ZKWZH/7:%4J#;W^
M]9=CD^%3&,4):+P3P2AG!!1S$@V3P$^#?L#_?3H2-/J50:?N==QNO0<+KPWJ
M;K?K]=RC]F!0Z7;[K;;7_M8&9?BM`]^LM%]]<&$BU4Y%DV*])=EDR/_U).H.
MAR3A7X)A$%Z3HW37^,`#/JA76M5J72]^G84L+#V>!E_][T%ZYH>CG5MEK?KJ
M0[5>J5AK-&>\FJ&W=RKWO4&UWSKJN]U*;^#6V[66>]0XZKB=>J73;-:.^IUN
MM?!4OD<#Z<?O1NW5C3-2_>LSG!F$_`#'$AX7DHIK'-A[$+412O"6T-0(I"UR
MA\9JU6DI`7;@))I<!^X4GKF"$W()U`Z>F2%EN>0!(M<.ZO!_R]5&&&TYOM-^
MI/".;(4A:DLJY5H8W2ODLYUVRVW1;ODH`-,-';'25L*0&VQ3OKG;?C1>;HC6
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M]6N#CN0^TI2\W7^OXVGD,%Z^UY!M-$RW'(5M"3L:(;EQZ0@RCVJ^*QUN`@'V
MWWX4Q/!F5T#/.Q\_]IRW_X8I.L<)'`AA^DYD\<&9`]_[E)3E'Q#1>N@+-.E"
MR-+!]V"8$9[Z?Q`P_`RT%N(HSTO.49:&49#"&'V0^TD\8V\@;-/Y/`&9N+PM
M.W^HY$'$PE;PS6H%)9S,X8&8#7H9L0=)$*7LLH3AG$2X+%^W"7,9^T70%:X,
M]UD';R.$S7QX8*S*2<@]`B/4&GFD9@WU+C+\!*:V!9BNYB=]GP@I/Y^(I$<Q
MIORV/['QX\6G&%5W'"8ICY(&(.98.Q&%"#F-&/@%]%#P]Z/<1,*40((94ARI
MPWCNLFN(F)3\?,GQ)S&P"O&'30,#Z-TD&0-G.]Q(Q+X;,V\:/5?DPW#O3D;.
M?^$AF);`KE7-8?A&7>F4G1RCR\X0"P2Y%>0@O,H%9B]9T[WQ]4K\R-R+'"46
M/^^M.1(L(<<]YJH7I^U<!&/$LJ<>!7&$O%"TCN6ILKNOK\Z#V3S`M!GN\5%I
ME_)!CT\J+E#"QAUEA*<&_4&T!;ZB]AFYJ`'QZ+_""0P[=T[2U`]A@\K]<HDP
ML$4SB#1(KD,.CJ0PC2B,DYQ"8GGP38$94Y<-)2.P)V:C'/JN@I:GA]-L.,2V
M!->!>EB@K:>&+H,Y:*;L`RO1I/-JP@=Y15&=."F8Y0G'620TO&2X=8#+:PMH
M\R9\N*VM+41S:BRTI)\0-=X1,@+'0A"QIK,C0R%-S!_!+!6.OM+/U)!@1K#G
M7XUWY,HT7>3\52IUY(`9Q6S4X:O)BOSQ'1>*P7@<4%0L=^E2&?;G8.FE5\[G
M\`HO9R&IFR1P@XFLGF.(_C7;Y-"A!VHS"HS675=XC@L!D2VL5'`/#"='=J$I
M/?!M5)MJ(99]LIPC,;7>7(*IT-D<L5KTD#F@O@$C7P3&%(A)K5FHD]Y?UL0%
M/UXO$B%-\UF<PDS-IES$T^HLOPDG$RIR9,MC<FM;)M[[6E/;)5;#AL,#[I.%
M#3M8D:P1_MSL]K!6)/24H[D['0GU6J\^N+5VH]ZX.Q1:L!Z;#MUIG,S#_Y&:
M.AWW@PNZ:F/L#`Z,:9A-=V[YL/JV>>6\<P6Y6S989NC\.1T3`P/CR$9QQW%R
M+D[/TZ0W\</I[NU]`X/@N<#@)@LJBH)^C-,4+^DL0!DPRZG*:3@B4\V(/>8=
M,_`Y>Q3.)?H4S*\P_(S*@*^EN^:70=^%V_+JC6HK'V1]$H+<%8H'YIWYX6CP
M':V('0S#`R=6J\UF>U44WEZ#O>)^8/0)VS7F0#&K-MH=O3ASNO9"SGPRU-.O
ML62%<QTPV#T-4B458B>/K%["NDDC,`JZ=4$`X#<)7'^-S*2=(X/7?/6A56G5
MO'6R2%:M;'4BAAP3%0&I9ZFM=S:YJ(4NW7JUU5SNC%^ZJ#RG\.-/KL+6%/(.
MK+3F-6J6^]J:LKV>\^PB#?Z;@:`,KDE:'MDO#2=1'1BT#Z=2#3:J6X<MZQX-
MW.91KS'P>MU>O=O8L=0:[9=NPW5$$\AA"CV'!!K12XT]8RUY6T5_`?HPC):)
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M:J71ZGM'E=;.1AFK9>><NNB1R]X@FZ/IYDC"[7^`4:W[+`FC83B;R.;SLBH`
M%,+^K_(T2QRKT&$<1AC90<?[''[!UW3N$,UQ3E]J;CP`<_&+W^%N`%R0BN@%
M.<7GU/\;FZS&-]C--X5#(QR%%,&#`3Y]*CDEISL!=H(__A[XD_G5$-WJOR5Q
M-LO5?OQ^8M5^T`?.>KU/C@]#W023"?I<05V/,0Q!\2PYLUZ<S&)9DL'E%[)W
M+(;Z7(QI'!X4U66DNC^VT_WT.WWS8_=C#Z0!5`I3*85#^SIP)OY-BD>R3TUW
MK\*+<.Y<B#@O6P8A;D>:@=$`$V7BP0Q+7#<SPWKX<$B-N*<X;WBQ))JF4__F
MJ]L4?NF+B`<_C1$S]2@'*V@`D;3&_M2IH`(J6NX$?'%K#O<6DU[9$P_[]'<$
M.T4DY7:G3+E`?Q'$0'[T'79JA[5=^I><'N<,@V3N4\MF]#=="AIRN$A]41-A
M'`0N-0Y&]4$.^AZV&8^3*/1+N*D.*W&J&4(D@3FC">AM,ZMI)*J`^"`YUN_D
M!^E*IQ;U/OR#&96,(_'QD4VP$G$!O\7[@U20'Z=OP_IU5#6_<QR5NXI3,@!#
M3"<4+CDK4%;(CAA+5D/@-&"&%";@ANA@(?(2[=<Q5#R:`N52S"Z@!N_BBT;_
M=RW\YLOX@(;X26]3T`KP%K?&A;=*3A*F?SOVUW#Y]N>R&1!<Q!F+Y8QD2$<<
M1:`1F*U:$4V9LXC[AZLP/FY+$&+!DS,#*_J6HB!#/TL#$8,H_A+NM)$/@*GA
MHB+-9!:P[PNY)?@^#$"%BC#^$*..U/@7;;XHN`15%B#P]>'!./&S$0E(3%,,
M0<@N83AB4/A@EM(?+_SH[R2;S8=TL"JML+=1O:]7H+HO2?J6[#2R8PPG#V4_
M(U&OPIDAL:E1A:IZEJ\AQ0&Q$);/`4-3'-K/YE?DI1!Q)5M$E#Z$:?Z-_"^S
ML>7-"E1,3*FA4HD;=7TKYH7!/#VQ,MD,?$^:W-(TC1.7!DDX]4]!@^(]3:73
MW'V>T>EAMBKGM`&*,8M!"O<![J1`$+HA#L6U4991L@Q;W9E)/"^P'C&8A%+^
MPLA8##RVMTR[DA)VFVHZ)TP2T&G[#&B@3-[/N:SW#6J?=GR)^94I]XA1JHSR
M@F<5*@84)@K5.&368;0?#PY_SG4"='3887\^X9;5#2`>$EA4(Q:=>"WKVYX:
MYK@%KJ]K2.0$2=)C.(RDI2D,%*$60=GQ<8<1?EJ,_(/OF#/54U"T(0F`-W)\
M[E"N('P<$QDHV0&>SB:4,U!DDV%FG)'U(/6],6-!.Y\`%%ES"6^#&$#:/9DP
M\'R54V!\$$Q*T\SB;#F9`#4*TB%L'<[X`LX$MN1@\FB/<F9='&&*PNBO3`8I
M5]6!4.H?^=LH/X%N-\+;"5-0EHQ-MYLXFXS$88./"0MF*/R!]!U5A1(GG*@Z
M2OP;?Y)*0R4_(31_D(+[*IA*]_S!YM0@G8=3O%KMO\Y!GB9W+)_7N+HEMVS<
M>C2U96'FX0&8DF!QX.T9[MV8/SB2%W#:=.V:$(*8FH*`C`N6#<B7)*;@]C2;
MRM0Y5`0^I6$)2P0U'WYEJF_Y\$(@K+:)$;W#GT<JI0:7-939-G-'OW-X8+TT
MMRP5SO(M(`;KG`#UY<*,I+V46@:3,\H(UT$O@R["2Q*']H5YMBUNQWZ8.-3&
M'0E[K+;B)(*K6S9=,V"SXT1$+Y<A-GA)--;]*?"1@=5%6:>)P:BC8(RF/USF
M\(5K>L%G&P&N&5?HX1"YH7RFDFJ_"'1J':?1"B'"ZQZ%9=!F0)MR3-EN4D!N
MG;>4<QK.><QWXI))Z'`HZ9B'BYER>"@CH,H<1#W.4G$95\7:ZEMZ8/+(@.X!
MTR,!;6(8M`IF1`Q")PE^BX1-?']JT`AE%T]J2G"=A4.X5J4QZABPAL+T"L72
MT=0Z/+@*084EPZM;89`H536<P$3)B<SS@)OT"+\87^!Y3;85Z8\L,GX31K.,
M?(HX8YH5;:GZ'ML0Q=\';84,D/$LY;I-?:CF((@!:_4/#]XN?)]]CRK@9V=M
MLOM,#0KO%ZR`D6L</3E1.R]NEG!'<R98&;("#GG'I>XC3A]3P1U-GOJOSO^3
MQ:C.);<1)"Q949P)S+^G?-;#`\I-IPNO.$\,GH;39&\5$I-F?A/;I#EAWF9O
M$>B3B%F`:"CXG@_L!+T<;#5R=N^$/)!AI']2_/8KLNJ>$XK$P2+5'P4Z8<25
M5.C9IXBV,GM0]5EVC^GRU6\)TUH9#RJ:CTHH"<83MI+PCK5H0Q6H3W$:H#=R
M7^G?%Y=&I`:3;(C%:3%59!2=,V,P5E.)*D)'A]9P2O&G1O#PKVQT.545**I^
M#W4W6:PAWOLL%2X/9W;6BP(J^W6-R,77;0P/B?Q7P1L3)8'"CZL^4=Z^3?<4
M-XXAK)?"1G0*TJDR]-,K!BS#?^!FP-\XI@#V@`@GD/(A-X7`2%K\*_`XI;[!
M03^#6_9W$C(D(IRY^N#%RW:FO"/I%<@43!:N]GP14-?[4%N:>RLF2\QIF7.]
M?0M:?C^WTFU^TY0W%12F!A@)QO1DOP<E=U0B)DM(T"5B%%N!YN5:SY&E;P)Q
M$%I,(M6(OE>B.1OXY*W1!AQY\51]FA!R,1FC!BTM.[_).W:)K<JY50F'16?B
MBZ*U!]TI*2*&*9LQ&+V7,B8@/@L:*8\3^-8XU$DMAC+GD^[-3`NF3KA89A3%
M,O`J"]+>D6.(KR'Y$C5%<E'V.@Z_(TT215WN:P0O1SR$>@'/0Z(E>_3RMWWE
MN^1;?$AZ8L(!/OM^A#/UR=:79ZFXASLG8W,G)%ZC\DV*JB7V:;KRAD`^0\4!
M/'4FHS5U/;^4`XD"LR^T:ESQ`N8BD=G?)NK`T0L*AT8ZBYEO1Z)>9&]UTE+Y
MU.S!:1TB1Q%X[CJ`O4*#"K@&];<22Y".>$B95%*NAD$PHFU6?.Q/8_%G8R3@
M<[5OTJ<C9%Y-PQ394`8%!4<='O!94A*7;MADXE$XMU/VJ-FZ(8RNX\DUUG<?
M2^0Q9/$0P]Q4U4J<,\X2MITUVYG*!JLK1T@77DC*@32R]@CADUAK#O?.%"Z_
MA9=.*?V&)!J>_QQW4I7H,NX4?F[4ET7<*56.QI&:[[$3V,@5MAWP3K&BR^LN
MD\:+?D;VUI35J:SN4HZA9C#MQ5![):%77.$`H8$+-1L;5O2)%+F>79N&4DP,
M[ZKX<V'-IW*"TC&I(\Y[NZL&($F$_13$>O;?K=C7#F>&1Q0UK((ABC$2+9P2
MN-GX(W&]G?I_8?(*<'T\I6QP<=^2T2`$Y*B_*3E>ZPWQ6JO<?$,L(KSA9:>;
M1ZXR/CB/YP2UH:QZE360@MBHKSIF@[+77IU2STO.ZW:G5.ETZ+NOZUZI`[_$
M#Z<SF36VU]RY([SA/8@WFF]P$.8-K[H.:W@/88U6I=2LM8$UO&:KU)*\T6Z7
M&NT?P!M%_]JR-J,B)_>(C)>>@>NP_WI-+7%`N8W`?[16YU3V.R24HN>Z>LP$
MHIN8RX;I3-1!4J1>$,3*FKQD:P*O/.+/$D(AEMY&>3FYC,+_Z>._,/`IK6&Z
MF=D.%;(R$7$DH/Q%QVZR*+%#=!A4X"<4GT-H(2<K7BX$,[(5AVWO<NHL6\G^
M#6)OW*`Q)9VPTBF++QXA&*%[/KR**:N>WT&K#A^8QJ-@HN._"D'8]+GN;4PD
M/RQG$.6P@1>P@\6G+RAZYTJ$8A.K^"8<S:]^<3JM-[\Z]Z@5T5";='$;^A/7
MQY3\I1BV:P%;BB6Y/,:ZZ*=FJRTQ$%;>R`EQ1ZY?'4$,.?:1C6#ZB'4PY4H#
MY)7^^:NS.!/QI?\#TF*T/T2I>6P66F\BRQJL/?U,%&JJ643X:)RR!"JVF'^!
M78`]+A,P8$8H/W&RB"E<B!HKY*K=8K!HV>7-$8W=*/7=18>GF>$GV[H4KU4,
MN0F&MGK%IO9FH,YRD$IN%`/@N=QYP"3>//X6_8DHOX7[4CB#?H@)?W!PW(;!
M9%2PE+5I=7\J%U-V%5[R4Q%S+7XOG,Q_8O3(B?`>(4D)CPJF7C%DE!G-7X(0
M93K\=VEOVKNP.8N<7JAN)G"?VB7:>7`4W-FI;]./KM<S?L\,O<="S!,2YUQK
MF0QM%SIBTH&,4M:,\=1*Y,-4P;;ID`$F=6685VF,A^E0E%8JK7I+#3BR8"M_
MJZ`T374WDN5;U#$>8_S\87V4DE<?(Q4"/=)*)U`?@[F-LXF#/8.EQI'?S5/D
MC_(Y?",A%^XMW(KP>,`<@6L*#06<_BH\QK`N4<_E[WGP1]^\;O)ZQ+ZY%5\"
M.32X_`8)_XMPC*\1$1-^*O`QL0E(NZ\NC7A]]:W$@<FM\[K:*%6\!KN0&O52
MK=[.N9!*M,7DJ,HBXR9M`FH2@H55PX5)\HBMA67'QHU>LJ+]MEFO*JH'5>]J
M^Z,BXQ@Y9M'9BD"F2AYBA(@V;_[&_7H<IBA2DL#YH6I;X[T]9>ESR]M!!;@Z
MND;`RO.8RB*4DP8#;3;B*N4@B%H0$6G6B-$Y],Y$U;J++%YBGL.#;!8O!'>$
M_E%#JT%%0JX612.H:6LM1T=FA7LWN*:B$$S0=:8QA:F`5[`_H(Y;VCI;,1K&
MM@0C(J-2\2,%;MG[C,G`[$&V9HU+EC/'7I66*RA=T`+E(ODNCFDI(`Y1(J1C
MSX<'KZN=4JU68^%O54M>`Z3(EGVD/A6\8-X2G56NV`Q+@L>&0TNSQ)!AI'U5
M>,H)3A:G[*V>?X+<`:(D5C;?R`05("I2/!W?6BY(4R9UE_,%KZ7<(?G`@M-1
M<)IR9>CV8K"_R&A[O5OD&S_R,76`BPTF%+X9^`D>-*ES!J)*0'O[[TGG549P
M+YQ@;3R"_#)D-G8J\"?#;)+S"^?M%)#2C)"N05,N01]>BM\M%`"C.&1SE8\F
MF,V70!5")Y9DLP)C8A>8;@K:D(PAM0R1);Q@4RV9ZCI8XWJN3L%4L311U3$I
MAKD'60\/%N<JYD%`$O$<$YZIVFR$7\$D'"LUK9"2^EPI&=_T4S<<RTP@3/<G
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M\V_CQ`ZYXXTFHB0Y3(E,8SQ.&!LE$46#_%-(6)J7B3\5ATL(EX%$8.TBSX?R
MU%F<@L1G$@_,0`8$:DK!NNSTXXBZ*,@V3'0>TO"F:X#4$N-N/7ZL\$=H<(G.
MA73!.V7`Z<;*K'"&L$LA6RUH'F%%ZB(ERT87'"ST#H.;5&053V>Q@+Q`EA&O
MFJ4JHBC3G]S^S_9;7OAPRP@N,'5<YC,1*(.1CJC_(N=Y`T?0%>'^E)0NQ*Y+
M\12L6C!0HI$H+!-9GY2X+\<062/(-:";&/A+%C4Q0XQ`>?O#6PG1DP:*;&50
M&H*`%EMIV4&+S<$;,E91R3))LY`VW-\33JG0LP1/'JZ_(XN(>J0]C0I/G/?\
M4_$D&/I$IQJ3YY'P$"0BO#3`V8N*,&AH@[O.!!A*FK/*+6/FR`BG]K5Q@=#.
M$%$&BY!2XH/2W0GBD$V%Y3\R4?3C2`$X),&<L%JP$B0$O4D>\K'@L6E,U>H2
M2DI))HO4+<U"=..Z)"%'`XLEF5*H269X<)"'Y))U7$C`JV6^!,&])1'98_%X
M?N.+9'Z39D22&KL!RLYQ!I=B`H,AC7H<?I]3X5_A6VWYUB=_B&*;Y/>,$L07
M7FN(U[9KHF`R>SB^?7(98N!;AYI2[+]!L;2DA=G,F>,RQ254E:>:L"7`QA1Y
MP%0U40&,]EBJD!.$!U6YLTS<`TRH'07C($$9@D_)FG0.*BBW\"3\.YB$5W$\
M8J@2X(#_J7L;O(8A@2@8AXSXPB5EDG5UQ\>"N3MRZB5['CG/K5H+>@APFAS?
M8G423!$V#H-@HQ!^G00$<2:1$.9FW:B!MU(,`,/N=)W$:%1$9`EJ%X7BHL;*
M4C$_WC!0CC`_^3085@Z?D$1]92B'J;TV<^U*MX5C4>!#GG+:@UNNMB.@1ZXT
M1>1*[D<EBN?!'*-*0M%\<&ZY/1V)[L5[*"M<Y>Z5V+F/L%AB$V&"&:CI"Q66
MS2+A9-K;P[A+'*3L+G'LB6`687X)<C!LEMH%$[87=P2+:JPM,8%\N1"'W#[F
MQQ262HJX^52E12@FS-3??1E$+DDLL-SOX54&28*#:\K'40RG)/9(H_"HYC5D
M\86%^EAEYJ;S8,;U;JF(4U-%')KW\`?N\:?",:J*3+.BR^MV<=TNLR*A!1#O
MZJ4B3UHK)75B+5+??J11$$\R-7V*_@A38#8+$"F,ZO+GJCC5C(AC$'YX%9%M
M#-9J*%%'$+E8S(D7*]J,&HL5&A%+TBR*T<O3(!``>DO6CNW\X@E'1C79C`L2
M3$-R%%^15J1-BSN6Q+)<V$&S9HLT,YHE:#?)3RE5[`AT/^>2BE]%G6Z#&N;B
M'4$J%)H=A[%()<AP(!I&E`X!NF@^"02>@3$=46PVPPM-G*43S*0*)R)$C%1;
M3C3S2-($A/]EZ>":MSR%L&C3P*)3<3]'A_WT6%B<""9I&=N!RND9@\X7UQ'%
MA+],T-(\=QBA:/)#X"WXMJ_G"]+B+IDQ[*>><N&Y<L<R8%Z@:.3$<$$!7`95
M^;("-`11RN@$T<D"#`8N;FUT)],VQ6*-H/E'&62U>@#++SP#,(EMFZBB[STZ
MRB2?[[^E*A=E.KDDCJ6(]"#R.5@=KNP>JFJUQ+L($:`OF8*[\A)@Q>[1)8'X
MFF7G-$M4\1?;3P(^#$,[,(1UU=,H"3#)*X7`3]IU/*8(E)$R(=U@,BE+OX#)
MH<(T%/DSLGTI6$03MLFUR!%H.%&%H>=U$^$K`ZX3T1>NT:5]<:M\*^(85G4A
M=%:GNC4%KTDLF"=!]$>T5343$YP>IW45WY#!;!!-:RFV=+'`96\-N9YF/KE$
M`U=6_HKA)LD103<1C:>O4T8,^'F%:V]@PQC\H/BG$!!>\A3P4!*`_<S[[ZMO
M9L2M47`9S^FZ#IL0!`2FS2C[25[$#/>88CG#[($#*&%4[:(IZHY+`B%[Y`*S
MXSMX&'*6HA;,B/D4L=_31:.8DC#Q:R25-W'R-P>3D0'I@\)M*%9"G8F["@$`
M$UZ&^452-J8(YF#'X6PV8S.#SD=^A@1:.:W1%J6L"T(P8:!?(J&E=-2'#($@
MD,+%'1Z!DHCQYFAJ`[):!"8Y+0WI)QV34B'<ZEW36DG>4JVE2/%<06"PV<S4
M3C0A-=P(`J#!O#.)H@M?Q*XULE06%THOF,"JLG^`V4C9%Y@I$EUXA(56B3(<
M$R0EJ*60G<[\6\,-P(8G_5'U/.96N[>J\P7&%Y!%B&K8`T0H5@=U,2/=:=7(
M47[Z"\<M$F$Z^@X*U32;J@]H@TBLO(A7S#)#O0Y+)R:(LLPR:$ND0).)-/AR
MZ?!`H'`Q#)T?1;0#(A=!N:15C%>&'>6G$5V3Y,`0=\K,]6G^!-2FYE:P+,55
M:;[2TM>ZS3Y!">F'AYZ*.$(A$`VO5O@Q$G83V/00`$`".T)`8\DL$14/R)1G
M1W$L^YND:]?`),IK@YM`'-I`<@.8G#LH"/V0,D:(FIAS$4>9J.0V^4CAD@I]
M-!/-YT3,*B-D"W4$&H"^RK]E'-BT"!6G`\D42I=.Z#1PK%VAZX!@`$RB]9,H
M3UD&5R_>/L1NI=89S%KIE;4LLE?0[QM<,^N@>S`9D?](`HV;^V8SNS0\M&[;
MVW/^N-BJ+#KLQ0[D3GHZW=1)CSO*Z09,;&DPZHX4%):+V#\J//_",ZC.!7E>
M2/M4\E[.(!;9F,"&NE^.Z1+-GUWF%I;D9%$"A8%J)?OJ\YUQK%`(5)".VR_)
M]P2P5I@XN2!T0#&))02F0TK`NX`A28:&Q7#2GYF*9*M).+Q5.#ZB%X<V?/5\
MD\"*&@N,?4((`B$8D_N:@C3LP)22)/`J68@LRW9Y\7EY.?_81LZ2VPCY`0JO
M))0S*LT"16G>BU$VQ"&GR"]4#\#L8P?&0CCTAG-G.5'M=CRX@XC3J3X%!A"?
M.KD=A>$X)TX4H>A+*.V@2;BWW.)'\#AG%Q5/YIW(("!U*L[S$/%)9T@.1FVB
MO\ECSR<&G=%T0`H"H5U%'S"4,O@HL;0JAK?M!5&0'R=8>(]_QS1$TFCB371^
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MQ=,+$5^`5?2M7@[GVKY.;G%;$"]DZN.*-->CT!6.1M2DCRU,D:I&<$K67"6D
MD;J&#>'"I55+$EP*Q08/.&.>B=4V2^;/&QTI!&RGMO%D'R^J&U%S9<WOPV,C
MU8B#RF=@LN+0DNU_,$XTR\#@'U(S&[QN*;.*[V7LW"@Z7'GGQ5OL#L<H+,U6
M=)TI7)!$KZ,9!R,%2HU^!NRSQADFJD69L3)4D31O"GLE=J6%S&AB?S5"3:FG
M?/71BP`8.A+GB4S"\A.9R:?N>K)-APGTF2,J-PGX/E,@D.:U%#:5'76^!?`\
M5SX/H#MW[IGIBX?J%*33]TBMHGZ%>^6DA#5#">::)Q;C6-B"$C`=;@\%/9V*
MJ*IA,T.)O<AF'QEMXA-%.[E($C3M*#A/]S]X6Q<]6?QJ?EY@>*KXA]$)"MB)
M\#`)B!;W9CP7IO/"/@I83[ZH+W1+,9\W1E**S&M0?G&EC&4KU"U)5`!A)&F&
M%^CY/%^;YDM=#T(E%(!=#9E08`:W;KK(3MP&TO,H]B*+/&4W33?/.<(`7)+7
M;%!,[HF</_9?-.<7COA**OID2<Y2UN@*&$>SKQ?P=I&UO:]GVK9R#8#R^L1J
MEQQU8)V`DH@N0\*FL[H`_!;'HQMY13W%VT_)^9.P@4&?G(G&J.<8O*Y*SE>O
MG,"FA0G9BU\Q*(AB]46QW1\1`<^3+?;_!2#7\-?/P26K]Y[,D>FR[VB-TZYM
MG\Q8`RVJ?L*<A;#L.&("3<%*A^.(UN3)-5W*-85Z37.Y)D.ZL?VZ**+XGUA3
M)->4S_MA?#"^1>6'*.G.)U83.!3'0J++"8+]G9OA77D[E"Q1^'KP';W^U#*X
M"#6\>%069S[,C9G$FH0\K+E"$;J6OBN,@RBL8)'"R"T+A/?`&8;),)MBG11Y
MR75?H,),&'$#9BUHE13[1N@;Z0YJ&6Y_W!$AMUTK;1CKG.$B*J/X7"7&D^I=
MQ%Q`!A#/J6,!3LNU3P1:HWTHJ)JX@E.AK2(#PJ>,U:"XT$_8G4'!"CR#(E!U
M#3IA1?`#;D$_)DEUY5=A?!Q6?D+@XUP@O-LK/@LL=2FJSH^[YT?JPG29A>SY
MI1-]C#DY2-2W$?_CW9)\1N!=T8>28P&F6E-V^D4,RI,=0>;U'X="7Y'Q.QCD
M(L[F_(:)4;[04#8`0B@?!D]8-?XRT:"-:X5*<Q(U+4L')[_+7^2YC2DG5C4V
M2,-IB$$M_#WL3XJB)BADA5LX6P[+OQ5=$5K`U"?2D)2Z0YN/I"9T);<%;8';
M3&?FGX$SBDE-L*-3U$?$AJW/^.G75"[^6[=[AK/.&V4"QR7FOJI&EIA*:7L>
MXJ,]"^?8$7*Y)`!QB%89^PJ`,.J4H]@A^A*-<VYN8%&,Y4'.OD90Q2`COBI!
M2%-.DQ)YLRK2)XWY!62,W$%VPZTG@I3K">2L*#-8'<NJ5\2RKV,!#P7$Q8%^
MAQU1<,":%PV:6"C\NO0F&DMV&YW<'=ZG>(.P>,1,\6\\594^NLP\`]$BF_4&
MV%I`,=_UBCQ/I6XBZ203S)`-F4UJRZAYY-]]DGLBJS:PCW/C'%=2*S&9"L76
M64]JX>*>$UNEXDH*,X2@BG0#]L2(@.RU-6">=_AO=^R#:K[]9?5X\C3\5Q8%
M;!(M*@#S)+3\[5SY#[\"04S)^R`J=9P%9:]:G:>6WTAL,T6D4(1@!\DHMH:5
M>9)T2@D?&04+5;S&[G9@5-)Q!Y@R-2(-_)%ID$O^MNX=O#K5%L\7L>L,VV-:
MAR@?TVI:!;.6Q."6>G:SD8N,H]C!D/$1S`QD03K#`-GPH%12>'@@Q9#N-ZL-
M'O*-84D$=@<=2UP+//822Q+EK*S#M^P\D`.+#F],]KJ7&A"'M^DOL0]O.>U]
M%7?8S$_^[;K'M=G%U*A$DKYR0S*+JGD(]8Y&I-R.$[S@L0\1R*HC$-KGH:,+
M;T^.OYR_DYI79&1Q@@GFVJ$D46-<58UK-CJA;`%"#<D[X.T^LE2V8+609H/9
M&$LNQ5@%3`QD8F[ZDUDQF8YC.N_T,,97,8HHV[[DH<G-MH16Q]:WW(:R]DYT
MFMS@U!4"7W##1NNI6/H=+?QWF<;<W&@SZ2HRC>]WR+X?A=?XTS_>9ZE[Z?NS
M7\XU"?5U]@QS'>!:]16,Y:-)//S[P^&!X_Q#OM/%VYCVQO5$?!WU-[SP)1C_
M\U403[Z=#9I>HUYS7=>K>A7WWY5*Q?MV_K7_K=9L?$.T"[A8>-\JK\B0H[?"
M-*Y7O=:W/\[[KX!?A[#9DY0`U<,1_'7TK5KSVIUOG>-JNS.HM-QV?=!QZX-N
MWVT?=YIN_:A9:S0J_>.C]O$W[UOGU0?X+OR?7FWQS.W5$6P==TXXF_C10%0+
M[-KJFK"Z3JU6,[:R<.+VXLY$;X2O<7=(HB[+I?&->3<:Z>K;75NP!_O9JE8:
M>L'K+\8FPF>*0IV.3[78W'NQUDH&5=B0%DR],1@<N_7>4=<]J@P&;N^X=MSM
M](Z/6M7>-WSM`PHCR*(\HXY//W_=L`.`.M\^=;_\=O)9G%JS[[\Z&PVFG%N(
M#GB:7/J1+'ZELF^=I-_#-J!#.P`N]<0:_JZ'S7*M@_YAG^C.,%5'PI!,G-_C
M"7HQX9F3:%C.A0GH6:LBDEV@:I[TV$*8"0,)5/PP`0/92&(G8"^9"!Y27961
M;$]!$%'F]C%.G2Y8W-3EM0</PY$5A3Z>CGX9YFP,00DI6*R'X47>6,I.0Q1K
M<2K)]!Z&)^(T`I6`)1K0PP$J\I9D<KA,B(9UR#GC\M._X3S%7+HL81P%];P`
M:AO'PTSD[_"ZX:D2''F1?RGSF(9QC$D#RC%!;O/`H@XNPD!VH9UPBC=--F-C
M8%%?I>A,-5[)%;\@L&5$U@!/E`%/U/06"V_$C`1&K2+W_"K!*#]\[P9&QT!U
M?(-I`%@J!VL&<7*-"1B@-KFU:%25$MJ""SSXZ9/-6$B_LVP"9AQ*K!+7'A+P
MCK'.>CU[,+P:\2K@,SPR/)+K=L6K`,*.Q[#/_EP2`3Z*6.FS5*>(%$`('1[P
M>F&Y)M^F^57^3I\W^-[YF,%V]"B[Z_#`>OIC]V,OMPYS_L).XN1KYTQ52IQA
M0B!(&PB_WAC5!_;L[-,[R<)"&E68'^5%LK(D"/MJC9*+Q0^)P;',$8;OO>.4
M7NOSYR*=LZO[WMYMS"T>;/;!=RJ!P1AEXF.</J'55J\?=;J]9M\]&C0\MUYI
M'+OM3K/F5@?'_6:_46_W:G4X'%NO/KAU#\Y1XZ`OF'=N8>@3^!Q'L?W@SBW.
M\\!J:]>KQM**9YZSVI;9-3H#3)GJCV3*=.NPDE;-<YN->@\VI%%S.X-6SZW5
MCZO=:GW0;G>ZA:;,/9H9/7:<KE/6!HGSP]&)MNVA6`)X)&_^(Y5!)%.1G[X7
MUR,WS8)+W4O7++-KUK(64AH52[5V>LPE[-?ZO<==PI.VLVK593LKL"&?NEG5
MZS7>7=ZCJEYJ--L/^/IF2_@)5KVEUD4*[ZU@UFL3]=';%=5*G96*:_,//I^U
M;%<#X;\EZM].D1$F6ZFMZGNW3SSQZ(MYZA9^-G9C8)G5.T+DEE=J-&K/@V$:
ME5+;:^P2O]R_2Z$%%HIU^X05NE/4+M4JS^3T<7>)9];7,;\ZRTSSCX&?!NB^
MI1SS)+XV4F^W<,E9?0]98L4MW(D?/K;>T<.#=LGKK#(R"Q;\$"/[V=%OE4P\
M"NU^C'+5,H,__>)TQ#[]1DG0IKOH\&"PBP=VM=$N-5K/1/%6J_52K59_1NHW
MSU^5<K411D(I8ZWN,FCSGTFWO*UZ8#ULZG1:,M=W/Q?E*M52J[XMRNV,3EZ4
MK6JY(3;O,^+1K`A8K$<6/=Z]--\2YRN-ZHSB[&(BE<@J7]G"-J\_;+U6JC97
M\<'=ZFI#$CPW"E;AZMO9Y.I[3PH^BP[@?;,+AP0)IH[)7K74:'>XX:GGH=6M
M:A[G-\'D6J`&RFK\Q<ZKHAVF;KQJMDM=(["_20#8#AUS./FK_UVD`QX)_.R=
MBXS77WUHM+V.7O.2F=O+P^YJ0`_\C]&"[XRV`0;`IH1!/^#_[EQ&8Q5S':JU
M:JMNI*ANLJ(E6[W%K("CSJ!Q7#MVCXZ:L)QVK>]V^IV.._"\>O^HU3CJ5EJ[
MFA7@5;$TXSEU5]G2L"8(".7!$12_:FHB>R&ICEZ8'9=K$<(9=U@6.\:>7)@W
MU3WO.<#HSENLO2/@T7.SR.=8I[@7PB<ASH17Z92L1A5=>P(G8@*\O69VII4E
M=G[</<>QK$RQ=R9P87ZQQ?U;#.A1!4RVI$E+(9X(E_[ZW^GM%6U;9%^J(&+H
M17Q%`!QWZ;7%+I)&GIZ#2$'C8(3@N0QC;*2-XE!87J4[1E*'6JJA%-ATG*M'
MG6R^4_$%[-QKK]1I>R70&7PF5DN59@5_S!ULC/N]Y-MW?E>@.V##%P>;MB#X
M+!:'C2BCDR`@X:K05@F7U4IM?T$&#*&S86ET=8K<=T(F%'PV5ZCP"!5-A"8&
MR^9QPC#8R""U^AMJDZ@3,1'[SJ)](.ML)-1F%#-O"GN!4B8%E"4A710T_N'.
M%HEL^T-IPCSVWF[+69:D6"*,!!/U6!.)30C[-0K@90$*4&NS@5=KU["OLJRD
M7M).NH#[*0&:.QG:@H!XX!>$0S*ECFV$:B9<+(0$0T68J&0QTSA)K\(9?GS*
M'9*H+\H;!@L3`#E8&Q8Q\'3@8GVQ!&T"12.`329^.C>&XT_DL$`43CFJ&-^8
M!H%LQA.-H9QJ.I4/#WZ/;X""B:VF1G'`E=)8D(V=`.:!7=(N@#:Q5A$;1B(\
MM<AL([J(,EE.T!5%7'H7;'ICSQ%!<.3Q0J(S?+'"DY0%ZZ`&$9P!47?GJH),
M(I!E\(KH.Y6*1B0"HVR/1<"H$#/+@5?U=2]HNH9]OXK.*MJ$W"\].E[3*\3T
M)`0=..A0_2]V&H,!7W=JM5*]*D^B6K74PF.I\&-\!BW>P$K`P7A>!X3W";L9
MIE=8*T%]$^<KI+BHNQQ!8%L]Y$2]!)/A6709>QEV>\/V"WA*)//N0"KO0S]`
M_UO53J5%,CYRLG![DUQA.5D5V9"!C2V[BZF$/X6C@R>Y/.J]EAMRRZ.M'Z-?
M,U*P\@OW201V1/[O[JSH90>>9$5;#(WFIGSOW7O$;7^DH8Q8]>HJ@>U-:,>)
MLBH&]>`)/6DA0;,J3L.[I_SY]"-?B0CH&2]%*Z@@AB\8_5X9^>O-<$WE)L=M
MW#6PE5M5[Y0:G54;O^7I/A]25KUJJ5VI/-ETG^X06#([`N)P&(G#<1%M+4B&
M8>I?K"K<V2.-V/9*K=:J).2?\Z#P*G>P^9X<%>M-DQH$HFN+D%--W]GSV,UF
MJ=/:ZF;N)556I<S^>/9^J.+^DV!TY^AI%P'`Y[%K#:]4KZS*%']AYMUCYD?4
MU11IM^/SSV,'O5*UWGKAZ[WBZX<JZ>YPF&!P;QX3TN'SV+*WK6:I\0C&XZI,
M\3TBQVYS\)8T,Z<6&;E&SV,OW[:\4J7V\.OB"VOO@7(V>C1ABL7SV+)VI]1I
MKJK@>C$S=H^3'T=)KXI#B?9E4;"J)N=910)759_D`X$/XHZ7`.Q]R=XI>0\S
M(W<^\KHL7!7,'94Z\]7_?GA`8-_/Y`@226XO9U`^.,OY?C_Y2?0?E1K9E:F1
M+[IQ43>^?00I6K6:#6XH/Q'1'T%$-R/Z4QY%#RP8WOIXF]3W;ILS"NJ3']E(
M?/A:7NC_!&MY%M7B7ZU^`+K^410(ROIPJJXI+@<_/.`JKE35<(G>P%1FD6&E
MS\6MX\]FDUO5IU&4>.E/'1Y(1'M."D_W+R7<T+1;S`-O[4,>N,Q9;ZZ="44W
M'<4OHFEFK@+P;:W^9I5ML@\99Y5-,LXJY96`2QO/]<WN77<YQXS;BCV3.^[;
M2KGR\$S;=UO8K$<,^#S+Z.6C;-P."MESS0="27N$@-QN2YH1BOKX;$)1N',/
M3^3:QLX]V'\;1RYUKDSQ9&.;)HC2NX`#]VSOFCNY=X^9%BQ!`(R"[6>S?2N1
MM_=`])YE".#A8>@[MF1?/13K@`,IU`UN0(R(3Q&"N%Q2MTC*%940,`AKP)BN
M8+M*+![ID$!<A327RX0-\>;8481Q@.0G"31#?0-!I!+LI4W-EH.449%`\_L3
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MCMU&Y^BX6FT,^@VOO[.0@ZVR0ZVIN6?[,X$<I`5T\0S%UJT!*.HKZM+[&S9]
M?1Y+W)]A3R/G.+A(2&5ZC9(`-UK9%MEYNUZG:H)]X),95+K#'L>S+!E>(9BJ
M:DQ;,-SB0_;(J'&=91QD#E7[U4`,Y-F7G"]^G(V=?U_!'R8E."^F8>!\&GX)
M;B-8)JSQ4[E?=H[^=7CP)4`8+CS3CO[E\`\T-/Z_TTW3&,%^D;X?/_9*`JR,
M.Q9;?8Y];BX_0MPIB<`3IBD:+3AVG,U3A*G$&$UZ!<L@LVOH<V-L<9O%!WWY
MQ1%!R4TF<*BC*W!FXGQ+<P>(#A>I\`(;'B\2V%`J-F7ARXMTE83S#P\,_,5A
MG,QB;A.<Z[G\^XDU:(GC4]:O.[^BD8"KQ18L:..]B/M3#/O'3"#<I;#)R'&"
M'Q<EKN000">!=&JV7`YE!G8,6#W,KV`;#?TI<SE%X9`#+>35$[!#R,`ZIZ%M
M)B1F3\A*G&0C8F:VKK+I!?>ZYPD='ABR@^"\#@;ZD"%+B'&(KUQ2SY*$`1=I
M!<"&_`%L3Z\[C\.*$:]U8:)2&OHA1VKMF2)P8?!]&(!%#9>=UYIB"-R6`!G&
MB*&H%:QQA8JL>]1-G&$G(KI%$8Y<?`$?EA<7TA8P8[4^D/J"W2&GE]Z$A;5@
MR350BMJ#+Y*]['R"R<826%'#--+<$*:P8$[9C.QU:V8UK$3"F0D)9WVV<F8#
M/XG<TZQH7KA9)5P9Z3N"VV/]CV,(-A*O,2`C436W4+$B\Y-%C(>+AY.*<"T=
M$]=2`:8Y:*42`J2"[,4/#HY.OO:[#GR1&L13X!U_G^<>9P1W)XK%(R`M`D.:
ML,&^ECW=VYZIS]068/'&AN/]HV>2%J]$@0]'T`@#V"0L73XFQ!QA59$2*<05
M3E*\LKAT91'K)5G"*USPWPR)*&#I%Z=U09BMXGA33)&?)EX);0;(S1($.3_-
M,"+!2A50Y-3_'DZSZ>(R@A#SZ!%]-G`*5X.26/P'\CK`K0[^@^D4%@GV]3SJ
M*D%$7$H$SAXBIB[!72JY*5+WH#%GL'*D9+Q@$X+.0L6)^@[OR[9I%VG.E5?R
MPP.=VX+2SWB50.SD.D1L:[((K^*4C1QX1SX1XV8Z5V1[`%LDEWXDD#!3QE"]
M(B1A1,XF'.&Y,PD(:C82$DON'_SV"`\(_Q)FACJ+`%S5.0"?Q^68`VCE7;+-
M-^9TTLSX>W(<X@!),)-4-`R[G$8:(SU?8[@,^8I%HH0?%78B0\,N@4$5^A9I
M.(\1^9-/@5MGG"5$)O$1GB&#B<-2]Y9UCZ1*C3/,AF)"AA(U.4CGA!_.IXE2
M\$++P(:@,I)V=>K,_$3@78:IJ5EO&&Y8CC9BKB*<WGB.%LG8#Q-"IU;8OY;J
M$M\S#'@]F<DMSX!L'I8$^/@\\:/4'UKXPMK^)CAR;A-2:[;PZ#P\>.N56@WS
M<'^WMWMJNMMBD)V0%)-C^-)\`R[?/%3%Q<FDTN+6&(^X\NJC]P/-AB@-1X&X
MIEAG-BB)"_E=-=I5&%RKG@(TB3DL"B%4@5]FF;Q;+5&B<&VT%E`,R,Z<1U:J
M'RD^UT1`4&+!"L@7&A6][)RK,QF5.[$RJ"7LY9'"48E?!LF1K,WV$#Z!)<&J
MUX#B=_EE_(LZ9K4FIZ%1V8/E-PWF)7D)92U(2.YZ"@7C)X'"MXY`>QD&HA`A
M4V[T54$[?<UY$9)ZWG&`\]$T$,CQ9(O^E:5S>H3T-)Q#`5(&A%,LV=0EQ`MR
M<#@!APJ"/)C.)D+]XIIP%8;BL5D+/>BH=?!K<982B\/U6+`+*S1T*D\+6SGL
M[_7WJPDG['#.99I-L4W`_T3K#Z`).NTC7S1YQO5/-$LJF.N"C:#'+:%?]")(
MV&SE96'N'HGM-33$UE);GWKO'AOBN/%TJ:T_;9CY3$O!#YG7+M,&F_=,MCFC
MC5(DUF;1,UM9P4##C`^,7Y['OOS@:>W"''XL:9X4V[>U%K9OOA.IVB@R=_4]
M25R0WN;]E#]5(4'5HZ7_N.F^D/*^T_V1":TK96S)!63!9Y#WNK]4%Q=4%XM[
M]FXMYF<A_H^`>/E!N<Z%E:YY,:]*,3^&*R_G/[.'`AV3MK@_A)V>>4URH[4%
MD7ZI#-^X<_A=Q_43U8>_),3OYM7FA32[=49Q=>ED$@^50]9VQK[X-%ZX>R>X
M>SL7J^4IE?-@>!51'NS?47SC7L4WSV.['\%0>I9B\'/ADBX(PF]Q/,+`[<N-
M=3=NK"]DW\YE8N=@25^PX%[N_;LQY^=P[W\65=<EH^R:D]<R6<"!^!:3P,B=
M69)NYD<16K27XE1W0@UK,@]2S/N=4^:2SN#"5&J11*/>,FJ/5!(Q55(8*7J8
MF8NU"X<'_(U@5'(*4L;,LH<K:G:O,[?TY`X/$/^?<N$$2W'I[M#/4I6V9:SE
MQOJ**(:(YHD_G(O$X1O,2-.%OB/.#:.G!7Y>F)KK$610:7"R*)B3%F%=L*'^
MI<R52ZF(=L3#CN-AEG(A-%8$7(88C8F<"/B`,]"PCF%_<[[V>=Y46GJ63:8Q
MY:/UDI`.<J>'!4>?U(Y2R1M-8Z]K44\CIYM=9NG<J:Y7VFDG]A\><"Q?)[I;
M19M6"<]9K_=)I<2"&EM1N4GU9_%$5(AP`2"*].*V8,'AXKZ4G;>O\'.OWH&"
MD<G^-((ADK+4@,H9\(L?X]3I1I<!5D1^S*)+IT>+M6L7/W8_]G+%BT9=)Q>9
M*+`#F7%83(NE-99<+<!C;58'2D3"L46A$R4_2KVL*SX=2HF4:<H%--'[*)0<
M#8I*C/8'B;!D4>>*JL4;7':65AB:_&'4G=@T%?2HB4BVC%^K'/\EK'-X@,.7
M1%4%G@44/*.S1WQ?YH-2HC$6P\"R7[=$P0>=K8<'8N:4<0KB]#<0407A,(67
MY[&W>KLKZARPZ&0Q?YY/9I%-*QF-@H[IG'+:L;K!W$S)"T9&MF(?/*P9=8..
M57S^\&#QA1*1]0;V<7+KQC>8/JZ00\#XX4V]PASXX/MPDJ4A@LQD\ZLXH41Y
M*M<#:8KBR)T*A8;',)8=N5/_;V0_C?_"G!9'ES'^_D*`4"#H2"(*C&!U//FC
M7*$`5S*E2FR7,?/2?'@2*;0O,*P+5@1*J4*LD;6G_SD9O"L)V2:#A:I@>0HA
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MS(,2$%:'_A]68K3)V&:5T5OA9]ALS<NPNG=):CX_@0&^N1&Y#X?`RY5Q"SRZ
M/,2_1O[9`W,J[LQE6*I[5C'XAJ.:6J=6O4,*EI0//6AK]S5!`JX3XSB9^H[&
M40DC^@VY,T-&])[!R87Q/0H!D:]Z%!)V&882PE1%QS"-PD\H("]1X1"Z!OZJ
M1E@#QGL]1&L;!5N:CV=L/7:C49=MQX_:<MP>+/9QI7Y\7*WTW('7\-SZX+CJ
M=MJ#BMMOU;N]_G&U-6CV"F&QCT\_?UUG\UX5;/RG[I??3CZ+[9Q]_]79:#`<
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MJ[*J<>5=WU]K$3NW[EJCU%[96>D!RUZ;+6_PVO`@7F3?!LT%__\4+!0X^"E5
M93DSWGL+[K=YAO<?_4B;\-K='_QQ:ZF4.E[M$3_X8Y09/71B-I'>0;[!F%'G
M>;#-JF*@K7',(^F9;JYKUB[1U;OC,KQ'++*5C_Y`[2+99@9W<+CN<M[6.'A8
MB..QB5Z]JPYHCQBH4:JW?\C)]'`]\ZMSUNWW3S[_YAZ=?OUZ^DE'!Q07^;<8
M:^"DM-`XN%8L>-F8:]%87#7ENQ?YJ$`A-=>,.&PRMNG[ZY2:E4T.Q.5D76N:
MSXY^]4JI4=OLTG,/&CR-SLU/3/NUOR($U`;;NJ%'O)#XMN]ZR=ZNNKIM.*JY
MJUZS5JJO#,/=O:T;TN"YD;!3+;7JFUV+[T6"E4&%15?Y/=W>MN_\E#/;H\N!
MR-=ZNHZ8]?I1I]MK]MVC`3K.*XUCM]UIUMSJX+C?[#?J[5ZM_LW[UGSUP:MU
MO%:]JI>^,&M[4=0@[X0*8/K4)NB,XA'_P11*ZO1!50D]HZ_YTZVZT:\,.G6O
MXW;KO:9;KPWJ;K?K]=RC]F!0Z7;[K;;7_M:N5)K?L`EHI?/J0[-F=0/=?''Y
M]J=#;',0]`/^[TG4AP&N*7#ST79[[U1GU#8V1JWD&J.NM11[_5^XC.7,3^:W
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M:\2)-Y!B6_Q_HUV:X&DY@FD"#3EF+4Z2G3O^ZGC\M3I>HZ87?\<:[`6?)3&V
M54R/DWC:QVKY>3@'\IR.95OIDZAG5*V=&_W&=^X,J(*.])HPH'$(/&!]-J$^
M!W,L"#CC*NC1T>T?<(Z>1,><'!%==E%>=_-LK(*1Y-:K'8,LZZ\FETPQ!8D6
MC>).Q^KQ'@GJK@F'A_S0JC9,HV#5`NREXJ].QZJ6=N<6]^I#W:M5:YV.7IP]
MY;L,NU-L'J5LY2[G+.X:[WJ@X=Q:J[':L"M:BKU\['R*^`M@#DLS.!R"BNR'
MDTPV,WNT=7^#F7SC(G:3!-5[[G0+2%`I5XP;SAVKX:7[T^#J%]/2%P>`.!SI
MIG`ZX[KE';W@H`17.[4:G&X;K,98_I\!WM2#4?<:>.,R^$R=C8E:@E3<VO'4
MP(1X."D6=_Z^,M[$Y5=:[4ZU(2BP^8(,:HCJ*WDM!H8AP>EE20(V'(O-]BXZ
M@P:LL5Z!7:]VX;;3;5;=HT:MX]8&WE&_T>UYQS!*T45GW3S&HHO.(R'9M,J.
M+%T;F*5KJR\W.Y_A::\(#79.QG3\J4S/"<E.]T?7E"&!S38%`L3A`?#V#(&?
MN)6?2*(H.6D\GM\@HL($_D#CXNVF'X(=/X^3/&K6Z/#@5-276']1`ZXP]Q_"
MU(98:%,0KRUB(#G.L<Q^)1-A>](!BJ\R&-3A%!QT6G`*]EON4:75<(_[_4:O
MWCQN5>K%B:([(!WMLL&KZE^2O<;2R*+[W/,1&WM=6GA2.`E\-C.#_%,6DA!=
MO[W*&_A8%()@P>4#+KKB<MSS)Q/*Y83K"=4$X+\_QW/$!!IE0=[O4&-1%?W0
M52=8D7S-S=15ANILX@]%]]7(.06IA#/$\9ITM>\X;].`O^1XWF)#W)ST/4QV
M#"'\+28S'`0^*<KI?B0I:_8&W=Z@VG3;_6K;K3=J<`:U>U6W[ATW&@VOTP%Q
MVU4IJY4=(I(CJ+3_DF0T+?Z__5F<@MHO:MI*\#PSE#I$8\F(E0DUD1T=B)?D
M#X?!C*H0..R!C\R2$$::(0Z9/YO!843B1!W1&9IHR'0L2=`QW8LVD""'"$.H
MX%MD61?!P?PWT\`N5A6JK'B(L%0"V\ED"2,I2B2DLO-[?!.`3.<\A-SS5K1-
MAZEGB406@KDB2J/J-)Q2]]WA,)N*3LDC`BN:$V[4ZVK)\UJE5J4M4+GR'LJR
M<Q(I/"!JDFX\P=G/B^B1ONB.0_AHC`>6F@>VG`)1XW6ST2G5JAY-5SL^?2?"
M'O%8`H(P%4,_O7+&D_A&+Q,W4KE1J#]SNU&J-QJRW3VWGH=_1.Q]W6^8HB)6
M'\545@/;/\E&W(5>MUE.&66+^%_`;*%S%*\"HJ<UP0Y-@%%#V`W%N"9W$N35
M%"\1U,@]"H;`DKCYZ16WMS<V_@+;1$NID>SI$#>0!!'/H@CM[S[$#..49_=Q
M1L[]<&[AEE$U]$4,IS;YR"/6/9K!-4<3!,-W?@8,XBP9XD0$G""F=9%3$MC]
MV@_YF!?8J(1!=HU3,@YI;#"GC8`(C0"ILPB13$`SCFC:*0E+!(+B(C::.7\2
MQR2^F5\1R*M"LN4&XC-05+B]&BE,K4"@(PI="&IFAIY]O/"&M*[447Q4(F#6
M+&+B3>+HDJ=Q&<--F.W]^.(OCFZ`*OP3HPC`?$'P-P'%^MA#W)B"Q&6<"YB[
M678!FAS&2!2A$.H"6%\96C`A."GF(IP!/_T%O#IWKH&48%&DH.)&80JG36CK
M]1*HL(NY-<R%'_V-B,P)E?,`*X!&1KOF\$!L*;ZM7MA;(?@<(PGXMI4"Q2-J
M1>^/`J$L=)1'-II/LR%N]SC#FD!4VE=A<$VU['AGG/@1G#%C2ZA$N:!4)KS/
MB$$X1ZA@O$T6;#I>/`E&<7*+LXAR1R9QS@5=2H<">7"(_D"#Y>\R7^^P.LU+
MHL"S/!US^U5R.%%8_3A.Z(<?F#:PIC.UUGCUH<-!\ONNR7(M*IW4!\G9GM%^
M5&OW*LU^S>W6C[I@M%>.W$ZM5W=K@VZSU^EY[7:_L6,1<L-L][S"V_'"M>XY
M!,N_+H5'UP<!:5E1-:D`,]>HF:0TJI//_0'.IU)NA-&OSLX3)#]L47EFN[';
MU9F@N&\2?_;/5_S?A^7`WGNP3?)6"VHJB[Y[[TK0K2SP65!K%;C7(RSP!Y9D
M6,ZY(V43%G7K6WN7]J(,YKFMYT>79@CADR>9VRG7"&1$/OIQ<(SJOEUNS1;K
MI@\/EOJ+\_9$B9PL<+[2@0M7'G*,2?],K52I-N'*4^!)WDR$[U7;O&F!0_XC
M]TCF7E7BL%#J?'C0Z#1+M>;#$N,+J+-FD<;/0V>O5*VW2XUV^TDI_83GR%IR
M_K/IX.>VGGTZ4\17VFL>(W1$'`<7"9T1?$2LJG9Y=H5O7N,NY/67TL'5%-RD
M@'\'JP9_,EWVW-;SU)`/5$*ZJ$<?G<X;@?G0&ZWZIC;MMGEE\S7<QU[<3:_"
M<DWW,4C37QR1P'9X<(:I1''T,YT8CW3[>CES=^#,75^M_F0'TW-;SPMVPQ-C
M-SS"Q>0GQVYX'._3P^$;MA3AO2B8TY8CS/*K2\(E3S&%IXCIAF2+5MY@L\U-
M<K?S#G<*FK''/=PB54ZCPX-\GG<IEY]##6%?@T2(GK#8PW6>&OGIL-;U%LD=
MQ#'Z(!/=..K@E;P*CRWSB#)L_RES.S'!]U8FO!%X.&848?2BA"E&JLDBYG==
MW:;8G3/"_,<D"RD[DKO[8GZ6S`QVAG$RBS$W[_!@EL$_4S4YVHP+S"95[2_]
M.;;4%$T=<=G<TGUR"Y^7*-!I,`W5[S%[7N\E??Y?V03_S1_A'9_ZF';&X%L7
M`17&(Q/@CW)4:QR1SH]_3S#_+&4&P^PFZFA,"\RB-!AF":7^7LQE%H78S.6)
M:*8NPZ32<'S["$D4/T#3('E)_)C&U',>+.*1RA,$UNA>(E.(;&P$KJ=</^>/
M*)R7G8$_O*)_,BH!(B(D8<HHWG$4W%V600425,'A(WO(%GROJPW&<"!FC##+
M]SIP*6WYQD]@0^>8_J8:??/3AP>Z$?7<S(DW,VADCV9,RV+^4J/,L*LER5@@
MET7-F=5DN%$L-YO!#-`T71!-(?9/S3O;5M8G$24I1P$!0.B^Z%9V+76[-G<Y
MX@#JW,R1I?H:G[8A)$A&[I?+)&8`#_%O9"&2TA'5O&$G!*Y-XVWSB2_]21JC
M]@J`/T:+7)):;)+-J+VZ5,T+W(*,0?EZI,0BV.40DRI!BP;),)0<PN4!E7*U
M@2T8>!2174XL30G`@D/AN]$E%S-PRBWS-PVA6W1SOKG.X[=S/BFE66A$TFJ>
M@Z49$\Y<1QIC6J@L,1QGD\ER`LF30RT=>QNG<UB6`#11LD'GR2P)W+D&_L#Z
MQ3"-,<M=]6K#3&14Q*-P$L('A]A4>=GN\M[/92%5">9--2<841<GF)]RB8IN
M;DC$D2>=+@CC;MK8)B"9W[J$)2,[8DCEE3\,)-H*'"28Z2P:#VLR"L9:PG^J
MV2*K2;$6$`M1%48GC81J\=-<Q9JJ9U'E]<!IHERA?'A@E9(LODE5#"`9C'*C
M>X33B)JCYJ3.K1V^1"G0SVIY)>[`&A8^MI5T<;U(LU1OM$GY*=@8,7^2K@7,
M'C+`5FB]G5=PN9,01=HL%D`YI$;TH`'(BEA@+E$*(%4&OTP20+802&@U+WM+
M#RG4M88DHI:13"FJL>`+7%OLJ&U_(\L:-U-%SH(F@J\O446XQC`U2S0-):E7
MC#A+?)*BFO0L/;G1T7QX(+7;./R."@(UH86@U-'";BI(T$%CX&OZY>&!_&U)
MM-!1.\/3)-T2_#?#\@B6DDF0@H+3\X<%Z06PE>TS<(!<#^D?F,`5W(KEKM'@
M5.46WX!I8OXRM4"=CB9QC/@#E\X4S8O9).3?>["I@@X(0#3-IHN3#[G$[C()
M_+F:<L6B>.*T0<>1!-#&#L[.C51JYS3"1WRF5Z[&+5=:-_5OJ="-ZWE8664S
MF$NS`MKTEFH3<%)`1BKOH8,?N=+E4K>%HO4BG81FUB@(I@Z9Z:3C9^RZE\3F
M6P??,^#1*<U$TB/B1:K]]"K5-TK++Y,>'A&G'8BO(][O)$M5KQJ2BRP2IZRX
MZLSCDG.1X<F`"II.-+Z!J4GA&?,D6G';^K$+)\1*[J!Z+XTQ!A<J"1*HZN9N
M^?;FXT:.W328JYNISJL3IXS>'IEDAT)#_,1&N-PYUFJZ/98M'J`'YHM,S;RP
M($JHTTA3HM![]7:#S8$E"MJ?#+%JU&#+HA73$4HU0*K>]O"`>JVYYT,0BD`*
MDHMS(&"Z>!1,M(&M,OJIMHBY*OV%3VNRV2;AF&_:=#+_ZK1!_-]8*N@ZQGGB
M;'YUX'+VMSM.`CJI!!?+NWJE7*/;.MKML"%8"H=E<"-"[J/)R(\"`8-D^L1\
M_21%%W_*:X,_G\,=4!M.>!EDLT!<!NA\!1K&IBV]]AU"GRW,9/*[HA+1-VXR
M5.W!A9"S,`E,K`'!T76[##%WJ&I&%9:KS8Z.Q8U8D[@Y.SH6-Y(IVB!V3']U
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M]HJ^F.WQY7BY\2<)FZ-;@2G53272`IIO*TU'.:BVHMBY6JTH'R$^?1G1WAH%
MSWG'"?N>^*TQ1EZ6.S`$I`<!2EA<9JQ2XY.P73<*<*?#R$)3L:62Q9!EDZ_%
M]SQ46;!:<!45\EG;_%151A[;X>M)Y_YRK0HPMI?%%PT'SUD2H\<2?9N%^=IT
M*#>V'F%\`K)@$/,<47ZF%,8T72,+44P[AME>$L(T:+=.$%/X<N$Z+<.6-W'R
M-TFM1*D`HSHC;`PG3B[]*!P*O`WA"E5'(+"J']$5#EZ)8-%7`K5;0/R$B<#K
MPK^I:&>:"X3B`SH4*K'X:(CW,+NAGY@8W8<'$H%(..YQ!0N14F=9H-0X,*U(
M:=L(E#K+XJ2'!_U@R!NG(J51`+I@,5+J+`9*=?QUO4BIHP*EAP=67&>C8.G.
M"P12KKV!YS=?Q7&WYW<AZO*8GM_V&UFH*`RAN]RS2^U=!6RW9N"T:$AS1F"3
MR;`-V4P8M4$HDAL!OJJ<J!=^"E0*\U`GH(20(+`3?AB9Y[RFHT6MM[$1]X-_
M4XI2[M:@%FJ]"0]3(H`"'E?;CS=\>U/><9R*L1=&`B'%(")?$&$]Z$5&Z)>(
MB4IP6P:"VH*O:J\E2`=X$4TF03"AA/&@!,I9GCD$%A82VLF3&#4C/KN"9"1:
M=(]C\<3&#.SQ)WTH=%HX_L4)W]'%4-GA?)FX"`*.E=XZ(MR(QYJ8$/M[G1!>
MG1NXCXK)%RZ:P%IX&.'YAD'61N6-7&Y^"3V]A#,:CE"F8F(6Y!'@EEJ%>`OX
MD7R)\\2G`X\<[$H)788$%,0.]SUFG2YM(<<G4#OH4(2QD?4%O"(5ADAC/,Z$
M?6T&#IC\GV6H8)U``1X"XKUERO;S\D!!Q/B),EK@W!DLR,4*8/KK!PO*;:+V
MCFXJ#X9H6G(\D;),2:7"'23((L/.E&CCU=05CRY\#7EU4Z'GN_O%4(1`]7UA
M>N)4]MMJ)Q6K+XKL?S!.>IMI50X@J5V4!SJ"8@.?G6RX8F3+Y>!!VR-3$:)/
MO?(XB#[2.RKK=Q'T:&LH/_='CN%A_@\PN2930)NE?UZ&'O.H]3@&@LV]4]KO
M7_KR-!4NFZQQ)PHV%AE&HYI4&:OA#M21>P!?W`5LL5'AH7JYVG@CBQ#O47NQ
M]C*>J&+5D%XT5>[%C5NJ3_HA+=\?F<LE88O`$GXNPCXFFQ;5A/XP:FY>@?6@
M*J$<=NG=^)L+'<P8I?\CYG_?$YKS6[U1[50:W^OU2J>ZQ?X_#?P?L(I??7!;
MU4JMWK1ZE^EUV$O\%$8QILA*(YV;G^;[13U\[;56O;6]M=>_M1"DM0UKAVE9
M?=O66^!JHLBGL26>:A=+8>#]H$N+N_RUFLO)LG2):W4"YA9*C]L*6-.HWFA[
M*YM%G7P^OB>!O&]UT16XUK![X=YCI3^J:?)22CTR-WG?&II8C]=`>=7[<,VC
MOSR"]D7:P$_P8Q-^JK8[VY*[CJ(4M=I>EU1JJ1M(W%.1Y]%$KJ-$3M!F?9G;
MC#[;%+-&K=EI;T_,:M^:LE-YM?D8@O8$;0V?EC8/:7+XM%J'R/%46D<P#K9`
M;+77YIPE<O4Q]J.4?.!?$W^D&E1]H?(RM+(?L[.;II#7;K5SRS]NP]IZG8;;
MJ`\&;OW(J[J=6JOK=HZ.!CVOTAQXW?J.@=GC4%3,6R\?'G2YZBUU-.WH;K+G
M1?V%"\-@*/7F&<G`G@BJ&"TQ..DH%:'`R00+[JC<Q_197_@3:JY1=KH1>K7C
M&]5-$2$JYN-LHNH)4RJ*5!U=*(00IX&C_ISH^<E0+B<;4FI*)":!UT+L8(*I
M*I3L>16F<S"2AY32C06'@<S\U*L17;@.#P),(U-%`N92BJ8!Q*'"X_]F?H(A
ML"`:(:<4^NA+3A&A*8C2Z=1+GM=6P,6^Z'M/04<DQ(6O4SA>UZNE1JM9DN6+
M*G-`=*X,H^LX'&)6,W6?_YV>^]C]V"LOGT"K4B]U6IZ:`,4>5DRA5B\AIEI!
M5HJW1I/Z>^FDIU7[3Z+HN=4O*?KV6A;4[BGZAM=NUW++KPQ@Q>UZUZUZGN?6
MJY6>VZVUCMQ.O7(\J%<;E4%UU[J6*$7?`/$UA(/U&7=I?6((E\W_M;V<S*VL
M=1F9C6:\0]/<5_%1RJK'[DMC8&A0ZI0>C`48CG\17[,S!S,",Y4+D,I*$ZDC
M,5]=U4]S$;X]5A5_%WP7M6J4/J23F3CS$%LWJ:)Z=6R)M/+ADAR[1U6&0GA)
M^NXOO#06C`:T#>>WXB?X&=.,Y^$XQ#2IX16<DO]\=36?SWYY__[FYJ:<!L/R
M97S]OG?R[U<?R)9OU^KHK-2OZ:'2X!*W3OT"?O7](IF,PE]@"R;8/?$3ITB.
M@$TH._2?K[0J%#7WY\,@\D$+=K^'Z:L/\L^BA3*__X_WA</JB;RW9_*/]]:B
M_\%H!,:\YW"L]^'['_!D<RM5M^+!&.JWZD$X]^5C^(Q;\W#HD?'0/]X;@__C
MO=BZQ]E'/J;V>Q^[.KOWY]Y+NCGM^UZRF:EUV$^ZI<N=!_NRP0-J,8F.F3C"
MPS>WT>I,///#T4G4XVJ`]7;[17ELA]->>.O9[F^1=_]Y[+;1AO-%>_Q([OI9
M^>FY[BDE)CR//?T<1W2UCR>3,+J4&0\_]_92+M+SV-XO`1:-!:.!GT2(F/PS
M;NS6MW)/R>/E/5>-=F7?/5>_Q?$H[4:C<^%#'`AOX^@X3EA23J)TGF0XPA/(
M0F6]S?:><K.+[L_[M?7[<7]^8<5-6/&%^9[M_MH7[.>D:G[D!?M%O:S+?B_F
M_+/:V-TRYW>`/)47K_4C,G\887+:W+J#R=]M>]->G(7[LE$O'L#]V[,7.V#W
M=^N''^Y/N>:7B_#C,ZKWU)OV<F;ORT:]G-G[MV<O9_;N[]8NG=E;7W/EY<Q^
M=$:M//6FO9S9^[)1+V?V_NW9RYF]^[NU2V?VUM?L55J[MF:P4UI;]J?4:Y7=
M6G/5K=3=6F63-6.1,"U8@*S(5Z:!CZ5['_C7_W@O?^8A\*W<^V:1<7X0\;=?
MX&^;C?0-)OXM-S-N):+7C^]]SJ:(CQY;<>`[O\ZT*7Z?ANT'43S%5@3%`Q?1
M1H^Y^/(_WAMS-Y>.RF[RRSB.Y]B^X6,8_>U\AR/L[U_@*+/9!I\LQ\GE^VJE
M4GN/?WZ/#[X2S\]O9_`\;"YA%RN2\?B3>"@>NTJP</K_4J7/]?I1I]MK]MVC
M0<-SZY7&L=ON-&MN=7#<;_8;]7:OAA@77DM^9^)?!!.C=GKC`7BB,",DSROG
M_:/.M/K0F5;7GJG<,_MK\K??&HUVK5UIU%]ML)_R97L"P&AQE@SQMU,@D(_8
MP4'D_G'^ZL.?^2X'44:'<CR6_0NH_PG!X$]GV9S;(`P)8&$43C+J_$,MYE5K
M`='L%;M,.6F(N!/4KV<\1K0,&)=>0\QXHYE!B-#D\]"5?ROS(:YI5$RY;B+W
M&LNI'\13\0K*^\GP#N*+)]Z/_>'<U9N`O:*2?[[RRA5[0^#QI=SPL#55=V%-
M^<U#I01_X%_#/_Y_4$L#!!0````(`,>"KT#%7#/?%`P``&><```5`!P`86UE
M:"TR,#$R,#$S,5]C86PN>&UL550)``/VNK)/]KJR3W5X"P`!!"4.```$.0$`
M`.U=;6_BN!;^OM+^AUSVRUUI*:4O,]-JNJN6=D9(G5+1SM[1_;(RB0%K@\W8
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M:[/?AASWKVIHA(=2W/`OKO_++7/#$:;!_"^BWAT-2#!MTS[CHPA]S9'M?^VV
M,S30F/D^&\$]H3AH!+/1VI!%&UJM-K;%WH6:?ST%,.ID'YW^)T+ACA'D/S)!
M9!<M'PE!^@1[ZU/0;/<M23PBCC>X&6LT'@QQ0%SD[YX6/-``;ROPLR9V`\TE
M]5333T-@/V2^!ZKQ[GL(`_6:>AV0!F^QT1@N82K(!.^`Q'H][?PVM)`8?O+9
MBVA3CW#L!EN166UM-X`?6(#%,UN,UD67X@$%(<>=?F<L)TD8P&)]`FNU7C6A
M)S*@\/RYB`;7K@OS;P#FPB/SB4N@!GX-;GSF_KU+DIH]5DW\,X-N6PQF6$YO
MB7!])D#VE3`NZZIJJO<,41%?YLC#\P>^BUU,)JCG8U&Q`#8#4+58(@SW!/6(
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MCV#%`M#LL?('(.P)_#V$CW<3^;V:`:_L9$;/33SPT@&?H0EE,?6DAS'^5?:U
M6S]IC*&Q!*)B9)KNSP@%X`!I9?KVI>.;\>S=GW4=>;?[2/0B%W<HZ@.$Q@T9
M!&A@/Q#S7Z*P0/VX.?-T_S+[^2\=NVNVFIEW[Z,>]J]JF[30,,@P69\_X$"/
M4FX5(QP\+QHK,&I@M=FF+30F`?)5\!6ES2"?R+B/Z-`VE>J`\>ECR-TA@M6R
M$GY!%2,<HF6\"FU\T1RNDJ&<*6,"I71KRUD?_DC[9X+\R`X(6HCS*=@!?R(_
MQ`KT>G6-L`*3AM'(N"LDL%S,#-;%JO*>T<$SYJ-H^IYI;"7TXEJ&F:2Q%#\"
M)95,\+C%?0R]>[$Q@"/OUPP/S#0*'B65]H7'`Z/N)E2R]<RPX:!B`C+!VL9/
M896]X9"(=AT:J5I&F(3X$V>CZWX?\(#Y7'(C%*4-(N\`%A=6_1V>]@%HT2BN
M:HC3,]N045E%$WQ`\Y``1OL$@X$,*\6!G!YB8TFMMDHJF>#QF3'OA?BJI<#B
ML@EL*5VB@)<N81@AF)FKKKIRV/G5#',I?B+W9*9:]@@KT*X4,X%U.=I=+&!5
M:1/('_G,U"I=JN25-(0X%5(OEG1^63.H%?%<]6Q26,4$ARX.$*'8NT.<PN):
MQF3#41B%K,!@)RY1,=&H:(*/MC[?$PV^"J--73_THHPR+CUZUT'`22\,Y/KU
MF4D#G=&`,Q^@#$KTZ(X:7\@EY2N_YED1(>[.0<#'%4=Y-A][5J(APE'LH:^#
MB36:U^^#,;SB:YMWQE1N+H=QH!GM&OAP?%QS7K#,>X^^P[<Q)]&,<E4[J3FA
M`'!L'+M+]Y6=QC([87QQ"(R+U>F";//X$,B6K442NLU#H)LL61)B)[816[)+
MTOPT'=[)$VO=72T@7QQM2S@?T@TOCG$EG$\/B+.>CROA?G9XW%<]DPG=\P.B
MJUB0)63?'1#9LLA,POJ]/:QS''%ISGF.C61JMLB"+N%9&@=-2%MD1)>0+@T(
M+4B?6&1,ZSIN%<,\S=HBZVL3UKMR*B0"LU,A:-BL6CEPB8ZPR)S3DT-9=D5"
MW2)K3H]Z<>@_(6Z17:='7!G92#A;9-YIWFR-6'9"WR([3V]&R`T))>K=HI6Y
M'M_55+V$K$4Z7(^L,E,XX6R1\M;CK!.W2NA;I,)W&Q`JM@K3(K)(XU<GHM7\
MA$1`F\P)^[GG)'M0C6F@LX-:3.32C^1H^5]$;R$P><Z%4&?^%U4QDQTMY)DX
MF$_`LE&A7BID)D=US#$,Q_@TK%R4F2)&\NHPQ1SY<BWHC0@E(N#1\F#F!56E
MVY74,L*$,R&/&^@KTS?2)4P@C)_Z>P`AW>KQ]M`0GJ3DX*`;W&<<+[:,XY7M
MQ"#Q;"OQ7/`%!T/FR:B,B+>?*B3PE@C,21APSP;B#8Q3]7A0E3:#/!9O\7.W
M7,H$T@<<)`-`@3-;Q@A*F'CC02VMG]21+"K$RO)&\C#G4.8'[J@R,%?*&45;
M.B[R2AK+<UV]Y45YKCFES>0N3C`-E0-B<=GH8B5G*LZN8^<<K,P-*6&W;)TJ
M<D'J^TW2@*V2<=?FJ10K8]*&!5DP#UJ9;I=K?:0)OZF\K4SLTQ1ACA6MB`GN
MN2HK-06SW)?L<$6*]2%Q+O8)*3*N#TD`2G/0R@1LY>(ADYQ<YO>Q,J51BWK6
M+6=E+F/!BBMSD].6JI7YN9I$<^Z[(FU35VT9#`ZL=]B[:;2KI[D;CVK,CQ25
MR4Z/'(](N!A=A:&-O'K&SCMJC\:(<"GC%HR'@?H4J?S"^W,"TB.&9TT:U!PC
M@6]Q_%<5M5FGB7]B.DHO>$90RWG\!=&!DGK[P*9-=?(8-2EJ-K9?O),]1VNS
M3%7=#TZY"8G:M/)K[PFS[,ZAI43FXOW^F[:V'\PC6V5ADA6>*JA9>3]X93<(
M:3-:JF:$BQ"AW.8#QJ4<-3!Z_H,X1Z`0/C$^=U5W>,M'9*2\56NU82@R*0T'
M6/!,"%BV-].O0NXT7C@TKEW0%$4*9HT&]HA?[)'<@E]>`WO$+U$&&_++:^"?
MR+GRA!<TC;S;S^S:!1.<8^49!0H*:S1@EM_<[Y]><)=RRJUDZ"0>%V,O"E#<
MDN@)CM]#EKR)IL6H8#Z1;]CTY''EQ".(JQ^?;5HT+8$NS+'Q+>KT-0Y]U:IJ
MB-.$R!>MPJ1ZR\)>T`_]N?&NYJ*N8B9'(1%H^E4@TK^BS%LHJ&+LC*).Y!.4
M:JO8YE,4-NHYW<09DPD<KS$96[EOK"(!Y5IC5NXRKTA`N>:XE=NRUE]O9+.@
MBK2D8HO^OD==MY*(WGQNY3[^+0538K(J-OG;.5@*EK/Y,BE?IBCV^!ZV?+99
M'EBY*WA]]\'2;)6?:VA7<MP6$E#E1=@_(VL*H'CM967^Q'8"6=-M;&7*T'82
M4BT3K<PJVDX4&CD85AZEMN4CI!OQM#*Y?<L1H\ASL?)4XUT/D[Q@OZ6IN+M^
M@/0"ZXK<W1]*6#F9/XI='S^46%0I"HKM'#^8;);3'"S=]5&1/BY..MONZ+BW
M3N-5O]SX`<7.@F37E)E$XX+7+Y,!)3`#2&=/?&NBHW!\(M^VG;R+><]0?V;1
MQAI84_'<-V/O&=Q[AJB(+W/DX7D>>F*3Y+[7?,](+!_]9P'DK`H6B_S_V+:)
MIRL+:"2NQM0&K#F91?EHGYD%;)0.9@NPZ\Q>%M!(G=PZ=S#L.>+%7EH+L*:C
MD*#OJ4!N-/5;`'UY"[<%D%=/])-E+0`NSQDE\0YXF1X0[;`?8.K:H4)N0D$H
M%I)%#Z[*KBU`+<-S^'L('^\F4=2S'.C'A@30@\4+?/D_4$L#!!0````(`,>"
MKT!L!?5/[18``#6P`0`5`!P`86UE:"TR,#$R,#$S,5]D968N>&UL550)``/V
MNK)/]KJR3W5X"P`!!"4.```$.0$``.U=;7/;-K;^OC/['W2]7^Z=65FVD[2-
M)]D=1[8[GG5BC^VTW?W2@4A(YBT%J""IV/?7WP.^B")%D"!%"B"#3J:V)0`\
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M3\[?O?_/=FNZ>F7.XMD?_;?U/]`86D*/TPPW_CZZ(=;QZ,)U1P^\J3=ZP!YF
M:VP?QR.Y,1]&P'+B?3S:@OXR8^XQ98L)C/UFDC0\^NM?1E'C\Q?/R73X]B9I
M?CKY[?/MH_6,EVCL$,]'Q,ITY(,5=3U]__[])/QVNS708?N;YMMDO9M$7T:M
M/>?<"Y]Y2ZV0D1)P1L(6_*]QTFS,/QK#?+PY/7[Q[*-_\`=^8-3%#W@^"BD^
M]U]7^..1YRQ7+CZ*/WMF>/[Q""WQ,Y\<^!?U_]LEM8(E)G[R$Q'[BOB._WI#
MYI0M0^J/1GS\KP\W&1AH15V7+F$&"?8G?KRT)[SI1&K4R;ZT/T#/WQ]]6*/\
M&7?S:X?`_#K(O:=>^')-7>1YSMS!=GT(DN,>$L0]8KC!9-08W'_&OF,AMWU8
M\/H#>7L1'P_1#FF6,]X:^O$9T#]3UX:-].K/`!;J!;'O@!ML2I<K^`H3SUGC
M%D#4>U+KTS!%WO.U2[]Y-\1V&+;\O<#LCM8.P5^HC[TGNEFMFT=Z7Y`?,'PW
MOUMQB0H+V*L/H-;H70-Z=!8$WC\+$?_"LD!:^Z!;W%/7L1SH@5_\3RZU_F@3
MI.03NP;^,X7'3BG(8T8N'<]RJ0>\[P1QU:.ZAGI+$?&BKQFR<?+"/V`+.VLT
M<['7,0.:$=`U6T(:;ATT<UR019TS0>9Q74.^9WB%'/OJ907;//8V6W_`N/"]
M\#SL=\V&IB1TS9H;XF.&/3^2?#%Y"76;]E/J=<ZA/2GI?@U1$$_^Z[W+=W!0
MK$&+6(7*=M<+I\9SNV9"++F\>_3*]R\@!SYA`;8/MY\T):%KUH"@6\,\.4#3
M)9YUO2HDGM;]SL'?TR?TTOF^4/*<KD$^8!=^Y5::_PI"G'C("A74CC'7>6S7
M+/CL$,I"'T*T/W<,7>9QG5L'/CPE8RWRMAT#EW]H]UO9<NGXT6Y+;-AJN*F"
MB=7]YE[SR5TSXE/@.01[G*P9?,M?P8X9(/G$SE^`8.;A/P/X]6K-_^YFP0L?
M$L-#S))%*/#B)OYA[KY]%P)'KGLTB@?>AK'IY1!_8CO+2=QFPCMT2`\\BKN>
M*!G;>(X"UZ]'W6[WP]!*E\@AC4F->G=):?B$\1(O9YC5)#/3M4,:GV$(9@4S
M/-YPIAZE10/$]-J;0!>/<V5HAI<,$YN[YJ-/^5#M!AA"$H`(>)4S3W9Y5(:R
M0G:%(#UL'2_H>F)C9\)#6?R7,*8U/CF-`R]_@X]^OX!'V_SQURY:),.Y:(;=
MCT>[WT\ZIR<VXJ]AHT;NOS%B5\2^A%VN@#1AT^ZI3.8L>O8]9@ZUK^$SKX!,
M<=M#T\EY)$=EVO)P-&XM>WC1\`U(MC)""YL?CMIH'L6+L[C=X>A[@F%+R`J_
M[IZ:<$/C/GGN7B@@)_O]@>AYG0(#&')O8.M^^1=^%=&UT^Y@]('F3DEHPX2Q
M-N\N\'G<G^=LB(DMZW0PRJ,M^0&O*./F!E=0"[>;TN:'HO8RUKP$U%UNJU;=
M4W/MN)A-89=84"9>D]E6AZ+M/IBYCG7M4N0+*=MN<RBZ'O#"\>`=)?X7M!1N
M,/EFAZ+N%^H&H->Q:-+$KT&^W:'H^Q6[[K\(_48>,?(HP?:-YP68">D4M>^>
MWEN\0&Y$Q,6+4\3)?(ON:>)Q2+YGO2YGU"V@*/O]AI[4G+A@6<K`%DF&B<T2
M.8LZ[C-G="FA(B6/I$42>$29C=G'H].3D^,3^`]:AY;6.?>:8/OCD<\"G'Y(
MB0\FT)4;^B#`A,,+_LO1:`4Z#_<[?CPZ.QH%'N"@*TX%ZHP/.2-U'XYD-:B$
M(<<GIYP=O4:6L_52:&>]AR90RU.(;P8#<<>62T&^'1C(C&&=PGS7>Y@YV9%"
M^Z'WT(H5LQ3ACP-!N&-$IA!_ZCU$L1<N1?F^]R@KM.`-U-.3@4`5F><ITOXK
M.0+3*X78?V6GT%^0`NR_JB/C!DOQ]E_K*7"RI/`4:3N%(;4\R$+_;H)JQVA/
M98>J#74GZ)H')'`T9"<J\1O6Q?-ADHTE=AM?E#S]T]A/,D?>+.1RX(T7"*TB
M9PEV?2_Y).\UB3_^72;M,!95.;]*DQ&:>X+V1YBFIW_!OARDPBY*,-BV$RW?
M>^38-V2*5HZ/\IZNJM9J*%_S0Y+>';DA/!L&Y.-]P*QGY.&\ZU"JBQ(,81:[
MB-KH2W5T52SE3!OE5%[,N"5J25&[::N":GX6C:?JP0^>M+A&;IB\YT\18Z^@
M]/R"W"`?Y*C75PFJ5(TK!9!OIH;632KX+26+)\R68<Y=+&>$I)?W4HQDFY;R
M%[>BDPH<EWB.X>EVI,+@\,A*3`_(1P&.BDZZX/A"B=4$2K:?&C0,MAC?66-I
ME:VTBS884M;6@;'52PF2`%^#!7,QGP,]H/173(2@M4+*[X`6"S/OCFTG[DO!
M*.^J"-,3;8BHJN-0,F.:<_>:V\KP[JTQ&!D^(@LNK"(53KR)5G12@>-G2NUO
MCBLRIS9?#RNWHCF_MG9;`<NV6RBF$!3QW1-(U607=],12X5))=U=,;;R_5@3
M/667#'GNZV#5Y@\A"JC>:::"UGR!A?(%(FJM@O)[%AL*E89V44M%%&]5<2CG
M='%;-50+2@B(M8_2+BHP/&`?U#=L7R%&'++@90""91">DN95_2Q'A$2BHPH\
MFTC'3H`M1W]!0Z7T%AV+$#120Z>D#J.)UK)+Q@VQW,`.BT.Q,(CH^\R9!3YG
MZ1/E9CLE/J,ND+*HD$\M#=Y?OE1H'2T_Y/!!>ZG8`0\$UW37;Z+$9_KEA=7&
M7![83*'JEQQ6'VII%'$#]8U^R6&UH<JYX5+(^F6)-86\ZS--4>J7*%8;I4#'
M3C'JERM6?R8K(D0I6/T2Q>IO2MGP>XI-54Z\VHPJ%7-5US>V/7UEOAR=C^.T
M@;TRMJ[S89TV&%`9<-3Y($_+JU_OXSQM@&W;Z-+YC%#+BT,0/M'Y#)&\L[[(
MFI)*A%6>$=XZ_*H<I11Q+Y:\E*Y:EC>3XAW*`A?&4U*H^CI%:DZM1-I'BEI?
M_T@]U*5S>Z9(B=\IBE`=*,A*[JQ[?H`U$>HQ1&"=IO.LKS](#J!$<F8*5E_K
M3`YL>00SQ:FO$2:'LRI3+$6JK[4EAS3-)4LQZ:LCUMESMA'IJP/*(9(WCE+,
MBO3`RK.?Y9%LC0^`RDQF%\'2G%-^-U5'Y^H1AV/-[EDAG>M-'(XOPK.8.M>H
M.!Q[9!*:=*YQ<3A.E?K5-"R-<3C.[*:IZEQ10^6*:9945;=>AX[%$K(7C*H]
M2PNT<"\3W^-"47F/65@E19">)=-3\>G@J,C+1>`_P\KXOW0BQ4AV>FB!(*P?
M)4U]W%H+RL5UIJ6ZU,.P>Y$*_V0G*!"[G;X2M.3;#<PRO\2%ATUR)-;M/92S
M=!U0\_N9.7=6:*S5W'0E.ZO');GU5G32!4?I!ES2P9Q=Z/CL0F>Y9\EU3]LJ
M<@^3S]I,IH,]7#TB$XEKQX=<6S/J0S*A;+A*3@#W(7NP">)=T=R'-,'F2!/A
MW8?\0#F44D9[']+[:L,M6[OZIC@UA+F[<'6.Y#2"6%R`5U5D1I<HI3)/972;
MMY(*KI'&$58UWGA,R2),G!'8!*5=U'B_/.#A(V9KQQ(6E<DU4E.G;,6PY43W
M@193F6FB@L8D\);(LT_(<ZP+`@JI&_A"4[RJEU8^,355HC#!#+D\,=Q>PG;"
MPS0\>S@^T"?@:U4O)4@8];Q[1N?"XA+;+510&.VFMT`$/Q@:W9<>P/*\`RD3
MOEG>)SRG#$?MGM`+]O(Q0^!X=I0H8/89@P)D\U/$7G0?NX`#AZ1`'8>![G@A
M?H)U*EX/HM9J*(_86_[>Y5L9'WK$ER_83Q>E@'?9-DJH!"4K>M%XV)J34C[;
MXO9:45]1MJ.ZGY(Z7`E),3&B5;/;3@MJ*W@N;J^4^LIWM*BELBIMNPM71+6@
MM9K*6VM,`N%RWGQM(E$Z5-$29"C\BIW%,]@G%VM84`O\)>!^EM!VB0V7JF2*
MIJ/T(>RD0=!)PO\E+2VWW6$[2F`?$@0;(2UW[^A\\]9>L(5RI0]'KQLA+M%Y
M^W#XNE+QRIR2JO*E].'X=2W$6<]A'XY<UX)78"0H/V!M$A[:#4&E"O-P,AKR
M@8?A9"YDG+S#25,HV96&DZ50Z`883E:"A'HTG-R$@X8RAI/O((Q/*$]U:.\U
MR+KB^W%\M#(SLHE'IA_G067FM#+XKOR`YW>?J1/.2[;:`[%#=\.4+L%(>^9,
M66.%"3T64!4==_R<69`[MQ3GVZEP_0J.PY=37MI'#8K_#6(I^D0%Y(4+9X;`
MV.,+!59)*+X?<#0+.#8BX,UWJ/V`+;J(%G+9_2^=/U;Q4<;25;#;KJ5#BRF7
M8N7A`8?U!\)'W87;4#Z>4J>G286*MDW.+DI@[1826MZVEU3O=11SO^L)PS)%
ML9?BZL5Z1F2![6O*DBH`8#<%?!LI?>$:#&329B+6Y4TRT`X8ACV96V/AYL`S
MSGF].@'KY?OK@"X2)@F-ESCZ*0E-T-DD.Y6D"Q54Z2A]DTN[Z'"-62GU@L9*
M$A<L3!"LUZ_$6V$K+"Q2*A?$[950+UDI8M_R$"TGB>2$JU>P[\OU,:DY->A-
MEJX,MS-MAYE0I--U;D)\_;[F+CJ%=QDP3G"H%40;T1?\+?Q*O`RE.FN'*_'X
M92WU)B`%(VF$.'0O-)S(7%_=4+4QC64#J?-AEUK`@M.FB2;7AXP<:7P53LL^
MI.=(8RTW+Y1GZ;0)562%*+\%X3M,ZZVTK/)5T^NZN'J1A%2'"05Q'_7I2.5U
MG6J9=IDX:?$KK7YAE[ZH[<(U5:$&F"196IRC[\EWK=<?[GVF7HVXP'#R]V3#
M!<-)XNL^/6`XF7N-7"3#R>IKXED82.J?;.;%<-+]A"F<&ILD^[_$6VZ_/IS&
MV_^]+02L2HK7LU"*HCX9V&(+5;EMHDNJJH[`)$W1&.K9H*!FUW0,\8WVB<=3
MY#U?N_2;=P.&(<.6KR2Y>%N3Y6HHL1P79^38$^64WC.Z=@#UI]>O'K^U<7,F
MZ<+RG75T=5YY:95.'J4D.3AS!/\2S_RDN/,]PTLG6(H84-E/"1I^F^/-<H4<
MQN=F"B)](8S@"1HK22N&E7)!;/Z#[W5KY(;;G#]%C+W"8BG+LY;KJP^J6@EX
MM890A9%O?-P=!+]&)];XZTWL33V+]%7G[XA+O8!5E<O:>]AA5Q`=2K+YUL%(
M[F\1,"W?2A&EF9?M,@C]@!?SN>/"=`HWV>I^.J"Y(1=6*+R`P:]<1^/5.RR+
M@<&T=9VN)$3)P?3"#3H,ANU5G)`FU54/3)<@'M9AS94FDU?<6Q-DT=MS!V^/
MA5G^?N?XH@YYI%*CZ8%\HS?''ND*^5EC`$WP\4.:J7$0WTHNBZVHLQZXP!H`
M!=NN*FA;T4UE+=Y2P;S5I)4#?DE(#2SJW!75UY2%?U0E[S4>1@F/-W2&1,$.
M]"M8+0B$"J<S3IBY8U,7.<)<]'ICF$-?&^]^D7NBP+@0L+W&`'KCJRI<7'\@
MC?"FAF/#^2P:0&]\S>:S;""-\!:X#^OA+!I`;WS-YE,W/VL_CFN"P9HD@O"$
M38:!K<!(__7>!8$*HI4[X59+L9%18P"U^)(\G^V**968"CLIP<&HA;$=%LRZ
M=,*=RP\8YE<U);E:4TH\ZCIVF*(0S#S'=A`3;Q?[C*B:`P]@*T13=#</;ZR,
M_2X24(5=%6%:.SR*"(KK)0UF_CQP$R>+&(NXBYK#TBE#XP29>P3O/X\0"3"4
M=C''8`=VH#1*0SD54KG51!F-4387%UGE?@M!8R5T!ZM5E&N.W"1X=$/FE"U#
MZ[Y"B9+MK2[1J<O8OD0M:V6'J_3A3+ET2CFE;][CH3A5TZN5LD[?S,I#L4ZT
M_:8\TK=V]:%X))&RD[)+WV,Y!WL;9>.#*=/TS?<]V!H3)%*E/-+WH(^ZA24.
M4J9\T_>X4%NI3(+,\],M+KS1=_6TR87F(;V44_JNE_I!^O*WIR@5I0_'[-KF
M@V221Q].U;7+FH*<LSZ<K6M[?12GBO3AG%W;G,@GE_3A\%U7NV9YXJ+ZTWO?
M7Y68YBD(V;H_90[U7EP-V0H?Y`(^O;@SLAU^5(0R^W!ZM1U.U$EE4G_$M3%7
M)%)=BM='=2B_#U5<6N+*/H'S/I1V:8=-=;+)^E#[I7FVD51%!'UMTW:`=^-1
MZT,ERM86CG0RG_*BE:9J6NMU5)J_&F?ZOAI[H2^51REZ?9TZ>Z$O57!3UZ^^
MIJWD!<2USG^GN/5UWNR#>^<T?PI8W[B_Y)XOFWR40M;7T)"?X_W"1"DO%%D3
M@RU!)#/)]=+ELB[8[7.!O:C4O`_87(&"NE6;#UN1*'0&/M'X#43N9N5Z7U!D
MYZ=74S>O4*17]8F!G4O<G:<LH24-3:YXQ[GB)B1D#.<#&D\%6X%R<:N+TJ2+
M7'UT%L29.Q:/*421Z+!@NNM8H/8^P4,_P6;VAY&U.LI:R;D3R`BYSD8F&YEL
M9/)@9++LEF'DM&9R^F?*$\PHL3`CJ3=J$`):4$JI"G&6!JDN1G$P`M8(6"-@
MN[IDI'++,F)5,[%Z2Q'QHJ\9LGGV=9B=GQYA\5H5MGM41M\Y7/,YLU;SM=%%
MS8=2LWE8`KG9,BR>^F9CJ4`=GY`J7<C9-DJ4CZI[4O-ZB+!]KZG__<RHJG7H
M+;K<2$1RIJU1L`>E8+=_$[-($5"N7+8--2<?E%\X;6RE=IV1#;4>]:==:EX\
MWN=[[@YUI9\6%X[K8AWK"*QBJNM>YJ>+`R#<<;:.6@_,MSY<DUEFX@0FI41/
M8^H8H\%XY0>C:4IM%LKM)UW4#UUD<[8\C)?8!W$%I:APCI'7G<MK07R^Z>QD
MR=MK*".EC90V4KKW4GJ_[<2(;<W$=EJ*A9\]BR<TF<]-^RGU!B>]19<"[L>0
M`H&YYXC]UTF,+#>RW,AR767YOAN>$>F:B71A[;F!"?#ABKI:,U@L6&H-8<2Y
M$>=&G/=>G#?;/HS\UDQ^RQ09URS1O2ZIQ;MGT]%,FKR.2HP1\$;`&P'?B8!O
MO.T:6:^9K)]2L@95S0&,R=V">XEU@5-;XC$%CFN)7D;T&M%K1*\1O8,7O=+;
MJ!&QFHG83575`;N_FV^]I=PIWHA+NQ@1;$2P$<%&!'=H_99O64;^:B9_M^]1
M?&*(>,@*Z\L.6!P/2Y35F<!BN5%G!".LC;`VPGHPPKK6YF%DMV:R.[GM-LD1
M-#*[)S);9N**Q89,3R.CC8PV,GHP,EIJLS"R63/9_.C#O,0WT/,,/_^5MS42
MNB<2^KN29P>E4_:U$$&0[6^DM9'6*FX%D5_@1F9K)K.G=+ET_"C+F]A3&M[H
M@HFE3T9W30J+]]":@Y@D,J.@&(/;B/#O1H37W62-'-=,CG\*/)A?C\OS&7S+
M'ZV)_):DK'AWE.QLY+61UT9>&WG]W<AKV4W5R&G-Y/1C,//PGP'\>K7F?QN?
MN!%ANHBP0](I?`T$)`O;&P%L!+`*G[=X`1N9*Y:Y'R;\$3/D8?CC_P%02P,$
M%`````@`QX*O0-NX>J/!*@``A"$"`!4`'`!A;65H+3(P,3(P,3,Q7VQA8BYX
M;6Q55`D``_:ZLD_VNK)/=7@+``$$)0X```0Y`0``S%UM<^,X<OZ>JOP'Q+FZ
MVJVR;)%ZG]V]*UF6=Y7U2(ZDF=UD*C5%4[#-&XK4D93'OE\?O)`420$D2%$`
MJW(9KPTTNIO/@]=&X^>_OVUM\`H]WW*=7RZTJ_8%@([I;BSG^9>+O=\R?-.R
M+O[^MW__MY__H]4"T]M?QTNP<&S+@6#6^@@#SWH#?YK0AIX10+`VWES'W;Z#
M>^,1VCZXMYQOCX8/+P'^_QO@.N#/F^4]T*\T`%Z"8/?A^OK[]^]7</-L>"V7
MR+TRW>TU:+6B-C]3[3Z`_I76O1HE_K)T]\[F`Q@,X6"XZ9BM44_OM+IZ_[%E
MM!^[+;/;,S>#WJ/6U\U$K8D'C0`)!!ND\0>@MS6]U>ZUM.Y:ZW[HMC_T1O^;
M+.WNWCWK^24`/Y@_HL*H)*JAI3QQ"6:.>07&M@V6N*@/EM"'WBO<7(62[-`/
M`+G;\7^Y2)C^]NC95Z[W?(UD=ZZC@A>TY(<WWTJ5_MZ)RFK7?WZ\7YDO<&NT
M+,</#,<\U,)B6/6TT6AT3?Z*BOK6!Y_4OW=-XA$!O0"W!/ZO5E2LA7_50H[M
M:%=O_N8"^0"`GSW7ADOX!(@"'X+W'?SEPK>V.QLK3G[WXL$GMA:VYUWC^M<.
M?$;?;8-;&+90([2%_PQ_?0%PH4_+62R%2-C[UPC,SX:QHT)L#,_KN,XUU8_\
M%D,VI2%\"Z"SP<7H;[&`'$]1^=C#1"@6ZYHI@39VM^LQ;2:RG@S_D0B,=,:(
MNX9V$%M!,-AJ:Y'UX:^_CDT3<2+P'XQWX]&&8V>#?N/MX>;>,AXMVPHLZ$_V
MG@>=(&J>&$VX7E["=6PB%I(RTH.^N_=,6,IK6,KI>GVU'VW"!"0#=V/0:7U:
M70!K\\N%M?FJ=[3AZ&NWIVOZX*OV5;OX6R0:A+(!$@Y"Z2`A'H3R?Z:*UFM[
M@'HY>"_=`7K*`;O0`09R@!$ZP#Z(9QD^]M+@-CPS,@#]6&!Y6.+:=%'GM0M:
M*0`\>>ZV(BY#A=P3O'?=4/;>6KYIN_[>@VO4,=T@;;Z=`!BFM(:QFJ&C&,"[
M6GM4DN&'ML`7W!H@S?U?<QE_FG-TIG,,MG.:SOX<9I3M";A>5=DK+*$)K5>L
M\T>X?81>`6J.BRO@=58)(6QVM>%@F"'N01#X0D4I)N4)END<RYI`,![(6`QB
MNZ`9%)G#0&R>RZZBE"H'1<1`U4-.X=,%26O&Q/5$`].L\6)AE\"!3,O44><8
M?/GTR?I##87^N;=\"V\#%`PO1^6DDB73NAB`].$H7NO%`I0/)-5-H5SX;4:F
M:@^3R4>U^.<@)PUZIK5*D+[9$#T,^\&P-C-G8NRLP.!^)EYIF:AGZR`VT6]K
MPV@R%8L!6`Z8.2"4I(@!)YNE9\S:(3DMRVF9?+.DL2(?92ENY/FA00S)'Q?R
MZZAG2XE.MM?ICPHYHWKXJ,E*2J&'V:2!9,D93HJM5T.<?^S]8(LF<O[:Y>BX
M>C$\2$[#)NYV!QV?'+TL(1T?X0IZKY8)'Z!GN1LT172?'2+ELV'O(1<+YVY6
M*GW/:XS@0KT]Z$0]0*P/6+L@IT,X:`62:H%8+Q`J!JAF(*$:(+JIZDH:XW'2
M&\U=/(+[+\`/7/-;BWK43'K41-H\*]Z1E$3U=*\GXT,I[SBQ6HYID77QS$$?
M'MZ[/OK]!&'BP7-?K0W<W+Q_0B;.G,4.!QY8SO/8#*Q7LGD[?O0#SS"Y&S]G
M:4I5!UF3`6(3AGY7'S$[Q5@+LMM$]0!8$?Q'K`J(=`$W[P!K@_O-6!]P4`A\
MB512-J]2ZET]Z]W`Q7M=H7<=Y%T;NQ7]%O],>LD?]MB?EO,C<&.'&K$.'QK3
M2=9,:V['6.M'4],9ON)@'G_AS)Q79)/KO3\@G+^@3MWGHC:OBM3.B:^(X`97
M9]"+.ADJ"RP<$$L#L3A5_4,M!NI)`]52M!AL::H5V5^=,CXTKY[=U^L-M"A;
MT`]9DJ!??1TCIF\PV^]LXSGSG1A_EP#_HU;%H-#N#R.L1Y4!KBT7VJ<HKXLI
M?VXT<U&!H<NQ3TG7OG6]P/H7F9,OGF[A8X!##?!QT(,'M]9^R^MUBNO)[.2+
MM!$#4+?3ZT;H/P@$BR>`18)()@B%*NKO:[15/[+5?0(;;.LFE*ET)!#%9FHX
M$'./>J[=60X:M]!,;^+Z`7<:E5M%&</2BHBM)GK].(8F0ZY8&B#B3J.52'3U
M.2T<8@L/%IFH>G,XQ,8<GSXL+RAACN^CI=-V9U@>'C(G=+>-]R$YA66RA:F"
M6,<\ZL;!,U@*.(@!$_XNHX1QYU2;R&"3L`;O&RBE1BZH4J3(,5T9'7+AKP#N
M@E#H:5HG`>\S@=D-#+L0S&4T[F.-UXOU^!Z,5ZOI>J4<N7RD*D=F0:!CNHQT
MG):*]!L,VKTD7,\;N2@&V_(&4/1BZ<"DE8'!99]<%.?%)1Y;JQS316<Y[+*J
M,%YJO[\[[`XT%M;5'X&<:!.9>4P^+9?3^;HQW3<'4%P"J#\&N-G[E@-]?^)N
M']'"`"\1Q"]_B5:62!4QE01O+[4[;<J=2"I(B&W6-:[:[=8S@<Q*AY5R*$W2
MK8Q?5/`/GQ>.G0W^9XI\_6K8^'QQ'$P,SWM'B_2\B"S!NA+9)Z21X/)2U_J4
M?.1H']^E)#\DY((Q6CZ'DL\8VK0C82Q39Y/'O[HM[Q++QZO?P%^-[>XG0'Z<
M_O>GV>?Q/1KQ5I=@.K^=S7\%-^/[\7PR/:/EJ\#P`IFV]PIMOYG^.IO/SVU^
M8:=;M^%Z#'=\Y8+$7<"#7)4=<*EN*MG_EG!1<[I?&K@V<TP/&CZ\A?3?4B#@
MB5#>&;,5$TSF,.P/BOKD,.HT:@!$+:A97)_)!V3M/9^NP>UTLIR.5U,PFX.<
M'JMYU,V'>#&#\URHBLAWMOM]CAR"?L1A(SX)N7(V\8''(?SJ,`4L6/N?+E8R
MX4]15G#UK75&B4X`-PC"%D'<).D;#B=FB=#+Y*I)\1:$1'_1D//%O$5ZAKO9
M'$U:\/1E/%G//L_6LZGR+J(.\F2[C=.=JZ0K<;=;B\9YXG[/=;#:$"E<)B].
M62$RNXE2JHF!O-.)[CXGI-,)0E)^L_9,SN8(/>L((^6(=Z5<KX3N%+,KN$T5
MCUUGA:_WY%XJ9923S,94ZX*A7KVA=B"<ZP`B0?%UT5-LT;.VJ"8)$SI9'C"L
M50SU!\-;>*L`!T61M36:J)/;6L6?C%]3#1UX^@ANJ(P&709!D%"P\``52S<-
M\9*57JM4SIH:3#[BT278(9M?>=NC"BA5!%$.R?*=HYAV1!-_O`]>7,_Z%S<@
M,;>&&IIE]1`\(QI&M_12]*+"P$&:<DJ=8!Z#2CZUS\BU3P&E>/#C4(GME$90
M:.;[>W'Z1*554H?J()@-H]=M\VE#)36$,J7-XM/%XMJEC"IIF.72).F(1E!D
ML0]P)G:</E_T8Z:JJ"1+0A'!6+=N>\AG3$)<0VA3S4`^=]Q\"Y41B`'"7!8=
M^44QE7(#*XZ*J:%,B?/CWK#/&E@4)GPYP8Z\-0SX2_NJW=9^`EJ[?=FF_SN>
MEET"?739Z?0N!X,NV7W3!Y?]\#]3@Q+Y8X)CP/#Q^R'_93A[PWL''>V2O-U!
M92!070)4=P?QQC6TE6_DL;#,86'E@W9C"U\PG]#_A6S"O_F:3/PR?<,_PB6T
M\>*,-+?8D:"Q##9*U:R9<QO7W.--2])N=;W$)D3#84_[VL$PIEL,[A/-,P3<
M'<TME$PT!&EC)`6'A].7;/8>AF+P`@$-P;DZ"X59O=!Y/!%U3`>;0[$@E!MV
M5Z%DN1W6>4PF?=@J^<W#SZRBSZC`6-R-E/9,33V+\PJ]P'JT8735-__,3;B6
M_!ZE2"<A0`V[(VU`>Y.$Q,/]=5D':CG]18UV:LKM+.HI:C16SQH[=P,UJ5I*
M4B_1/8BY0\UT/];MWG6>U]#;$O^&KW)P)ZX%M:0N!G)U$<P%U(\C=A)(P_(`
M%D@Q%SW,HFJQ4)>=1XQR5#&J)`K3\W8!=]0]V)(6PHM)GQR#)@V`FRC51D%?
M6%A;X>!;H)L0NOJ]H<X8A(GHR^A6W25(B(]SRR@;C.NS^ZCWH'U&=)E0FM7"
M0W-]IK,[E$OU*74J\I<U<@MY2_$(GNP`\R^C%U52,WXS5!$\UN_U.SP"1J^I
M*7U[IS8C>53#64C=)_"7?J]SV=;[ZJE7#IZ<D9WK*S5$\X/%4YBXF9>&)%M(
M*I&230OFNM7:\9ZX'^"L5%%]53RI:`/EQ6*U!HL[L)HN/\\FB@/&F6A)X_S8
MUO/G[`QI=(>Z!L/^'VAX4V=S:P39E5Y^44F9/'D*".;%''2C02&<@U%!`$L"
M2!3`LN2G^*S!*KV*53)R?Q:A*TH#FN\#%;W[+7R"2*?PY@4DF=]"+>>0-XTJ
MJB2Q]\]711!;HVX8$!I)"R\H09JB,%[,S-DO_9U_?*C-2L*@!P_BEZK`4RIO
MX664+$CE\"$&Q^1P(N*:IA`+WWBJPJU,/<7T2FDC^+B*UNGG,NP@LUDDJVIK
M+L]LO+^*U&&F%%;)-"8^B\C&<)$:ONT\:%JL33]V$:DL.C0L!J*^WAE&A#G4
M5<6+2MKK(MK+0_LQ.M+`SMJH!L.>]6K@`*+$8_#Y.UKY5:1BG*^(X`5);3"*
M,!_)`@EA:K>R:K)/S]AGA\*4!HR)X"[-EB)?-(8]A]&IS'=-UE+-H8,NHONE
MW4$NC0X"&\2D2E82,OUA>)Z!$TPWEDG'&"PD4]8=M9SHWH8'H]&_AK.9.@'R
MV,QY<KTM&?PX64\JU)=]JEM&.Q&,]3#(VO1<-Y()6B#^$<?]T@9`HH5SIR[A
M'NZ>R7PM97Y"N`+;\X]XS^0`O=;O+^7DMPK/X[/?\FX\_^9]I`O=-Z4)IN[0
M[[*G405E)6W?<S40?==*&V5H%VYUAPG4B"SY^_=UF*57,4O&!GXAPJ(=_`(O
MR.8"/D,08T*BI!(>Q.V+GO=$#T=DX4(.?!K!@2HF,1F0;Y)\_!^ABHW^C/WR
ML)\8BNXM!\X"N,TC`+NX9!:PE!#M.?M9*J0F'%@<(/(D3[MJ-$^O;)Y,=N3A
M+DL1OD/D\>0ARD_-B73@E)/,C%3KHEVI/LQ0(IQ%J(MO.-4<O:PY,I'/1%(6
M\@S+Y6%]C<3F?!7Z9\G(QHT*(R#;Q^/*ZE!<4G5=2'69B$WB(0O4@W%*]JGW
M\`ZI.WYZLFP+,:7@@(=76N:^-%L'P3C%3GRLLX<`RP&Q(,5'.B>;I4=F8?P!
M(Q*D=`<Z'UVIG><\^Q4R8X$4,M''PSG=7//;BVMOT'\)T:2@JGS.Y"HDAK1V
M+WKO)"90))4F+#S(;02?ZC*9D&L)36B]DIL,A&-N*+P!%!."*8-O`OY11+ZU
M6Y%ZA17E$J]`'<'L[)TH32BFW=IM+NGJ,S<>SP*W*4P3Q&2&9T(N4<&RJ>$Y
MEO/L1RE*;PS?,L=HR639>_YKY86U)/*K0!?!V1-:-E!R1>(.N78!D4A2Q(<R
MU3"K/D,)K6[&J]D$C.>WX'9V_VD]O07XF9C[Q6H%'J9+L/IMO&0^5B6+:X+(
M3!)-R$/GWP(@YY,6]->,U`V,OTO:!$BU*KH5.@QW`:+*X`NIKF!CMZKZNJCZ
M,C8#F,B(=@,8%DK"ZOL$C4&>8<^<#7S[';[SW']<3B9VLZV+;@=%H?YA<$0H
M!1`Q`,E1A.43S-'+FB,-VSPDI3#.MEP:UL63U(I6DLN"D_.XMOM=/4V))N6K
MK=U2G6/II:"I$LDCF+JVC(NDT8JN9)9PAU-R.,_X^0-F&$A^<;E48BHA/+EH
MITD4WA>+I0$J3AE[3C5.KVB<1+[D8B[#E!QWR.+(K;LUK&RP\/&?I7*`-BHZ
M^6B/4IC_0FNK6@Z45UX75%X>AM.82&,V:9XLC-Y9-O0F1@"?78^_$,B4DHK8
M5-NB_=FHDP(ND0$B(:K@6]42O90E\K#,Q$X:T@R392'[8?]H6^:=[1K9DP-.
M&:FH3K0LO!),S^*I!$!$J$)T-2OT$E;(0S,#+VDL'QDK"\E+^&SA&P].,#>V
MW!W&HV)2\9QN7+1S&_12D#X(`5B**E17MD4O9XL\;+,1E(8WRVI9"/_LVGLG
M,#PZ7O"7D4?EI&(\T[HH,*(LI2$P8BET+%>V8*QNC5[2&GDXY^`H#72FX;*0
M_@>T[=\=][NS@H;O.G!#'O'*O@`L4%XJ\CE:".=.2\]<L#1`Q(%('GUASE/%
MA=/MTS/VM;Z)VB>/'0782[,DUR5*0A?^N:<[H#ND#;X@RMA<*2@K,TR!I8'@
MNVN#0;352(2`6(JB#9BZ;-)+VR0M^"`/6ZF0`[X+5'#BSG*L`-Y;KXB>^*[T
M,T[?._9]&/C\%&]%E22R)%\5P1=QV]'"F$H#1!PXR`-4H+K,;K5920B4,,P@
M,E021PR`20:).$,%E7Z%#O0,>^QLQILMTA$OA7!6E/!E*<ZG+:PED4P%NHCA
MK*>WPS5Y*(X$PJ4%1F^DJ6%3?6;J23-Q/@TC)5`EKP31F"26D%]J2>3SJVLY
MSQ-LA.<(/H)66$5VNIX"A810-.@/M3!##Q$'0GG->/NL/@LUM1;FY]VISTS]
MR$QE*70$&19GS1%R@I)1U74W/NJ2HGS[TS?S!7T'N+ES/3J7GCFHHR)<_0BW
MCT<[(:<(DCGVEE9/<)P:MCL1_U`+9#".V@!Q(P"U`L*%U:$=\(6VI&BU>%:7
MT$=,J62EXW1E?*>&[HJN4L7H[Y:=]]7IGR6S#S<JN!<Q'"0XA>NI(TA)K?4B
MK67B/HF"+)H/=BG!J.?Z_H/G/EF\/9!4"9E(/;0K^FR"%JW'<%5`ZYX'L&Y@
MV+F`K:1\GRB_Q!>-EM//T_DGI=>,&-!(83=KH@KXSAS3W<)[I`F^KXNF=8'E
M[-$$;[&#'EG0^#?PR?4@+;<VWJ#_T7)<CXP3J-N!?H`&D[04.HQ\A,&+B_[R
MBHK@P83WGI94#2323Z)=8@SI:='\C@H%6"J]9'_0#AS4`U0_$)8F&H)(11#I
M2*:)1P+#"2+5%"145=.;-/-;D-Z*W(J\F=XMEE,PFT\6'Z=@/?Y3[<MF"CJ%
M9,<H_6NIZWAQJ#C$FG"241>6EMZA'>D@^$Y&>Z"E.I]8CK)4RO79I5>P2RZ7
MN3@[YAW'$>HX@@A>O/,K5D4Z6]B*B&T^='K#-&60L&9LAM9LHYZV4>U#]2*8
M.R9-G@^4,@<_KFOQ<FT<E5+!#]JVZ+LRHT&6$N0!:$M1XHSJ5A#04_7)RVF;
MO8>GW\$+!._04!*]50`>)NJ3=BL%>GCT>`,=R-^*X996`?RT#F+]I3[H'1$@
M.B('H23%3*AL5OB0H/MJ^3@;,IKA`XL:&1AOC>`#&V-,7K"\H(@?'C1\>`O#
M?S.)$'-V98KJR>5,OC:"'6^G?V`/$00BB>`X8^>)>Q7$Q'W\@1)&7COPV>!G
MP*K3V"$[:Z?J&988)#/$$G%*$R@V<\:FZ>Z=``V-[SCA#@Z3,4UO#S>)9Z\$
M/[ZH,(5D%%-1<#G=B>*1CQDZ<T#4$`A;H@%CM*WDPV_*AL#S.H:,D+$/=J$/
M2#19Z`,[WP>J*%Z.$GF\+^/39G4&A_2NI>&3K-H(HA\4$D.O/NJ.1&A]D-N0
ML?=$DX<IPGJYUJGGYC%"Q9B8=4TS>,=\;%+XLW-J*V4?4R?!0*;X57HF`=G/
MIS9E%#W5;CUEM^6`[TUZ1[4D<O,IF>.JAK`RG1@<!Z()9]^N+$TM:T5T%!M3
MM/X@;Q@]SIE/0CAKS]]=X^A:MW/2Z]WKIB3W/I$'!9P7]V$S^H#P'-]YGA@[
M*S#LXK-O80%*F<Y32_"9[\%(RR%W+!R$TIMP;EZ_`\A8/2$1R3X>JNFU0[+&
M3:QM/S2+S$6`SN=OOM<:0MG@!7JQHO0*I3@LF)754I6ADF"6>ZV;MT-%!"?(
M.N9>FU4RWIYH]Y`>T4!R8OED.89C8B--UU>24*L:7@O8R/50,Y@8>C__JG!Q
M-:7L2RLC&#$Y&G9S>!>!LI;KPC42KK*I*:I!6KUA<U@V%//IQ?*'&F+10-$B
M'F5*2:5-JFW!8X+!X80SC,]6S8BJ5@Q35D"^%?((P(1,&N\,:VNY!Q])I@$&
MH7RTU"/#U1T=B0U[@@9B7_":_*D29=^B/TU?L;O9O9X^HI?L8^"%<38_A`W^
M2)8B=)87-PI(J\VXBB_-31K+35$HTK@13LJ_S2_-4WJS9LTU]B=Q4H`Z?*ER
M&I`;))LLHF`"(!Q8VNLDH@-#7JH,C:VDOIY2OWFAL<=X84T`J@;%\D9_W]\C
M"L'%4^)5EL^&O8=W+GWT\0;-KC<X5QPB'G\(K2)&^CA?7DDA>`V[6G<0#NYA
M$\!]2C]01)HAD:?DOUND)9!L2O)@?E9?:"E?+)B^N(M\`23YHF#,/JM#:*8/
M^G)3X()'""R<B'1#$.%'J5!^F+L!!%KO1W6#=_7NX#!B5_6DDF$Z5I9HAB86
M?]`C?!\K&WZ8A3>Q#6O+W9<N)T/F0%]&,[$5=+<;Y1U)\IL2&<_-HP8HOR-D
M+SQ`&U$T8SB3'_1LG^]3BB=9K712407=J5E'><>=/P?Y/7PV;)K?>?QFL?+L
M'Y60E&<\TZ[PZSAAZE=2'40O/6$)"AZIJFZ#7L(&&?G".3B),H0S#54Q!A5'
M$:J*%"P=%=<=Z6$TX-FC_8HR<U33G63.6&/938EX+XC4:T0T7D*)3)`0S8Y1
M_(DXU=1@G:F,X'W#7K]S1(#C:#DJ4CDQ3C64LF6Q'M^#^]GX9G8_6\^F*S">
MWX+5>C'Y_;?%_>UTN?JKL7/]G\#M]&XVF:T;0J9<H'(8EN.O)M*N(/Q-O'J#
M:%@N\JLW;'>%Z:@\[NT,MM,YF3`WE8:_E85S&9*J#WU+:)@?C,XJJ(:`I:*D
M=7W(&/EJ"0NO8:0K;TIB)FB&#TDW;T:8$\[-,[X9V!<?FHXJ*.5"J2ZXU^EW
MVEQ.-&FXJ6X=#:O^M%Q.Y^OD)+`I(PD';_E,:<!HX1J.CX\#_/7_5W<NS6WC
M2`#^*SCL(:G*S$B494DU)\66$]4ZDLJ2D]W*88N6:)M5MN@A)6<\OW[Q(/@$
M0/`A-'S8W61#--"M_MC$JSMT=\F&=WHA4N,P3DM9)CEK,D*]=_EXP'.=T4X0
M[071;C)G23(]V7&.Q)1E*+[JR]'&H&WC\CF>F]L,`O5BAE&))Y0?,PAHL7/-
MTY9]OAA22NX+0U,+-2@HBV#_&_;D`^[MB1P<\17:F,)&YCY9(L1ZV^#L^E%,
MJR4@$HW?PX,!KTY43H%M52SJ5N,$J(L,4*K7`Q10FE%'VSHV8,>O3Y#KO72Q
MA&_T:O[TBO:`"$I'I?F>/Y.#F%P-HM?@V7$'+MT.&KM0/DX#]=?1CWQR+@>%
MWA.Y@H'V[R#P5?JTBM8*Z]G`[,H+?9)B/G_Q2=,[9(T!:14/27.%;M2;R%!E
M<E'I,I\=F+;6FC)Z20IC^G='5D[C$$@!92>2V%*X3;"JG5E%JLJ`$)@NW`..
M\<O[M(:$Q!-$#QK$K]R]WBI?;W(^9J@Q">2X7RH#!JI6NE"`EN&#N_?_H8WI
MQ:OU\?G9#=_HP6WL;OZ6%`UF:<@(3ZO@R=\"K_O+/2W+B\PV(&QXAPLW>J2I
MEW?>[O/;;40*9E_QFTK3[<%_51U\JB/`)$O:P]),)C8<<\:\`R*B$9>-/K\A
M(IU<14_DH[0#F)VUDQC@G!M@2PQP)$K[^\RU-E>IM#$*:_MTCLZ:AK.;VHI=
MO":"K*2XWL&+OC-L2C/XGN!);<+V"J?KK^CJ>OECC:YNEM_0U7PQ75S,%U_0
M]&(S_PZ_>=C<_9N!#K_9*!DKJV;6(DP+!<`#+AB6YORKS\N8*L%.Y-L:IML9
M(!^F7[@![M[0!Q*S/[ZCH*WP<`V6I6:TF^%F05LIR$JF:Y;;&X_.&K)M:]#N
MQB;"H#U??)^M-_8';0WW;P:ZM4$[33#7,&@+!<`#+AB6YD7-_D#G:SR36-'.
MH-W.`.*Y=9`H;7685OBT!KU2P]E-;;,PK11D)<7USIP.1[U^0YIM#=/=V$08
MII>KV<WT'81I#?=O!KH583JM%RYWC.PS9C%->]8]-LH30!`"X^QLI#D85(TT
M<+@&3R<;ND:@;S1T%LMG&W2]7*^!:2[[=@'4HH8@#&)5TKUQOI'\S7N^\T+9
M;Z-L8I)0Q4`T3]N->$:FO*STQ,1/)@XJ+':C87*>$(ET!,5$P_URU%0:!`BB
M9+J02\8H_UEESYO%1SP*S?=M<B0P*ZB0DQ0H>G2@6>:.8T#OP=B0#KS2T0JL
MJ*Q@%2A5,[KJ=C:`4V]NTN\[_4J`X&=F'2K+CA=MOLYNT.P_J]EB#3WETG5'
M+:S:3*@D*4C93:T@R>6[/K@'CR3RE"V!:+<RG6"T>DQZ?C3J]QR63Y3=5CP$
MF637J=!38R-Z/72O9S_5<P.CISHQ:*?*.FU_5"-90/6)3))^ZEH)(B#']>N4
M\[W",P8#;:YGS3@SYJDVXL;`,[BF*C@9%2!#I-!!LN%0H""((_.0'`=CV7JB
MX#F3#EWL73/]GC..4P>FB_<SQ73D]#.L-HID9U:).C;,KJ0^E/-WL>96^'S%
M+$KQ/"0#-0]>#!TI"^"3I2YT<_*Z<3!`)TJ5GJ8DQ(+/G/R$3;'?)'P2@HZ:
MVQ_#_F!2XN+D.U#:8:*1-C10?"`[.1_1?'&Q_#;+;=TN%Z`[/`J?$M)@PVX/
M3?:BG6U/^K1)'L1CT'N?CGI./(EFJ8R,9=^KC!.MM9)5S0`E0NU=.2I4!K"!
M#/WD*UHM`8EIG(K$Z9T-9/18E7RE6XW9)7)2D8BDLYCBZ>V3[QY`TW_5<$X5
M9%:E7:&#*Z^EJWYBT=.FP2J/03,G^!F_'\-@$FSY`,+32BLGU<J7*F(4%;E;
ME?"0:0Z!Q,I]H\O"FX#FF0F]54C&=GA;X=_@,-WO2+[FEV?Y!UL=`0;!T1^6
M9JJ"T20^MLXED^V16#;BPA&53A-9)O*!ZC&?Q`"T5#,]Y<M*G`8A>L%#?R1Y
M78)[<OF,F8%D</!4!C"%9GWWSM):UX:P`//,+.LTQ8QLQ:&J$0BHHJ%HKF$Y
M(P&<22JBK$!P&EMJ.2ZF&WH/V8;T?%1,GMQ>(+1A61Z>-K*2!BLW7(9T:W5'
M"RJNO)`.4^8$FHU-TJ<U),V-EOXP_MQ,I,:9^;!<4G*028[KC6+9#$R83]#.
M%7?RBD=$["<<)D/T2B2"XE?+:7,8UK`2/(YL:6IZ/#SB-\8_\G=Q12,P_(I#
MT5R:&_*,ZD7LXJ6Z5*`-J+504HQ87./356H)@YK,(>6(B:UC"UISNMQ;XV?F
M#8"18L/07%X8]<^4.,VE:]XP*-563HP1_%)^M<=5<9,U!3PS-$9J_9#QDV"4
MT/YU/<CIB?'X+OO,,8U%76TJOMS0OWJ_]WI]]"<:?NKU>N0_Y9CS)YF#V;`?
MIG!!.3T9BP%A0Y:3XJ,;ZOUAR;-FT2F/0.\K9M(;#!)XZ`H:OW$!NC/<5B,G
MJY$-A^J4#E7`0*9Y)W<I\O(C7OJ&E[6*(N^@L>O;3I3I6Q<-!ZKE;Z.A,QFQ
MJQB;1P_MTAWAG1=M0_^.G$S`_W`1/+^X^S=63#-"+[%ODF5I=K&.EQ!TZ7!^
M-WM?X_06$KUCHDQ]+5[RCO5EQ\ZZ(=,X(M.`7>UH^8)([GNTLAM,S`^VGK>+
M2(&'2Y_F\V)YLM,*$!?!/@J>_!U9;UH?[R)_Y[NA/']6*XE&OQ\:CU,W>?-H
MPM\`K"M6)273&4D:GZFE@K(=HFR/4!\D)DSD))N9(2U%AU6GQV^VB6BRO1+<
MH^_S&>S73&M4\M\\+8T+_;JXP:\ZMCNTO*?WW%;N&RDCJ.%,\J9`+P#9@#2S
M./>&YR+24ZD$=':_,18,#W0'*CLYE0DM?WR(A:)#\)$0_.J%!Q]+Q?/R`_1D
M1-]U99RJ;08$I/@DA/XAUGHBS`*J/3#-=:;AN9.`*CTI9,=W^(FMX.2LX%:=
ME#)(:6U_+M!:TUI64;OPY`MNJB8V4(D'HKE//QA,-"C$\BPCKIZ&9<*2HWCH
M-[07:P?.6<8#M;A*;`+$T:L?X>G!51!>!L>[P_WQ*:Y.I9B>*IJ8Y4@Z$,W-
M^'%OG'#$9"$L#'%IO%`7W.RQ"P4I1I_='=IY=P>^K`V,3J73%="IL`,$.C>L
MA.G*Q5!O0G<?D537>+ZI_]U82X)!L&J,2W.5HG\>+^7&HA&5C;+"[?IF/(T)
M'+4)()ELX,U91&O;"X;8=/*9'?`E?B]*_4#5Q"B3\H'H>>#@C)>VS:^JY/V1
MR`,Z6MZ1BN/<%41>:/H%2P(N0J#C?GFFJNP!`]'!]??>;N:&>W__$.%`?'P^
MTM%=>O?^UI>C5-W0*%!5P]',$3SI]3A63"+B(E%&)HJ%0H6S#I6-B[FGJNWD
MJIEC2]<K\X3IF<4&SI19YF0/`_)4)\]V;^)(&8+-0-=:JQ(LBO<`%"SR_'0J
M]6&@>/7V1^G.>?K/1AV?=:KY!AV<)5]AK!V48]<>-9N]S+[/%K<ST.1!12_(
M>VQ6+P@?76^]O1OZP>T^>O&V_KV/@TGPC#&2_!**YPUZL704FM/;\WY\()0+
M0AE)Z">3!?02[T(W)ZO;)VWE3"%1Z7191BKL`0(-/8>^/!ZB@[O?X5`C^RG+
MSYF$I-B[9CXVAY<`C6_>9"2<A(@7#_^ZN]E^IZ2BA3)G;$D9/[?UT`=_']\C
M^'A";=8'//<]E3[#&OH80UJ&1`YEL=(@"/L/>_PNV9+M+;8XCX>S"I[PUZX7
M52V%ZS8V";O6D'1O%_3B!?",5)2*15RN!4O?G>O-0N?Q^=D-W\@IQ`H3@#)7
MRX=S(-:P&@B=/&\^V7<^O)%[!<&>IM'_VY=-IRK:F&11-1+-,SN37IS4(1&&
MF#24BD,_B4`H\#I2TLDI^:F6EL9`TW'''%_5Q@'%ZMK?>W/\QTJ6,@]"`)1T
MKYG4<<)K_*74_"0R$!4"34H3;9QZVA@GHN1)0@P*FH/Z_O*>7#ZX>@I^5271
M5S>!X$$P$,WJY\ZD7R1C><\J1U-QX/GT.]*QP$M00T?C["@\44B1U#+`/"7E
MCE9!Y).#%/I<*9K"\"4=D)X/#IW!F8"SM,05%VL3;UWH7.:NMLX`_%5ZKH3#
M"HL!\TB32\0Y^]@'J#Z0JK8P1,I'I'TX^UR`9%8LGW18Q&0G6I>AS(IEU_3U
M=`=@L]J+)7!6F0Z43KZ;H;.0D7\6@K[L"#2WGYQ)B;9DD\V*]8J&.A77*324
M,@Z-R+F$D)1M``K%1G&/N/@0!`8;_8NRH\'0*2U!T/;0?E]7B>+*@UP)XWZ^
MD5W>%2D+X]G%$"3]=<H/&O7P8O>:1Y>'3K(\7?J,@JD_UDJ5M$XEK'_+O";O
MXV)%[?#S^7[[=-S1W:203HP.+&4ZX7$3++`1TH3I//.%]B_:3#@H3TV&K.>X
MY_WQ6,H@2OI%<<<HVS/)TY_O.\E+`WC$P[3QLN="0,^"F%9\>&K%&[RM3ZQR
MIA)Q5)X#6W`GH-M7J3I@-+?U^PTRE4M@W7;R[H).O>4E9S+HG2#X6+`"!V1+
M-MO:+"_^_75Y?3F[6<=OILO9U?QBO@$M"7T:`+M_1=FPS%?4@Z2-TK]C7Z,]
MZ`M&,BK-7&(CGHY9].X@HNVZ77\*]9V"^CQEK@7WK6K[L!IDI:W`&&4E"_JJ
M7SQYQ#1I<<>ZU_;&V4`<E\E`?4!4ZH^?TG#E^CSU?W"/ML'S,_YNH-_J<7Y_
MY.])BL&]1Y,UH%_^X1&YI$`@VX*-T`?Z[NB/8`_""]RK1$C.1,`07!Y#$F;9
M5)4>T%]XO^@_R3>H]!K#@*,8DN8=BW/'$2#%Y"(FF%>EP:+9OP-=C.Q<[VRQ
M^1@[6VZ8U')9"7*51K(.1OK?G]W(VY%3Q-X^$E4`:"7)%DS%X]/<L1I-1&%0
MR"S]'T0[0MF>+"2XM4DHS@M2IY2<@J31]+<[JODV(Q!M<3\/V#3O`74U$-K<
MJTQKT4N`U@AJ&)"+;>%!SX](MP+V>%*)-BMN:FDT;JQU.1A;2*780S4X%)G%
M-O*ZB+Y*098PV2+0#,\&HZ$FH.\B]'9CD'J1UU:N6P?;2F."$;]\(8,@"8[C
M\CTJ+Q$\;)K<TA!T`TGO/$LG$T,S</,Z3(#TM5$J74-%`5/*@FS!:M<J`2/1
M'P2*XUWD_74DEU9?R575RKT*^?,FT9"-0K?`-<_EE@I"3)(-.P\=*.<(E0-%
MI,K1<I2H30`#RLO+$SUEZC[Q"WGS_7T0/KLZE]]T6QN%2&M,FM?!TNV]C-CT
M&B;*2(;?[^]<<\;;[6IU/?LV6VRF-_]%E_/UQ?5R?7LS6Z/E%;J8KK^BJ^OE
M#S1?7"UOODTW\^4"%LA:#IW'LX;]FL,:>=O?'X+7/W:>SSC%?RCBB?^O_VU"
MEYP96+\]WP7%GUSP[P80*_6JN2UV?AY_M<6-$6MMEI(V@W?T!G]J'Y=Z!?%B
MB7Z=U"#^X?D/CP=O-WWU0O?!6QQ)+E(\!_*WE_[3D53XJT@BUUB*Z<K#]<>H
MY4;GY\-!CQ4=YCV@N`O$^J`7&DLYZM"O1X\M,OA;6H8G'@4B2P^D2G&$1TW_
M(?1>@I#^2X1<%.&V3Q["ZIUF0B1Z.YS>?GV5_9B-N'T,I?M35R(^J3'H.^G'
M;/[EZV9VB:;?9S?3+S.T_CKED7GY[=MR@>@Q/+2\W:PWT\7E?/'E$_H\7<\O
M$/X;#N;7M[@U6.GBYN^5I&IQ4QNS%TNL^346B?^._X;_0!:V\%_^#U!+`P04
M````"`#'@J]`=\N>!_P7```U!P(`%0`<`&%M96@M,C`Q,C`Q,S%?<')E+GAM
M;%54"0`#]KJR3_:ZLD]U>`L``00E#@``!#D!``#M75%SVSB2?M^J_0\Z[\M=
MU<J.G61FDIKLEB/;4ZYU;)?MS,SN2XHB81DW%*`!2<6^7W\-DA)%B2!!BA1H
MJ*=28UL"P.Z/0.-#H]'X^9_/4W\P)R*@G'TZ.#Y\<S`@S.4>99-/!U_OAZ?W
MH\O+@W_^XZ]_^?F_AL/!^=DOIW>#&^931@:7PR\D%/1Y\+M+?"*<D`P>G&?.
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MF,;2'PQD^U_O+G-J.#/N^WP*[X21\"A,N^N1+'JDU>K1MK+?0<UO]S`RB'S&
MS>,%9?#&J./?\H#*1XQ\)PCH(R5>?14TV]VE$K>.(`U>1HW&PR<24M?QVU<+
M!C2(MY7P:1/MB.;2X4K3]T^@_1/W/3"-YW]&T%%/F7<#:(@1G\[@*\(".B<M
M*%'O2:V_AI$3/%WX_'MPR3PJB!MNI<QF:^T(?,U#$CSP96]=/C*X=L)(D)O'
MFYF<):$#!_45J-5ZUPK=TPF#\><Z+#QU79A_0^`+M]RG+H4:Y#G\['/WCS:5
MU'QBUXK_PN&Q(PXSK&!G-'!]'@#VG6A<]:BN5;WB#@N2KX7CD<6`OR,NH7-G
M[).@8P":"=`U++$,5]094Q_FHLY!T'E<URH#EY\YU#M_GH&9)\'2]$="3KZG
M04#"KF%H*D+7T%RRD,!*)TQFOE2\A73+\B,>=([0EI)TWX<X3$_ARZTO+3@0
M:V`1LYAL=]UQ:CRW:Q#2F2NX=5ZD_0)QX!,1$6]W]J2I"%U#`Q/='-X3!9G.
MR+CK7J'QM.XMAQRG#\YSYW:AY#E=*WE'?/A5KM+"%YC$6>"X,4'M6.<ZC^T:
M@B^4<1'[$!+[W+'J.H_K?'40PE-RJT59MF/%]1_:O2F;3FF86%OF@:F12Q7"
MW.Z->\TG=PW$YRB@C`12K#%\*X=@QP!H/K'S`1"-`_)G!+^>S^7?W71XY4-2
M]68K+GCI@<_I"84)\Z2+,?E4/JQ=1VDL!(@!(N6>[$OO,A=YB-,'QR[D@+B'
M$SX_\@@]DDYV^4OL;1^^.4X=R'^#C[Z=PJ,]^?@+WYDLFO.=,?$_'6Q^?]2Y
M/.EBY`(ZG./_FSCBG'EG\+8*1%,6K2?E9L>4GWS3>3VGXR`4CO2DY82K7[][
M7!=B)&C=$D&Y=P&?!07`JLON6D[Y5O6DS$KN3L:5-PFF@5R"32D3M+#X[J1-
MWJ-Z.!67VYU\#]!LB5CQU]U+$X]1Z0V5"[L"<?+?[TB>EQ$`(!S_$B:;YW^1
M%Y5<&^5V)A]P)LYB]ACO<@0W42CW4.4.N%K8LDH[DSR91.[(C`M)]"0U*#0W
MI<5W)>T9GSJ4*:5+O]Z5-!?4)V($5F+"A;I/YDOM2K;;:.Q3]\+GSOKL7%QF
M5W+=D0F5DSX+KYVITL"L%]N5=+]R/P*J(I*7IAX&Z^5V)=]OQ/?_Q?AW=D^<
M@#/B709!1(123E7Y[N6](A/'3X0X?:9%2*Z7Z%XFN0,D;=;+=,S]`HGRWR_E
M65T"G8J\;(YP%PW!KQOKGWPT2UKB:!;'&PS=)^HOETZ/@D^;,.>%-+QH>AYP
MX1$11V3!?P<#T.21@`'WKA*EE9+&8H;0LTE<4M:DL4?HT\')P2`*0$L^DW(X
M9G#29:$+6/(<*T/E>*]165O[9K"<[#4LB@5#!L];A*=HA9H!]`X!*G8U9!"]
MWVN(UF;B#)8?]AJ68HJ<H?,CHK/I"LC@^6FOX5%[CC.$/NPU0A5KJ"5,Q_M-
MELL=0QE*^TV>%0Z##)[])M&%'K(,G/VFT#I.XPRK_6;3!>[,#!K[6'3A_LL"
MBPVGFLW^G5(DRGO0`I8W;VP$1N%:S0^8Q4[)[GK(ST?KL2)=1Y!HGE-K[%=^
M=()QC$@4#">.,TN<R\0/@\4GZU[F].-O.@&R*<%:\T,W::&YYWQ[#;.#%-<D
MU%.IL(H1'3R/)EWXUJ'>)1LY,QHZZSL#5:7-2#Z7!W2#&W;)9-P6L*O;2+A/
M3D#6MUJTJAC1(3YOH9(V^=*<7!5=.5?&N)2*.*SRLB:DEJ<F95`I_)#AM7/'
M)S+,-!PY0KP`[?W5\:/U3>%Z=8UHE1'Y4@76BYF1=7EHX8JSR0,1TS@Z-)UG
ME**7US*LR:HLY0.WHI()/<Y21I90&!(?KDKE@?E1H4=%I;[H<<V9VT25?#TS
MV@@P,2&=$VW*5EJE-SIDT-918Z66$4TB<@'KG]/'1Y`'2'_%BU"4-BCY#<CB
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MHAE<=D69-H5KT_.=(617H&EMA!2KK`P?NV)-Z_>@BOW%#"B[`DWK&_!\X$>&
M2Y,H4QXZ?C]QZ7$(H9D.4M<5O-IGRER7MIZG;0.WRC`46T_;M@%>Y;Z^K2=Q
M6QZQVY['[:^-;P.HMOT/MA[R;;E3*G96MSL$_*IZ:@V7A%9\O:W'A9I!5Q4V
MF:%E_3#56CR5A0%F6-EU,K\95LJMY0PF.SVI-;N41O1<AIB=3M5ZB)7VJ9,F
MB]+^SX?J'5^ERZ*`:IW8Z3W5`T<C(#T#RLXENAY0Y1$?&49VKL3U,*J*RLU0
MLG/)K8=2%O.;X6$GZ:YCGU?1:$*J;9FM]%?(&5YV$NLZ\5%YGTP^!LEVUWQQ
MS-7>I<.HAJ-L(-J;#:/;4*FU3>;-X&-;,\_M#M;-D].VYJK;':;*K!:VYK?;
M';0Z8>6VYL?;'<JEVQ^-TNJ]!@+=-:J;AY1LS<9GLJ<V"UW?+M=?G=[=UR1=
MM_';?"(A=4%6LSE<0!;IEI=6/28EMT3$^1D5(?0Z-0UGI4G22YY&X1/TCO_+
M7J1:DXT:O=`@SM2K+7U:NA>2J^^#TJK2RHU^ZSN_Z;;!5^9,I;&"MRRON93[
MZFLBUJUM2PX'N_(+Y)>P-8V<9F7S>FF:NHI*?=&CU."55,`SJGA&M?8958Q!
M[X%GMW`#I?;T;7OHN>Z^MMZ,9WNL>1.T-N=1VX/*FZ.TF*5MO=VI'D):*VG;
M@\%K0U4VWBS?`Z\'T>9@LW7SK1$\Q7>(6+N9AF$4&$9A81B%43?])7.AD)%K
M,Y*53*S><DBS21RYJUC,EE8QX_H-`,-[(N;456;R7"MD)CDT="8PF!(XA92Y
M(B9D7.RS+WCC9R>@[BF#A:X?A4J_6%4M6]S36Z3F)8P(QY?'YKPI9?%MH_*,
M4YI#0X%K52TCF@@>!+>"/RHS^JV6,"%A8DVO0`B9QV7$X=VS"+KGS8R(>&0%
MG\DC%R0I]^`\DV!]JQX0S[>2[#5_(;!8\&2RH2"4EEME;'8I@3F$EQ-8A>]6
M5=J<Y(!X.H0^PPA3]V15:3.2)QVCW&*LE\*MN`27:Q)FPTF!7;Z,$2F!'B8F
M0L:J2%'*W[:Z?*^DK[`/U?6,I&U>B)0*H^HUF^5Z(6T%YNKR1J6O'*-%)8TE
M]=[LN"JI%:7-)&J>$Q8IN_/R:]S0[D."8D5@T6^$3IY@974ZAPXU(=?1=$Q$
MO.I*EUQ5,5!-6S'I1*I@G?OH;L1=_;4^HLU!5GO+!K76B]..98R61B+!*!Y?
M1PS>2>PNL0FF<E^A7D3UOF&FY`FVITAJA%;)^F>[)$G]/XY22>!SA_ZKO(FV
MITFJA5;>[VY[:J1:T!0L<K=+A-3_@::WRY^MDC"PKVB/#0/X-O9"MHO6LV7@
ME)@?#-93^KJV"\ZSI>]H<$8,T=OY#N=V87^V]$WEQN'>1/R5#]W\_MIVB2]>
M>Y]I[**U/Y.%3E^JC$':+C7%*X()@T<Q>+0R>#0>(_FL?LR+_8XC/@4)GF"Z
MHG-B,,;4!:F2$/$O1%I!56#I1CD3>WJ*9$[EDI?6,:/%_T8I@WO@"O'BCC-V
M`N+)C@*]).ZG=R1Y"R1=[(,5IMR[(RZ?L+B5LGN@.W^LX=02I;U@LUQ+220R
ME%+R>4?B#%CQHVYB4[2^45ZG)D;G)F93PL49]-U"0<O+&HG$Y=R+T[JF7KGS
M9_?)81/B77"QR(T$Z^9(#L?2CMN@(8PK3*!;7U;#+"L(V#:YHHX'F3P\)W.A
M*Z#7K]\'[1*CO)#QC"0_-5535,9HT))XRH+<9:4CN;2*F6BS?/[&4ND5A8U$
M=KF$.=!?O[)@1MPX85KIK*`N;T1ZS0Q8VZ:],BSMMQ.S47]K5"`HF*?TZF"L
M9:WD0=4WO:FS!Y74-:K5PH#H]*%<63OC7MN2LYULH0K]6FD<<2ELW)AM3SDW
MS-^1D"+'K#69>J[)]_@K]0#5JMP[O19>]KQ'IHF2BI9ZI''L1FKX(M?J]DVK
M-EYC64,F]P!*/32*]"R+M8;MP9#:V%2XMFV/C-3&J7SA;?M-D=HPJ=;VVUT4
MV5^`\+#-^L9LE9-D_:*ZNMYJZV-OZP!8L(VZ-U&X99Z67.A(L>VR?B!JQ=64
MIJMK$+,\2XA_Z(C0"GC:OEJD29BS99C6V![#_*1U=MPP#GHW42Z8\[2Q]P@#
MHYLZ;.R_-E`C];Y>T!-&3!?$,^Q-?'0]NOOM9,L;^!)R=LX\*^!I:YMFN[OT
M[,-48_=H98EP\GY_!ZC>#LT*6.^MMF8Z@0W[F.1(*U8B!XS:K;8W&.'1H7(X
M-%V,*4`G"-#:J%L>KT)D]O+4V<@)GBY\_CVX!&XM",Q0ID\Y2><-<ZE/<JNA
M!RXEO15\3D'KSR]?8;5]R99)&$[=D,YI2"L3IG;R*",GPW)9W,[(.%Q<8G<K
MR)1&4Q4`E?6,:!,$\`JF,X<*^6Y&P+0GRK`>16$C9\J@IYPR3_Z0$\_<\>,Y
M)QPY0KQ`9RD[9*=7UTJM#$4%%LM6ZS1,K29,Z2@-NESGPZ])"A!IMIBW3/68
MF3`Y]GT>1*(JN??6S=I]4XLM)RA7,LW(W1<%:.NE#$F:&VQG4;P;>?KX2'UX
MG<K)H[I>'[2Y9*=N/"D#P"^2N,H<D:XK(B"@U!F#J'*8::JHV5B_]`9N1L"\
MJL\E:%7MATYG,#W,X\R>35Y><>V>:):,GAL8/2ZL>61<V(KO*[UH65]3K=;Z
MH?ER/9#N3U=?GJ/;0$_TDYE'LD6/I-SZ7;:P<C_T@E4.+!R\JNMW*JJ9O#FH
M=&)>*=)*UHI%8,_-XTI$?LSA+[B(_Z@ZJ="X&2,8+^6,A0(+]!NL6QR85*2<
M:<CKC1CY#E4>M*S7!F9@6.Y]%[E="A87"MAK--!O_:JN6:K?4(_TS1:.#=]G
M40/]UJ_9^RQKJ$?Z%KA%Z^E9U$"_]6OV/OOF/WX=N5-@P;H("Y7')@0!6`'(
M\.76APD5IE;IA)M-U8N,&@V8U6\1,;R:!K!2I\)*1O00W"7$BS,0G]'8<H61
M(/)*[$7$^(BS@/O4BX/_HG%`/>H(M;G8ID73"-S!6B%Y13>/USPD"[^+AJK*
MJH9TFM,`N#@0US,>C</'R%\X6=2ZJ*N8R5R4`9J&GMXZ,/[ESI="A](JF..E
M5HZ7Y?ZR?FJ7S2J8&T4KD\"Q4LJ5(L9D3&*]Y;1;[GM1%#8B=S2;^?'[=?Q%
MK[QDCUQ,DPB6BBZM6=MD=$R7D1<:=S=9=K)\UZB6S\\9RG:>J=@5RC5]@AGL
M=I[:V!7LJDDCP]?.P_*[PE<C@"R#NLE56`AU[1WA#'`[K];:6=]6A!-F^-IY
M.-U<AU9OAV>8VWG$O:V`.\61JN,5!-_:V6O;1+#YIG6&LIW]M'X(2_F(+PK4
MTDMG$6OP.B\/;QM$S?@IO?05B*LZ%E0OBP4B6!'_I9?2`F%4AIOI);I``&O&
M0=N:*@-S5:YUK^9A5/F4IV6;@GK)15[Q&&T'1+T=[ZVRBNQ-AZR*`\E0+',,
M[7V7K!-$FD%JYUWMS0,4BSMF=0"67A92^SII74BWB97:*BOIZS6G-2&N$WR\
M7<+25VL':GI\E:GI['26M0-:-^YXV^]W:*W#:L>K;W<51/]-@';VR>9]\<3.
MOK@5<J635H;</J?5;4+[LXT:.UT<>LC5RV628=8D%LP6"Z>9UR8#JX$ST;+,
M_[KI?%9`V_N,O+I1PQED=KK&]'O8=KO_&8YVKHEUCE-@0MGUHQJ8++6W&2\-
MX5+O-$=^6W(U]8;UUYEM`]1:_K#=76VV^S2J\4;7`T]G*<=?#JO@VDD\NNG:
M65YQ84EJ.<N2CFR^I[R@)05;2:^C[D**PV6ZM?"8:L='/#$(9/=`U!PRR(DK
MW6\%]L]Z=H.KA=>U6N@3L;NG$T8?J2MC'Y+`Q/B>)9^Z%&K`0S_#?/4'DKUV
MR=Y>D">]GJ4@*7J5D10B*;1N(D-2V/;^A:8E0J*(1!&)HL+L_,+E@1?.7")8
MMF=E!4-4L+$JC0NH6%459*ZO@KDBPT.&APRO7Y-T(</3L]/(ZY#7(:]3&)LK
M[K`@^5HXGCR.'!^4SY)@!*VRO2UN5-Q(S_&%3,=$*.8[97%;[D3K"R-LY^TV
MZX;%K[Y96\B#U]])FL2E=)CERQAAO^I+U8N)L+(\KC5JR%MTU[U*Y%Q97"'A
M"@E72"W2W2K[ESO`J211UB^2ZL"T-O/M+N:SCXOL+2F:7A(%"\`KFA%SADG=
M`ZVW4>BA:.BAR'>J%)@3!`9=-V$0F]^5K'&6;<OUT=FQ%\M^C6ZE<`9HU,1%
M-BY7K9O8<;G:\EI#RP99OV1%UHSDL"DYS.=I#A:K]30#>Y+^&@GCGA-&A71-
M^TZ!R$V;0IJ(--&ZF0QI8IMQ7XVM%/)&Y(W(&Q5&*,O9+!.?I(-K,;:6Y4<\
ML(X^*LC0EH`4<*(M6T12_!J\J$@FD4PBF>P9`U"3R6VM/')*Y)3(*96^2,45
M*Y8Q2.1:9KA6K?Y5S&QJ-8%\$OFD=5,;\LF6][#K624DD$@@D4"JC(_&G;D]
M.Z9:5]3B";)I:WC(%5DT,DQDF+V:^Y!AMLPP&\\U2#:1;"+95-BA$6=S6+=1
M@.J,C+?W42JX@\9C"KB#1BWD?LC]D/LA]^O55(3<K\W=:IVY`SD><CSD>,HH
MQ_1:-XMWH)O/KJ7H%,^UI560`R('1`Z('!`Y8+O^OW([C000"2`20(6QN2,^
M_.K=.B)\>1`."\#PP.-M.]."7,H,EZK3O8J)2YT6D"TB6[1N7D.VV#);K&63
MD#PB>43RJ+`]7RB+A5T<&D/2^$INF=!Y<<7,0*<FTF`DB4@2D23V"Z)Z)%'+
M0B(Y1'*(Y%!A<^Y#&"-/W`?M`WGD*WR199$BHE\1"54]0K53.74'K4H%W?I(
M%Y$N]AFB>G2QQKA!THBD$4FC\LS)=$K#Q`@Q;\2AH[`)@4*].==<4\+B:;)F
M(WB2!1DR,F1T.?9J@D,.V3*'K#NS()%$(HE$4F%^/D<!@!!(0CF&;^6C>T(@
M-24KG@`U*R-A1,*(A!$)8Z\F,B2,+1-&W9D$B2(2122*JFWJ:!R0/R/X]7PN
M_\9M:>10R*'ZMBVM'*0*D97ED0$B`^PS1#6WG=7C`DD?DK[^D[Z?CZ2<8R<@
M\,?_`U!+`P04````"`#'@J]`\N6?CX<(``!#0P``$0`<`&%M96@M,C`Q,C`Q
M,S$N>'-D550)``/VNK)/]KJR3W5X"P`!!"4.```$.0$``.U<;6_BN!;^OM+^
M!U^^[*XT(0TM[12ULZ)`9]`RI0)F=W2_C$QBP-K$9FRG+?OK[[&30(`T#:'W
MJJ,;J6J3^)S'YYSGQ&^Q>_7[4^"C!R(DY>RZYM1/:H@PEWN4S:]K7\96>]SI
M]VN_?_CYIZM_61;J=3^V1VC(?,H(ZEN?B1+T"7UUB4\$5@1-\!-G/%BAL;L@
M`7Z'IE@2#W&&OMZ,!JA1=Q!:*+5LV?;CXV.=>',L+&[@ZBX/;&19255_1D:U
MT'G=.:M?IDI&/&1>"UV\)Q?OO5/7NFPV3JVSQOG4PB?3,\L]:[K>17/JG#?<
ME%9'$*P`$'E@:`LU3IR&==*TG+.)<]8Z.VDU+_^=EN;+E:#SA4*_NK^!,$B"
MAK,5@'>HS]PZ:OL^&FE1B49$$O%`O'J,)$T4$,28R>M:RO''TSH7<QMP'?OK
MYT$4K=K//Z%(MO4T%3[=TM!/$IU3FS*I,'-)2@4L^CM'0Q=K,M*5[*G$9CF7
MEY>V*4U)A]*:8[Q<R\^PG!KIN,#6\;%.'.O4V=92JR61F6JF)%L/!V2Q91I>
M<M_G`<26$:5UX&=+@W'&PB`[`IX2MJ[,!B$+I(B@;EKU9;T]'2WCJ;5:.MA-
M.RI,2;N0LDJLML4E<>MS_F#'A=F!\`C-UH*";`W*'HA4V4I1V:Z>PF).U!W$
M7"ZQ2XK&'5[Z@#!URT70)3,<^E#I]Q#[=$:)5T-80>,P#179$@C91N2#1KG"
MC'%E7DUSKY\LEY3->'P+#W0JM@3WR03(0/KBRZB?8Z:*FR%;B]I=[H;:T.0O
M9EZ/*:I6?:A$!*;J&J+>=:V0Y-JLQ#"/S"BCQ@'GQ$$62M33EP"%(BR4`KNR
M=Q%VP4-H/X?L@[EVL>^&OE$<P'VL'$OD*2X%-$Q,E=#<6/:\7OPTX>>U:!N#
MO2;!AK-;RJ"UH]B_Y](8T_&QE'&>:>)&H/"MH$(^?Z=`VAH(KCO#N_%PT.^V
M)[TNNFD/VG>='AI_ZO4FXXJ\8\F[QP)$%D11B,[!3!KM%^@\*TXG^G7+G-\J
M>@O1"V,@$,HF+R[+IZB91]%X`G\^]^Z`GN$M&M[W1NU)'P0J<@J1,UY`2B^X
M[\%@NO<]A-ZGS;PAI+CH\`"<6Q`FZ0/9X]"E5FF4?+;/B[,]G@P[?WP:#KJ]
MT?@7U.W=]CO]245\(>([6"YN??XH^\RC@K@J^P7=%\MG[Z(X>YWV^!.Z'0S_
MJM[5',KNN")RPM>]W#JX\@ZK4)#A;+C44VNP3:8H/$@MG]+W>I1*I>MS"8IP
M,Q1SS.@_T619#UO'81!@L4)\!I-H:CI'U';-K(6R.;KG/G4ID17-96@>TSF#
MT8R+F=K$-`GIA#RI&Y^[?Q>BOB!4?CI<[J9#BOU4!54"O%8"?.00PPYG+A%L
M$_C#F'\)(Y=RYV27<@.'8KR*U3*L#CAF,BH6V"/)>&E$7$(?\-0GLBS7Y9#S
M,\#9S8`-6D5_&?H-)0.*I]0'T\J3700GG]K&+K7=D*"9X`%JSV:`"C55%)>A
M^%Z0):9>[VD)LQ\BUS.B4.A%A+:41)6FO2QV?BJ<[J9"7`U*ZJD2H4PB])DB
MX)&*IK]Q+!/*UO(=+LOGPY%5Y*?%V7-I,8N`82C@`G*5'.5:"0X3,;6Z]_6H
MG'EZ^61I/C&4;AH.`,PGOKE/?(0=?:Q(@"OBRQ`?SX_D/5[I810P!4]$2+Q7
M&!64Q<Y/A_/==$BJ07$])BWBFE"JJBI!RB0(3*\>X&6C$-@NF99N#PK`Y--^
ML4M["A&9>BM^RPT+=%\]P4_E._T<@'Q.]];T(BR]/:>BLQR=(P)!,-\<U0HF
MWDQBUZRNEF7W$+Q\LO=6[&)H9+!1&KRBO@SUGRGCPFP"B4;A92DO@I-+=6-O
MI>Z.,PO::P4>^'J@GD!71)=:BU=`P=9W3BU;EN[B:/FD[RW.I8!_D:@+LBZM
M&"\Y"`L"JJ)!-?/TFP1O$6'N$8/S`R'SN=];O4NAF^'X!G]594"9#+@))65$
M:MJF4*JM*\M\0:A\QO<6Z=HNM!W1UJ>J_R[7K(=32;Z'<-E[T/<'-N//:N<3
MN;>LM@%"$=+_`9OZE]YU/B(S9#:4M_1VZNN:I,'2)[7X&1:NUL_?BFXOH]4I
M:$?M!#8!V-/>WOMN\F,G?K%5"<)"D-EU3>\ZMY(]SM]`H_X4^(F(HDK7TMG@
M(`TDWR'L^S7[[7J^36,!QT$AP_'N&N8'\=O'4^(7=!ED,UP>:(0?Q-O=U[R`
MTZ"2X?1]"BC+]RL[O3\?[K;W[U^!ZUPHQ#*/$SQSC`5%)V4&W#5`.2KZSDKT
M+/W(<AK6J5-_DEYLXB$6;")]F`6)WJ$69)X3*5IWHJ`K;1:J+O>TS7/5FBHS
MC_?8Q%=RC65ML`Z/_M[1FD)!V-72D;C4X7?.CS$A=2KH0#,XNRMG2=[QJ2.(
MT4\.Y>6EPTBYYF3I)3='&;)SOJF0$8F.OCBJ\OUS4H7J3ZG%U\]8$1^=,F;`
MD(('^HNN`8X_[L9K>&:J/URFMG_J%OQ;486H,S*'"5L!AS$S%JL^C&OU2*V&
M\%0J@5UU79MAWW0V1A`Z(<J]B5'U0A$?CXK*IMC7[>YUS17$H]!R,>K[^MO0
M=4V)4+>B,,B%?B342A\%#Y=)]12J?<[[8A]"8L]?%HZ\CLX#ME3RO*3?K^N@
MF6;$VSB^0"FD(OV'>-H-_<ID._JBTM$T1_VIVF/9(]-7(KG(R;IV;&@J"H>I
MI>,`SRB;9T4A\N&_S'FA79W&Q1<EWUHZO\9^%^/YL4!O+C!2AOJ]&<[T*AUG
MIBW^$_NA/@%K;F[T:?ATXYV.1AGM'Z*!S]G(L/_&%Q%^0^_Y4;L`C<.E$=Y:
M^O]%]#]!(%X;^BT\)S`NGA(!.4O=+O5#/3;1Q\CD,%2ZL]'_82(5A3+*6VE@
MBO]GSE_9T7`0+O\#4$L!`AX#%`````@`QX*O0+#S:="Q>```-WX#`!$`&```
M`````0```*2!`````&%M96@M,C`Q,C`Q,S$N>&UL550%``/VNK)/=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`QX*O0,5<,]\4#```9YP``!4`&```````
M`0```*2!_'@``&%M96@M,C`Q,C`Q,S%?8V%L+GAM;%54!0`#]KJR3W5X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`,>"KT!L!?5/[18``#6P`0`5`!@`````
M``$```"D@5^%``!A;65H+3(P,3(P,3,Q7V1E9BYX;6Q55`4``_:ZLD]U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`#'@J]`V[AZH\$J``"$(0(`%0`8````
M```!````I(&;G```86UE:"TR,#$R,#$S,5]L86(N>&UL550%``/VNK)/=7@+
M``$$)0X```0Y`0``4$L!`AX#%`````@`QX*O0'?+G@?\%P``-0<"`!4`&```
M`````0```*2!J\<``&%M96@M,C`Q,C`Q,S%?<')E+GAM;%54!0`#]KJR3W5X
M"P`!!"4.```$.0$``%!+`0(>`Q0````(`,>"KT#RY9^/AP@``$-#```1`!@`
M``````$```"D@?;?``!A;65H+3(P,3(P,3,Q+GAS9%54!0`#]KJR3W5X"P`!
@!"4.```$.0$``%!+!08`````!@`&`!H"``#(Z```````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisitions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>17. Acquisitions</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Aligned Healthcare Group</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On February 15, 2011, Apollo Medical Holdings, Inc. (the
&#x201C;Company&#x201D;) entered into a Stock Purchase Agreement (the
&#x201C;Purchase Agreement&#x201D;) with Aligned Healthcare Group
&#x2013; California, Inc., Raouf Khalil, Jamie McReynolds, M.D. BJ
Reese and BJ Reese &amp; Associates, LLC, under which the Company
acquired all of the issued and outstanding shares of capital stock
and associated Intellectual property and related intangibles (the
&#x201C;Acquisition&#x201D;) of Aligned Healthcare, Inc., a
California corporation (&#x201C;AHI&#x201D;), from AHI&#x2019;s
shareholders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Upon the signing of the Purchase Agreement, 1,000,000 shares of the
Company&#x2019;s common stock became issuable (the &#x201C;Initial
Shares&#x201D;) and are included in the number of shares
outstanding. In addition, if the gross revenues of AHI and an
affiliated entity (the &#x201C;Aligned Division&#x201D;) had exceeded
$1,000,000 on or before February 1, 2012, then the Company would
have been obligated to issue an additional 1,000,000 shares of
common stock (the &#x201C;Contingent Shares&#x201D;). Moreover, the
Company would be obligated to issue up to an additional 3,500,000
shares of common stock (the &#x201C;Earn-Out Shares&#x201D; and,
collectively with the Initial Shares and the Contingent Shares, the
&#x201C;Shares&#x201D;) over a three year period following closing
based on the EBITDA generated by the Aligned Division during that
time. Under the agreement, ApolloMed would issue twelve shares of
its Common stock for each dollar of Actual EBITDA earned in the
first 12-month period. In subsequent periods, ApolloMed would be
required to issue twelve shares of its common stock for each dollar
of Actual EBITDA in excess of the maximum EBITDA earned in either
the first 12-month period or first 12-month period and second 12
month period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Additionally, in Accordance with the Purchase Agreement, if prior
to February 15, 2012, AHI had not entered into an agreement for the
provision of certain services to a hospital or certain other health
organizations that has a term of at least one year and provides
aggregate net revenues to AHI of at least $1,000,000, the Company
would have the right to repurchase all of the Initial Shares for
$0.05 per share, at which time the Company&#x2019;s obligation to
issue any further Shares would terminate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Based on our initial internal estimate of contingent shares to be
issued as part of this agreement, we had estimated that the total
fair value of the common stock shares issued and contingently
issuable for this transaction on the acquisition date was $367,500
(1,750,000 shares).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company originally recognized a liability based on the
acquisition date fair value of the acquisition-related contingent
consideration based on the probability of the achievement of the
targets stipulated in the Purchase Agreement. Based on the
Company&#x2019;s estimation, an initial liability of $367,500 was
recorded. Subsequently, we have reassessed our estimates and have
determined that the initial terms of the agreement have not be met,
and as the result, we have determined that there will be no
additional shares contingently issuable under the terms of the
Purchase Agreement and we have recorded an adjustment to revise our
initial estimate of the purchase price in contemplation that no
contingent consideration as was previously reported in our interim
financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The following table summarizes the preliminary and final
determination of the purchase price and fair value of AHI&#x2019;s
assets acquired at the date of acquisition:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">Preliminary</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">Final</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-size: 10pt">Purchase price calculation:</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 72%; font-size: 10pt; text-align: left; padding-left: 10pt">
Common stock issued (1,000,000 shares)</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
210,000</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
210,000</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 10pt">
Contingent consideration (1,750,000 shares of common stock)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
367,500</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
-</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 20pt">Fair
value of total consideration</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
577,500</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
210,000</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt">Allocation of purchase price:</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-left: 10pt">
Intellectual property and technical know-how</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">577,500</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left; padding-left: 10pt">
Goodwill</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
-</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
210,000</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
577,500</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
210,000</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
As of January, 31, 2012, based upon the completion of the
Company&#x2019;s annual goodwill impairment test, it was determined
that the goodwill associated with the AHI acquisition has been
impaired, and as the result, the Company has recorded an impairment
loss of $210,000. The cause of the impairment was the result of
contracts that were anticipated to result from this acquisition
that have not materialized and management has decided to focus its
energies on new initiatives.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Pulmonary Critical Care Management, Inc</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On August 2, 2011, Apollo Medical Holdings, Inc. entered into a
stock purchase agreement (the &#x201C;PCCM Purchase
Agreement&#x201D;) with the sole shareholder of Pulmonary Critical
Care Management, Inc. ("PCCM"), a provider of management services
to the Los Angeles Lung Center (&#x201C;LALC&#x201D;), under which
the Company acquired (the &#x201C;PCCM Acquisition&#x201D;) all of
the issued and outstanding shares of capital stock of PCCM and the
associated intangible asset in the management services agreement
that PCCM has with LALC (the &#x201C;PCCM Services
Agreement&#x201D;). Upon the signing of the PCCM Purchase Agreement,
the Company issued 350,000 common shares to the sole shareholder of
PCCM, which was valued as of the date of issuance at $70,000, based
on the fair market value of our shares.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
At the time of the acquisition, the assets of PCCM consisted only
of the PCCM Services Agreement with LALC. Through this PCCM
Services Agreement, our wholly-owned subsidiary, PCCM, has
exclusive authority over all non-medical decision-making related to
the ongoing business operations of LALC. Based on the provisions of
the PCCM Purchase Agreement, we have determined that LALC is a
variable interest entity (VIE), and that we are the primary
beneficiary because we have control over the operations of the VIE.
Consequently, we consolidated the accounts of LALC beginning on the
PCCM Acquisition date. As a result of this consolidation, we
recorded additional non-controlling interest of $164,276.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The following table summarizes the fair value of LALC&#x2019;s
assets acquired and liabilities at the date of acquisition of PCCM
and consolidation of LALC:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 87%">Purchase Price</td>
<td style="width: 1%">&#xA0;</td>
<td style="width: 1%; text-align: left">&#xA0;</td>
<td style="width: 10%; text-align: right">70,000</td>
<td style="width: 1%; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left">Fair value of net assets acquired</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Cash</td>
<td>&#xA0;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">164,210</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left">Prepaid expenses</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">9,472</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Property and equipment</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">26,041</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left">Management services agreement</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">38,000</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Accounts payable and accrued
liabilities</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">(1,447</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left">Due from officer</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">(34,000</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt">Non-controlling interest</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(164,276</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left">Net assets acquired</td>
<td>&#xA0;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">38,000</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="padding-bottom: 2.5pt">Goodwill</td>
<td style="padding-bottom: 2.5pt">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">
$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">
32,000</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Proforma financial information is not presented as PCCM did not
exist in the comparative period herein presented.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51, 52<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1500-128463<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7000-128479<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6927-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7008-128479<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1490-128463<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6996-128479<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Appendix F<br><br> -Paragraph F4<br><br> -Subparagraph e<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1383-128463<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1392-128463<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1497-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 67-73<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1524-128463<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 88-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1486-128463<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Critical Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Summary of Critical Accounting Policies</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>1.
Organization and Summary of Critical Accounting Policies</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Apollo
Medical Holdings, Inc. (&#x201C;Apollo&#x201D; or the
&#x201C;Company&#x201D;) is a leading provider of hospitalist
services in the Greater Los Angeles, California area. Hospitalist
medicine is organized around the admission and care of patients in
an inpatient facility such as a hospital or skilled nursing
facility and is focused on providing, managing and coordinating the
care of hospitalized patients. Apollo Medical Holdings, Inc.
operates as a medical management holding company that focuses on
managing the provision of hospital-based medicine through a wholly
owned subsidiary-management companies, Apollo Medical Management,
Inc. (&#x201C;AMM&#x201D;) and Pulmonary Critical Care Management,
Inc. (&#x201C;PCCM&#x201D;). Through AMM and PCCM, the Company
manages affiliated medical groups, which primarily consists of
ApolloMed Hospitalists (&#x201C;AMH and Los Angeles Lung Center
(&#x201C;LALC&#x201D;). AMM and PCCM operate as a Physician Practice
Management Company (PPM) and is in the business of providing
management services to Physician Practice Companies (PPC) under
Management Service Agreements.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ConvertibleNotesCurrentUnamortizedDiscount', window );">Convertible notes, debt discount</a></td>
        <td class="nump">$ 653,026<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
        <td class="nump">29,335,774<span></span></td>
        <td class="nump">27,635,774<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
        <td class="nump">29,335,774<span></span></td>
        <td class="nump">27,635,774<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ConvertibleNotesCurrentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible Notes, Current, Unamortized Discount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ameh_ConvertibleNotesCurrentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ameh_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>12. Income Taxes</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company uses the liability method of accounting for income
taxes as set forth in ASC 740 (formerly Statement of Financial
Accounting Standards No. 109, &#x201C;Accounting for Income
Taxes&#x201D; (&#x201C;SFAS 109&#x201D;)). Under the liability method,
deferred taxes are determined based on differences between the
financial statement and tax bases of assets and liabilities using
enacted tax rates. As of January 31, 2012, the Company had federal
and California tax net operating loss carryforwards of
approximately $1,981,000 and $2,060,000, respectively. The federal
and California net operating loss carryforwards will expire at
various dates from 2028 through 2031.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company&#x2019;s effective tax rate is different from the
federal statutory rate of 34% due primarily to operating losses
that receive no tax benefit as a result of a valuation allowance
recorded for such losses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Pursuant to Internal Revenue Code Sections 382 and 383, use of the
Company&#x2019;s net operating loss and credit carryforwards may be
limited if a cumulative change in ownership of more than 50% occurs
within any three-year period since the last ownership change. The
Company may have had a change in control under these Sections.
However, the Company does not anticipate performing a complete
analysis of the limitation on the annual use of the net operating
loss and tax credit carryforwards until the time that it projects
it will be able to utilize these tax attributes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Significant components of the Company&#x2019;s deferred tax assets
as of January 31, 2012 and January 31, 2011 are shown below. A
valuation allowance of $933,420 and $232,700 as of January 31, 2012
and 2011, respectively, has been established against the
Company&#x2019;s deferred tax assets as realization of such assets
is uncertain.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Deferred tax assets consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt">
</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
January 31,</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">
January 31,</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">2012</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">2011</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 62%; font-size: 10pt; text-align: left">NOL carry
forward</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 15%; font-size: 10pt; text-align: right">
849,591</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 15%; font-size: 10pt; text-align: right">
212,800</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Stock Option -
exercisabe</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">81,775</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">10,800</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">Contribution
carryforward</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">6,970</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Warrant
liability</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">51,408</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">State income
taxes</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">1,247</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Accrual to cash</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(76,500</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">State income taxes,
deferred</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(71,035</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Impairment loss</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">89,964</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
Other, net</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
-</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
9,100</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Net Deferred Tax
Assets</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">933,420</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">232,700</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
Valuation Allowance</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(933,420</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(232,700</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
-</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
<td style="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
-</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The provision for income taxes for the year ended January 31, 2012
differs from the amount computed by applying the federal income tax
rate as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 86%; font-size: 10pt; text-align: left">Tax
computed at the statutory rate (34%)</td>
<td style="width: 2%; font-size: 10pt">&#xA0;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&#xA0;</td>
<td style="width: 10%; font-size: 10pt; text-align: right">
0.34</td>
<td style="width: 1%; font-size: 10pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Stock options</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(0.01</td>
<td style="font-size: 10pt; text-align: left">)%</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">Accrual to cash</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">0.01</td>
<td style="font-size: 10pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Warrant
liability</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(0.05</td>
<td style="font-size: 10pt; text-align: left">)%</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">Impairment Loss</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(0.08</td>
<td style="font-size: 10pt; text-align: left">)%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Non-cash stock
compensation</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(0.06</td>
<td style="font-size: 10pt; text-align: left">)%</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="font-size: 10pt; text-align: left">Change in
valuation</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">(0.15</td>
<td style="font-size: 10pt; text-align: left">)%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt">&#xA0;</td>
<td style="font-size: 10pt; text-align: left">&#xA0;</td>
<td style="font-size: 10pt; text-align: right">-</td>
<td style="font-size: 10pt; text-align: left">%</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
As of January 31, 2012, the Company does not have any unrecognized
tax benefits related to various federal and state income tax
matters. The Company will recognize accrued interest and penalties
related to unrecognized tax benefits in income tax expense.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The Company is subject to U.S. federal income tax as well as income
tax of multiple state tax jurisdictions. The Company and its
subsidiaries&#x2019; state income tax returns are open to audit
under the statute of limitations for the years ended January 31,
2009 through 2012. The Company does not anticipate any material
amount of unrecognized tax benefits within the next 12 months.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jan. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">AMEH<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">APOLLO MEDICAL HOLDINGS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001083446<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--01-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,635,774<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 988,413<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>13.
Related Party Transactions</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">During
the twelve months ended January 31, 2012 and 2011, the Company
generated revenue of $514,000 and $577,000, respectively, by
providing management services to ApolloMed Hospitalists (AMH), an
affiliated company with common ownership interest. Commencing
August 1, 2008, the management services fee income reported by AMM
was eliminated in consolidation against similar costs recorded at
AMH.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 04<br><br> -Paragraph b<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5QAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Jan. 31, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Jan. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
        <td class="nump">$ 5,110,806<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 3,896,584<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">COST OF SERVICES</a></td>
        <td class="nump">4,132,399<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">3,314,722<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS REVENUE</a></td>
        <td class="nump">978,407<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">581,862<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,379,153<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">566,649<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">12,589<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">11,198<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">1,391,742<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">577,847<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(LOSS) INCOME FROM OPERATIONS</a></td>
        <td class="num">(413,335)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">4,015<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER EXPENSES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(131,534)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(126,431)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Financing cost</a></td>
        <td class="num">(172,500)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(37,500)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
        <td class="nump">2,842<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,185<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses</a></td>
        <td class="num">(301,192)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">158,746<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">LOSS BEFORE INCOME TAXES</a></td>
        <td class="num">(714,527)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(154,731)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
        <td class="nump">5,819<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,600<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
        <td class="num">$ (720,346)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (156,331)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedAverageNumberBasicDilutedSharesOutstanding', window );">WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED</a></td>
        <td class="nump">29,078,925<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">27,490,476<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">$ (0.01)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Weighted average number of shares used to compute basic and diluted loss per share is the same since the effect of dilutive securities is anti-dilutive.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedAverageNumberBasicDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ameh_WeightedAverageNumberBasicDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ameh_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Alternate captions include Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 8<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to services rendered by an entity during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 2<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1(i)<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-BRD<br><br> -Chapter 4<br><br> -Paragraph 80<br><br> -Subparagraph Exhibit 4-4<br><br> -IssueDate 2006-05-01<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid Expenses<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock', window );">Prepaid Expenses</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>7. Prepaid Expenses</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Prepaid Expenses represent amounts paid in advance for medical
malpractice insurance, software licenses and Director&#x2019;s and
Officer&#x2019;s insurance.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The disclosure describes the Company's prepaid and other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ameh_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ameh_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Due from Affiliate<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Due from Affiliate</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>6. Due from Affiliate</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Amounts due from affiliate represents advances made by the Company
to Apollo Medical Associates (&#x201C;AMA&#x201D;). These balances
are due on demand, non-interest bearing and are unsecured. AMA is
an unconsolidated affiliate of the Company and currently has no
operations and is inactive. No management agreement currently
exists between AMM and AMA.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>18.
Subsequent Events</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">As of
March 7, 2012, an entity affiliated with Mr. Augusta, SpaGus
Capital Partners, LLC, had provided a $270,000 seven-month loan to
the Company. The Company prepaid interest expenses of $15,000 and
closing costs of $5,000.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Non-Controlling Interest<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Non-Controlling Interest</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>14&#xA0;&#xA0;Non-Controlling Interest</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Activity within non-controlling interest for the twelve-months
ended January 31, 2012 consisted of the following:</p>
<p style="MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.3in" cellspacing="0" cellpadding="0">
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="WIDTH: 82%">Beginning balance as of January 31,
2011</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%">228,115</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td>Acquisition-related non-controlling interest</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">164,276</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Distributions to
non-controlling interest shareholder</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
(154,290</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt">Ending balance as of January 31,
2012</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
238,101</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterestDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>10.
Accounts Payable and Accrued&#xA0;Liabilities</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Accounts payable and accrued liabilities consisted of the
following:</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">January&#xA0;31,<br />
2012</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">January&#xA0;31,<br />
2011</td>
<td>&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; WIDTH: 74%">Accounts payable</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">109,704</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">35,815</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">D&amp;O insurance payable</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">11,444</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">10,913</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">Income taxes payable</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">4,219</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">Accrued interest</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">Accrued professional fees</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">27,500</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">5,483</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Accrued payroll
and income taxes</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
9,609</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
40,534</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt">Total</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
163,476</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
92,745</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid financing cost<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock', window );">Prepaid financing cost</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>8.&#xA0;&#xA0;Prepaid financing cost</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Prepaid financing cost represents unamortized financing cost
associated with 10% Senior Subordinated Callable Convertible Notes
due January 31, 2013 paid by the Company on the closing of the
placement on October 16, 2009 (see Note 11).</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest Income (Expense) and Other Financial Costs Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ameh_InterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ameh_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>9.</b> <b>Property and Equipment</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Property and Equipment consisted of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">
January&#xA0;31,<br />
2012</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">
January&#xA0;31,<br />
2011</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="width: 74%">Website</td>
<td style="width: 1%">&#xA0;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">4,568</td>
<td style="width: 1%; text-align: left">&#xA0;</td>
<td style="width: 1%">&#xA0;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">4,568</td>
<td style="width: 1%; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Computers</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">13,912</td>
<td style="text-align: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">13,912</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td>Software</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">155,039</td>
<td style="text-align: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">155,039</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Machinery and equipment</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">71,553</td>
<td style="text-align: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">50,815</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left">Furniture and fixtures</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">5,302</td>
<td style="text-align: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt">Leasehold
improvements</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
8,198</td>
<td style="padding-bottom: 1pt; text-align: left">&#xA0;</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
-</td>
<td style="padding-bottom: 1pt; text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left; padding-left: 9pt">Gross Property and
Equipment</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">258,572</td>
<td style="text-align: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left">&#xA0;</td>
<td style="text-align: right">224,334</td>
<td style="text-align: left">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Less
accumulated depreciation</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(215,311</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">
&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">
(202,741</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,255,204)">
<td style="text-align: left; padding-left: 9pt; padding-bottom: 2.5pt">Net
Property and Equipment</td>
<td style="padding-bottom: 2.5pt">&#xA0;</td>
<td style="text-align: left; border-bottom: Black 2.5pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2.5pt double">
43,261</td>
<td style="text-align: left; padding-bottom: 2.5pt">&#xA0;</td>
<td style="padding-bottom: 2.5pt">&#xA0;</td>
<td style="text-align: left; border-bottom: Black 2.5pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2.5pt double">
21,593</td>
<td style="text-align: left; padding-bottom: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Depreciation expense was $12,589 and $11,198 for the twelve month
periods ended January 31, 2012 and 2011, respectively.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Notes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ConvertibleDebtDisclosureTextBlock', window );">Convertible Notes</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>11.&#xA0;&#xA0;Convertible Notes</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The
Company&#x2019;s long-term debt consists of the following:</p>
<p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"></p>
<table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td nowrap="nowrap">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">January&#xA0;31,<br />
2012</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">January&#xA0;31,<br />
2011</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">Subordinated Borrowings:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -9.35pt; PADDING-LEFT: 18.7pt; WIDTH: 74%">
10% Senior Subordinated Convertible Notes, net of debt discount of
$653,026, due January 31, 2013</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%">
$</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%">
596,366</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%">
$</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%">
1,248,588</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-INDENT: -9.35pt; PADDING-LEFT: 18.7pt">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -9.35pt; PADDING-LEFT: 18.7pt">
8% Senior Subordinated Convertible Notes due February 1, 2015</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
150,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">Total Convertible Notes</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">746,366</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">1,248,588</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Less: Current
Portion</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
596,366</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt">Total</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
150,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,248,588</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;<b>&#xA0;</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Subordinated Borrowings</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><i>10%
Senior Subordinated Callable Convertible Notes due January 31,
2013</i></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On
October 16, 2009, the Company issued $1,250,000 of its 10% Senior
Subordinated Callable Convertible Notes. The net proceeds of
$1,100,000 will be used for the repayment of existing debt,
acquisitions, physician recruitment and other general corporate
purposes. The notes bear interest at a rate of 10% annually,
payable semi annually on January 31 and July 31. The Notes mature
and become due and payable on January 31, 2013 and rank senior to
all other unsecured debt of the Company.</p>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The 10%
Notes were sold through an Agent in the form of a Unit. Each Unit
was comprised of one 10% Senior Subordinated Callable Note with a
par value $25,000, and one five-year warrant to purchase 25,000
shares of the Company&#x2019;s common stock. The purchase price of
each Unit was $25,000, resulting in gross proceeds of
$1,250,000.</p>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In
connection with the placement of the subordinated notes, the
Company paid a commission of $125,000 and $25,000 of other direct
expenses. The agent also received five-year warrants to purchase up
to 250,000 shares of the Common Stock at an initial exercise price
of $0.25 per share adjustable pursuant to changes in public value
of our shares and cash flow of the Company from July 31, 2011 until
the note is paid in full. The agent also received 100,000 shares of
restricted common stock for pre-transaction advisory services and
due diligence. A commission of $125,000 paid at closing, is
accounted for as prepaid expense and will be amortized over a
forty-month period through January 31, 2013, the maturity date of
the notes. The $25,000 of other direct expenses were paid at
closing and reported as financing costs in the Operating Statement.
In addition, financing costs included $4,000 related to the value
of the 100,000 shares granted to the placement agent. Interest
expense of $36,458 was recorded in the year ended January 31,
2010.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The 10%
Notes are convertible any time prior to January 31, 2013. The
initial conversion rate is 200,000 shares of the Company&#x2019;s
common stock per $25,000 principal amount of the 10% Notes
adjustable pursuant to changes in public value of our shares and
cash flow of the Company. This represents an initial conversion
price of $0.125 per share of the Company&#x2019;s common stock. The
note is fixed from August 1, 2009 through July 31, 2011. After July
31, 2011, the conversion price will equal to the lesser of $0.125
per share or the average of the monthly high stock price and low
stock price as reported by Bloomberg multiplied by 110%. The
minimum conversion price is the greater of $0.05 per share or 8
times cash EPS.&#xA0; On or after January 31, 2012, the Company
may, at its option, upon 60 days notice to both the
Note-holder&#x2019;s and the placement agent, redeem all or a
portion of the notes at a redemption price in cash equal to 102% of
the principal amount of the notes to be redeemed plus accrued and
unpaid interest to, but excluding, the redemption date.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">At
January 31, 2012, the Company has recorded a derivative liability
and an off-setting debt discount in the amount of $653,026 as the
result of the change in the conversion price. At January 31, 2012,
the conversion price reset to $0.11485. The Company&#x2019;s
calculation of the derivative liability was made using the
Black-Scholes option-pricing model with the following assumptions:
expected life of 1 year; 80.0% stock price volatility; risk-free
interest rate of 0.30% and no dividends during the expected
term.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;&#xA0;&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The
Warrants attached to the Units are exercisable into shares of
Common Stock at an initial exercise price of $0.125. The Warrants
have a five-year term and expire on October 31, 2014. The
Company&#x2019;s calculations were made using the Black-Scholes
option-pricing model with the following assumptions: expected life
of 5 years; 48.0% stock price volatility; risk-free interest rate
of 2.16% and no dividends during the expected term. These warrants
were estimated to have a fair value of $2,653 using the
Black-Scholes pricing model which was recorded as unamortized
warrant discount on the grant date and $2,418 as of January 31,
2010.</p>
<p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In
connection with this offering, the Company also issued warrants to
purchase 250,000 shares of our common stock to the placement agent
at an exercise price of $0.25 per share, and are exercisable
immediately upon issuance and expire five years after the date of
issuance. The Company&#x2019;s calculations were made using the
Black-Scholes option-pricing model with the following assumptions:
expected life of 5 years; 48.0% stock price volatility; risk-free
interest rate of 2.16% and no dividends during the expected term.
These warrants were estimated to have a fair value of $2,200, which
was recorded as unamortized warrant discount on the grant date. The
exercise price of the warrants are adjustable according to the same
terms as the 10% Notes.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">At
January 31, 2012, the warrant exercise price reset to $0.11485. As
the result, the Company has recorded a warrant liability of
$120,000 and recognized additional financing costs of $120,000 for
the year ended January 31, 2012. The fair value of the warrant
liability was determined using the Black-Scholes model option
pricing model with the following assumptions: expected life of 2.75
years; 30% stock price volatility; risk-free interest rate of 0.30%
and no dividends during the expected term.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><i>8%
Senior Subordinated Convertible Promissory Notes due February 1,
2015</i></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On
September 1, 2011, the Company issued $150,000 of its 8% Senior
Subordinated Promissory Convertible Notes. The net proceeds will be
used for working capital to support organic growth including the
expansion to new hospitals and hiring of new physicians,
acquisitions of physician practices and/or care management
businesses and for general corporate purposes. The notes bear
interest at a rate of 8% annually, payable semi annually on
December 31 and June 30. The Notes mature and become due and
payable on January 31, 2013 and rank senior to all other
subordinated debt of the Company.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The 8%
Notes are convertible any time prior to February 1, 2015. The
initial conversion rate is 100,000 shares of the Company&#x2019;s
common stock per $25,000 principal amount of the 8% Notes, which
represents an initial conversion price of $0.25 per share of the
Company&#x2019;s common stock. The conversion price of the 8% Notes
will be adjusted on a weighted average basis if the Company issues
certain additional shares of common stock (or warrants or rights to
purchase share of common stock or securities convertible into
common stock) for a consideration per share which is less than the
then applicable conversion price.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The
Company may require the holders of the 8% Notes to convert to
common stock at the then applicable conversion rate at any time
after June 30, 2013 if: i) our 10% Notes have been fully repaid or
converted and ii) the closing price of our common stock has
exceeded 150% of the then applicable Conversion Price for no less
than 30 consecutive trading days prior to giving notice.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">At any
time on or after June 30, 2014, the Company may, at its sole option
redeem all of the Notes at redemption price in cash equal to 108%
of the principal amount of the Notes to be redeemed plus any
accrued and unpaid interest to, but excluding the redemption
rate.</p>
<p style="MARGIN: 0pt 0.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="COLOR: black">Interest expense was $130,000 and
$125,000 for the years ended January 31, 2012 and 2011,
respectively.</font></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The
following table represents the principal repayments of all the
outstanding debt as of January 31, 2012:</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 40%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.5in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center">
Year&#xA0;ending&#xA0;January&#xA0;31,</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td colspan="2">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; WIDTH: 72%">2013</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 25%">1,250,000</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">2014</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">2015</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">2016</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">150,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ConvertibleDebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible Debt Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ameh_ConvertibleDebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ameh_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingency<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingency</a></td>
        <td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>16.</b> <b>Commitments and Contingency</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On March 15, 2009, the Company entered into a Consulting Agreement
with Kaneohe Advisors LLC (Kyle Francis) under which Mr. Francis
became the Company&#x2019;s Executive Vice President, Business
Development and Strategy. Under the terms of the Agreement, Mr.
Francis is compensated at a rate of $8,000 per month. In addition,
Mr. Francis received 350,000 shares of restricted stock at the date
of the Agreement and is entitled to 350,000 additional restricted
shares on the first and second anniversaries of the Agreement,
provided the Agreement is not terminated. The initial 350,000
shares, along with 50,000 shares granted to Mr. Francis in the year
ended January 2009, were issued in the third quarter ended October
31, 2009. On March 15, 2010, the second anniversary of the
Consulting Agreement, Mr. Francis was granted an additional 350,000
shares. On March 15, 2011, Mr. Francis was granted an additional
350,000 shares on the third anniversary of the before mentioned
Consulting Agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
On September 4, 2008, Apollo Medical Management, Inc. executed an
employment agreement with Jilbert Issai, M.D., to provide services
as Senior Vice President. The agreement is for an initial one-year
term with provision for successive one-year periods. Under the
agreement, Dr. Issai is entitled to a nominal salary and may be
granted options to purchase an aggregate of 300,000 shares of the
Company&#x2019;s common stock at an exercise price of $0.15 per
share when and if the Company is to adopt a stock compensation
plan. The Company granted Dr. Issai 300,000 options on December 9,
2010.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&#xA0;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Effective as of January 1, 2012, Suresh Nihalani was re-elected to
the Company&#x2019;s Board of Directors. In connection with his
service to the Company as a director, In connection with his
service to the Company as a director, Mr. Nihalani entered into the
Company&#x2019;s form of Director Agreement, which provides for Mr.
Nihalani to be a director and Mr. Nihalani received a restricted
stock grant of 400,000 shares of the Company's Common Stock. The
shares will vest monthly at a rate of 1/36 per month over a three
year time period.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4QCI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Service</div>
        </th>
        <th class="th">
          <div>AHI and PCCM</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Service</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>AHI and PCCM</div>
        </th>
        <th class="th">
          <div>APIC</div>
        </th>
        <th class="th">
          <div>APIC

</div>
          <div>Service</div>
        </th>
        <th class="th">
          <div>APIC

</div>
          <div>AHI and PCCM</div>
        </th>
        <th class="th">
          <div>Non- controlling Interest</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jan. 31, 2010</a></td>
        <td class="num">$ (46,393)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 27,041<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 939,483<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 228,115<span></span></td>
        <td class="num">$ (1,241,031)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jan. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27,041,328<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">594,446<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47,378<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">595<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,783<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash stock-based compensation charges</a></td>
        <td class="nump">72,152<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">72,152<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(156,331)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(156,331)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jan. 31, 2011</a></td>
        <td class="num">(83,194)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,058,418<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">228,115<span></span></td>
        <td class="num">(1,397,362)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jan. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27,635,774<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,350,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">280,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,350<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">278,650<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestIncreaseFromStockIssuance', window );">Acquisition related non-controlling interest</a></td>
        <td class="nump">164,276<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">164,276<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Distributions to non-controlling interest shareholder</a></td>
        <td class="num">(154,290)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(154,290)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Non-cash stock-based compensation charges (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">350,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Non-cash stock-based compensation charges</a></td>
        <td class="nump">63,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">350<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">62,650<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CompensationExpenseRelatedStockOptions', window );">Stock option expense</a></td>
        <td class="nump">29,333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(720,346)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(720,346)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jan. 31, 2012</a></td>
        <td class="num">$ (421,220)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 29,336<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,429,051<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 238,101<span></span></td>
        <td class="num">$ (2,117,708)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jan. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,335,774<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CompensationExpenseRelatedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock option compensation expense recorded during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ameh_CompensationExpenseRelatedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ameh_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestIncreaseFromStockIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents an increase in noncontrolling interest from issuance of additional equity interests to noncontrolling interest holders or the sale of a portion of the parent's controlling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569655-111683<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4616395-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterestIncreaseFromStockIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568740-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterestPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568740-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4I<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4590271-111686<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Publisher AICPA<br><br> -Number 51<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568447-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Receivable<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Accounts Receivable</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Receivable</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>4.
Accounts Receivable</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Accounts Receivable is stated at the amount management expects to
collect from outstanding balances. An allowance for doubtful
accounts is provided for those accounts receivable considered to be
uncollectible, based upon historical experience and management's
evaluation of outstanding accounts receivable at each quarter end.
As of January 31, 2012, Accounts Receivable was $994,118, net of a
provision for bad debt of $42,576, and represents amounts invoiced
by AMH and LALC. Accounts Receivable was $704,971, net of the
provision for bad debt of $34,746, on January 31, 2011.</p>
</div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Officer</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Receivable</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>5.
Receivable from officers</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Receivable from officers represent compensation payments made in
fiscal year 2010 above contractual amounts. These amounts were
expensed in fiscal year 2012 in exchange for additional physical
services provided to the company.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for claims held for amounts due a company. Examples include trade accounts receivables, notes receivables, loans receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5066-111524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 9<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 13<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5162-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3,4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5074-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>33</ContextCount>
  <ElementCount>120</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>8</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/DocumentDocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/StatementOfIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Organization and Summary of Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsNatureOfOperations</Role>
      <ShortName>Organization and Summary of Critical Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock</Role>
      <ShortName>Going Concern</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock</Role>
      <ShortName>Receivable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Due from Affiliate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Due from Affiliate</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock</Role>
      <ShortName>Prepaid Expenses</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Prepaid financing cost</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsInterestIncomeExpenseAndOtherFinancialCostsDisclosureTextBlock</Role>
      <ShortName>Prepaid financing cost</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsConvertibleDebtDisclosureTextBlock</Role>
      <ShortName>Convertible Notes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Non-Controlling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsMinorityInterestDisclosureTextBlock</Role>
      <ShortName>Non-Controlling Interest</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Stockholder's Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholder's Deficit</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Commitments and Contingency</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingency</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock</Role>
      <ShortName>Acquisitions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jan. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>ameh-20120131.xml</File>
    <File>ameh-20120131.xsd</File>
    <File>ameh-20120131_cal.xml</File>
    <File>ameh-20120131_def.xml</File>
    <File>ameh-20120131_lab.xml</File>
    <File>ameh-20120131_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholder's Deficit<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder's Deficit</a></td>
        <td class="text"><div style="FONT: 10pt Times New Roman, Times, Serif">
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>15.
Stockholder&#x2019;s Deficit</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The
Company issued a total of 1,350,000 common shares during the twelve
months ended January 31, 2012 related to acquisitions (see Note
17).</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The
Company authorized the issuance 600,000 shares of common stock for
compensation related to consulting and directors fees during the
twelve months ended January 31, 2012. The shares were valued at
$90,000 based on the fair values of the shares at the issuance
dates. These shares were not issued as January 31, 2012 and as such
have been recorded as shares to be issued in current
liabilities.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The
Company issued 350,000 shares of common stock for compensation to
the CFO during the twelve months ended January 31, 2012. The shares
were valued at $63,000 based on the fair value of the shares at the
issuance date.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The
Company issued a total of 594,446 common shares in the twelve
months ended January 31, 2011, including 244,446 shares issued to
officers and directors and 350,000 shares issued to Kanehoe
Advisors related to professional services related to the issuances.
The total shares were valued at $47,378 based on the fair value of
the shares at the issuance dates.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>Warrants outstanding:</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center">
<tr style="VERTICAL-ALIGN: bottom">
<td nowrap="nowrap">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Aggregate<br />
intrinsic<br />
value</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Number&#xA0;of&#xA0;warrants<br />
issued</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="WIDTH: 62%">Outstanding at January 31, 2011</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 16%">-</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 16%">1,655,333</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td>Granted</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td>Exercised</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">,</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 1pt">Lapsed</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
(155,333</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt">Outstanding at January 31,
2012</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,500,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;&#xA0;</p>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Exercise&#xA0;Price</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrants<br />
outstanding</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted<br />
average<br />
remaining<br />
contractual&#xA0;life</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Warrants<br />
exercisable</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">
<p style="TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Weighted</p>
<p style="TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
average</p>
<p style="TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
exercise&#xA0;price</p>
</td>
<td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 18%">0.114850</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 17%">1,250,000</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 17%">2.75</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 17%">1,250,000</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 17%">0.114850</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">0.114850</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">250,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2.75</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">250,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">0.114850</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In
conjunction with the completion of the private placement on October
16, 2009, as described in Note 11, the Company issued a total of
1,500,000 warrants. Of this amount, 1,250,000 warrants were issued
to the holders of the Convertible Notes and 250,000 warrants were
granted to the placement agent. The 1,250,000 warrants held by the
note holders are exercisable into shares of Common Stock at an
initial exercise price of $0.11485. The Warrants have a five-year
term and expire on October 31, 2014. The 250,000 warrants conveyed
to the placement agent also have a five-year term, expire on
October 31, 2014, and are exercisable at $0.11485 per share.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;<b>&#xA0;</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>2010
Equity Incentive Plan</b></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On
March 4, 2010, the Company&#x2019;s Board of Directors approved the
2010 Equity Incentive Plan (the &#x201C;Plan&#x201D;). The Plan
provides for the granting of the following types of awards to
persons who are employees, officers, consultants, advisors, or
directors of our Company or any of its affiliates:</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Under
the Plan, the Company may issue a variety of equity vehicles to
provide flexibility in implementing equity awards, including
incentive stock options, nonqualified stock options, restricted
stock grants and stock appreciation rights. The exercise price of
stock options offered under the Plan shall not be less than the
fair market value of the Company&#x2019;s common stock on the date
of the grant. The exercise price of an ISO granted to any person
who owns, directly or by attribution under the Code (currently
Section 424(d)), stock possessing more than 10% of the total
combined voting power of all classes of stock of the Company or of
any affiliate (a &#x201C;10% Stockholder&#x201D;) shall in no event
be less than 110% of the fair market value (determined in
accordance with Section 6.1.10) of the stock covered by the option
at the time the option is granted.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Subject
to the adjustment provisions of the Plan that are applicable in the
event of a stock dividend, stock split, reverse stock split or
similar transaction, up to 5,000,000 shares of common stock may be
issued under the Plan. Options granted under the Plan generally
vest over a three-year period and generally expire five years from
the date of grant.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">As of
January 31, 2012, options to purchase an aggregate of 883,332
shares of common stock were exercisable under the Company&#x2019;s
stock option Plan. During the year ended January 31, 2012, the
Company did not issue options to purchase shares of common stock
with exercise prices below the fair market value of the common
stock on the dates of grant.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"></p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Stock
option transactions under the Company&#x2019;s stock option plans
for the year ended January 31, 2012 are summarized below:</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td>&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Shares</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Weighted<br />
Average<br />
Per&#xA0;Share<br />
Exercise<br />
Price</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Weighted&#xA0;Average<br />
Remaining<br />
Contractual&#xA0;Term</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Aggregate<br />
Intrinsic&#xA0;Value</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td>Balance, January 31, 2011</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-LEFT: 9pt; WIDTH: 48%">Granted</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">1,150,000</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">0.15</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-LEFT: 9pt">Exercised</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-LEFT: 9pt">Expired</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Forfeited</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 1pt">Balance, January 31, 2012</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,150,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
0.15</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">8.9 years</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">Vested and expected to vest</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,150,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">0.15</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">8.9 years</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td>Exercisable, January 31, 2012</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">883,332</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">0.15</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">8.9 years</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">-</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">As
January 31, 2012, options available for future grant under the Plan
amounted to 3,850,000.</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
Information regarding stock options outstanding at January 31, 2012
is as follows:</p>
<p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td colspan="2" nowrap="nowrap">&#xA0;</td>
<td nowrap="nowrap">&#xA0;</td>
<td nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="10" nowrap="nowrap">
Options&#xA0;Outstanding</td>
<td nowrap="nowrap">&#xA0;</td>
<td nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="6" nowrap="nowrap">
Options&#xA0;Exercisable</td>
<td nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap">
Range&#xA0;of&#xA0;exercise<br />
prices</td>
<td nowrap="nowrap">&#xA0;</td>
<td nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap">
Number<br />
outstanding&#xA0;at<br />
January&#xA0;31,<br />
2012</td>
<td nowrap="nowrap">&#xA0;</td>
<td nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap">
Weighted<br />
average<br />
remaining<br />
contractual&#xA0;life</td>
<td nowrap="nowrap">&#xA0;</td>
<td nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap">
Weighted<br />
average<br />
exercise&#xA0;price</td>
<td nowrap="nowrap">&#xA0;</td>
<td nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap">
Number<br />
exercisable&#xA0;at<br />
January&#xA0;31,<br />
2012</td>
<td nowrap="nowrap">&#xA0;</td>
<td nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2" nowrap="nowrap">
Weighted<br />
average<br />
exercise<br />
price</td>
<td nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%">0.15</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%">1,150,000</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%">8.9 years</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%">0.15</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%">883,332</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 13%">0.15</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
